<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Bioeng Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Front Bioeng Biotechnol</journal-id><journal-id journal-id-type="pmc-domain-id">2507</journal-id><journal-id journal-id-type="pmc-domain">frontbb</journal-id><journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id><journal-title-group><journal-title>Frontiers in Bioengineering and Biotechnology</journal-title></journal-title-group><issn pub-type="epub">2296-4185</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9732709</article-id><article-id pub-id-type="pmcid-ver">PMC9732709.1</article-id><article-id pub-id-type="pmcaid">9732709</article-id><article-id pub-id-type="pmcaiid">9732709</article-id><article-id pub-id-type="pmid">36507266</article-id><article-id pub-id-type="doi">10.3389/fbioe.2022.1052436</article-id><article-id pub-id-type="publisher-id">1052436</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Bioengineering and Biotechnology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19</article-title><alt-title alt-title-type="left-running-head">Valenzuela-Fern&#225;ndez et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fbioe.2022.1052436" ext-link-type="uri">10.3389/fbioe.2022.1052436</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Valenzuela-Fern&#225;ndez</surname><given-names initials="A">Agust&#237;n</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/104725/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cabrera-Rodriguez</surname><given-names initials="R">Romina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1625832/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ciuffreda</surname><given-names initials="L">Laura</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1785182/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Perez-Yanes</surname><given-names initials="S">Silvia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1709539/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Estevez-Herrera</surname><given-names initials="J">Judith</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gonz&#225;lez-Montelongo</surname><given-names initials="R">Rafaela</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1299663/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alcoba-Florez</surname><given-names initials="J">Julia</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2027045/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Trujillo-Gonz&#225;lez</surname><given-names initials="R">Rodrigo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez de Artola</surname><given-names initials="D">Diego</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gil-Campesino</surname><given-names initials="H">Helena</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>D&#237;ez-Gil</surname><given-names initials="O">Oscar</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lorenzo-Salazar</surname><given-names initials="JM">Jos&#233; M.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Flores</surname><given-names initials="C">Carlos</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/119071/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Garcia-Luis</surname><given-names initials="J">Jonay</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Laboratorio de Inmunolog&#237;a Celular y Viral</institution>, <institution>Unidad de Farmacolog&#237;a</institution>, <institution>Secci&#243;n de Medicina</institution>, <institution>Facultad de Ciencias de la Salud</institution>, <institution>Universidad de La Laguna</institution>, <addr-line>San Crist&#243;bal de La Laguna</addr-line>, <country>Spain</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Research Unit</institution>, <institution>Hospital Universitario N. S. de Candelaria</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Genomics Division</institution>, <institution>Instituto Tecnol&#243;gico y de Energ&#237;as Renovables</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Servicio de Microbiolog&#237;a</institution>, <institution>Hospital Universitario N. S. de Candelaria</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Departamento de An&#225;lisis Matem&#225;tico</institution>, <institution>Facultad de Ciencias</institution>, <institution>Universidad de La Laguna</institution>, <addr-line>Santa Cruz de Tenerife</addr-line>, <country>Spain</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>CIBER de Enfermedades Respiratorias</institution>, <institution>Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff7">
<sup>7</sup>
<institution>Faculty of Health Sciences</institution>, <institution>University of Fernando Pessoa Canarias</institution>, <addr-line>Las Palmas de Gran Canaria</addr-line>, <country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/527716/overview" ext-link-type="uri">Donato Zipeto</ext-link>, University of Verona, Italy</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/852152/overview" ext-link-type="uri">Massimiliano Perduca</ext-link>, University of Verona, Italy</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/526164/overview" ext-link-type="uri">Giuseppe Bardi</ext-link>, Italian Institute of Technology (IIT), Italy</p></fn><corresp id="c001">*Correspondence: Agust&#237;n Valenzuela-Fern&#225;ndez, <email>avalenzu@ull.edu.es</email></corresp><fn fn-type="other"><p>This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Bioengineering and Biotechnology</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">400073</issue-id><elocation-id>1052436</elocation-id><history><date date-type="received"><day>23</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>09</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>11</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>10</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-04 16:25:36.183"><day>04</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Valenzuela-Fern&#225;ndez, Cabrera-Rodriguez, Ciuffreda, Perez-Yanes, Estevez-Herrera, Gonz&#225;lez-Montelongo, Alcoba-Florez, Trujillo-Gonz&#225;lez, Garc&#237;a-Mart&#237;nez de Artola, Gil-Campesino, D&#237;ez-Gil, Lorenzo-Salazar, Flores and Garcia-Luis.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Valenzuela-Fern&#225;ndez, Cabrera-Rodriguez, Ciuffreda, Perez-Yanes, Estevez-Herrera, Gonz&#225;lez-Montelongo, Alcoba-Florez, Trujillo-Gonz&#225;lez, Garc&#237;a-Mart&#237;nez de Artola, Gil-Campesino, D&#237;ez-Gil, Lorenzo-Salazar, Flores and Garcia-Luis</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fbioe-10-1052436.pdf"/><abstract><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the associated coronavirus disease 2019 (COVID-19), which severely affect the respiratory system and several organs and tissues, and may lead to death, have shown how science can respond when challenged by a global emergency, offering as a response a myriad of rapid technological developments. Development of vaccines at lightning speed is one of them. SARS-CoV-2 outbreaks have stressed healthcare systems, questioning patients care by using standard non-adapted therapies and diagnostic tools. In this scenario, nanotechnology has offered new tools, techniques and opportunities for prevention, for rapid, accurate and sensitive diagnosis and treatment of COVID-19. In this review, we focus on the nanotechnological applications and nano-based materials (i.e., personal protective equipment) to combat SARS-CoV-2 transmission, infection, organ damage and for the development of new tools for virosurveillance, diagnose and immune protection by mRNA and other nano-based vaccines. All the nano-based developed tools have allowed a historical, unprecedented, real time epidemiological surveillance and diagnosis of SARS-CoV-2 infection, at community and international levels. The nano-based technology has help to predict and detect how this Sarbecovirus is mutating and the severity of the associated COVID-19 disease, thereby assisting the administration and public health services to make decisions and measures for preparedness against the emerging variants of SARS-CoV-2 and severe or lethal COVID-19.</p></abstract><kwd-group><kwd>nanoreagents</kwd><kwd>personal protective equipment</kwd><kwd>vaccines</kwd><kwd>lipid nanoparticles</kwd><kwd>modified mRNA</kwd><kwd>recombinant proteins</kwd><kwd>surveillance and diagnosis</kwd><kwd>genome sequencing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>In the last days of the year 2019, Chinese Health Authorities reported a cluster of twenty seven patients affected with &#8220;pneumonia of unknown etiology&#8221; (seven presenting sever symptoms), which appeared to be epidemiologically associated to a seafood and wet animal wholesale market in the city of Wuhan (Hubei Province, China) (<xref rid="B29" ref-type="bibr">Anderson et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>). The microorganism responsible of these &#8220;pneumonia of unknown etiology&#8221; was rapidly identified in bronchoalveolar lavage samples collected from three patients of the Wuhan Jinyintan Hospital (30 December 2019) (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>). In this regard, the first named 2019-nCoV virus (2019 novel coronavirus), later on named SARS-CoV-2 (severe acute respiratory syndrome coronavirus virus 2) (<xref rid="B302" ref-type="bibr">ICTV, 2020</xref>), was identified by local hospitals using a surveillance mechanism for &#8220;pneumonia of unknown etiology&#8221;. This mechanism was already established in the 2003 SARS outbreak crisis with the aim of allowing timely identification of novel pathogens and reaction in future outbreaks (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B302" ref-type="bibr">International-Committee-on-Taxonomy-of-Viruses, 2020</xref>). Importantly, this surveillance system allowed the identification of some cases that were epidemiologically unrelated to Wuhan market outbreak (<xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>; <xref rid="B6" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B302" ref-type="bibr">International-Committee-on-Taxonomy-of-Viruses, 2020</xref>).</p><p>The associated illness was first named &#8220;novel coronavirus-infected pneumonia&#8221; (NCIP) and the World Health Organization (WHO) recommended that the interim name of the agent causing the current outbreak should be 2019-nCoV and was considered the causative agent of the &#8220;pneumonia of unknown etiology&#8221; (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B656" ref-type="bibr">Shimabukuro, 2021</xref>). This name complied with the WHO Best Practices for Naming of New Human Infectious Diseases, which were developed through a consultive process among partner agencies. On 30 January 2020, WHO declared that coronavirus disease 2019 (COVID-19) was a &#8220;public-health emergency of international concern (PHEIC)&#8221; (<xref rid="B27" ref-type="bibr">Amaechi et al., 2020</xref>). The name of the disease was provided by the WHO International Classification of Diseases (ICD; on 11 February 2020) as COVID-19, and the official name of the virus was given by the International Committee on Taxonomy of Viruses (ICTV; on 11 February 2020), as SARS-CoV-2 (<xref rid="B302" ref-type="bibr">ICTV, 2020</xref>). On 11 March 2000, the WHO declared the SARS-CoV-2/COVID-19 outbreak a global pandemic (<xref rid="B158" ref-type="bibr">Cucinotta and Vanelli, 2020</xref>; <xref rid="B656" ref-type="bibr">Shimabukuro, 2021</xref>).</p><p>The first complete sequences of the new CoV (SARS-CoV-2) genome obtained from Wuhan&#8217;s patients were submitted to GISAID (Global Initiative on Sharing All Influenza Data; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gisaid.org/" ext-link-type="uri">https://www.gisaid.org/</ext-link>; (<xref rid="B422" ref-type="bibr">Liu et al., 2020d</xref>)) (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B439" ref-type="bibr">Lu et al., 2020</xref>) and GenBank (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MN908947">MN908947</ext-link>) where the virus strain was designated as Wuhan-Human 1 CoV (Wuhan-Hu-1 or WHCV) with a whole genome sequence of 29,903 nucleotides (nt) (<xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>). At the same time, it was reported the epidemiological data of nine inpatients, from at least three hospitals in Wuhan, who were diagnosed with viral pneumonia of unidentified cause (<xref rid="B62" ref-type="bibr">Barton et al., 2020</xref>). Furthermore, some early cases were not epidemiologically associated with the market of Wuhan (<xref rid="B6" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B302" ref-type="bibr">International-Committee-on-Taxonomy-of-Viruses, 2020</xref>). The sequencing of bronchoalveolar lavage fluid samples of the above nine patients again identified the new CoV (<xref rid="B62" ref-type="bibr">Barton et al., 2020</xref>). More evidence for the presence of this CoV was obtained by virus isolation form the clinical specimens, viral culture, and cytotoxicity assays together with virus morphology analysis by electron microscopy (<xref rid="B62" ref-type="bibr">Barton et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>), all of which are methods and devices that clearly use key nanotechnologies for SARS-CoV-2/COVID-19 detection and diagnosis (<xref rid="B100" ref-type="bibr">Caldas et al., 2020</xref>; <xref rid="B581" ref-type="bibr">Prasad et al., 2020</xref>; <xref rid="B9" ref-type="bibr">Akilesh et al., 2021</xref>; <xref rid="B312" ref-type="bibr">Jefferson et al., 2021</xref>; <xref rid="B680" ref-type="bibr">Sung et al., 2022</xref>).</p><p>The disease symptoms vary from person to person, from a paucisymptomatic or mild respiratory illness to an acute distress respiratory syndrome (ARDS). However, the prevalent reported symptoms associated with SARS-CoV-2/COVID-19 are fever, cough, fatigue, dyspnea (shortness of breath) and anosmia (partial or complete loss of the sense of smell), sore throat, headaches, ocular manifestations, chest pain and diarrhea. It also includes abnormal coagulation and lymphopenia that together with cytokine storm, hyper-inflammation, sepsis and septic shock accompany severe pneumonia, ARDS and multiorgan dysfunction, including neuropathogenesis, liver, kidney and heart failure (<xref rid="B81" ref-type="bibr">Bizzarro et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>; <xref rid="B6" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="B27" ref-type="bibr">Amaechi et al., 2020</xref>; <xref rid="B38" ref-type="bibr">Arslan et al., 2020</xref>; <xref rid="B49" ref-type="bibr">Baig et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B62" ref-type="bibr">Barton et al., 2020</xref>; <xref rid="B91" ref-type="bibr">Brann et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B118" ref-type="bibr">Chan et al., 2020</xref>; <xref rid="B128" ref-type="bibr">Chen et al., 2020</xref>; <xref rid="B135" ref-type="bibr">Cheung et al., 2020</xref>; <xref rid="B137" ref-type="bibr">China-National-Health-Commission-(Beijing), 2020</xref>; <xref rid="B151" ref-type="bibr">Corbett et al., 2020</xref>; <xref rid="B177" ref-type="bibr">Devaux et al., 2020</xref>; <xref rid="B181" ref-type="bibr">Diao et al., 2020</xref>; <xref rid="B229" ref-type="bibr">Gavriatopoulou et al., 2020</xref>; <xref rid="B234" ref-type="bibr">Gibson et al., 2020</xref>; <xref rid="B242" ref-type="bibr">Goyal et al., 2020</xref>; <xref rid="B246" ref-type="bibr">Guan et al., 2020</xref>; <xref rid="B263" ref-type="bibr">Hariri and Hardin, 2020</xref>; <xref rid="B274" ref-type="bibr">Helms et al., 2020</xref>; <xref rid="B302" ref-type="bibr">International-Committee-on-Taxonomy-of-Viruses, 2020</xref>; <xref rid="B375" ref-type="bibr">Kuster et al., 2020</xref>; <xref rid="B387" ref-type="bibr">Lechien et al., 2020</xref>; <xref rid="B389" ref-type="bibr">Ledford, 2020</xref>; <xref rid="B406" ref-type="bibr">Levi et al., 2020</xref>; <xref rid="B418" ref-type="bibr">Lipsitch et al., 2020</xref>; <xref rid="B463" ref-type="bibr">Mazzoni et al., 2020</xref>; <xref rid="B472" ref-type="bibr">Menter et al., 2020</xref>; <xref rid="B539" ref-type="bibr">Ouyang et al., 2020</xref>; <xref rid="B586" ref-type="bibr">Puelles et al., 2020</xref>; <xref rid="B616" ref-type="bibr">Ruan et al., 2020</xref>; <xref rid="B640" ref-type="bibr">Seah and Agrawal, 2020</xref>; <xref rid="B706" ref-type="bibr">Toscano et al., 2020</xref>; <xref rid="B707" ref-type="bibr">Tsivgoulis et al., 2020</xref>; <xref rid="B729" ref-type="bibr">Verdoni et al., 2020</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>; <xref rid="B656" ref-type="bibr">Shimabukuro, 2021</xref>). Therefore, COVID-19 infections affect various organs in the body, including the central nervous system (<xref rid="B49" ref-type="bibr">Baig et al., 2020</xref>; <xref rid="B781" ref-type="bibr">Wu et al., 2020</xref>), cardiovascular system (<xref rid="B823" ref-type="bibr">Zheng et al., 2020</xref>), kidneys (<xref rid="B133" ref-type="bibr">Cheng et al., 2020b</xref>), gastrointestinal tract (<xref rid="B778" ref-type="bibr">Wong et al., 2020b</xref>), and liver (<xref rid="B812" ref-type="bibr">Zhang et al., 2020a</xref>; <xref rid="B56" ref-type="bibr">Bangash et al., 2020</xref>) (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Furthermore, a common cause of death is an uncontrolled hyperinflammatory response (i.e., with uncontrolled cytokine levels), which can lead to stroke due to blood clots, organ failure, and heart attacks (<xref rid="B266" ref-type="bibr">Hasanzadeh et al., 2021</xref>). Since the SARS-CoV-2 must bind to angiotensin-converting enzyme 2 (ACE2) to enter and infect host cells in humans (<xref rid="B824" ref-type="bibr">Zhou et al., 2020a</xref>; <xref rid="B649" ref-type="bibr">Shang et al., 2020b</xref>; <xref rid="B743" ref-type="bibr">Walls et al., 2020b</xref>; <xref rid="B751" ref-type="bibr">Wang et al., 2020e</xref>; <xref rid="B382" ref-type="bibr">Lan et al., 2020</xref>), the expression (partly determined by the stage of development) and body localization of ACE2 are important to understand COVID-19 symptoms and disease (<xref rid="B259" ref-type="bibr">Hamming et al., 2004</xref>; <xref rid="B800" ref-type="bibr">Yang et al., 2020b</xref>; <xref rid="B514" ref-type="bibr">Ni et al., 2020</xref>) (<xref rid="F1" ref-type="fig">Figure 1A</xref>). Noteworthy, ACE2 is a zinc metallopeptidase involved in regulation of blood pressure and cardiac function (<xref rid="B702" ref-type="bibr">Tikellis and Thomas, 2012</xref>). It has recently been reported that SARS-CoV-2-targeted ACE2-expressing organs lead to severe pathobiological manifestations followed by multiple organ failure (<xref rid="B623" ref-type="bibr">Salamanna et al., 2020</xref>) (<xref rid="F1" ref-type="fig">Figure 1A</xref>, <italic toggle="yes">scheme representing the different organs and tissues that express ACE2, and could be infected by SARS-CoV-2</italic>). The ACE2 receptor for SARS-CoV-2 infection was previously reported to be the receptor for the Sarbecovirus SARS-CoV-1 (<xref rid="B408" ref-type="bibr">Li et al., 2003</xref>) and for the human coronavirus (HCoV)-NL63 (<xref rid="B283" ref-type="bibr">Hofmann et al., 2005</xref>), an alphacoronavirus known to cause mild upper respiratory tract infection. The entry steps of the SARS-CoV-2 viral particles are mediated by the external S glycoprotein, which is arranged as a homotrimers (peplomers) (<xref rid="B114" ref-type="bibr">Cavanagh, 1995</xref>) that give the characteristic Sun&#8217;s corona-like aspect to the viral particles (<xref rid="B420" ref-type="bibr">Liu et al., 2020b</xref>; <xref rid="B421" ref-type="bibr">Liu et al., 2020c</xref>) (see images at NIH (NIAID) website &#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.flickr.com/photos/niaid/albums/72157712914621487" ext-link-type="uri">https://www.flickr.com/photos/niaid/albums/72157712914621487&#8221;</ext-link>), therefore classified as the <italic toggle="yes">coronaviridae</italic> family (<xref rid="B169" ref-type="bibr">de Groot et al., 1987</xref>). SARS-CoV-2 fusion with cell-plasma membrane and cell entry are therefore initiated by the interaction of the receptor binding domain (RBD) of the S protein to human ACE2 at the cell-surface (<xref rid="B408" ref-type="bibr">Li et al., 2003</xref>; <xref rid="B409" ref-type="bibr">Li et al., 2005</xref>; <xref rid="B796" ref-type="bibr">Yan et al., 2020a</xref>; <xref rid="B751" ref-type="bibr">Wang et al., 2020e</xref>; <xref rid="B746" ref-type="bibr">Wan et al., 2020</xref>) (<xref rid="F1" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">scheme representing key viral and cell molecules involved in virus attachment and fusion with target cell that mediate viral entry and infection</italic>). Then, the S protein, anchored to ACE2 in its prefusion state (<xref rid="F1" ref-type="fig">Figure 1B</xref>), undergoes proteolytic cleavage catalyzed by several host proteases, such as furin that cleaves at the polybasic region (RRAR685|S), and TMPRSS2 (transmembrane serine protease 2) that recognizes the canonical S1/S2 cleavage site, as well as other sites at the S protein (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B76" ref-type="bibr">Bestle et al., 2020</xref>; <xref rid="B281" ref-type="bibr">Hoffmann et al., 2020b</xref>; <xref rid="B751" ref-type="bibr">Wang et al., 2020e</xref>; <xref rid="B220" ref-type="bibr">Fraser et al., 2022</xref>) (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Likewise, the S protein could be also cleaved by cathepsin B/L, within endosomes after virus ACE2-mediated endocytosis, promoting virus-endosome membrane fusion (<xref rid="B281" ref-type="bibr">Hoffmann et al., 2020b</xref>; <xref rid="B84" ref-type="bibr">Bollavaram et al., 2021</xref>; <xref rid="B537" ref-type="bibr">Ou et al., 2021</xref>) (<xref rid="F1" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">Inbox scheme</italic>). All these proteolytic cleavages expose the fusion peptide of the S2 subunit of the virus, facilitating virus-cell membranes fusion (<xref rid="F1" ref-type="fig">Figure 1B</xref>) and the entry of viral RNA + genome into the cell, starting the SARS-CoV-2 infection process (reviewed in (<xref rid="B558" ref-type="bibr">Peng et al., 2021a</xref>; <xref rid="B816" ref-type="bibr">Zhang et al., 2021a</xref>; <xref rid="B305" ref-type="bibr">Jackson et al., 2022</xref>)). Furin could also cleave the S protein into the S1 and S2 subunits, which remain associated, during the late steps of the viral cycle in virus-producing cells (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B648" ref-type="bibr">Shang et al., 2020a</xref>). This event leads to new viral particles that easily expose the S2-fusion peptide favoring cell-cell spread and cell infection (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B648" ref-type="bibr">Shang et al., 2020a</xref>; <xref rid="B544" ref-type="bibr">Papa et al., 2021</xref>) (<xref rid="F1" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">Bottom scheme</italic>). The furin cleavage site at the S protein is thought to be responsible for the virulence of SARS-CoV-2 (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B318" ref-type="bibr">Johnson et al., 2020</xref>; <xref rid="B319" ref-type="bibr">Johnson et al., 2021</xref>). Furthermore, several cofactors have been involved in SARS-CoV-2 entry and infection (<xref rid="F1" ref-type="fig">Figure 1B</xref>, <italic toggle="yes">Top scheme</italic>). Thus, Neuropilin-1 (NRP1) appears to trigger SARS-CoV-2 viral entry and infection (<xref rid="B105" ref-type="bibr">Cantuti-Castelvetri et al., 2020</xref>; <xref rid="B165" ref-type="bibr">Daly et al., 2020</xref>). NRP1 has been proposed to mediate SARS-CoV-2 entry into the brain via the olfactory bulb (<xref rid="B105" ref-type="bibr">Cantuti-Castelvetri et al., 2020</xref>), since NRP1 is expressed in respiratory and olfactory epithelia (<xref rid="B105" ref-type="bibr">Cantuti-Castelvetri et al., 2020</xref>; <xref rid="B165" ref-type="bibr">Daly et al., 2020</xref>). Moreover, high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) has been reported to promote SARS-CoV-2 entry, in an ACE2-dependent manner (<xref rid="B764" ref-type="bibr">Wei et al., 2020</xref>), whereas the transmembrane glycoprotein CD147 (also named BSG (basigin (Ok blood group) (<xref rid="B329" ref-type="bibr">Kaname et al., 1993</xref>) or EMMPRIN (extracellular matrix metalloproteinase inducer) (<xref rid="B80" ref-type="bibr">Biswas et al., 1995</xref>)), could mediate viral entry and infection by endocytosis, even in cells lacking ACE2 expression (<xref rid="B749" ref-type="bibr">Wang et al., 2020c</xref>). Moreover, it seems that CD147 and ACE2 cooperate during SARS-CoV-2 infection, since ACE2 levels are modulated by CD147 density and they are coregulated by viral infection (<xref rid="B209" ref-type="bibr">Fenizia et al., 2021</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Cells, tissues and organs that express the ACE2 receptor and are infected by SARS-CoV-2, and the mechanisms of early SARS-CoV-2 infection. <bold>(A)</bold> Scheme representing cells, tissues and organs expressing the ACE2 receptor that allows the SARS-CoV-2 virus to infect them, thereby being associated with tissue damage and organ failure. <bold>(B)</bold> Scheme representing the main viral and cellular molecules involved in SARS-CoV-2 attachment and fusion with target cell that mediate viral entry and infection. The S protein (with its S1 and S2 subunits in the prefusion state) interacts with ACE2 leading to conformational changes in the protein that facilitate the proteolytic cleavage of the S protein that further exposes the fusion peptide (FP). This S cleavage is catalyzed by several host proteases, such as TMPRSS2 that recognizes the canonical S1/S2 cleavage site, as well as other sites at the S protein (e.g., S2&#8217;) (<italic toggle="yes">Top scheme</italic>), and furin that excises at the polybasic region (RRAR|S) located between S1 and S2 subunits, and near the S2-fusion peptide (<italic toggle="yes">Bottom scheme</italic>). The S protein could also be cleaved by the endosome enzymes cathepsin B/L, after ACE2-mediated endocytosis of the virus, promoting virus-endosome membranes fusion (<italic toggle="yes">Inbox scheme</italic>). All these proteolytic cleavages expose the fusion peptide (FP) of the S2 subunit of the virus, facilitating virus-cell membranes fusion and the entry of viral RNA + genome into the cell, starting the SARS-CoV-2 infection process. Several cofactors have been reported to be involved in SARS-CoV-2 entry and infection, such as NRP1, reported to mediate SARS-CoV-2 entry into the brain via the olfactory bulb, the SR-B1 receptor, proposed to promote SARS-CoV-2 entry (in an ACE2-dependent manner) and the transmembrane glycoprotein CD147 (BSG or EMMPRIN) that could mediate viral entry and infection by endocytosis cooperating with ACE2 (<italic toggle="yes">Top scheme</italic>). Designs and templates are created with BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fbioe-10-1052436-g001.jpg"/></fig><p>Therefore, nano-based strategies to battle SARS-CoV-2/COVID-19 must confront all symptoms of the disease, particularly to avoid severe outcomes, and to neutralize the infection of cells from different tissues and organs that could be targeted by the virus, through vaccine-elicited specific and optimal immune responses, mainly driven against the S viral immunogen.</p><p>In this scenario, viral isolation, culture and sequencing were key methods, based on nanotechnology and nano-reagents or materials that help to achieve fasts diagnosis and to endorse and develop urgent public health measures and responses, as the WHO preparedness for emerging epidemic threats recommends (<xref rid="B465" ref-type="bibr">McCloskey et al., 2014</xref>; <xref rid="B195" ref-type="bibr">Elbe and Buckland-Merrett, 2017</xref>; <xref rid="B309" ref-type="bibr">Jain et al., 2018</xref>; <xref rid="B363" ref-type="bibr">Kluge et al., 2018</xref>; <xref rid="B236" ref-type="bibr">Global-Preparedness-Monitoring-Board-(GPMB), 2019</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>). These nano-based tools and strategies allowed the detection of a new RNA+ genome from patients&#8217; samples, and the identification of the new SARS-CoV-2 virus of the lineage B of the genus betacoronavirus (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>). In general, nanomaterials and nanotechnological approaches to combat viral infections consist in diagnostic sensors, vaccine formulations, and protective coatings, and vehicles for delivery of anti-viral vaccines and adjuvants, as well as for new treatments to palliate COVID-19 associated symptoms and to limit disease severity (reviewed in (<xref rid="B103" ref-type="bibr">Campos et al., 2020</xref>; <xref rid="B113" ref-type="bibr">Cavalcanti and Cajub&#225; De Britto Lira Nogueira, 2020</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>; <xref rid="B252" ref-type="bibr">Gupta et al., 2020</xref>; <xref rid="B569" ref-type="bibr">Pisani et al., 2020</xref>; <xref rid="B687" ref-type="bibr">Talebian and Conde, 2020</xref>; <xref rid="B766" ref-type="bibr">Weiss et al., 2020</xref>; <xref rid="B42" ref-type="bibr">Asdaq et al., 2021</xref>; <xref rid="B149" ref-type="bibr">Constantin et al., 2021</xref>; <xref rid="B563" ref-type="bibr">Petkar et al., 2021</xref>; <xref rid="B598" ref-type="bibr">Rashidzadeh et al., 2021</xref>; <xref rid="B724" ref-type="bibr">Varahachalam et al., 2021</xref>; <xref rid="B238" ref-type="bibr">Goharshadi et al., 2022</xref>; <xref rid="B672" ref-type="bibr">Souri et al., 2022</xref>)). Nanoreagents and derived materials have intrinsic antipathogenic properties that are able to inactivate and degrade the SARS-CoV-2 virus, as well as other viruses, bacteria and microorganisms via generation of reactive oxygen species in contact with the virus or triggered by photocatalysis. We have considered materials used in face masks and protective personal equipment (PPE) for prevention. These nanomaterials could offer new tools and disinfection methods in healthcare facilities. Vehicles used for drug delivery are similar to those used for vaccine-associated immunogen delivery, which could function as adjuvants for immune system activation (reviewed in (<xref rid="B563" ref-type="bibr">Petkar et al., 2021</xref>)). We have considered nano-based vaccines as the real treatment for prevention and treatment of SARS-CoV-2 infection and COVID-19 disease. We have summarized the main diagnoses tests used (serological and RT-qPCR, useful in point-of-care facilities) (<xref rid="B717" ref-type="bibr">Valera et al., 2021</xref>) and emphasizing genome-mediated approximations based on nanopore technology (<xref rid="B2" ref-type="bibr">Abraham et al., 2008</xref>; <xref rid="B143" ref-type="bibr">Ciuffreda et al., 2021b</xref>; <xref rid="B415" ref-type="bibr">Liefting et al., 2021</xref>; <xref rid="B417" ref-type="bibr">Lin et al., 2021</xref>; <xref rid="B323" ref-type="bibr">Ju et al., 2022</xref>), an outstanding electrochemical biosensor on nanoscale used for SARS-CoV-2 detection and sequencing (<xref rid="B794" ref-type="bibr">Yakovleva et al., 2022</xref>), and viral whole genome sequencing (WGS) (<xref rid="B239" ref-type="bibr">Gohl et al., 2020</xref>; <xref rid="B613" ref-type="bibr">Rosenthal et al., 2022</xref>). These strategies are considered high performance nanotechniques for virus genome sequencing, diagnosis and virus surveillance, where their utility to combat SARS-CoV-2/COVID-19 have been clearly demonstrated in this pandemic crisis. All these nano-based designs, tools and strategies have allowed a historical, unprecedent, real time epidemiological surveillance, diagnosis of SARS-CoV-2 infection and transmission, at community and international levels, predicting how this Sarbecovirus is mutating and the severity of the associated COVID-19 disease.</p><p>In this review we aimed to address all these nano-based strategies to battle SARS-CoV-2/COVID-19 that assist the administration and public health services to make decisions and measures for preparedness against the emerging variants of SARS-CoV-2 and severe or lethal COVID-19.</p></sec><sec id="s2"><title>2 Nanomaterials in the battle against SARS-CoV-2: Physical barriers, vaccines, genomics-based virosurveillance and diagnosis</title><sec id="s2-1"><title>2.1 Physical barriers for prevention: Face masks and protective personal equipment</title><p>The entire world has witnessed that prevention strategies against the still ongoing COVID-19 pandemics have included vaccines, antiviral drugs and, since the beginning, personal protective countermeasures, such as facemasks together with physical distancing (<xref rid="B138" ref-type="bibr">Chu et al., 2020</xref>; <xref rid="B89" ref-type="bibr">Brainard et al., 2020</xref>; <xref rid="B413" ref-type="bibr">Li et al., 2021b</xref>; <xref rid="B594" ref-type="bibr">Raman et al., 2021</xref>; <xref rid="B615" ref-type="bibr">Rowan and Moral, 2021</xref>). In fact, nanomaterials and associated technologies are also crucial to control person-to-person virus transmission and viral community spreading (i.e., face masks, sanitizers and disinfectants, drugs and vaccines) (<xref rid="B65" ref-type="bibr">Barycka et al., 2020</xref>; <xref rid="B138" ref-type="bibr">Chu et al., 2020</xref>; <xref rid="B89" ref-type="bibr">Brainard et al., 2020</xref>; <xref rid="B109" ref-type="bibr">Carraturo et al., 2020</xref>; <xref rid="B300" ref-type="bibr">Ilyas et al., 2020</xref>; <xref rid="B42" ref-type="bibr">Asdaq et al., 2021</xref>; <xref rid="B413" ref-type="bibr">Li et al., 2021b</xref>; <xref rid="B178" ref-type="bibr">Dhama et al., 2021</xref>; <xref rid="B278" ref-type="bibr">Hodgson et al., 2021</xref>; <xref rid="B473" ref-type="bibr">Meo et al., 2021</xref>; <xref rid="B610" ref-type="bibr">Rohilla, 2021</xref>; <xref rid="B615" ref-type="bibr">Rowan and Moral, 2021</xref>; <xref rid="B625" ref-type="bibr">Salian et al., 2021</xref>; <xref rid="B685" ref-type="bibr">Tabatabaeizadeh, 2021</xref>; <xref rid="B697" ref-type="bibr">Thompson et al., 2021</xref>; <xref rid="B733" ref-type="bibr">Vitiello et al., 2021</xref>; <xref rid="B347" ref-type="bibr">Kianpour et al., 2022</xref>). If these measures to control transmission are neglected it will lead to the emergence of a plethora of new variants of the SARS-CoV-2 virus [including the variants of concerns (VOCs)] with may associate with increased infectious and transmission properties that compromise natural and vaccine-elicited immune responses and protection, as well as the effectiveness of the assays for rapid detection and diagnosis (<xref rid="B14" ref-type="bibr">Alcoba-Florez et al., 2020a</xref>; <xref rid="B765" ref-type="bibr">Weisblum et al., 2020</xref>; <xref rid="B52" ref-type="bibr">Bal et al., 2021</xref>; <xref rid="B77" ref-type="bibr">Bian et al., 2021</xref>; <xref rid="B83" ref-type="bibr">Boehm et al., 2021</xref>; <xref rid="B102" ref-type="bibr">Camp et al., 2021</xref>; <xref rid="B428" ref-type="bibr">Liu et al., 2021d</xref>; <xref rid="B282" ref-type="bibr">Hoffmann et al., 2021</xref>; <xref rid="B594" ref-type="bibr">Raman et al., 2021</xref>; <xref rid="B626" ref-type="bibr">Salleh et al., 2021</xref>; <xref rid="B663" ref-type="bibr">Singh et al., 2021</xref>; <xref rid="B692" ref-type="bibr">Tao et al., 2021</xref>; <xref rid="B18" ref-type="bibr">Alejo-Cancho et al., 2022</xref>; <xref rid="B476" ref-type="bibr">Mertens et al., 2022</xref>; <xref rid="B670" ref-type="bibr">Sonnleitner et al., 2022</xref>).</p><p>The main transmission route of SARS-CoV-2 from person to person is aerosol (<xref rid="B492" ref-type="bibr">Morawska and Cao, 2020</xref>; <xref rid="B645" ref-type="bibr">Setti et al., 2020</xref>), among respiratory droplets, oral-fecal transmission and contact (i.e., fomites), bloodborne, mother-to-child (reported to occur at low rates) and animal-to-human transmission (<xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>; <xref rid="B6" ref-type="bibr">Ahmed et al., 2020</xref>; <xref rid="B27" ref-type="bibr">Amaechi et al., 2020</xref>; <xref rid="B38" ref-type="bibr">Arslan et al., 2020</xref>; <xref rid="B44" ref-type="bibr">Aydillo et al., 2020</xref>; <xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B85" ref-type="bibr">Bonato et al., 2020</xref>; <xref rid="B91" ref-type="bibr">Brann et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B110" ref-type="bibr">Carvalho et al., 2020</xref>; <xref rid="B121" ref-type="bibr">Chang et al., 2020</xref>; <xref rid="B135" ref-type="bibr">Cheung et al., 2020</xref>; <xref rid="B185" ref-type="bibr">Dona et al., 2020</xref>; <xref rid="B200" ref-type="bibr">Eslami and Jalili, 2020</xref>; <xref rid="B244" ref-type="bibr">Grassia et al., 2020</xref>; <xref rid="B246" ref-type="bibr">Guan et al., 2020</xref>; <xref rid="B251" ref-type="bibr">Guo et al., 2020c</xref>; <xref rid="B281" ref-type="bibr">Hoffmann et al., 2020b</xref>; <xref rid="B292" ref-type="bibr">Huang et al., 2020a</xref>; <xref rid="B302" ref-type="bibr">International-Committee-on-Taxonomy-of-Viruses, 2020</xref>; <xref rid="B317" ref-type="bibr">Jin et al., 2020</xref>; <xref rid="B344" ref-type="bibr">Khanh et al., 2020</xref>; <xref rid="B387" ref-type="bibr">Lechien et al., 2020</xref>; <xref rid="B390" ref-type="bibr">Lednicky et al., 2020</xref>; <xref rid="B401" ref-type="bibr">Lescure et al., 2020</xref>; <xref rid="B448" ref-type="bibr">MacIntyre and Ananda-Rajah, 2020</xref>; <xref rid="B489" ref-type="bibr">Mondelli et al., 2020</xref>; <xref rid="B518" ref-type="bibr">Nishiyama et al., 2020</xref>; <xref rid="B524" ref-type="bibr">Nzediegwu and Chang, 2020</xref>; <xref rid="B549" ref-type="bibr">Pastorino et al., 2020</xref>; <xref rid="B573" ref-type="bibr">Poggio et al., 2020</xref>; <xref rid="B614" ref-type="bibr">Rothe et al., 2020</xref>; <xref rid="B633" ref-type="bibr">Santarpia et al., 2020</xref>; <xref rid="B654" ref-type="bibr">Shereen et al., 2020</xref>; <xref rid="B722" ref-type="bibr">van Doremalen et al., 2020</xref>; <xref rid="B738" ref-type="bibr">Voskarides, 2020</xref>; <xref rid="B752" ref-type="bibr">Wang et al., 2020f</xref>; <xref rid="B789" ref-type="bibr">Xu et al., 2020a</xref>; <xref rid="B22" ref-type="bibr">Al-Sharif et al., 2021</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>; <xref rid="B79" ref-type="bibr">Birkhead et al., 2021</xref>; <xref rid="B119" ref-type="bibr">Chan et al., 2021</xref>; <xref rid="B125" ref-type="bibr">Chaubey et al., 2021</xref>; <xref rid="B126" ref-type="bibr">Chaudhary et al., 2021</xref>; <xref rid="B150" ref-type="bibr">Conti et al., 2021</xref>; <xref rid="B159" ref-type="bibr">Cuicchi et al., 2021</xref>; <xref rid="B190" ref-type="bibr">Dumitriu et al., 2021</xref>; <xref rid="B372" ref-type="bibr">Kumar et al., 2021</xref>; <xref rid="B376" ref-type="bibr">Kutter et al., 2021</xref>; <xref rid="B506" ref-type="bibr">Musa et al., 2021</xref>; <xref rid="B554" ref-type="bibr">Peacock et al., 2021a</xref>; <xref rid="B636" ref-type="bibr">Sawatzki et al., 2021</xref>; <xref rid="B656" ref-type="bibr">Shimabukuro, 2021</xref>; <xref rid="B716" ref-type="bibr">Valencak et al., 2021</xref>; <xref rid="B801" ref-type="bibr">Yang et al., 2021a</xref>; <xref rid="B808" ref-type="bibr">Zaneti et al., 2021</xref>; <xref rid="B120" ref-type="bibr">Chan et al., 2022</xref>; <xref rid="B155" ref-type="bibr">Costa et al., 2022</xref>; <xref rid="B171" ref-type="bibr">de Oliveira-Filho et al., 2022</xref>; <xref rid="B310" ref-type="bibr">Jairak et al., 2022</xref>; <xref rid="B333" ref-type="bibr">Kang et al., 2022</xref>; <xref rid="B339" ref-type="bibr">Katona et al., 2022</xref>; <xref rid="B377" ref-type="bibr">Kyle et al., 2022</xref>; <xref rid="B550" ref-type="bibr">Patane et al., 2022</xref>; <xref rid="B556" ref-type="bibr">Pecora et al., 2022</xref>; <xref rid="B741" ref-type="bibr">Wake, 2022</xref>; <xref rid="B771" ref-type="bibr">WHO, 2022</xref>). The average size of this virus is 60&#8211;140&#160;nm with a volume of about 10<sup>6</sup>&#160;nm<sup>3</sup> (<xref rid="B58" ref-type="bibr">Bar-On et al., 2020</xref>; <xref rid="B829" ref-type="bibr">Zhu et al., 2020c</xref>). The likelihood of airborne transmission is very low unless droplets (less than 5&#160;&#956;m in diameter) are contaminated with the virus and remain in the air for long periods. The air transports exhaled droplets that might contain the virus, when expired, the liquid content evaporates, diminishing their size. These small droplets are free to travel in the air, thereby being easily transported by air currents, carrying their viral content several meters from where they originated and occupying the entire volume of a room (<xref rid="B88" ref-type="bibr">Bourouiba, 2020</xref>; <xref rid="B645" ref-type="bibr">Setti et al., 2020</xref>). SARS-CoV-2 is highly stable in aerosol and on surfaces compared to SARS-CoV-1, maintaining the virus infectious for hours in the aerosol (<xref rid="B31" ref-type="bibr">Anfinrud et al., 2020</xref>; <xref rid="B492" ref-type="bibr">Morawska and Cao, 2020</xref>; <xref rid="B553" ref-type="bibr">Paules et al., 2020</xref>; <xref rid="B722" ref-type="bibr">van Doremalen et al., 2020</xref>; <xref rid="B530" ref-type="bibr">Ong et al., 2021</xref>). These facts imply that in the absence of face masks the distance of 1&#8211;2&#160;m among people is not enough to safeguard from SARS-CoV-2 infection risk (<xref rid="B547" ref-type="bibr">Parshina-Kottas et al., 2020</xref>), as it has been reported to happen in hospitals (i.e., SARS-CoV-2 RNA has been detected in air samples collected inside the hospitals, thereby the airborne route has to be considered an important pathway for contamination), schools and other indoors spaces (<xref rid="B424" ref-type="bibr">Liu et al., 2020f</xref>; <xref rid="B519" ref-type="bibr">Nissen et al., 2020</xref>; <xref rid="B633" ref-type="bibr">Santarpia et al., 2020</xref>; <xref rid="B8" ref-type="bibr">Akhmetzhanov et al., 2021</xref>; <xref rid="B124" ref-type="bibr">Chau et al., 2021</xref>; <xref rid="B182" ref-type="bibr">Ding et al., 2021</xref>; <xref rid="B372" ref-type="bibr">Kumar et al., 2021</xref>; <xref rid="B374" ref-type="bibr">Kumari et al., 2021</xref>; <xref rid="B396" ref-type="bibr">Leeman et al., 2022</xref>; <xref rid="B457" ref-type="bibr">Marchese et al., 2021</xref>; <xref rid="B483" ref-type="bibr">Miyoshi et al., 2021</xref>; <xref rid="B504" ref-type="bibr">Murewanhema et al., 2021</xref>; <xref rid="B530" ref-type="bibr">Ong et al., 2021</xref>; <xref rid="B627" ref-type="bibr">Salmenjoki et al., 2021</xref>; <xref rid="B630" ref-type="bibr">Sami et al., 2021</xref>; <xref rid="B631" ref-type="bibr">San et al., 2021</xref>; <xref rid="B325" ref-type="bibr">Jung et al., 2022</xref>; <xref rid="B357" ref-type="bibr">Kirsten et al., 2022</xref>; <xref rid="B380" ref-type="bibr">Ladhani et al., 2022</xref>; <xref rid="B399" ref-type="bibr">Leng et al., 2022</xref>; <xref rid="B507" ref-type="bibr">Nagy et al., 2022</xref>; <xref rid="B575" ref-type="bibr">Polechova et al., 2022</xref>; <xref rid="B732" ref-type="bibr">Viner et al., 2022</xref>; <xref rid="B767" ref-type="bibr">White et al., 2022</xref>). Therefore, SARS-CoV-2 is transmitted by bioaerosols (&lt;10&#160;&#956;m) and droplets (&gt;10&#160;&#956;m) projected during breathing, speaking and coughing (<xref rid="B361" ref-type="bibr">Klompas et al., 2020a</xref>; <xref rid="B78" ref-type="bibr">Binder et al., 2020</xref>; <xref rid="B424" ref-type="bibr">Liu et al., 2020f</xref>; <xref rid="B519" ref-type="bibr">Nissen et al., 2020</xref>; <xref rid="B722" ref-type="bibr">van Doremalen et al., 2020</xref>; <xref rid="B811" ref-type="bibr">Zhang and Duchaine, 2020</xref>; <xref rid="B23" ref-type="bibr">Alsved et al., 2022</xref>), with an estimation of about 4.8&#215;10<sup>5</sup> virus gene copies/mL in bioaerosol samples (<xref rid="B115" ref-type="bibr">Cevik et al., 2021</xref>; <xref rid="B452" ref-type="bibr">Malik et al., 2021</xref>; <xref rid="B320" ref-type="bibr">Johnson et al., 2022</xref>).</p><p>On the other hand, we must consider that with SARS-CoV-2, it has been shown that contagiousness commonly occurs before developing any symptom (<xref rid="B35" ref-type="bibr">Arons et al., 2020</xref>; <xref rid="B825" ref-type="bibr">Zhou et al., 2020b</xref>; <xref rid="B385" ref-type="bibr">Le et al., 2020</xref>; <xref rid="B481" ref-type="bibr">Mirjalali et al., 2020</xref>; <xref rid="B485" ref-type="bibr">Moghadas et al., 2020</xref>; <xref rid="B48" ref-type="bibr">Bae et al., 2021</xref>; <xref rid="B500" ref-type="bibr">Muller, 2021</xref>; <xref rid="B503" ref-type="bibr">Murata et al., 2021</xref>; <xref rid="B773" ref-type="bibr">Wilmes et al., 2021</xref>; <xref rid="B205" ref-type="bibr">Fakhruddin et al., 2022</xref>; <xref rid="B498" ref-type="bibr">Mugglestone et al., 2022</xref>; <xref rid="B540" ref-type="bibr">Overton et al., 2022</xref>; <xref rid="B565" ref-type="bibr">Pettifor et al., 2022</xref>; <xref rid="B593" ref-type="bibr">Rajme-Lopez et al., 2022</xref>), compared with seasonal flu, for example, where most transmissions occur after a person has developed symptoms (<xref rid="B404" ref-type="bibr">Leung et al., 2015b</xref>; <xref rid="B303" ref-type="bibr">Ip et al., 2017</xref>; <xref rid="B221" ref-type="bibr">Furuya-Kanamori and Yakob, 2018</xref>). The average SARS-CoV-2 incubation period is thought to be about 5&#160;days, while peak infectiousness begins 2&#160;days before symptoms reveal themselves (<xref rid="B797" ref-type="bibr">Yan et al., 2020b</xref>; <xref rid="B825" ref-type="bibr">Zhou et al., 2020b</xref>; <xref rid="B291" ref-type="bibr">Hua et al., 2020</xref>; <xref rid="B464" ref-type="bibr">McAloon et al., 2020</xref>; <xref rid="B520" ref-type="bibr">Noh et al., 2020</xref>; <xref rid="B688" ref-type="bibr">Tan et al., 2020</xref>; <xref rid="B48" ref-type="bibr">Bae et al., 2021</xref>; <xref rid="B503" ref-type="bibr">Murata et al., 2021</xref>; <xref rid="B798" ref-type="bibr">Yan et al., 2021</xref>). Moreover, viral loads in asymptomatic and symptomatic infected individuals have been reported to be similar (<xref rid="B35" ref-type="bibr">Arons et al., 2020</xref>; <xref rid="B393" ref-type="bibr">Lee et al., 2020b</xref>; <xref rid="B825" ref-type="bibr">Zhou et al., 2020b</xref>; <xref rid="B279" ref-type="bibr">Hoehl et al., 2020</xref>; <xref rid="B354" ref-type="bibr">Kimball et al., 2020</xref>; <xref rid="B365" ref-type="bibr">Kociolek et al., 2020</xref>; <xref rid="B385" ref-type="bibr">Le et al., 2020</xref>; <xref rid="B665" ref-type="bibr">Sohn et al., 2020</xref>; <xref rid="B710" ref-type="bibr">Uhm et al., 2020</xref>; <xref rid="B833" ref-type="bibr">Zou et al., 2020</xref>; <xref rid="B265" ref-type="bibr">Hasanoglu et al., 2021</xref>; <xref rid="B592" ref-type="bibr">Ra et al., 2021</xref>; <xref rid="B621" ref-type="bibr">Sah et al., 2021</xref>; <xref rid="B834" ref-type="bibr">Zuin et al., 2021</xref>), as the efficiency to transmit the virus (<xref rid="B410" ref-type="bibr">Li et al., 2020a</xref>; <xref rid="B35" ref-type="bibr">Arons et al., 2020</xref>; <xref rid="B777" ref-type="bibr">Wong et al., 2020a</xref>; <xref rid="B47" ref-type="bibr">Bae et al., 2020</xref>; <xref rid="B226" ref-type="bibr">Gao et al., 2020b</xref>; <xref rid="B351" ref-type="bibr">Kim et al., 2020b</xref>; <xref rid="B411" ref-type="bibr">Li et al., 2020b</xref>; <xref rid="B588" ref-type="bibr">Qian et al., 2020b</xref>; <xref rid="B825" ref-type="bibr">Zhou et al., 2020b</xref>; <xref rid="B167" ref-type="bibr">Day, 2020</xref>; <xref rid="B753" ref-type="bibr">Wang et al., 2020g</xref>; <xref rid="B262" ref-type="bibr">Hao et al., 2020</xref>; <xref rid="B268" ref-type="bibr">He et al., 2020</xref>; <xref rid="B316" ref-type="bibr">Jiang et al., 2020</xref>; <xref rid="B485" ref-type="bibr">Moghadas et al., 2020</xref>; <xref rid="B607" ref-type="bibr">Rivett et al., 2020</xref>; <xref rid="B665" ref-type="bibr">Sohn et al., 2020</xref>; <xref rid="B235" ref-type="bibr">Glenet et al., 2021</xref>; <xref rid="B265" ref-type="bibr">Hasanoglu et al., 2021</xref>; <xref rid="B321" ref-type="bibr">Joshi et al., 2021</xref>; <xref rid="B548" ref-type="bibr">Passarelli et al., 2021</xref>; <xref rid="B621" ref-type="bibr">Sah et al., 2021</xref>). Hence, the majority of infections occur pre-symptomatically, with the infected people ignoring that they have the disease (<xref rid="B211" ref-type="bibr">Ferretti et al., 2020</xref>; <xref rid="B268" ref-type="bibr">He et al., 2020</xref>; <xref rid="B485" ref-type="bibr">Moghadas et al., 2020</xref>).</p><p>In this pandemic scenario, the most basic method of prevention against COVID-19 is therefore to wear face masks (<xref rid="B288" ref-type="bibr">Howard et al., 2021</xref>; <xref rid="B322" ref-type="bibr">Ju et al., 2021</xref>). The face mask must be worn by either non-infected or infected people (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Thus, in infected individuals, facemasks could prevent the aerosol spread of the virus to other people, whereas the mask could protect against SARS-CoV-2 in non-infected individuals by covering their faces (<xref rid="B566" ref-type="bibr">Pezzini and Padovani, 2020</xref>; <xref rid="B112" ref-type="bibr">Catching et al., 2021</xref>). Face masks retain on their surface of the textile the virus and the constant use of this PPE (protective personal equipment) forces to renew the mask constantly, particularly in people who are exposed to the virus as in shops, pharmacies, schools, administration buildings, offices and hospitals, among other professions and sensitive infrastructures to reduce viral transmission and infection (<xref rid="B72" ref-type="bibr">Beesoon et al., 2020</xref>; <xref rid="B632" ref-type="bibr">Sanchez et al., 2020</xref>; <xref rid="B217" ref-type="bibr">Forum, 2020</xref>; <xref rid="B233" ref-type="bibr">Gholami et al., 2021</xref>; <xref rid="B288" ref-type="bibr">Howard et al., 2021</xref>; <xref rid="B301" ref-type="bibr">Ingram et al., 2021</xref>; <xref rid="B402" ref-type="bibr">Lessler et al., 2021</xref>). N95 and filtering facepiece 2 and 3 (FFP2 and FFP3) respirators that can filter from 95 to 99% of airborne particles, respectively, and surgical masks (filters around 80% of contaminants of certain size) are the most common face masks used during COVID-19 pandemics which provide protection against the airborne virus and larger infectious particles (<xref rid="B63" ref-type="bibr">Bartoszko et al., 2020</xref>; <xref rid="B337" ref-type="bibr">Karim et al., 2020</xref>; <xref rid="B667" ref-type="bibr">Sommerstein et al., 2020</xref>; <xref rid="B146" ref-type="bibr">Clinkard et al., 2021</xref>; <xref rid="B179" ref-type="bibr">Dheda et al., 2021</xref>; <xref rid="B602" ref-type="bibr">Regli et al., 2021</xref>; <xref rid="B611" ref-type="bibr">Rohit et al., 2021</xref>) (<xref rid="F2" ref-type="fig">Figure 2A</xref>). These face masks have also been improved by using nanomaterials that present antimicrobial and antiviral properties, such as nanoparticles (NPs) (i.e., melt-blown polypropylene and nylon-cotton with antiviral zinc oxide-NPs) (<xref rid="B240" ref-type="bibr">Gonzalez et al., 2021</xref>), metal NPs (i.e., silver NPs (AgNPs)) (<xref rid="B715" ref-type="bibr">Valdez-Salas et al., 2021</xref>), spray or polymers of copper, gold, silver, zinc oxide (this could be washed and reused) or TiO<sub>2</sub> (TiO<sub>2</sub>Ag-based facemasks are able to degrade 99.99% of viruses under zero light conditions) (<xref rid="B53" ref-type="bibr">Balagna et al., 2020</xref>; <xref rid="B367" ref-type="bibr">Konda et al., 2020</xref>; <xref rid="B450" ref-type="bibr">Mahapatra et al., 2020</xref>; <xref rid="B515" ref-type="bibr">Nickels, 2020</xref>; <xref rid="B673" ref-type="bibr">Sportelli et al., 2020</xref>; <xref rid="B754" ref-type="bibr">Wang et al., 2021a</xref>; <xref rid="B511" ref-type="bibr">Nbic+, 2022</xref>; <xref rid="B584" ref-type="bibr">Promethean-Particles-Ltd, 2022</xref>; <xref rid="B671" ref-type="bibr">Sonovia-SonoMask, 2022</xref>), in order to stop the virus transmission chain (<xref rid="F2" ref-type="fig">Figure 2A</xref>). These metal oxide-derived NPs, embedded in face masks, act as antiviral or, in general, as antimicrobial compounds by inhibiting the catalytic activity of the microorganisms&#8217; enzymes (i.e, viral polymerases and proteinases), which are key for their survival and pathogenicity (<xref rid="B99" ref-type="bibr">Cai et al., 2019</xref>; <xref rid="B754" ref-type="bibr">Wang et al., 2021a</xref>; <xref rid="B469" ref-type="bibr">Melk et al., 2021</xref>; <xref rid="B542" ref-type="bibr">Pachaiappan et al., 2021</xref>; <xref rid="B471" ref-type="bibr">Mendes et al., 2022</xref>). Moreover, due to their small size, these metal oxide-derived NPs enhance the surface contact with viruses and bacteria, as reported for Ag-TiO<sub>2</sub> single atom nanozyme (SAN) that allows efficient adsorption for SARS-CoV2 through the association of Ag atoms with Cys and Asn residues of the RBD sequence of the viral S1 subunit (<xref rid="B754" ref-type="bibr">Wang et al., 2021a</xref>). These metal oxide-derived NPs, in contact with virus could also trigger the formation of reactive oxygen species (i.e., hydrogen peroxide anions and superoxide radical anions) which cause damage to the viral membranes and cell wall of bacteria, as well as to internal components, thereby impairing their uncoating, growth and integrity (<xref rid="B99" ref-type="bibr">Cai et al., 2019</xref>; <xref rid="B260" ref-type="bibr">Hamza et al., 2021</xref>; <xref rid="B469" ref-type="bibr">Melk et al., 2021</xref>; <xref rid="B542" ref-type="bibr">Pachaiappan et al., 2021</xref>; <xref rid="B471" ref-type="bibr">Mendes et al., 2022</xref>). Noteworthy, the effects of these metal oxide-derived NPs could depend on their composition and dose (<xref rid="B807" ref-type="bibr">Zanet et al., 2019</xref>; <xref rid="B754" ref-type="bibr">Wang et al., 2021a</xref>). Therefore, the use of these NPs, polymers and sprays for face masks production or treatment implies accurate techniques and procedures, in order to assure the maximal protection of face masks against SARS-CoV-2.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Nanomaterials used for protective personal equipment. <bold>(A)</bold> FFP2/NP95 masks are the appropriate protective respirators against this virus mainly transmitted by aerosol compared with surgical masks. Face masks and PPE robes have been incorporated nanoreagents and nanomaterials to improve personal protection against SARS-CoV-2 airborne infection and transmission to neutralize the virus in contact with these personal equipments. These nanomaterials are indicated in panel <bold>(A)</bold>. <bold>(B)</bold> Personal training and correct protocols for wearing (applying) and removing these PPEs from the body are critical to ensure right protection of health personnel against SARS-CoV-2 infection. Designs and templates are created with BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fbioe-10-1052436-g002.jpg"/></fig><p>All these nanoparticles are also used to produce PPE robe (<xref rid="B601" ref-type="bibr">Reddy et al., 2019</xref>; <xref rid="B68" ref-type="bibr">Bauchner et al., 2020</xref>; <xref rid="B314" ref-type="bibr">JH et al., 2020</xref>; <xref rid="B532" ref-type="bibr">Ortega et al., 2020</xref>) (<xref rid="F2" ref-type="fig">Figure 2B</xref>), where PPE innovation will also help to overcome the important COVID-19 PPE waste challenge (<xref rid="B299" ref-type="bibr">IFC, 2021</xref>). Face masks and PPE robes have been also improved to fight and prevent COVID-19/SARS-CoV-2 infection by using nanofibers to create a dense weblike surface area against infection in the PPEs (<xref rid="F2" ref-type="fig">Figure 2</xref>). These webs of nanofibers could nucleate some chemical reagents, such as &#946;-cyclodextrin and p-iodobenzoic acid that allow nanofibers to act against SARS-CoV-2, thereby degrading the virus and reducing the risk of inhaling the virus or to be contaminated by contact with masks or PPE robes carrying the virus (<xref rid="B596" ref-type="bibr">Ramaseshan et al., 2006</xref>; <xref rid="B326" ref-type="bibr">Kadam et al., 2021</xref>; <xref rid="B599" ref-type="bibr">Rasmi et al., 2021</xref>; <xref rid="B541" ref-type="bibr">Owida et al., 2022</xref>). The nanofibers could be also presented in a variety of layers, including a water repellent and a skin-friendly silk layer with a 98% filtration guide, leading to an efficient protective PPE mask or robe that avoid SARS-CoV-2 transmission and infection (<xref rid="B126" ref-type="bibr">Chaudhary et al., 2021</xref>). Moreover, it has been reported that SARS-CoV-2 can remain on fomites for more than 9&#160;days and potentially infectious (<xref rid="B328" ref-type="bibr">Kampf et al., 2020b</xref>; <xref rid="B96" ref-type="bibr">Bueckert et al., 2020</xref>; <xref rid="B286" ref-type="bibr">Hosseini et al., 2021</xref>; <xref rid="B456" ref-type="bibr">Marcenac et al., 2021</xref>). Therefore, several nanomaterials have been used to disinfect or remove this Sarbecovirus from different contaminated surfaces, such natural NPs-, metal NPs- and nanopolymers-based disinfectants (reviewed in (<xref rid="B672" ref-type="bibr">Souri et al., 2022</xref>)).</p></sec><sec id="s2-2"><title>2.2 COVID-19 vaccines by nano-based strategies: Prevention and treatment</title><p>Physical barriers are required and are therefore very useful to protect ourselves and the others from infection, contagion and community spreading of the virus, lowering the concomitant emergence of viral variants (<xref rid="B675" ref-type="bibr">St&#345;&#237;&#382;ov&#225; et al., 2020</xref>; <xref rid="B683" ref-type="bibr">Swain, 2020</xref>; <xref rid="B470" ref-type="bibr">Mello et al., 2022</xref>), which threatens individual and community immunity that might have been generated during previous infections or by vaccines (<xref rid="B36" ref-type="bibr">Arora et al., 2021</xref>; <xref rid="B83" ref-type="bibr">Boehm et al., 2021</xref>; <xref rid="B104" ref-type="bibr">Caniels et al., 2021</xref>; <xref rid="B37" ref-type="bibr">Arora et al., 2022</xref>; <xref rid="B624" ref-type="bibr">Salehi-Vaziri et al., 2022</xref>), as it has happened with the appearance of several Omicron VOCs (<xref rid="B108" ref-type="bibr">Cao et al., 2022</xref>; <xref rid="B212" ref-type="bibr">Flemming, 2022</xref>; <xref rid="B255" ref-type="bibr">Hachmann et al., 2022</xref>). Therefore, vaccines are the tools to elicit immunity against SARS-CoV-2 infection, reinfection by VOCs and severe COVID-19 disease, where face masks enhance vaccine efficiency in this crucial community and worldwide task. The community use of face masks therefore lower both virus transmission rates and the severity of the disease allowing to save more lives (<xref rid="B362" ref-type="bibr">Klompas et al., 2020b</xref>; <xref rid="B201" ref-type="bibr">Esposito et al., 2020</xref>; <xref rid="B223" ref-type="bibr">Gandhi and Rutherford, 2020</xref>; <xref rid="B405" ref-type="bibr">Leung et al., 2020</xref>). Likewise, it should be considered that combining vaccination and face masks is much less costly to apply than the use of a plethora of non-efficient drugs together with hospital intensive cares measures which are associated with high economic, social and live costs (<xref rid="B72" ref-type="bibr">Beesoon et al., 2020</xref>; <xref rid="B201" ref-type="bibr">Esposito et al., 2020</xref>; <xref rid="B232" ref-type="bibr">George et al., 2020</xref>; <xref rid="B243" ref-type="bibr">Grasselli et al., 2020</xref>; <xref rid="B275" ref-type="bibr">Hill et al., 2020</xref>; <xref rid="B297" ref-type="bibr">Iannaccone et al., 2020</xref>; <xref rid="B400" ref-type="bibr">Lerner et al., 2020</xref>; <xref rid="B612" ref-type="bibr">Rosenthal et al., 2020</xref>; <xref rid="B646" ref-type="bibr">Shaffer, 2020</xref>; <xref rid="B662" ref-type="bibr">Singh et al., 2020</xref>; <xref rid="B145" ref-type="bibr">Cleary et al., 2021</xref>; <xref rid="B180" ref-type="bibr">Di Fusco et al., 2021</xref>; <xref rid="B366" ref-type="bibr">Kompaniyets et al., 2021</xref>; <xref rid="B528" ref-type="bibr">Ohsfeldt et al., 2021</xref>; <xref rid="B64" ref-type="bibr">Bartsch et al., 2022</xref>; <xref rid="B94" ref-type="bibr">Br&#252;ssow and Zuber, 2022</xref>; <xref rid="B579" ref-type="bibr">Popescu et al., 2022</xref>).</p><p>Before presenting the different vaccine designs used against SARS-CoV-2/COVID-19, we summarize the immune responses elicited against SARS-CoV-2 infection and how the virus pervert immune protection leading to the COVID-19 pathology.</p><p>The innate immune responses are rapidly developed against this Sarbecovirus which very early during the infection leads to the production of type I interferons (IFNs), key antiviral cytokines that induce a large range of proteins that impair viral replication in infected cells (<xref rid="B431" ref-type="bibr">Lokugamage et al., 2020</xref>; <xref rid="B449" ref-type="bibr">Madden and Diamond, 2022</xref>). SARS-CoV-2 evades the host innate immune system by reducing IFN levels, its mediated signals and activation pathways through different SARS-CoV-2 proteins (<xref rid="B657" ref-type="bibr">Shin et al., 2020a</xref>; <xref rid="B397" ref-type="bibr">Lei et al., 2020</xref>; <xref rid="B480" ref-type="bibr">Miorin et al., 2020</xref>; <xref rid="B784" ref-type="bibr">Xia et al., 2020</xref>; <xref rid="B756" ref-type="bibr">Wang et al., 2021c</xref>; <xref rid="B757" ref-type="bibr">Wang et al., 2021d</xref>; <xref rid="B267" ref-type="bibr">Hayn et al., 2021</xref>; <xref rid="B355" ref-type="bibr">Kimura et al., 2021</xref>; <xref rid="B479" ref-type="bibr">Min et al., 2021</xref>; <xref rid="B502" ref-type="bibr">Munnur et al., 2021</xref>; <xref rid="B597" ref-type="bibr">Rashid et al., 2021</xref>; <xref rid="B726" ref-type="bibr">Vazquez et al., 2021</xref>; <xref rid="B136" ref-type="bibr">Chiale et al., 2022</xref>; <xref rid="B526" ref-type="bibr">Oh and Shin, 2022</xref>; <xref rid="B535" ref-type="bibr">Osipiuk et al., 2022</xref>; <xref rid="B832" ref-type="bibr">Znaidia et al., 2022</xref>). Moreover, genetic and immunological defects in the type-I IFN responses are known to cause fatal outcomes in otherwise healthy SARS-CoV-2 infected patients (<xref rid="B815" ref-type="bibr">Zhang et al., 2020d</xref>; <xref rid="B818" ref-type="bibr">Zhang et al., 2022a</xref>). Likewise, SARS-CoV-2 escape the translation inhibition as a result of some viral proteins (i.e., Nsp14 with the concert of Nsp10) (<xref rid="B290" ref-type="bibr">Hsu et al., 2021</xref>) and mRNAs that elude translation inhibition by a stem loop structure in the 5&#697; untranslated region (UTR) of all viral transcripts (<xref rid="B701" ref-type="bibr">Tidu et al., 2020</xref>).</p><p>Adaptative immune responses against SARS-CoV-2 antigens are important to control viral infection and the severity of the COVID-19 disease (<xref rid="B617" ref-type="bibr">Rydyznski Moderbacher et al., 2020</xref>). Specific and effective CD8<sup>+</sup>&#8201;T cell response is associated with viral clearance and mild disease (<xref rid="B74" ref-type="bibr">Bergamaschi et al., 2021</xref>; <xref rid="B522" ref-type="bibr">Notarbartolo et al., 2021</xref>). In acute COVID-19, effective CD8<sup>+</sup> and CD4<sup>+</sup> T cell responses are associated with positive clinical outcomes (<xref rid="B181" ref-type="bibr">Diao et al., 2020</xref>; <xref rid="B677" ref-type="bibr">Su et al., 2020</xref>; <xref rid="B522" ref-type="bibr">Notarbartolo et al., 2021</xref>; <xref rid="B605" ref-type="bibr">Rha et al., 2021</xref>). This T cell activation is also observed in asymptomatic SARS-CoV-2 infected individuals (<xref rid="B245" ref-type="bibr">Grau-Exposito et al., 2021</xref>; <xref rid="B384" ref-type="bibr">Le Bert et al., 2021</xref>). However, exacerbated T cell responses could exhaust these immune cells, being associated with poor clinical outcomes (<xref rid="B443" ref-type="bibr">Lucas et al., 2020b</xref>; <xref rid="B181" ref-type="bibr">Diao et al., 2020</xref>; <xref rid="B460" ref-type="bibr">Mathew et al., 2020</xref>; <xref rid="B668" ref-type="bibr">Song et al., 2020</xref>; <xref rid="B677" ref-type="bibr">Su et al., 2020</xref>), particularly in patients presenting comorbidities (<xref rid="B443" ref-type="bibr">Lucas et al., 2020b</xref>; <xref rid="B806" ref-type="bibr">Yu et al., 2021</xref>). In fact, humoral response has been reported to be retarded in patients with severe COVID-19 and in fatal outcomes (<xref rid="B444" ref-type="bibr">Lucas et al., 2021</xref>). Follicular T and B cell cooperation in germinal centers (GCs) are key to create specific memory cells against viral antigens and humoral and cellular long-lasting repertoires and responses (<xref rid="B19" ref-type="bibr">Allen et al., 2007</xref>; <xref rid="B369" ref-type="bibr">Kr&#228;utler et al., 2017</xref>; <xref rid="B160" ref-type="bibr">Cyster and Allen, 2019</xref>). Severe SARS-CoV-2 infection and illness have been associated with the absence of GCs (<xref rid="B330" ref-type="bibr">Kaneko et al., 2020</xref>) as observed by the decrease in the number of T follicular cells. This could be in agreement with the robust extrafollicular B cell responses with concomitant increase in proinflammatory cytokine levels and the neutralizing antibody titers observed in severe COVID-19 patients with critical pneumonia (<xref rid="B779" ref-type="bibr">Woodruff et al., 2020</xref>), where delayed production and responses of specific neutralizing antibodies (nAbs) (<xref rid="B444" ref-type="bibr">Lucas et al., 2021</xref>) and the pre-existence of type-I IFN auto-Abs (<xref rid="B66" ref-type="bibr">Bastard et al., 2020</xref>; <xref rid="B67" ref-type="bibr">Bastard et al., 2021</xref>; <xref rid="B755" ref-type="bibr">Wang et al., 2021b</xref>) have been reported.</p><p>Therefore, effective vaccine designs against SARS-CoV-2 infection and COVID-19 disease should induce robust and persistent GC reactions, in order to generate high-affinity and durable neutralizing antibody responses together with T cell memory coordinated responses and reservoir (<xref rid="B93" ref-type="bibr">Brouwer et al., 2020</xref>; <xref rid="B307" ref-type="bibr">Jagannathan and Wang, 2021</xref>; <xref rid="B694" ref-type="bibr">Teijaro and Farber, 2021</xref>; <xref rid="B709" ref-type="bibr">Turner et al., 2021</xref>; <xref rid="B774" ref-type="bibr">Winkler et al., 2021</xref>). Innovative nanovaccine formulations, as we further describe, have demonstrated to successfully achieve optimal activation of both innate and adaptive immune responses against SARS-CoV-2 infection (i.e., mRNA vaccines-mediated GC-B cell response to SARS-CoV-2 (<xref rid="B388" ref-type="bibr">Lederer et al., 2020</xref>; <xref rid="B709" ref-type="bibr">Turner et al., 2021</xref>; <xref rid="B381" ref-type="bibr">Laidlaw and Ellebedy, 2022</xref>)), in order to achieve herd immunity (reviewed in (<xref rid="B658" ref-type="bibr">Shin et al., 2020b</xref>; <xref rid="B127" ref-type="bibr">Chauhan et al., 2020</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>; <xref rid="B149" ref-type="bibr">Constantin et al., 2021</xref>; <xref rid="B447" ref-type="bibr">Machhi et al., 2021</xref>; <xref rid="B248" ref-type="bibr">Guerrini et al., 2022</xref>)). Apart from the efficacy and immunogenicity of vaccines, safety and protection against reinfections are other challenges that must be considered in the development of vaccines (<xref rid="B770" ref-type="bibr">WHO, 2020</xref>; <xref rid="B130" ref-type="bibr">Chen et al., 2021b</xref>; <xref rid="B427" ref-type="bibr">Liu et al., 2021c</xref>; <xref rid="B266" ref-type="bibr">Hasanzadeh et al., 2021</xref>; <xref rid="B694" ref-type="bibr">Teijaro and Farber, 2021</xref>). The spike (S) gene/protein of SARS-CoV-2 has been chosen as the main antigen to design vaccines to immunize, either by itself (i.e., in form of mRNA or derived DNA gene or recombinant protein) or present as protein in attenuated or inactive viral particles or in viral like particles (VLPs) (<xref rid="B273" ref-type="bibr">Heinz and Stiasny, 2021</xref>; <xref rid="B459" ref-type="bibr">Martinez-Flores et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>), because the targeting of this protein with vaccine-elicited nAbs could be important to impair the entry of the virus into the host cells and cause infection (<xref rid="F3" ref-type="fig">Figure 3B</xref>, <italic toggle="yes">see inbox: nAbs action in the S-tertiary structure</italic>), therefore, inhibiting viral replication, spread and cause the disease (<xref rid="B93" ref-type="bibr">Brouwer et al., 2020</xref>; <xref rid="B152" ref-type="bibr">Corbett et al., 2021</xref>; <xref rid="B194" ref-type="bibr">Earle et al., 2021</xref>; <xref rid="B346" ref-type="bibr">Khoury et al., 2021</xref>; <xref rid="B467" ref-type="bibr">McMahan et al., 2021</xref>) (see <xref rid="F1" ref-type="fig">Figure 1A,B</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Nano-based COVID-19 vaccines. <bold>(A)</bold> The scheme summarizes the different nano-based strategies used for immunization against SARS-CoV-2 infection and severe COVID-19 based or different nanomaterials and reagents to deliver the modified viral genome (coding for the immunogen S protein) and recombinant immunogen S protein or its subunits, such as the LNP-mRNA vaccines, the rAd vectors containing the DNA S gene, chemically inactivated SARS-CoV-2 viral particles, VLPs bearing recombinant S protein, and recombinant subunit vaccines (i.e., adapted full-length S protein or fragments as the RBD region) in emulsion with nanoreagents. All nanomaterials and nanotechnology used for vaccine development are indicated in the different vaccine strategies. <bold>(B)</bold> Schemes represent the primary and tertiary structures of the S viral protein, used as immunogen for vaccine developments, stabilized in its prefusion state by two key protein mutations (K986P and V987P; named S-2P immunogen) and modifying the polybasic domain (RRAR) to render it non-cleavable by the furin proteinase. The S protein domains and its trimeric organization on virus membrane and on infected-cell plasma membrane are shown, together with the RBD sequence where nAbs bind to neutralize SARS-CoV-2/ACE2 interaction and subsequent virus infection. The S-associated modifications introduced by the different vaccine designs are indicated. Designs and templates are created with BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fbioe-10-1052436-g003.jpg"/></fig><p>The design and generation of the above indicated genomic or protein-based viral immunogens are part of the nanotechnology employed for vaccination (<xref rid="B127" ref-type="bibr">Chauhan et al., 2020</xref>; <xref rid="B750" ref-type="bibr">Wang et al., 2020d</xref>), summarized in <xref rid="F3" ref-type="fig">Figure 3</xref>. Moreover, nano-based technology used for vaccine formulation and immunogen administration has been useful to achieve specific anti-viral immune responses and facilitate the positive outcome from severe SARS-CoV-2 infection and illness (<xref rid="B369" ref-type="bibr">Kr&#228;utler et al., 2017</xref>; <xref rid="B29" ref-type="bibr">Anderson et al., 2020</xref>; <xref rid="B744" ref-type="bibr">Walsh et al., 2020a</xref>; <xref rid="B745" ref-type="bibr">Walsh et al., 2020b</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>; <xref rid="B304" ref-type="bibr">Jackson et al., 2020</xref>; <xref rid="B501" ref-type="bibr">Mulligan et al., 2020</xref>; <xref rid="B574" ref-type="bibr">Polack et al., 2020</xref>; <xref rid="B270" ref-type="bibr">Heath et al., 2021</xref>; <xref rid="B473" ref-type="bibr">Meo et al., 2021</xref>; <xref rid="B709" ref-type="bibr">Turner et al., 2021</xref>; <xref rid="B713" ref-type="bibr">Vahedifard and Chakravarthy, 2021</xref>; <xref rid="B772" ref-type="bibr">Widge et al., 2021</xref>; <xref rid="B705" ref-type="bibr">Toback et al., 2022</xref>). Indeed, the use of these NPs or reagents in vaccine designs protect the genomic o protein immunogen from fast degradation by host proteinases, thus enhancing their stability (<xref rid="B477" ref-type="bibr">Miles et al., 2005</xref>; <xref rid="B703" ref-type="bibr">Tinkle et al., 2014</xref>; <xref rid="B821" ref-type="bibr">Zhao et al., 2014</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>). Likewise, NPs facilitate the delivery of the vaccine in the organism and the further uptake of viral antigens by antigen-presenting cells (APCs) (<xref rid="B639" ref-type="bibr">Schwendener, 2014</xref>; <xref rid="B703" ref-type="bibr">Tinkle et al., 2014</xref>; <xref rid="B826" ref-type="bibr">Zhu et al., 2014</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>). Vaccine stability and solubility has been promoted by the use of NPs such as liposomes (<xref rid="B557" ref-type="bibr">Peek et al., 2008</xref>; <xref rid="B25" ref-type="bibr">Alving et al., 2016</xref>; <xref rid="B97" ref-type="bibr">Bulbake et al., 2017</xref>; <xref rid="B561" ref-type="bibr">Perrie et al., 2017</xref>), lipids (<xref rid="B664" ref-type="bibr">Sivakumar et al., 2011</xref>; <xref rid="B69" ref-type="bibr">Baz Morelli et al., 2012</xref>; <xref rid="B148" ref-type="bibr">Comber and Philip, 2014</xref>; <xref rid="B639" ref-type="bibr">Schwendener, 2014</xref>; <xref rid="B140" ref-type="bibr">Cibulski et al., 2016</xref>), biodegradable polymers (i.e., polyanhydride copolymers based on 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), 1,6-bis-(p-carboxyphenoxy)-hexane (CPH), and sebacic anhydride (SA)) or dendrimer-based formulations (<xref rid="B117" ref-type="bibr">Chahal et al., 2016</xref>; <xref rid="B740" ref-type="bibr">Wafa et al., 2017</xref>; <xref rid="B54" ref-type="bibr">Banerjee et al., 2019</xref>; <xref rid="B426" ref-type="bibr">Liu et al., 2021b</xref>) and emulsions (i.e., MF59<sup>&#174;</sup>, squalene and Montanide ISA&#8482;51) (<xref rid="B477" ref-type="bibr">Miles et al., 2005</xref>; <xref rid="B40" ref-type="bibr">Ascarateil and Dupuis, 2006</xref>; <xref rid="B174" ref-type="bibr">Della Cioppa et al., 2012</xref>; <xref rid="B527" ref-type="bibr">O'Hagan et al., 2013</xref>; <xref rid="B175" ref-type="bibr">Della Cioppa et al., 2014</xref>; <xref rid="B41" ref-type="bibr">Ascarateil et al., 2015</xref>; <xref rid="B647" ref-type="bibr">Shah et al., 2015</xref>; <xref rid="B721" ref-type="bibr">van Doorn et al., 2016</xref>; <xref rid="B335" ref-type="bibr">Kantipakala et al., 2019</xref>; <xref rid="B635" ref-type="bibr">Savoji et al., 2019</xref>). The nature or the physicochemical characteristics of these NPs determine the efficiency of antigen delivery and the potential adverse effects observed during immunization (reviewed in (<xref rid="B482" ref-type="bibr">Mitchell et al., 2021</xref>)). Thus, lipid-based NPs (LNPs), such as liposomes and emulsions, allow simplicity during NPs formulation and self-assembly, offering high biocompatibility, bioavailability, and flexibility to accommodate different antigen sizes (<xref rid="B215" ref-type="bibr">Fonseca-Santos et al., 2015</xref>; <xref rid="B643" ref-type="bibr">Sercombe et al., 2015</xref>), since LNPs could be modified for these purposes during synthesis (<xref rid="B26" ref-type="bibr">Alyautdin et al., 2014</xref>; <xref rid="B403" ref-type="bibr">Leung et al., 2015a</xref>; <xref rid="B643" ref-type="bibr">Sercombe et al., 2015</xref>; <xref rid="B634" ref-type="bibr">Sarfraz et al., 2018</xref>; <xref rid="B641" ref-type="bibr">Sedighi et al., 2019</xref>). Moreover, LNPs allow to deliver hydrophilic, hydrophobic or lipophilic agents, as well as lipophilic and hydrophilic compounds together in the same LNP preparation (<xref rid="B26" ref-type="bibr">Alyautdin et al., 2014</xref>; <xref rid="B215" ref-type="bibr">Fonseca-Santos et al., 2015</xref>; <xref rid="B643" ref-type="bibr">Sercombe et al., 2015</xref>; <xref rid="B641" ref-type="bibr">Sedighi et al., 2019</xref>). Although LNPs achieve low encapsulation efficiency, they are the most approved NP system for drug delivery (<xref rid="B210" ref-type="bibr">Fenton et al., 2018</xref>; <xref rid="B33" ref-type="bibr">Anselmo and Mitragotri, 2019</xref>), as occurred with the mRNA-based vaccines against SARS-CoV-2 infection and COVID-19 disease (reviewed in (<xref rid="B695" ref-type="bibr">Tenchov et al., 2021</xref>)). Natural (i.e., heparin, hyaluronan, chitosan or dextran (<xref rid="B433" ref-type="bibr">Lombardo et al., 2019</xref>; <xref rid="B831" ref-type="bibr">Zieli&#324;ska et al., 2020</xref>)) or synthetic [i.e., saturated poly (&#945;-hydroxy esters), such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and poly (lacticcoglycolide) (PLGA) (<xref rid="B660" ref-type="bibr">Shive and Anderson, 1997</xref>; <xref rid="B416" ref-type="bibr">Lin et al., 2012</xref>; <xref rid="B134" ref-type="bibr">Chenthamara et al., 2019</xref>; <xref rid="B224" ref-type="bibr">Gangapurwala et al., 2020</xref>; <xref rid="B831" ref-type="bibr">Zieli&#324;ska et al., 2020</xref>)] polymeric NPs, such as dendrimers or nanospheres, permit the precise control of the physicochemical particle characteristics, allowing posterior surface modifications and being flexible for hydrophilic and hydrophobic cargo accommodation (<xref rid="B334" ref-type="bibr">Kannan et al., 2014</xref>; <xref rid="B788" ref-type="bibr">Xu et al., 2014</xref>; <xref rid="B552" ref-type="bibr">Patra et al., 2018</xref>; <xref rid="B813" ref-type="bibr">Zhang et al., 2020b</xref>; <xref rid="B567" ref-type="bibr">Pinelli et al., 2020</xref>; <xref rid="B714" ref-type="bibr">Valcourt et al., 2020</xref>; <xref rid="B735" ref-type="bibr">Volpatti et al., 2020</xref>; <xref rid="B831" ref-type="bibr">Zieli&#324;ska et al., 2020</xref>). These characteristics together with their biocompatibility, biodegradability and low toxicity (<xref rid="B134" ref-type="bibr">Chenthamara et al., 2019</xref>; <xref rid="B433" ref-type="bibr">Lombardo et al., 2019</xref>; <xref rid="B567" ref-type="bibr">Pinelli et al., 2020</xref>) make polymeric NPs a good choice for vaccine delivery (<xref rid="B813" ref-type="bibr">Zhang et al., 2020b</xref>). Of note, these types of polymeric NPs could present a high degree of aggregation that could be toxic and difficult antigen delivery, therefore compromising the optimal antigen concentration in target cells and tissues for immunization (<xref rid="B364" ref-type="bibr">Knight et al., 2019</xref>; <xref rid="B831" ref-type="bibr">Zieli&#324;ska et al., 2020</xref>).</p><p>These NPs or vehicles also favor immunogenicity because they act as adjuvants triggering the immune cell activation and promoting immune responses (<xref rid="B40" ref-type="bibr">Ascarateil and Dupuis, 2006</xref>; <xref rid="B664" ref-type="bibr">Sivakumar et al., 2011</xref>; <xref rid="B69" ref-type="bibr">Baz Morelli et al., 2012</xref>; <xref rid="B826" ref-type="bibr">Zhu et al., 2014</xref>; <xref rid="B41" ref-type="bibr">Ascarateil et al., 2015</xref>; <xref rid="B725" ref-type="bibr">Varypataki et al., 2015</xref>; <xref rid="B25" ref-type="bibr">Alving et al., 2016</xref>; <xref rid="B140" ref-type="bibr">Cibulski et al., 2016</xref>; <xref rid="B341" ref-type="bibr">Khabazzadeh Tehrani et al., 2016</xref>; <xref rid="B561" ref-type="bibr">Perrie et al., 2017</xref>; <xref rid="B740" ref-type="bibr">Wafa et al., 2017</xref>; <xref rid="B342" ref-type="bibr">Khademi et al., 2018</xref>; <xref rid="B335" ref-type="bibr">Kantipakala et al., 2019</xref>; <xref rid="B635" ref-type="bibr">Savoji et al., 2019</xref>; <xref rid="B563" ref-type="bibr">Petkar et al., 2021</xref>). The NP surface could be modified by presenting monosaccharides (i.e., mannose) or immune ligands (i.e., toll-like receptor ligands), in order to improve elicited vaccine delivery of the immunogen and immune stimulation (<xref rid="B34" ref-type="bibr">Apostolopoulos et al., 2013</xref>).</p><p>In this scenario against SARS-CoV-2/COVID-19, LNPs have been developed and used to deliver and immunize with modified mRNA of the entire S protein or only the RBD segment of the viral glycoprotein (i.e., novel LNP-encapsulated mRNA based vaccine (<xref rid="B747" ref-type="bibr">Wang et al., 2020a</xref>) or LNP-encapsulated mRNA encoding RBD vaccine (<xref rid="B686" ref-type="bibr">Tai et al., 2020</xref>)) (<xref rid="F3" ref-type="fig">Figure 3A</xref>), or by using a self-amplifying RNA (saRNA or SAM) (<xref rid="B560" ref-type="bibr">Perri et al., 2003</xref>) that encodes the alphaviral replicase to drive the expression of a pre-fusion stabilized SARS-CoV-2 S-gene/protein. This strategy allows to reduce the injection dose (tenfold lower than mRNA vaccines) and follow a &#8220;one-dose prime-boost&#8221; regime (<xref rid="B734" ref-type="bibr">Vogel et al., 2018</xref>; <xref rid="B199" ref-type="bibr">Erasmus et al., 2020</xref>; <xref rid="B638" ref-type="bibr">Schoenmaker et al., 2021</xref>) instead of the &#8220;two-dose&#8221; strategy per recipient of the non-replicative mRNA-COVID-19 vaccines. SAM vaccines in development are the LNP-nCoV-saRNA vaccine by the Imperial College London (<xref rid="B466" ref-type="bibr">McKay et al., 2020</xref>; <xref rid="B638" ref-type="bibr">Schoenmaker et al., 2021</xref>), and the ARCT-021 or LUNAR-COV19 vaccine (see information in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nature.com/articles/d43747-021-00073-3" ext-link-type="uri">https://www.nature.com/articles/d43747-021-00073-3</ext-link>) by Arcturus/Duke-NUS (<xref rid="B438" ref-type="bibr">Low et al., 2021</xref>; <xref rid="B638" ref-type="bibr">Schoenmaker et al., 2021</xref>). The LNP-nCoV-saRNA vaccine has been assayed in a Phase I clinical trial, being immunogenic at low dose levels, but failed to induce 100% seroconversion. Some modifications are being developed to optimize humoral responses against the viral S antigen (<xref rid="B578" ref-type="bibr">Pollock et al., 2022</xref>). In the case of ARCT-021 (LUNAR-COV19) vaccine, the mRNA is a replicon that comprises the Venezuelan equine encephalitis virus (VEEV) genome in which the structural genes have been replaced with the SARS-CoV-2 full-length S-gene, and formulated with the proprietary LUNAR<sup>&#174;</sup> LNP (<xref rid="B438" ref-type="bibr">Low et al., 2021</xref>). ARCT-021 protects K-18 human ACE2 transgenic mice from lethal SARS-CoV-2 challenge producing a strong Th1-predominant humoral and cellular immune responses against the S protein (<xref rid="B168" ref-type="bibr">de Alwis et al., 2021</xref>), with promising 1&#8211;2 phase clinical trial results (<xref rid="B438" ref-type="bibr">Low et al., 2021</xref>).</p><p>In the case of liposomes, Moderna&#8217;s candidate vaccine mRNA-1273 (Moderna/National Institute of Allergy and Infectious Diseases; commercially available under the brand name Spikevax) for COVID-19 used them as a carrier for drug delivering and as an adjuvant, thereby encapsulating the nucleoside modified mRNA that encodes the SARS-CoV-2 S glycoprotein (<xref rid="B101" ref-type="bibr">Callaway, 2020</xref>; <xref rid="B294" ref-type="bibr">Huang et al., 2020c</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>; <xref rid="B161" ref-type="bibr">Dai and Gao, 2021</xref>; <xref rid="B695" ref-type="bibr">Tenchov et al., 2021</xref>), whereas LNPs were used for this purpose by BioNTech/Fosun Pharma/Pfizer, BNT162b2 mRNA vaccine (commercially available under the brand name Comirnaty) (<xref rid="B101" ref-type="bibr">Callaway, 2020</xref>; <xref rid="B574" ref-type="bibr">Polack et al., 2020</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>; <xref rid="B161" ref-type="bibr">Dai and Gao, 2021</xref>; <xref rid="B695" ref-type="bibr">Tenchov et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The LNPs components of these two efficient mRNA vaccines are: 1) for mRNA-1273, SM-102, PEG2000-DMG, 1,2-Distearoyl-sn-glycero-3 phosphocholine (DSPC) and cholesterol; 2) for BNT162b2, ALC-0315, ALC-0159, DSPC and cholesterol (reviewed in (<xref rid="B352" ref-type="bibr">Kim et al., 2021a</xref>; <xref rid="B638" ref-type="bibr">Schoenmaker et al., 2021</xref>; <xref rid="B727" ref-type="bibr">Verbeke et al., 2021</xref>)) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Furthermore, Pfizer/BioNTech and Moderna vaccines both uses a ribonucleotide modified mRNA by using 1-methyl-pseudouridine (m1&#936;) instead of uridine (<xref rid="B574" ref-type="bibr">Polack et al., 2020</xref>; <xref rid="B45" ref-type="bibr">Baden et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). In fact, the m1&#936; nucleotide is a natural archaeal tRNA component (<xref rid="B783" ref-type="bibr">Wurm et al., 2012</xref>) that could be chemically synthesized and used for production of m1&#936; mRNAs by <italic toggle="yes">in vitro</italic> transcription (reviewed in (<xref rid="B510" ref-type="bibr">Nance and Meier, 2021</xref>)). The presence of the m1&#936; nucleotide in the mRNA construct provokes changes in the secondary structure of the mRNA that has been associated with high protein expression (<xref rid="B30" ref-type="bibr">Andries et al., 2015</xref>; <xref rid="B820" ref-type="bibr">Zhao and He, 2015</xref>; <xref rid="B682" ref-type="bibr">Svitkin et al., 2017</xref>; <xref rid="B718" ref-type="bibr">Van der Jeught et al., 2018</xref>; <xref rid="B218" ref-type="bibr">Foster et al., 2019</xref>; <xref rid="B256" ref-type="bibr">Hadas et al., 2019</xref>; <xref rid="B461" ref-type="bibr">Mauger et al., 2019</xref>; <xref rid="B513" ref-type="bibr">Nelson et al., 2020</xref>; <xref rid="B546" ref-type="bibr">Parr et al., 2020</xref>; <xref rid="B510" ref-type="bibr">Nance and Meier, 2021</xref>; <xref rid="B488" ref-type="bibr">Mokuda et al., 2022</xref>). Likewise, the introduction of these m1&#936; nucleotides inside mRNA fragments has been reported to stabilize the mRNA and reduce its recognition by RNA-binding proteins, thereby minimizing undesirable innate immune responses against this foreign mRNA immunogen (<xref rid="B30" ref-type="bibr">Andries et al., 2015</xref>; <xref rid="B820" ref-type="bibr">Zhao and He, 2015</xref>; <xref rid="B718" ref-type="bibr">Van der Jeught et al., 2018</xref>; <xref rid="B218" ref-type="bibr">Foster et al., 2019</xref>; <xref rid="B461" ref-type="bibr">Mauger et al., 2019</xref>; <xref rid="B513" ref-type="bibr">Nelson et al., 2020</xref>; <xref rid="B510" ref-type="bibr">Nance and Meier, 2021</xref>; <xref rid="B488" ref-type="bibr">Mokuda et al., 2022</xref>).</p><p>Moreover, Pfizer/BioNTech and Moderna vaccines both uses a mRNA encoding a modified S protein stabilized in its prefusion conformation (<xref rid="B199" ref-type="bibr">Erasmus et al., 2020</xref>; <xref rid="B289" ref-type="bibr">Hsieh et al., 2020</xref>; <xref rid="B780" ref-type="bibr">Wrapp et al., 2020</xref>), in order to maintain a stable conformational state exposing the S1 distal domain of the S protein, against which vaccine-elicited protective nAbs are aimed to be generated (<xref rid="B199" ref-type="bibr">Erasmus et al., 2020</xref>; <xref rid="B289" ref-type="bibr">Hsieh et al., 2020</xref>; <xref rid="B787" ref-type="bibr">Xia, 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>, <italic toggle="yes">see inbox: nAbs in the S-tertiary structure</italic>). The strategy to stabilize the immunogenic prefusion conformation on the membrane-anchored S protein consists in modifying two key amino acid residues for proline in the S protein (i.e. K986P and V987P), leading to the known S-2P immunogen (<xref rid="B745" ref-type="bibr">Walsh et al., 2020b</xref>; <xref rid="B151" ref-type="bibr">Corbett et al., 2020</xref>; <xref rid="B529" ref-type="bibr">Olia et al., 2021</xref>; <xref rid="B787" ref-type="bibr">Xia, 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>). These consecutive residues are located in the central helix region of the S protein, a segment placed between the Heptad-Repeat (HR) domains HR1 (912&#8211;984 residues) and HR2 (1,163&#8211;1,213 residues) of the S protein (<xref rid="B294" ref-type="bibr">Huang et al., 2020c</xref>; <xref rid="B289" ref-type="bibr">Hsieh et al., 2020</xref>; <xref rid="B787" ref-type="bibr">Xia, 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>). The K986P and V987P mutations prevent structural transitions from prefusion to postfusion state, thereby stabilizing the S-2P protein at the prefusion state and contributing to vaccine efficiency (<xref rid="B294" ref-type="bibr">Huang et al., 2020c</xref>; <xref rid="B289" ref-type="bibr">Hsieh et al., 2020</xref>; <xref rid="B787" ref-type="bibr">Xia, 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>). Other vaccine developments that contain the S-2P immunogen are the Sanofi design, the subunit/VLP Novavax vaccine and the Janssen (Johnson and Johnson) adenovirus (Ad)-based vaccine (<xref rid="B247" ref-type="bibr">Guebre-Xabier et al., 2020</xref>; <xref rid="B474" ref-type="bibr">Mercado et al., 2020</xref>; <xref rid="B237" ref-type="bibr">Goepfert et al., 2021</xref>). Furthermore, another strategy to stabilize the immunogenic prefusion conformation of the SARS-CoV-2 S glycoprotein consists in changing the furin cleavage site in the S protein (<xref rid="B28" ref-type="bibr">Andersen et al., 2020</xref>), in order to avoid this cleavage that releases the S1 subunit of the S viral protein that would compromise the appropriate immunogenic state of the S protein for vaccination (<xref rid="B743" ref-type="bibr">Walls et al., 2020b</xref>; <xref rid="B780" ref-type="bibr">Wrapp et al., 2020</xref>; <xref rid="B319" ref-type="bibr">Johnson et al., 2021</xref>; <xref rid="B529" ref-type="bibr">Olia et al., 2021</xref>). In fact, the SARS-CoV-2 S protein must be cleaved into the S1 and S2 subunits, in order to be able to trigger fusion and host-cell entry (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B743" ref-type="bibr">Walls et al., 2020b</xref>; <xref rid="B308" ref-type="bibr">Jaimes et al., 2020</xref>) (<xref rid="F1" ref-type="fig">Figure 1B</xref>). SARS-CoV-2 presents a four-amino acid &#8220;SPRRAR|S&#8221; sequence (preceded with P) named as the polybasic site or the furin cleavage site, which is inserted at the junction of the S1 (containing the RBD sequence) and S2 (bearing the fusion domain) subunits of the S glycoprotein (<xref rid="B28" ref-type="bibr">Andersen et al., 2020</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>). This polybasic site has been associated with the pathogenesis of SARS-CoV-2 infection and COVID-19 pandemic severity (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B28" ref-type="bibr">Andersen et al., 2020</xref>; <xref rid="B649" ref-type="bibr">Shang et al., 2020b</xref>; <xref rid="B743" ref-type="bibr">Walls et al., 2020b</xref>; <xref rid="B308" ref-type="bibr">Jaimes et al., 2020</xref>; <xref rid="B318" ref-type="bibr">Johnson et al., 2020</xref>; <xref rid="B383" ref-type="bibr">Lau et al., 2020</xref>; <xref rid="B398" ref-type="bibr">Lemmin et al., 2020</xref>; <xref rid="B319" ref-type="bibr">Johnson et al., 2021</xref>; <xref rid="B768" ref-type="bibr">Whittaker, 2021</xref>; <xref rid="B731" ref-type="bibr">Villoutreix et al., 2022</xref>). It is interesting to note that the sequence of the ancestral (Wuhan-Hu-1) SARS-CoV-2 furin cleavage site (RRxR) does not follow those of the prototypical furin cleavage sites (RxK/RR) (<xref rid="B690" ref-type="bibr">Tang et al., 2021</xref>), and that during the COVID-19 pandemic this site has been adapted in some VOCs, such as B.1.1.7 (Alpha) and B.1.617 (B.1.617.1 named Kappa and B.1.617.2 named Delta) (<xref rid="B17" ref-type="bibr">Aleem et al., 2022</xref>) where the first proline has been replaced by a histidine (HRRAR|S) or an arginine (RRRAR|S), respectively (<xref rid="B555" ref-type="bibr">Peacock et al., 2021b</xref>; <xref rid="B512" ref-type="bibr">Neerukonda et al., 2021</xref>; <xref rid="B768" ref-type="bibr">Whittaker, 2021</xref>; <xref rid="B441" ref-type="bibr">Lubinski et al., 2022</xref>). Altogether, this information shows that some vaccine designs have incorporated mutations at the furin cleavage site to improve the immunogenic activity of the S-2P immunogen (<xref rid="F3" ref-type="fig">Figure 3B</xref>). Furthermore, the Ad26CoVS1 or Ad26. CoV2 vaccine [Janssen Pharmaceutical Companies (Johnson and Johnson)] presents a substitution of the S-2P &#8220;RRAR (R682-R685)&#8221; sequence with the non-cleavable SRAG sequence (<xref rid="B86" ref-type="bibr">Bos et al., 2020</xref>; <xref rid="B474" ref-type="bibr">Mercado et al., 2020</xref>; <xref rid="B161" ref-type="bibr">Dai and Gao, 2021</xref>), whereas the NVX-CoV23 vaccine (Novavax) substitutes the furin-polybasic domain (R682-R685) with the non-cleavable QQAQ sequence (<xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B340" ref-type="bibr">Keech et al., 2020</xref>; <xref rid="B161" ref-type="bibr">Dai and Gao, 2021</xref>; <xref rid="B699" ref-type="bibr">Tian et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>).</p><p>Noteworthy, other mRNA-based LNP-driven strategies have also been developed, such as the CureVac N.V. vaccine (i.e., CVnCoV vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV-2 S protein encapsulated in LNP (<xref rid="B370" ref-type="bibr">Kremsner et al., 2021</xref>; <xref rid="B600" ref-type="bibr">Rauch et al., 2021</xref>; <xref rid="B620" ref-type="bibr">S&#225;ez-Llorens et al., 2022</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>), which was expected to be cheaper and more stable in refrigerated storage than those developed by Pfizer-BioNTech and Moderna. These last vaccines contain a pseudouridine mRNA nucleotide in place of the normal uridine nucleotide to circumvent immune inflammatory reactions (<xref rid="B336" ref-type="bibr">Karik&#243; et al., 2005</xref>) that could be activated through detection of the foreign S viral mRNA (<xref rid="B491" ref-type="bibr">Morais et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Although CureVac&#8217;s vaccine bears normal uridine (<xref rid="B370" ref-type="bibr">Kremsner et al., 2021</xref>), it was developed altering the S viral mRNA genome code in a way that the protein is not affected (<xref rid="B370" ref-type="bibr">Kremsner et al., 2021</xref>), but helps to evade immune detection ((<xref rid="B600" ref-type="bibr">Rauch et al., 2021</xref>; <xref rid="B620" ref-type="bibr">S&#225;ez-Llorens et al., 2022</xref>); analyzed in (<xref rid="B184" ref-type="bibr">Dolgin, 2021</xref>)). The formulation of CurveVac&#8217;s LNPs consists in cationic lipid (Acuitas Therapeutics), phospholipid, cholesterol and PEG-lipid conjugate (reviewed in (<xref rid="B352" ref-type="bibr">Kim et al., 2021a</xref>; <xref rid="B638" ref-type="bibr">Schoenmaker et al., 2021</xref>; <xref rid="B727" ref-type="bibr">Verbeke et al., 2021</xref>)) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Unfortunately, CureVac&#8217;s mRNA vaccine falls on efficacy in clinical trials (analyzed in (<xref rid="B50" ref-type="bibr">Baker and Dolgin, 2021</xref>; <xref rid="B184" ref-type="bibr">Dolgin, 2021</xref>)). All the nanocarriers used in the above vaccines protect the immunogen against biodegradation and favor their uptake inside cells that should express and present the immunogen to the immune system (<xref rid="B34" ref-type="bibr">Apostolopoulos et al., 2013</xref>; <xref rid="B101" ref-type="bibr">Callaway, 2020</xref>; <xref rid="B42" ref-type="bibr">Asdaq et al., 2021</xref>; <xref rid="B672" ref-type="bibr">Souri et al., 2022</xref>).</p><p>Another nano-strategy followed to develop a vaccine against COVID-19 is the use of viral vector vaccines to deliver the S gene and express the S protein of SARS-CoV-2 to trigger specific and protective immune responses (<xref rid="B101" ref-type="bibr">Callaway, 2020</xref>; <xref rid="B583" ref-type="bibr">Premkumar et al., 2020</xref>; <xref rid="B161" ref-type="bibr">Dai and Gao, 2021</xref>), such as well-known adenoviruses (Ads) (<xref rid="B693" ref-type="bibr">Tatsis and Ertl, 2004</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Hence, recombinant non-replicating Ad (rAd) has been used by the University of Oxford/AstraZeneca (AZD1222-ChAdOx1 vaccine; a replication-deficient simian Ad-vectored vaccine) (commercially available under the brand names Covishield and Vaxzevria), Gamaleya National Research Centre for Epidemiology and Microbiology (Sputnik V or Gam-COVID-Vac; rAd26 and rAd5 vaccines), CanSino Biological Inc./Beijing Institute of Biotechnology (Ad5-nCoV vaccine) and Janssen Pharmaceutical Companies (Johnson and Johnson) (Ad26CoVS1 or Ad26.CoV2.S vaccine) (<xref rid="B827" ref-type="bibr">Zhu et al., 2020a</xref>; <xref rid="B86" ref-type="bibr">Bos et al., 2020</xref>; <xref rid="B828" ref-type="bibr">Zhu et al., 2020b</xref>; <xref rid="B101" ref-type="bibr">Callaway, 2020</xref>; <xref rid="B214" ref-type="bibr">Folegatti et al., 2020</xref>; <xref rid="B429" ref-type="bibr">Logunov et al., 2020</xref>; <xref rid="B474" ref-type="bibr">Mercado et al., 2020</xref>; <xref rid="B618" ref-type="bibr">Sadoff et al., 2021a</xref>; <xref rid="B619" ref-type="bibr">Sadoff et al., 2021b</xref>; <xref rid="B157" ref-type="bibr">Creech et al., 2021</xref>; <xref rid="B203" ref-type="bibr">Ewer et al., 2021</xref>; <xref rid="B430" ref-type="bibr">Logunov et al., 2021</xref>; <xref rid="B595" ref-type="bibr">Ramasamy et al., 2021</xref>; <xref rid="B674" ref-type="bibr">Stephenson et al., 2021</xref>; <xref rid="B684" ref-type="bibr">Swanson et al., 2021</xref>; <xref rid="B739" ref-type="bibr">Voysey et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>).</p><p>The use of the attenuated or inactivated natural SARS-CoV-2 virus is another strategy that has been applied in this important COVID-19 pandemic crisis (<xref rid="B225" ref-type="bibr">Gao et al., 2020a</xref>; <xref rid="B748" ref-type="bibr">Wang et al., 2020b</xref>; <xref rid="B785" ref-type="bibr">Xia et al., 2021</xref>), due to the potential efficacy and production speed (<xref rid="F3" ref-type="fig">Figure 3A</xref>). This procedure implies the culturing of high amounts of infectious viral strains, isolated from patients, expanded, for example, in infected Vero cells as performed for the BBIBP-CorV (Sinopharm/Wuhan Institute of Biological Products) and CoronaVac vaccine (formerly named PiCoVacc; Sinovac Biontech) vaccines (<xref rid="B225" ref-type="bibr">Gao et al., 2020a</xref>; <xref rid="B748" ref-type="bibr">Wang et al., 2020b</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The Vero continuous cell line (CCL) allows highly efficient virus proliferation and conserves its genetic stability, being both requirements for the development of an inactivated virus vaccine. Hence, high viral genome homology between the expanded virus and the primary strain must be confirmed, as it was analyzed for BBIBP-CorV vaccine with no amino acid variations observed within ten passages (<xref rid="B748" ref-type="bibr">Wang et al., 2020b</xref>) or for PiCoVacc vaccine (<xref rid="B225" ref-type="bibr">Gao et al., 2020a</xref>). In fact, Vero was the first CCL approved by the WHO to produce human vaccines (<xref rid="B769" ref-type="bibr">WHO, 1987</xref>; <xref rid="B60" ref-type="bibr">Barrett et al., 2009</xref>; <xref rid="B348" ref-type="bibr">Kiesslich and Kamen, 2020</xref>). Thus, amplified and purified infectious viral particles are further inactivated by different procedures. Here, we would like to remark the viral chemical inactivation as performed for the BBIBP-CorV vaccine (<xref rid="B748" ref-type="bibr">Wang et al., 2020b</xref>). This is inactivated by using &#946;-propiolactone (at a ratio of 1:4,000 at 2&#8211;8&#176;C for 20&#8211;24&#160;h) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The BBIBP-CorV vaccine also contains aluminum hydroxide (alum) as the adjuvant (<xref rid="B748" ref-type="bibr">Wang et al., 2020b</xref>) and it has been reported as safe, well tolerated inducing high humoral responses (<xref rid="B785" ref-type="bibr">Xia et al., 2021</xref>; <xref rid="B786" ref-type="bibr">Xia et al., 2022</xref>). The Sinopharm/Wuhan Institute of Biological Products consortium has also developed two other inactivated virus vaccines based on two primary viral strains, WIV04 and HB02 (<xref rid="B10" ref-type="bibr">Al Kaabi et al., 2021</xref>) which offer 72.8 and 78.1% of protection, respectively, against moderate-to-severe forms of the COVID-19 disease. The Sinovac Biontech virus vaccine has been similarly developed (<xref rid="B225" ref-type="bibr">Gao et al., 2020a</xref>), expanded in Vero cells and chemically inactivated by using &#946;-propiolactone and mixed with alum adjuvant (<xref rid="B225" ref-type="bibr">Gao et al., 2020a</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). In clinical trials, safety, tolerability and immunogenicity have been also reported for the CoronaVac vaccine (<xref rid="B817" ref-type="bibr">Zhang et al., 2021b</xref>; <xref rid="B261" ref-type="bibr">Han et al., 2021</xref>; <xref rid="B691" ref-type="bibr">Tanriover et al., 2021</xref>; <xref rid="B782" ref-type="bibr">Wu et al., 2021</xref>). Bharat Biotech together with the Indian Council of Medical Research and the National Institute of Virology have developed the BBV152 vaccine (Covaxin) (<xref rid="B652" ref-type="bibr">Sharma et al., 2021</xref>; <xref rid="B792" ref-type="bibr">Yadav et al., 2021</xref>). This inert, safe and quite efficient virus vaccine has been obtained from the NIV-2020-770 isolate, which presents the emerged D614G mutation that increases infectiveness and case fatality rate (<xref rid="B70" ref-type="bibr">Becerra-Flores and Cardozo, 2020</xref>; <xref rid="B814" ref-type="bibr">Zhang et al., 2020c</xref>; <xref rid="B193" ref-type="bibr">Eaaswarkhanth et al., 2020</xref>; <xref rid="B368" ref-type="bibr">Korber et al., 2020</xref>; <xref rid="B435" ref-type="bibr">Lorenzo-Redondo et al., 2020</xref>; <xref rid="B166" ref-type="bibr">Daniloski et al., 2021</xref>; <xref rid="B455" ref-type="bibr">Mansbach et al., 2021</xref>; <xref rid="B499" ref-type="bibr">M&#252;ller et al., 2021</xref>; <xref rid="B570" ref-type="bibr">Plante et al., 2021</xref>), and it was formulated with imidazoquinoline (IMDG; a toll-like receptor 7/8 agonist molecule (<xref rid="B478" ref-type="bibr">Miller et al., 2020</xref>)) and absorbed in Alum-gel (Algel) as adjuvants (<xref rid="B196" ref-type="bibr">Ella et al., 2021a</xref>; <xref rid="B197" ref-type="bibr">Ella et al., 2021b</xref>; <xref rid="B652" ref-type="bibr">Sharma et al., 2021</xref>; <xref rid="B792" ref-type="bibr">Yadav et al., 2021</xref>).</p><p>Another nano-based vaccination strategy consist in exposing the immunogenic viral antigen at the surface of empty spherical non-infectious structures named VLPs (viral like particles) (<xref rid="B12" ref-type="bibr">Al-Barwani et al., 2014a</xref>; <xref rid="B186" ref-type="bibr">Donaldson et al., 2018</xref>), which could be named or classified in enveloped and non-enveloped VLPs (eVLPs and neVLPs, respectively) [reviewed in (<xref rid="B521" ref-type="bibr">Nooraei et al., 2021</xref>)] (<xref rid="F3" ref-type="fig">Figure 3A</xref>). VLPs are obtained <italic toggle="yes">in cellulo</italic> by the self-assembly mechanism of viral proteins, during the expression of the immunogenic protein of interest (<xref rid="B809" ref-type="bibr">Zeltins, 2013</xref>; <xref rid="B12" ref-type="bibr">Al-Barwani et al., 2014a</xref>). VLP-based vaccines could be considered a kind of subunit vaccines, presenting therefore a characteristic immune response associated with exogenous antigens (<xref rid="B227" ref-type="bibr">Garcea and Gissmann, 2004</xref>; <xref rid="B496" ref-type="bibr">Moser et al., 2011</xref>; <xref rid="B629" ref-type="bibr">Salvador et al., 2011</xref>; <xref rid="B440" ref-type="bibr">Lua et al., 2014</xref>; <xref rid="B521" ref-type="bibr">Nooraei et al., 2021</xref>). VLPs could be chemically modified by conjugating receptor ligands onto the surface of VLPs to drive their binding to and uptake into APCs expressing the corresponding receptor (<xref rid="B13" ref-type="bibr">Al-Barwani et al., 2014b</xref>; <xref rid="B521" ref-type="bibr">Nooraei et al., 2021</xref>). Polysorbate 80, sodium borate/phosphate, L-histidine, and 2-phenoxyethanol are often used in the formulation of VLP-based vaccines as a surfactant stabilizer, preservative and buffering agents (<xref rid="B440" ref-type="bibr">Lua et al., 2014</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). VLP-derived vaccines are significantly safer than live-attenuated or inactivated virus vaccines, as well as subunit or particulate vaccines, due to the noninfectious nature of the VLPs (<xref rid="B572" ref-type="bibr">Plummer and Manchester, 2011</xref>; <xref rid="B440" ref-type="bibr">Lua et al., 2014</xref>; <xref rid="B20" ref-type="bibr">Alon et al., 2017</xref>). In fact, some commercially successful vaccines to immunize against human papillomavirus (HPV), hepatitis B virus (HBV) and hepatitis E virus (HEV) are VLP vaccines (<xref rid="B82" ref-type="bibr">Block et al., 2006</xref>; <xref rid="B490" ref-type="bibr">Monie et al., 2008</xref>; <xref rid="B186" ref-type="bibr">Donaldson et al., 2018</xref>; <xref rid="B391" ref-type="bibr">Lee et al., 2019</xref>; <xref rid="B587" ref-type="bibr">Qian et al., 2020a</xref>). Therefore, VLPs are resembling natural virions but being empty and bearing at the surface membrane of the assembled particle the immunogenic protein (<xref rid="B809" ref-type="bibr">Zeltins, 2013</xref>; <xref rid="B12" ref-type="bibr">Al-Barwani et al., 2014a</xref>; <xref rid="B186" ref-type="bibr">Donaldson et al., 2018</xref>; <xref rid="B486" ref-type="bibr">Mohsen et al., 2020</xref>). In the case of COVID-19 vaccine developments, it bears the entire S glycoprotein of SARS-CoV-2 or just the recombinant RBD region of the S protein (<xref rid="B230" ref-type="bibr">Geng et al., 2021</xref>; <xref rid="B582" ref-type="bibr">Prates-Syed et al., 2021</xref>; <xref rid="B805" ref-type="bibr">Yilmaz et al., 2022</xref>). Promising results have been obtained with a VLP-based RBD vaccine which provide highly effective protection against SARS-CoV-2 infection in a mouse model (<xref rid="B230" ref-type="bibr">Geng et al., 2021</xref>). Likewise, a VLP-based vaccine carrying an hexaproline prefusion-stabilized S viral protein (S-6p) (<xref rid="B289" ref-type="bibr">Hsieh et al., 2020</xref>) has been developed with excellent results in several animal models for SARS-CoV-2 infection (i.e., mice, rats and ferrets) (<xref rid="B805" ref-type="bibr">Yilmaz et al., 2022</xref>). This VLP vaccine contains alum and a K-type synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG (5&#8242;-Cytosine-phosphate-Guanine-3&#8242;) motifs (CpG ODN) as a vaccine adjuvant (<xref rid="B360" ref-type="bibr">Klinman et al., 2009</xref>; <xref rid="B204" ref-type="bibr">Ezoe et al., 2020</xref>) to promote cellular and humoral immunity (<xref rid="B805" ref-type="bibr">Yilmaz et al., 2022</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). This CpG ODN/alum-adjuvanted 6p-VLP vaccine (VLP-58-1023-Al-K3) is currently being evaluated in a clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04818281">NCT04818281</ext-link>). Furthermore, some VLP developments include other SARS-CoV-2 proteins to stabilize the VLP, such as M (membrane), E (envelope) and N (nucleocapsid) proteins, thereby favoring assembling and expression of the immunogenic S protein (<xref rid="B790" ref-type="bibr">Xu et al., 2020b</xref>; <xref rid="B571" ref-type="bibr">Plescia et al., 2021</xref>). Worth of mention is the Novavax subunit vaccine (NVX-CoV2373) that uses a recombinant modified nanoparticle S protein of SARS-CoV-2 (<xref rid="B658" ref-type="bibr">Shin et al., 2020b</xref>; <xref rid="B127" ref-type="bibr">Chauhan et al., 2020</xref>; <xref rid="B340" ref-type="bibr">Keech et al., 2020</xref>; <xref rid="B216" ref-type="bibr">Formica et al., 2021</xref>; <xref rid="B270" ref-type="bibr">Heath et al., 2021</xref>; <xref rid="B699" ref-type="bibr">Tian et al., 2021</xref>; <xref rid="B191" ref-type="bibr">Dunkle et al., 2022</xref>) together with a Matrix-M adjuvant (<xref rid="B73" ref-type="bibr">Bengtsson et al., 2013</xref>) assembled in non-enveloped VLPs (neVLPs) (<xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). As indicated above, the immunogenic S protein used in this NVX-CoV2373 vaccine is a S-2P protein (1-1273 amino acids) stabilized in the prefusion state, expressed using a baculovirus/insect cell system and then incorporated into polysorbate 80 detergent (<xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>). This full-length S protein has been modified in the polybasic domain at the R682RAR685 sequence, mutated by the Q682QAQ685 sequence (<xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B340" ref-type="bibr">Keech et al., 2020</xref>; <xref rid="B699" ref-type="bibr">Tian et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3B</xref>), to avoid its processing by the host furin proteinase (<xref rid="B280" ref-type="bibr">Hoffmann et al., 2020a</xref>; <xref rid="B28" ref-type="bibr">Andersen et al., 2020</xref>; <xref rid="B649" ref-type="bibr">Shang et al., 2020b</xref>; <xref rid="B743" ref-type="bibr">Walls et al., 2020b</xref>; <xref rid="B308" ref-type="bibr">Jaimes et al., 2020</xref>; <xref rid="B318" ref-type="bibr">Johnson et al., 2020</xref>; <xref rid="B398" ref-type="bibr">Lemmin et al., 2020</xref>; <xref rid="B319" ref-type="bibr">Johnson et al., 2021</xref>; <xref rid="B768" ref-type="bibr">Whittaker, 2021</xref>; <xref rid="B731" ref-type="bibr">Villoutreix et al., 2022</xref>). The NVX-CoV2373 is a safe vaccine against SARS-CoV-2 infection (<xref rid="B270" ref-type="bibr">Heath et al., 2021</xref>), commercially successful as a COVID-19 vaccine (<xref rid="B451" ref-type="bibr">Mahase, 2021</xref>; <xref rid="B659" ref-type="bibr">Shinde et al., 2021</xref>). The Radbound University and AdaptVac (a company part of the EU H2020 funded PREVENT-nCoV consortium) have also developed a promising neVLP SARS-CoV-2 vaccine (ABNCoV2 vaccine) based on the S RBD (<xref rid="B219" ref-type="bibr">Fougeroux et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>), which is currently in phase 1/2 clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04839146">NCT04839146</ext-link>) and phase 3 results are expected by the end of 2022.</p><p>On the other hand, recombinant protein-based vaccines are promising candidates for immunization because they offer a safety profile with no live or attenuated viral components in its formulation, avoid potential genomic integration issues, since there are no genomes to be delivered into host cells, and seem to be suitable for immunocompromised individuals (<xref rid="B576" ref-type="bibr">Pollet et al., 2021a</xref>; <xref rid="B358" ref-type="bibr">Kleanthous et al., 2021</xref>; <xref rid="B378" ref-type="bibr">Kyriakidis et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The above presented Novavax NVX-CoV2373 vaccine could be also considered as a recombinant protein-based vaccine (<xref rid="B55" ref-type="bibr">Bangaru et al., 2020</xref>; <xref rid="B270" ref-type="bibr">Heath et al., 2021</xref>; <xref rid="B451" ref-type="bibr">Mahase, 2021</xref>; <xref rid="B659" ref-type="bibr">Shinde et al., 2021</xref>), as well as some developments focused on the RBD sequence of the S1 subunit of the viral S protein (<xref rid="B454" ref-type="bibr">Malladi et al., 2021b</xref>; <xref rid="B358" ref-type="bibr">Kleanthous et al., 2021</xref>; <xref rid="B395" ref-type="bibr">Lee et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The RBD fragment has been assayed as a protein-recombinant vaccine candidate by delivering soluble monomers or dimers of the RBD region (<xref rid="B799" ref-type="bibr">Yang et al., 2020a</xref>; <xref rid="B162" ref-type="bibr">Dai et al., 2020</xref>; <xref rid="B163" ref-type="bibr">Dalvie et al., 2021a</xref>; <xref rid="B453" ref-type="bibr">Malladi et al., 2021a</xref>; <xref rid="B454" ref-type="bibr">Malladi et al., 2021b</xref>; <xref rid="B577" ref-type="bibr">Pollet et al., 2021b</xref>; <xref rid="B131" ref-type="bibr">Chen et al., 2021c</xref>; <xref rid="B759" ref-type="bibr">Wang et al., 2021f</xref>; <xref rid="B679" ref-type="bibr">Sun et al., 2021</xref>), fused to NPs (<xref rid="B742" ref-type="bibr">Walls et al., 2020a</xref>; <xref rid="B446" ref-type="bibr">Ma et al., 2020</xref>; <xref rid="B39" ref-type="bibr">Arunachalam et al., 2021</xref>; <xref rid="B353" ref-type="bibr">Kim et al., 2021b</xref>; <xref rid="B269" ref-type="bibr">He et al., 2021</xref>; <xref rid="B356" ref-type="bibr">King et al., 2021</xref>; <xref rid="B202" ref-type="bibr">Eugenia Toledo-Roman&#237; et al., 2022</xref>) or exposed on VLPs (<xref rid="B163" ref-type="bibr">Dalvie et al., 2021a</xref>; <xref rid="B164" ref-type="bibr">Dalvie et al., 2021b</xref>; <xref rid="B332" ref-type="bibr">Kang et al., 2021</xref>; <xref rid="B689" ref-type="bibr">Tan et al., 2021</xref>; <xref rid="B810" ref-type="bibr">Zha et al., 2021</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). These recombinant protein-based vaccines present several advantages for development and distribution, since they are produced in large scale, their designs and formulations are safe and immunogenic as those developed using the full-length S protein, they are temperature-stable vaccines and doses have an affordable cost (<xref rid="B454" ref-type="bibr">Malladi et al., 2021b</xref>; <xref rid="B358" ref-type="bibr">Kleanthous et al., 2021</xref>; <xref rid="B395" ref-type="bibr">Lee et al., 2021</xref>). Remarkably, one the most promising recombinant protein vaccines is the new PHH-1V vaccine by HIPRA for intramuscular administration, developed in a consortium with different research centers and Hospitals (<xref rid="B59" ref-type="bibr">Barreiro et al., 2022</xref>; <xref rid="B154" ref-type="bibr">Corominas et al., 2022</xref>; <xref rid="B386" ref-type="bibr">Leal et al., 2022</xref>) (<xref rid="F3" ref-type="fig">Figure 3A</xref>). The PHH-1V vaccine is a highly purified RBD heterodimer (i.e., to avoid limited immunogenicity obtained with monomeric RBD protein (<xref rid="B162" ref-type="bibr">Dai et al., 2020</xref>; <xref rid="B802" ref-type="bibr">Yang et al., 2021b</xref>)) which is formulated with SQBA, an oil-in-water adjuvant produced by HIPRA, and prepared as an emulsion that does not need to be reconstituted or thawed before administration (<xref rid="F3" ref-type="fig">Figure 3A</xref>). Importantly, the PHH-1V vaccine consists in a fusion heterodimer that contain S-RBD sequences from two SARS-CoV-2 VOCs (<xref rid="B59" ref-type="bibr">Barreiro et al., 2022</xref>; <xref rid="B154" ref-type="bibr">Corominas et al., 2022</xref>; <xref rid="B386" ref-type="bibr">Leal et al., 2022</xref>), B.1.1.7 (Alpha) and B.1.351 (Beta). PHH-1V RBD sequences carry key mutations of epidemic relevant VOCs of SARS-CoV-2, such as the K417N, E484K and N501Y22 humoral escape mutations (<xref rid="B760" ref-type="bibr">Wang et al., 2022a</xref>; <xref rid="B762" ref-type="bibr">Wang et al., 2022c</xref>), in order to elicit humoral and cellular immune responses against these VOCs or future emerging variants bearing these escape mutations. Hence, the RBD of the S glycoprotein of B.1.351 (Beta), P.1 (Gamma) and B.1.621 (Mu) variants present E484K and N501Y mutations (<xref rid="B760" ref-type="bibr">Wang et al., 2022a</xref>; <xref rid="B762" ref-type="bibr">Wang et al., 2022c</xref>), whereas both K417N and N501Y immune escape mutations (i.e., for natural and vaccine elicited immunity) are characteristics of the B.1.351 (Beta) and the currently predominant Omicron (B.1.1.529 and BA lineages) variants (<xref rid="B129" ref-type="bibr">Chen et al., 2021a</xref>; <xref rid="B760" ref-type="bibr">Wang et al., 2022a</xref>). The European Commission has signed a joint procurement contract with the Spanish HIPRA pharmaceutical firm for the supply of the PHH-1V recombinant protein COVID-19 vaccine, which will be commercially available once the European Medicines Agency (EMA) approve it.</p><p>COVID-19 vaccines are not protective against SARS-CoV-2 infection and reinfections, due to the absence of antigen specific immunity elicited in the nasal cavities (considered the main route of entry of SARS-CoV-2 into the organism together with oral cavities and ocular conjunctiva) (<xref rid="B105" ref-type="bibr">Cantuti-Castelvetri et al., 2020</xref>; <xref rid="B165" ref-type="bibr">Daly et al., 2020</xref>; <xref rid="B231" ref-type="bibr">Gengler et al., 2020</xref>; <xref rid="B87" ref-type="bibr">Bougakov et al., 2021</xref>; <xref rid="B222" ref-type="bibr">Gallo et al., 2021</xref>; <xref rid="B295" ref-type="bibr">Huang et al., 2021</xref>; <xref rid="B468" ref-type="bibr">Meinhardt et al., 2021</xref>; <xref rid="B609" ref-type="bibr">Rodr&#237;guez-Ares et al., 2021</xref>; <xref rid="B462" ref-type="bibr">Maurin et al., 2022</xref>; <xref rid="B568" ref-type="bibr">Pipolo et al., 2022</xref>) and the associated mucosal epithelial cells, such as ciliated cells and mucus-producing goblet cells (<xref rid="B392" ref-type="bibr">Lee et al., 2020a</xref>; <xref rid="B287" ref-type="bibr">Hou et al., 2020</xref>; <xref rid="B533" ref-type="bibr">Osan et al., 2020</xref>; <xref rid="B775" ref-type="bibr">W&#246;lfel et al., 2020</xref>; <xref rid="B7" ref-type="bibr">Ahn et al., 2021</xref>; <xref rid="B87" ref-type="bibr">Bougakov et al., 2021</xref>; <xref rid="B468" ref-type="bibr">Meinhardt et al., 2021</xref>; <xref rid="B509" ref-type="bibr">Nakayama et al., 2021</xref>; <xref rid="B608" ref-type="bibr">Robinot et al., 2021</xref>; <xref rid="B494" ref-type="bibr">Morrison et al., 2022</xref>; <xref rid="B534" ref-type="bibr">Osan et al., 2022</xref>; <xref rid="B568" ref-type="bibr">Pipolo et al., 2022</xref>). In these tissues, viral infection is cleared by nasal-associated lymphoid tissue (NALT), including lymphocytes (B and T cells), dendritic cells (DCs), and macrophages. However, these immune responses are not protecting against reinfections (reviewed in (<xref rid="B222" ref-type="bibr">Gallo et al., 2021</xref>)). Therefore, sterilizing vaccines should promote mucosal immunity at that level, in order to render nasal cavities and NALT as barriers for SARS-CoV-2 infection and reinfections (reviewed in (<xref rid="B213" ref-type="bibr">Focosi et al., 2022</xref>)). In this regard, promising results have been obtained in animal models with the NSP16-deficient SARS-CoV-2 virus, which acts as a live attenuated vaccine that confers sterilizing immunity after intranasal administration of a single dose (<xref rid="B803" ref-type="bibr">Ye et al., 2022</xref>). Other studies also reported positive results in animal models (mice, golden hamsters, and ferrets) for nasal-mucosal, inhaled vaccination conferring long-lasting systemic and mucosal immunity (<xref rid="B493" ref-type="bibr">Moreno-Fierros et al., 2020</xref>; <xref rid="B497" ref-type="bibr">Mudgal et al., 2020</xref>; <xref rid="B43" ref-type="bibr">Ashraf et al., 2021</xref>; <xref rid="B545" ref-type="bibr">Park and Lee, 2021</xref>; <xref rid="B700" ref-type="bibr">Tiboni et al., 2021</xref>; <xref rid="B213" ref-type="bibr">Focosi et al., 2022</xref>; <xref rid="B271" ref-type="bibr">Heida et al., 2022</xref>). These vaccine developments would achieve the desired sterilizing immunity for mucosal cells and tissues against SARS-CoV-2, just at the door of our organism for viral infection. However, intranasal or mucosal vaccines should follow the tissular dynamics followed by SARS-CoV-2 to accomplish neutralizing immunity, and therefore all designed vaccines and associated adjuvants must be safe, avoiding reaching and affecting the central nervous system (CNS) via the olfactory bulb that could compromise the life of the inoculated individuals. Fortunately, for vaccine developments with SARS-CoV-1 S protein, it has been reported that the use of rAd vectors via sublingual administration induce systemic and mucosal immunity without redirection of the viral rAd vector to the brain (<xref rid="B655" ref-type="bibr">Shim et al., 2012</xref>). Similar immunoprotection results have been obtained with a recombinant adeno-associated virus (rAAV) expressing the RBD of the SARS-CoV-1 S protein (RBD-rAAV) intranasal administered (<xref rid="B189" ref-type="bibr">Du et al., 2008</xref>). Although these studies show that mucosal immunization against SARS-CoV-1 S protein did not provide full sterilizing immunity, they prevent virus dissemination to the lung and prevent respiratory distress, being appropriated models to achieve SARS-CoV-2 sterilizing vaccines. Moreover, the use of appropriate nanoreagents to form stable and safe nanoparticles for intranasal administration of Abs, proteins or genomic fragments as immunogens would be key to accomplish the desired sterilizing immunity. Thus, a recent study has reported that it is possible to deliver a mRNA to the lung via nebulization of LNPs made of lipids, neutral or cationic helper lipids and polyethylene glycol (PEG). The intranasal administration of nebulized LNPs carrying a mRNA encoding for a broadly nAb targeting haemagglutinin protects mice from lethal challenge of the H1N1 subtype of influenza A virus (<xref rid="B432" ref-type="bibr">Lokugamage et al., 2021</xref>).</p><p>Therefore, nano-based COVID-19 vaccine designs use different nanomaterials, nanocarriers and technologies to enhance the bioavailability of the viral immunogen, control its delivery and faster uptake by target host cells and tissues, and also acting as adjuvants to activate the immune responses against the viral antigen, in order to promote specific and protective immune activities against SARS-CoV-2 infection and severe COVID-19 disease (reviewed in (<xref rid="B103" ref-type="bibr">Campos et al., 2020</xref>; <xref rid="B127" ref-type="bibr">Chauhan et al., 2020</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>; <xref rid="B687" ref-type="bibr">Talebian and Conde, 2020</xref>; <xref rid="B149" ref-type="bibr">Constantin et al., 2021</xref>; <xref rid="B157" ref-type="bibr">Creech et al., 2021</xref>; <xref rid="B447" ref-type="bibr">Machhi et al., 2021</xref>; <xref rid="B598" ref-type="bibr">Rashidzadeh et al., 2021</xref>; <xref rid="B724" ref-type="bibr">Varahachalam et al., 2021</xref>; <xref rid="B248" ref-type="bibr">Guerrini et al., 2022</xref>; <xref rid="B672" ref-type="bibr">Souri et al., 2022</xref>)) (<xref rid="F3" ref-type="fig">Figure 3</xref>).</p></sec><sec id="s2-3"><title>2.3 Virosurveillance: Genomics to trace SARS-CoV-2</title><p>Surveillance of infectious diseases, and particularly of emerging and new emerging virus diseases, is key for ensuring community and global health in the XXI century. In 7&#160;years from 2011, WHO alerted and followed nearly 1,500 epidemic events in several countries due to emerging viruses, such as SARS, MERS, influenza, Zika virus (ZIKV), Yellow Fever virus (YFV), and Ebola virus (EBOV), among other viruses (Global-Preparedness-Monitoring-Board-(GPMB), 2019). The world began to realize the fragility of our societies and economies in facing severe non-curable and/or lethal emerging virus when the 2014&#8211;2015 ZIKV pandemic seriously affected two of the biggest world sports events: the Olympic Games in Brazil (2016) and the World Soccer Championship in Brazil (2018) (<xref rid="B562" ref-type="bibr">Petersen et al., 2016</xref>; <xref rid="B628" ref-type="bibr">Salvador and Fujita, 2016</xref>). These epidemic events announce the new global era the world is facing with fast-spreading outbreaks, difficult to manage and having impact on lives, health systems, administration and the economy of companies, families and countries, as is occurring nowadays with the worldwide SARS-CoV-2 infection (<xref rid="B604" ref-type="bibr">Reports, 2020</xref>) responsible for the still ongoing COVID-19 pandemic (<xref rid="B71" ref-type="bibr">Beech and Anseel, 2020</xref>; <xref rid="B90" ref-type="bibr">Brammer and Clark, 2020</xref>; <xref rid="B516" ref-type="bibr">Nicola et al., 2020</xref>; <xref rid="B651" ref-type="bibr">Shankar, 2020</xref>; <xref rid="B728" ref-type="bibr">Verbeke, 2020</xref>; <xref rid="B272" ref-type="bibr">Heinberg and Steffen, 2021</xref>; <xref rid="B359" ref-type="bibr">Klebe et al., 2021</xref>; <xref rid="B531" ref-type="bibr">Onyeaka et al., 2021</xref>; <xref rid="B580" ref-type="bibr">Poudel et al., 2021</xref>; <xref rid="B650" ref-type="bibr">Shang et al., 2021</xref>; <xref rid="B653" ref-type="bibr">Sheng et al., 2021</xref>; <xref rid="B666" ref-type="bibr">Sohrabi et al., 2021</xref>; <xref rid="B804" ref-type="bibr">Yen et al., 2021</xref>; <xref rid="B123" ref-type="bibr">Chang et al., 2022</xref>; <xref rid="B176" ref-type="bibr">Desai et al., 2022</xref>). Surveillance of these emerging viruses involves producing information to guide actions at different levels (<xref rid="B95" ref-type="bibr">Buckeridge and Cadieux, 2006</xref>) to protect all sectors that are in danger because of the absence of preparedness policies (<xref rid="B236" ref-type="bibr">Global-Preparedness-Monitoring-Board-(GPMB), 2019</xref>; <xref rid="B394" ref-type="bibr">Lee et al., 2020c</xref>). Therefore, surveillance is a fundamental tool for public health and our societies, where genomics for virus-surveillance has gain relevance as the worldwide tracking system of the different emerged SARS-CoV-2 variants, as it has been demonstrated in different countries. A remarkable example is the first WGS obtained from patients&#8217; viral samples. A few days passed from the first observed Wuhan patients, affected by the new unknown disease, to the world-wide communication of the viral sequence (<xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>; <xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B439" ref-type="bibr">Lu et al., 2020</xref>).</p><p>The knowledge of a complete new CoV genomic sequence (available at GISAID and GenBank (accession number <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MN908947">MN908947</ext-link>) (<xref rid="B107" ref-type="bibr">Cao et al., 2020</xref>; <xref rid="B439" ref-type="bibr">Lu et al., 2020</xref>)), designated as Wuhan-Human 1 CoV (Wuhan-Hu-1 or WHCV) (<xref rid="B4" ref-type="bibr">Ackermann et al., 2020</xref>), allowed the rapid development of probes, reagents and tools for specific and sensitive detection of viral sequences in the patients infected by SARS-CoV-2 (<xref rid="B132" ref-type="bibr">Cheng et al., 2020a</xref>; <xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B192" ref-type="bibr">Dutta et al., 2022</xref>). One of the first epidemiological parameters that these tools helped to assess was the basic reproduction number or R<sub>0</sub> (R naught) value for virus community transmission, estimated from 2.2 to 2.68 for the ancestral Wuhan-Hu-1 strain (<xref rid="B423" ref-type="bibr">Liu et al., 2020e</xref>). These tools allow: 1) specific diagnosis and virosurveillance of outbreaks and community virus spreading, 2) to follow how the virus is evolving and the potential relationships between the genome viral sequence, 3) its mutations, virus infectiveness and disease severity, and 4) to understand natural and vaccine-elicited immunity breakthrough events that help to adapt new vaccines and drugs (<xref rid="B14" ref-type="bibr">Alcoba-Florez et al., 2020a</xref>; <xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B142" ref-type="bibr">Ciuffreda et al., 2021a</xref>; <xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>; <xref rid="B144" ref-type="bibr">Ciuffreda et al., 2022</xref>). A historical and paradigmatic genomic virosurveillance global action, near to real-time and an unprecedented scale (<xref rid="B228" ref-type="bibr">Gardy et al., 2015</xref>; <xref rid="B442" ref-type="bibr">Lucas et al., 2020a</xref>), started after at that moment by fostering a continuous communication and classification of the obtained viral sequences through different resources (e.g., GISAID, GenBank, Nextstrain, Pangolin, among others) (<xref rid="B257" ref-type="bibr">Hadfield et al., 2018</xref>; <xref rid="B28" ref-type="bibr">Andersen et al., 2020</xref>; <xref rid="B422" ref-type="bibr">Liu et al., 2020d</xref>; <xref rid="B345" ref-type="bibr">Khare et al., 2021</xref>; <xref rid="B536" ref-type="bibr">O'Toole et al., 2021</xref>; <xref rid="B637" ref-type="bibr">Sayers et al., 2021</xref>; <xref rid="B711" ref-type="bibr">Underwood et al., 2022</xref>)), where WGS, GWAS (genome-wide association study) and nanopore sequencing approaches and technologies have gain relevance for surveillance and diagnose (<xref rid="B37" ref-type="bibr">Arora et al., 2022</xref>) (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Nanotechnology and reagents used for genome sequencing technologies and serological approaches for SARS-CoV-2 surveillance and diagnose. <bold>(A)</bold> Viral RNA+ extraction from patients&#8217; samples have allowed to prepare a library or primers for WGS that is very useful for virus surveillance and the detection of VOCs bearing key mutations associated with immune responses escape and vaccine breakthrough. Likewise, viral RNA+ extraction have permitted to develop specific, sensitive, scalable, rapid and low-cost RT-qPCR tests for diagnose, both in hospitals and in PoC facilities. Nanomaterials used for RNA+ isolation and purification that allow scalation of RT-qPCR and other gene-based diagnose tests are indicated. Moreover, nanotechnology and nanoreagents used for serological lateral flow tests permit PoC detection of the viral S and N antigens (i.e., from saliva or anterior nasal swabs (nasopharyngeal exudate or other upper/lower respiratory samples)) or Igs (IgM, IgG and IgA) against SARS-CoV-2 S and N proteins from patient blood samples. All nanomaterials and associated strategies (i.e., lateral flow test, colorimetric test, and RT-qPCR) to detect viral genomes and proteins are shown. <bold>(B)</bold> SARS-CoV-2 genome sequencing using ONT (Oxford nanopore technology). Rapid sequencing of the SARS-CoV-2 is key for a correct public health response during a pandemic. Through nanopore sequencing, RNA samples are retrotranscribed (1), and the whole genome amplified with various sets of primers (2). Amplified fragments can incorporate barcodes through a transposase (2) and then samples can be pooled and sequenced through nanopores (3). SARS-CoV-2 RNA+ is also read directly by nanopore. Detected current patterns over time define the specific nucleobases in a sequence (3), which can be demultiplexed, assembled and analyzed, thus allowing the detection of sensitive, single point mutations in the viral genome and tracing circulating VOCs (3). Designs and templates are created with BioRender.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fbioe-10-1052436-g004.jpg"/></fig><p>WGS provides a deep insight into the DNA sequence of the viral genome and, when combined with metadata analysis at the individual or community level, it has allowed to analyze the origins of the COVID-19 pandemic (<xref rid="B10" ref-type="bibr">Al Kaabi et al., 2021</xref>; <xref rid="B663" ref-type="bibr">Singh et al., 2021</xref>; <xref rid="B155" ref-type="bibr">Costa et al., 2022</xref>), and to characterize outbreaks in a community or region (<xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>; <xref rid="B5" ref-type="bibr">Aggarwal et al., 2022</xref>; <xref rid="B144" ref-type="bibr">Ciuffreda et al., 2022</xref>), hospitals (<xref rid="B607" ref-type="bibr">Rivett et al., 2020</xref>), farms (<xref rid="B46" ref-type="bibr">Badiola et al., 2021</xref>; <xref rid="B538" ref-type="bibr">Oude Munnink et al., 2021</xref>), schools (<xref rid="B296" ref-type="bibr">Huang et al., 2022</xref>) and homes (<xref rid="B380" ref-type="bibr">Ladhani et al., 2022</xref>), among other social or industrial entities (<xref rid="B61" ref-type="bibr">Bartik et al., 2020</xref>; <xref rid="B505" ref-type="bibr">Murti et al., 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). Moreover, public health responses to the COVID-19 pandemic are supported by sequencing WGS from circulating SARS-CoV-2 VOCs and analyzing the risk host factors. WGS enables mapping of community and international viral transmission, thereby identifying and tracking the SARS-CoV-2 emerging variants (<xref rid="B239" ref-type="bibr">Gohl et al., 2020</xref>; <xref rid="B607" ref-type="bibr">Rivett et al., 2020</xref>; <xref rid="B5" ref-type="bibr">Aggarwal et al., 2022</xref>; <xref rid="B525" ref-type="bibr">Obermeyer et al., 2022</xref>; <xref rid="B613" ref-type="bibr">Rosenthal et al., 2022</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>), even helping in clinical care using samples collected from patients-rapid antigen test devices (<xref rid="B239" ref-type="bibr">Gohl et al., 2020</xref>; <xref rid="B37" ref-type="bibr">Arora et al., 2022</xref>; <xref rid="B613" ref-type="bibr">Rosenthal et al., 2022</xref>). Host genetics is also a key element in this scenario. WGS and genome-wide association studies (GWAS) have been used to identify host genetic factors that predict COVID-19 severity and patient survival. In this regard, it was of special interest the GWAS analysis associating inborn errors of immunity (i.e., mainly INF and TLR genes and associated pathways) with severe COVID-19 (<xref rid="B66" ref-type="bibr">Bastard et al., 2020</xref>; <xref rid="B139" ref-type="bibr">Chung et al., 2020</xref>; <xref rid="B198" ref-type="bibr">Ellinghaus et al., 2020</xref>; <xref rid="B243" ref-type="bibr">Grasselli et al., 2020</xref>; <xref rid="B696" ref-type="bibr">The-Covid-Host-Genetics-Initiative, 2020</xref>; <xref rid="B10" ref-type="bibr">Al Kaabi et al., 2021</xref>; <xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>; <xref rid="B67" ref-type="bibr">Bastard et al., 2021</xref>; <xref rid="B111" ref-type="bibr">Castano-Jaramillo et al., 2021</xref>; <xref rid="B206" ref-type="bibr">Fallerini et al., 2021</xref>; <xref rid="B517" ref-type="bibr">Niemi et al., 2021</xref>; <xref rid="B543" ref-type="bibr">Pairo-Castineira et al., 2021</xref>; <xref rid="B689" ref-type="bibr">Tan et al., 2021</xref>; <xref rid="B338" ref-type="bibr">Karlsen, 2022</xref>; <xref rid="B436" ref-type="bibr">Loucera et al., 2022</xref>; <xref rid="B526" ref-type="bibr">Oh and Shin, 2022</xref>). In these critically ill patients, the SARS-CoV-2 infection have generally been diagnosed mainly by specific and sensitive retrotranscription and quantitative polymerase chain reaction (RT-qPCR) technique (<xref rid="B156" ref-type="bibr">COVID-19-Host-Genetics-Initiative, 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). In fact, this quantitative, real-time PCR allows to identify specific features in some concerning variants, like S-gene target failure (SGTF) found in the B.1.1.7 (Alpha) and Omicron variants, further confirmed by S-gene sequencing (<xref rid="B736" ref-type="bibr">Volz et al., 2021</xref>; <xref rid="B5" ref-type="bibr">Aggarwal et al., 2022</xref>; <xref rid="B776" ref-type="bibr">Wolter et al., 2022</xref>). In other studies, single-cell RNA sequencing data has been combined with viral WGS analysis, leading key results corelating the level of expression of CCR1 and CXCR6 chemokine receptors on CD8<sup>+</sup> T cells and monocytes with COVID-19 severity (<xref rid="B23" ref-type="bibr">Alsved et al., 2022</xref>). The presence of SARS-CoV-2 VOCs are detected by genomic sequence analysis. It was used to identify the first VOCs B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) and those that emerged later on, such as B.1.617.2 (Delta) and Omicron BA.1 and BA.2 lineages associated with enhanced viral transmission and pathogenicity, and immune escape (<xref rid="B9" ref-type="bibr">Akilesh et al., 2021</xref>; <xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>; <xref rid="B24" ref-type="bibr">Altmann et al., 2021</xref>; <xref rid="B276" ref-type="bibr">Hirotsu and Omata, 2021</xref>; <xref rid="B508" ref-type="bibr">Nakamichi et al., 2021</xref>; <xref rid="B21" ref-type="bibr">Alsafar et al., 2022</xref>; <xref rid="B144" ref-type="bibr">Ciuffreda et al., 2022</xref>; <xref rid="B264" ref-type="bibr">Harrigan et al., 2022</xref>; <xref rid="B445" ref-type="bibr">Lyngse et al., 2022</xref>; <xref rid="B763" ref-type="bibr">Wawina-Bokalanga et al., 2022</xref>). In fact, the viral WGS is appropriated for the identification of the viral genomic variants that are associated with severe disease patterns (<xref rid="B282" ref-type="bibr">Hoffmann et al., 2021</xref>; <xref rid="B277" ref-type="bibr">Hoang et al., 2022</xref>; <xref rid="B540" ref-type="bibr">Overton et al., 2022</xref>; <xref rid="B737" ref-type="bibr">von Wintersdorff et al., 2022</xref>).</p><p>One sequencing approach that has gained relevance in the context of real-time surveillance of SARS-CoV-2 entails the long-read sequencing technology from Oxford Nanopore Technologies (ONT) (<xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B551" ref-type="bibr">Pater et al., 2021</xref>). ONT technology relies on a nanoscale modified protein pore, named nanopore, that functions as a biosensor which is embedded in a polymer membrane with electric resistant properties (<xref rid="B172" ref-type="bibr">Deamer et al., 2016</xref>; <xref rid="B719" ref-type="bibr">van Dijk et al., 2018</xref>) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Negatively charged single-stranded DNA (ssDNA) or RNA molecules, contained in an electrolytic solution, are driven by an ionic current (created under constant voltage) through the nanopore. These charged nucleic acid molecules move from the negatively charged &#8220;cis&#8221; side to the positively charged &#8220;trans&#8221; side of the nanopore (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Importantly, a motor protein that acts as an anchored bar pass the ssDNA or RNA molecules through the nanopore in a controlled manner thereby reducing the translocation speed. RNA or ssDNA changes the ionic current during translocation. Using computational algorithms translate these current changes into the nucleotide sequence present in the sample, allowing real-time sequencing of single molecules (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Moreover, the motor protein presents a helicase activity that unwound the double-stranded DNA (sdDNA) or RNA-DNA duplexes into single-stranded molecules that pass through the nanopore (reviewed in (<xref rid="B172" ref-type="bibr">Deamer et al., 2016</xref>; <xref rid="B758" ref-type="bibr">Wang et al., 2021e</xref>)). Previously, for assuring SARS-CoV-2 genome sequencing and considering that viral RNA extracted from patients samples could be degraded and not the best quality, a series of shorter amplicons (i.e., 400 nucleotides) are used for amplifying across the virus genome and cover the whole sequence (<xref rid="F4" ref-type="fig">Figure 4B</xref>), thereby the viral RNA is converted into DNA by reverse transcription and PCR is used for amplicons generation to cover all the sequence and identifying overlapping amplicons (<xref rid="B350" ref-type="bibr">Kim et al., 2020a</xref>; <xref rid="B98" ref-type="bibr">Bull et al., 2020</xref>; <xref rid="B92" ref-type="bibr">Brejov&#225; et al., 2021</xref>; <xref rid="B676" ref-type="bibr">St&#252;der et al., 2021</xref>; <xref rid="B761" ref-type="bibr">Wang et al., 2022b</xref>; <xref rid="B414" ref-type="bibr">Li et al., 2022</xref>; <xref rid="B791" ref-type="bibr">Xu et al., 2022</xref>) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Then, samples were barcoded by using specific kits and following ligation with a sequencing adapter, in order to generate a library for nanopore sequencing (<xref rid="F4" ref-type="fig">Figure 4B</xref>). The protocol for nanopore sequencing of tiled PCR-generated amplicon pools has been developed an adapted by the Artic Network (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://artic.network/" ext-link-type="uri">https://artic.network/</ext-link>). These procedures have been used for other emerging RNA viruses and microorganisms (<xref rid="B590" ref-type="bibr">Quick et al., 2016</xref>; <xref rid="B591" ref-type="bibr">Quick et al., 2017</xref>; <xref rid="B143" ref-type="bibr">Ciuffreda et al., 2021b</xref>). ONT or nanopore sequencing offers several advantages to obtain viral WGS because these devices do not require large supporting laboratory infrastructures, are portable and are inexpensive, allowing rapid sequencing analysis to be scalable and at reach for any laboratory (<xref rid="B147" ref-type="bibr">Coloma et al., 2016</xref>; <xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B143" ref-type="bibr">Ciuffreda et al., 2021b</xref>). Nanopore sequencing allows to detect single nucleotide variants and small insertion/deletions in circulating SARS-CoV-2 with high accuracy and high sensitivity (<xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B520" ref-type="bibr">Noh et al., 2020</xref>; <xref rid="B50" ref-type="bibr">Baker and Dolgin, 2021</xref>; <xref rid="B143" ref-type="bibr">Ciuffreda et al., 2021b</xref>; <xref rid="B241" ref-type="bibr">Gonz&#225;lez-Recio et al., 2021</xref>; <xref rid="B551" ref-type="bibr">Pater et al., 2021</xref>), as for the key mutations in SARS-CoV-2 VOCs (<xref rid="B379" ref-type="bibr">La Rosa et al., 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Moreover, nanopore technology allows to directly sequence the SARS-CoV-2-RNA + genome from patients&#8217; samples (<xref rid="B730" ref-type="bibr">Viehweger et al., 2019</xref>; <xref rid="B350" ref-type="bibr">Kim et al., 2020a</xref>; <xref rid="B712" ref-type="bibr">Vacca et al., 2022</xref>; <xref rid="B791" ref-type="bibr">Xu et al., 2022</xref>) (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Nanopore sequencing combined with a machine learning algorithm permits rapid hospital diagnoses of SARS-CoV-2 from saliva samples of the patients (<xref rid="B285" ref-type="bibr">Horejs, 2021</xref>). Nanopore sequencing could be used in SARS-CoV-2 diagnose with other technologies, such as the reverse transcription (RT) loop mediated isothermal amplification (LAMP; (<xref rid="B523" ref-type="bibr">Notomi et al., 2000</xref>)) (RT-LAMP; (<xref rid="B296" ref-type="bibr">Huang et al., 2022</xref>)) underlying the LamPORE approach (<xref rid="B311" ref-type="bibr">James et al., 2020</xref>). LamPORE is considered a high-throughput substitute of RT-qPCRs for rapid and accurate diagnosis of SARS-CoV-2 infection (<xref rid="B564" ref-type="bibr">Peto et al., 2021</xref>; <xref rid="B585" ref-type="bibr">Ptasinska et al., 2021</xref>) while used for SARS-CoV-2 genotyping (<xref rid="B495" ref-type="bibr">Morsli et al., 2021</xref>). Moreover, ONT sequencing has been applied for accurate tracking of intra-hospital SARS-CoV-2 transmission (<xref rid="B437" ref-type="bibr">L&#248;vestad et al., 2021</xref>). Thus, this affordable and easy-to-scale viral sequencing technology has been a widespread solution for tracking SARS-CoV-2 VOCs (<xref rid="B606" ref-type="bibr">Rios et al., 2021</xref>; <xref rid="B793" ref-type="bibr">Yakovleva et al., 2021</xref>; <xref rid="B57" ref-type="bibr">Barb&#233; et al., 2022</xref>), and help decision making for local public health agents without the need of large genomic infrastructures.</p><p>The ability of SARS-CoV-2 to evolve forces constant virosurveillance and the adaptation of the required tools, especially at the genetic level for tracking emergence of new VOCs (<xref rid="B442" ref-type="bibr">Lucas et al., 2020a</xref>). The rapid detection and characterization of new variants is therefore crucial to informing the potential efficacy of vaccines and therapeutics (<xref rid="B442" ref-type="bibr">Lucas et al., 2020a</xref>). The next-generation genome sequencing technologies, as well as nanopore allow to rapidly adapt protocols and reagents for accurate and sensitive detection of new emerging SARS-CoV-2 VOCs (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p></sec><sec id="s2-4"><title>2.4 Point-of-care: Rapid diagnosis and control of outbreaks in the field</title><p>Point-of-care (PoC) facilities and detection technologies have been stablished all around the world because they enable decentralized (i.e., from hospitals), rapid, sensitive, low-cost diagnosis of SARS-CoV-2 infection in neighborhoods health offices and identification of COVID-19 symptoms (<xref rid="B349" ref-type="bibr">Kilic et al., 2020</xref>; <xref rid="B720" ref-type="bibr">van Dongen et al., 2020</xref>; <xref rid="B717" ref-type="bibr">Valera et al., 2021</xref>). The PoCs have accomplished a crucial role in epidemiology surveillance and <italic toggle="yes">in situ</italic> first triage of ill patients, avoiding sample transport to a clinical laboratory for analysis, thereby easing Hospital work and management of more sever COVID-19 patients (<xref rid="B723" ref-type="bibr">Vandenberg et al., 2021</xref>). PoCs have been of importance for prevention of SARS-CoV-2 transmission to the community and to determine who requires quarantine. In fact, the above reported, first viral genetic sequences enabled the rapid development of PoC real-time RT-qPCR diagnostic tests specific for the new CoV (<xref rid="B327" ref-type="bibr">Kampf et al., 2020a</xref>; <xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B279" ref-type="bibr">Hoehl et al., 2020</xref>; <xref rid="B614" ref-type="bibr">Rothe et al., 2020</xref>; <xref rid="B253" ref-type="bibr">Gupta et al., 2021a</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). In these PoCs the technology used for testing patients permits minimum samples processing, the use of saliva or anterior nasal swabs (nasopharyngeal exudate or other upper/lower respiratory samples) for accurate SARS-CoV-2 detection (i.e., viral RNA or mainly S and/or N antigen proteins), as well as Abs able to recognize viral proteins, either in symptomatic or asymptomatic patients (<xref rid="F4" ref-type="fig">Figure 4B</xref>). Therefore, COVID-19 tests are developed for molecular diagnostics (viral genome), antigen (viral proteins) and antibody tests (<xref rid="B349" ref-type="bibr">Kilic et al., 2020</xref>; <xref rid="B717" ref-type="bibr">Valera et al., 2021</xref>). For personnel using these tests, it is important to know the accurate protocol for taking samples (i.e., it is key to have skills to know the most appropriate moment for taking samples) and use of these techniques, in order to minimize non-specific results (false positives or negatives reads) due to inappropriate handling or inadequate interpretation of the obtained results, since this information is considered together with the symptomatology of patients for making clinical decisions (<xref rid="B306" ref-type="bibr">Jacofsky et al., 2020</xref>).</p><p>Infected individuals have been determined by using gold-standard COVID-19 diagnosis to detect SARS-CoV-2 genomic fragments in patients&#8217; samples, associated with viral proteins, such as the S glycoprotein, N, E and the RNA-dependent RNA polymerase (RdRp), and using RNA purification and one-step RT-qPCR (<xref rid="B14" ref-type="bibr">Alcoba-Florez et al., 2020a</xref>; <xref rid="B15" ref-type="bibr">Alcoba-Florez et al., 2020b</xref>; <xref rid="B343" ref-type="bibr">Khailany et al., 2020</xref>; <xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">see RT-qPCR schemes</italic>). As presented above, the Chinese authorities published in GenBank and in the GISAID portal database the complete genome of SARS-CoV-2. Thanks to this contribution, the microbiological diagnosis of COVID-19 has been based on the detection of the viral genetic material (RNA+) of SARS-CoV-2 from the collection of respiratory samples from patients with compatible symptoms (<xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B192" ref-type="bibr">Dutta et al., 2022</xref>). Various laboratories began development for the detection of SARS-CoV-2 in accordance with WHO guidelines, which initially published five protocols for diagnosis using RT-qPCR (<xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>; <xref rid="B192" ref-type="bibr">Dutta et al., 2022</xref>). The first validated RT-qPCR detection test was developed by the Berlin Institute of Virology (<xref rid="B153" ref-type="bibr">Corman et al., 2020</xref>). The laboratory PCR procedure consists in the extraction of nucleic acid and the amplification reaction. These processes could be automated for rapid diagnose and to reduce errors (<xref rid="B132" ref-type="bibr">Cheng et al., 2020a</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">see RT-qPCR schemes</italic>). Moreover, this RT-qPCR technique could be adapted to rapidly detect SARS-CoV-2 (i.e. by 1&#160;h), bypassing the time consuming RNA extraction step and accelerating viral detection, without test sensitivity reduction and allowing sample scaling to increase testing capacity by sample pooling, being of importance during severe outbreaks with large number of people to be tested in a short period of time (<xref rid="B14" ref-type="bibr">Alcoba-Florez et al., 2020a</xref>; <xref rid="B15" ref-type="bibr">Alcoba-Florez et al., 2020b</xref>; <xref rid="B16" ref-type="bibr">Alcoba-Florez et al., 2021</xref>). Likewise, functionalized coated magnetic nanoparticles (MNP) with a negatively charged polymer (i.e., created from 3-aminopropyl triethoxysilane (APTES) polymerized with diacrylate-amine to obtain the poly (amino-ester), poly-NH2-MNPs) allows viral RNA extraction and purification, in order to implement the detection of the SARS-CoV-2 virus by RT-qPCR on a large scale (<xref rid="B116" ref-type="bibr">Chac&#243;n-Torres et al., 2020</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>).</p><p>Serological tests are diagnostic methods used for rapid detection of Immunoglobulins (Igs) (i.e., IgG, IgM and IgA) against SARS-CoV-2 S and N proteins (<xref rid="B183" ref-type="bibr">Dinnes et al., 2020</xref>; <xref rid="B708" ref-type="bibr">Tuaillon et al., 2020</xref>; <xref rid="B795" ref-type="bibr">Yamayoshi et al., 2020</xref>). These tests are named &#8220;rapid tests&#8221; (about 15&#160;min) and consist in immunochromatographic lateral flow assays to detect Abs that indicate that individuals are infected or have been recently infected by SARS-CoV-2 (<xref rid="F4" ref-type="fig">Figure 4</xref>, <italic toggle="yes">see lateral flow test schemes</italic>). Serological tests for detection of anti-SARS-CoV-2 Abs to support infected individuals diagnose were first used by the Duke-NUS Medical School in Singapore. This test, named cPass&#8482;, was developed in a consortium with GenScript Biotech Corporation and A*STAR, and measures nAbs in an hour (<xref rid="B324" ref-type="bibr">Jung et al., 2021</xref>). Lateral flow Ab tests for SARS-CoV-2 require a drop of blood from the patient, usually from a finger prick, similar to tests to monitor blood sugar in certain types of diabetes. This capture and binding process produces a color change along the test and control lines that can be seen with the naked eye, producing one, two, or three lines depending on the type of antibodies (Abs) present (IgM or IgG) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">see lateral flow schemes</italic>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). These tests work very differently from the RT-qPCR technique and focus on detecting the patient&#8217;s immune response to the virus rather than detecting the virus itself. These Ab tests require knowledge about the structure and key infection epitopes of the viral proteins, specifically, those proteins to which the immune system responds by triggering the production of nAbs that could neutralize the virus (<xref rid="B250" ref-type="bibr">Guo et al., 2020b</xref>; <xref rid="B315" ref-type="bibr">Jiang and Zhang, 2020</xref>; <xref rid="B822" ref-type="bibr">Zhao et al., 2020</xref>). In this matter, the generation of Abs against SARS-CoV-2 begin about the sixth day of the onset of symptoms, when a decrease in viral load could be observed. Half of the infected cases have total Abs around the seventh day post-infection and 15&#160;days after infection, almost 100% of infected individuals presented Abs both in mild and severe cases (<xref rid="B250" ref-type="bibr">Guo et al., 2020b</xref>; <xref rid="B306" ref-type="bibr">Jacofsky et al., 2020</xref>; <xref rid="B434" ref-type="bibr">Long et al., 2020</xref>; <xref rid="B822" ref-type="bibr">Zhao et al., 2020</xref>). These Ab-based techniques seek to detect the immune response of patients, which increases as the infection progresses, and therefore offer the possibility to detect active disease (<xref rid="B306" ref-type="bibr">Jacofsky et al., 2020</xref>). Of note, the presence of Abs does not exclude the possibility of continuing to be contagious and is not indicative of having sterilized immunity against recurrent SARS-CoV-2 infections, either in vaccinated or in vaccinated people where reinfections frequently occur (<xref rid="B75" ref-type="bibr">Bergwerk et al., 2021</xref>; <xref rid="B254" ref-type="bibr">Gupta et al., 2021b</xref>; <xref rid="B258" ref-type="bibr">Hagan et al., 2021</xref>; <xref rid="B669" ref-type="bibr">Song et al., 2021</xref>; <xref rid="B704" ref-type="bibr">To et al., 2021</xref>; <xref rid="B3" ref-type="bibr">Acharya et al., 2022</xref>; <xref rid="B371" ref-type="bibr">Kuhlmann et al., 2022</xref>; <xref rid="B603" ref-type="bibr">Ren et al., 2022</xref>; <xref rid="B661" ref-type="bibr">Singanayagam et al., 2022</xref>).</p><p>Antigen serological tests are based on the detection of viral proteins specific to SARS-CoV-2, such as the N protein and the S1 or S2 subunits of the S viral glycoprotein (reviewed in (<xref rid="B207" ref-type="bibr">Falzone et al., 2021</xref>; <xref rid="B407" ref-type="bibr">Li and Li, 2021</xref>)) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">see lateral flow tests for immune assays</italic>). Considering that viral replication is more accentuated in the acute phase, the antigenic test should be carried out in the first five-seven days after the onset of symptoms. The biological samples used to detect viral proteins come from nasopharyngeal, oropharyngeal or sputum exudates (reviewed in (<xref rid="B207" ref-type="bibr">Falzone et al., 2021</xref>; <xref rid="B407" ref-type="bibr">Li and Li, 2021</xref>)). The test contains a strip of nitrocellulose paper where a line has been painted with Abs that adhere to the virus (<xref rid="F4" ref-type="fig">Figure 4</xref>, <italic toggle="yes">see lateral flow test schemes</italic>). The sample is mixed with a diluent to be dispensed into the test in the window intended for the sample. In this sample-window, the sample is met by colloidal gold- or latex-labeled Abs that make them visible. Later, in the test line (T), more Abs (unmarked) are placed that will serve to confirm whether or not there is an infection. It seems that the viral load is higher in sputum and nasopharynx, being higher in the initial stages of infection, but if the sample viral load is in the limit of detection, false negative reads will occur, instead the person is infected (reviewed in (<xref rid="B207" ref-type="bibr">Falzone et al., 2021</xref>)).</p><p>Innovative tools for SARS-CoV-2 detection have also been developed using nanomaterials and derived technology. Multiple characteristics have made these nanomaterials good candidates for diagnosis support: the variability in size, structure and geometry, the surface reactivity that have allowed their functionalization with other biomolecules, the electrical conductivity and/or magnetic properties or the quantum or fluorescent characteristics (<xref rid="B331" ref-type="bibr">Kang et al., 2009</xref>; <xref rid="B32" ref-type="bibr">Ansari et al., 2010</xref>; <xref rid="B106" ref-type="bibr">Cao et al., 2011</xref>; <xref rid="B284" ref-type="bibr">Holzinger et al., 2014</xref>; <xref rid="B678" ref-type="bibr">Sun et al., 2017</xref>; <xref rid="B482" ref-type="bibr">Mitchell et al., 2021</xref>). For example, gold nanoparticles (AuNPs), magnetic NPs and quantum dots (QDs) have been engineered to detect SARS-CoV-2 genes and proteins, as well as anti-SARS-CoV-2 Igs by using optical, fluorescence, magnetic and optomagnetic biosensors (reviewed in (<xref rid="B484" ref-type="bibr">Moabelo et al., 2021</xref>)) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">lateral flow tests and colorimetric assays</italic>). Thus, AuNPs have been used in colorimetric assays for detecting target regions on N and RdRp viral genes (<xref rid="B487" ref-type="bibr">Moitra et al., 2020</xref>; <xref rid="B373" ref-type="bibr">Kumar et al., 2022</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>), or by using quantitative paper-based electrochemical sensor chip to detect the N gene (<xref rid="B11" ref-type="bibr">Alafeef et al., 2020</xref>). Moreover, AuNPs allow to detect specific IgM and IgG Abs that recognizes SARS-CoV-2 proteins (S and N) by using a colloidal AuNPs-based lateral-flow assay, where AuNPs are coated with S or N viral proteins to capture Abs (<xref rid="B419" ref-type="bibr">Liu et al., 2020a</xref>; <xref rid="B293" ref-type="bibr">Huang et al., 2020b</xref>; <xref rid="B559" ref-type="bibr">Peng et al., 2021b</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>, <italic toggle="yes">lateral flow tests for viral antigen detection</italic>). AuNPs-based lateral flow tests allow to detect the S or N viral proteins by using S or N protein monoclonal Abs (mAbs) coated to the AuNPs (<xref rid="B475" ref-type="bibr">Mertens et al., 2020</xref>; <xref rid="B412" ref-type="bibr">Li et al., 2021a</xref>; <xref rid="B425" ref-type="bibr">Liu et al., 2021a</xref>), or with sialic acid-coated AuNPs for S protein detection (<xref rid="B51" ref-type="bibr">Baker et al., 2020</xref>) (<xref rid="F4" ref-type="fig">Figure 4A</xref>). Likewise, gold nanoislands (AuNIs) have been useful to detect viral genes, such as ORF1ab, RdRp and E by using functional plasmonic photothermal biosensors (<xref rid="B589" ref-type="bibr">Qiu et al., 2020</xref>). A real-time optomagnetic biosensor has been applied to detect the RdRp gene by using iron oxide NPs (IONPs) (<xref rid="B698" ref-type="bibr">Tian et al., 2020</xref>), whereas graphene oxide (GO) nanosheets, coupled to an anti-S protein Ab, have been used to detect the S antigen in clinical samples by a field-effect transistor (FET)-based biosensing device (<xref rid="B642" ref-type="bibr">Seo et al., 2020</xref>). The fluorescence-linked immunoassay technique allows to detect anti-SARS-CoV-2-specific IgG Abs from serum by using MnFe3O4 nanospheres and quantum dot (QD) nanobeads (<xref rid="B249" ref-type="bibr">Guo et al., 2020a</xref>). Noteworthy, dye streptavidin coated polymer NPs (SA-DNPs) have been used to detect ORF1ab and N genes by using a multiplex reverse transcription LAMP (mRT-LAMP) coupled with a nanoparticle-based lateral flow biosensor, termed a mRT-LAMP-LFB assay (<xref rid="B830" ref-type="bibr">Zhu et al., 2020d</xref>).</p><p>These tests are generally low-cost methods useful for PoC facilities and of importance in low-resource settings and regions (<xref rid="B170" ref-type="bibr">De Nardo et al., 2020</xref>; <xref rid="B208" ref-type="bibr">Fauziah et al., 2021</xref>). Therefore, these genomic, Abs and antigen rapid tests have demonstrated their crucial application for virus surveillance, detection and control of viral outbreaks and community viral transmissions, assisting health systems to rapidly derive only severe ill patients to Hospitals (<xref rid="B170" ref-type="bibr">De Nardo et al., 2020</xref>; <xref rid="B458" ref-type="bibr">Mardian et al., 2021</xref>) (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p></sec></sec><sec id="s3"><title>3 Concluding remarks</title><p>The COVID-19 pandemic has demonstrated the relevance of nanomaterials, reagents and technology to combat SARS-CoV-2 infection, community outbreaks and international spreading of the virus and disease. The use of nanotechnology has made possible to detect virus genomic and protein materials from patients&#8217; samples in a rapid, specifically and affordable manner, being able to assume thousands of samples to be tested per day at microbiology hospital departments. This is a task of great magnitude never faced before at region and international levels. Moreover, nanomaterials and derived diagnose techniques (i.e., RT-qPCR and serology test) are responsible for the success of PoC facilities to undertake the mission of virus outbreak control in cities, towns and neighborhoods, and protecting health worker for infection by wearing high-protective PPEs. PoCs have assured rapid and accurate diagnose of infected individuals, helping to derive sever ill patients to the hospital, and assenting public health policies and administrations to make epidemiological and economic decisions.</p><p>Although several drugs and Abs have been used for COVID-19 treatment, there are no specific anti-viral treatments available to eradicate SARS-CoV-2 from the organism and revert severe COVID-19 clinical condition in terminal patients (<xref rid="B188" ref-type="bibr">Dro&#380;d&#380;al et al., 2021</xref>). For this reason, we have decided not to address all the nano-based drug developments and related delivery systems. However, several nanomaterials and technology are candidate to help in the prevention, diagnosis and treatment of SARS-CoV-2 infection and COVID-19 disease. This is the case of some RNA interference (RNAi) formulations to knock-down key viral genes to limit or inhibit viral infection and progression (<xref rid="B298" ref-type="bibr">Idris et al., 2021</xref>; <xref rid="B819" ref-type="bibr">Zhang et al., 2022b</xref>; <xref rid="B622" ref-type="bibr">Saify Nabiabad et al., 2022</xref>). Several <italic toggle="yes">in vitro</italic> studies using these RNAi preparations have obtained promising results against SARS-CoV-2. However, the <italic toggle="yes">in vivo</italic> efficacy of these nanoreagents have been compromised or not yet explored as in clinical trials. Likewise, carbon-based nanomaterials (CBNs) have been developed to analyze their effect on SARS-CoV-2, such as graphene, fullerene, or carbon dots that have been positively assayed on other RNA+ viruses <italic toggle="yes">in vitro</italic> (reviewed in (<xref rid="B644" ref-type="bibr">Serrano-Aroca et al., 2021</xref>)). It seems that graphene derivatives with long aliphatic chains limit SARS-CoV-2 replication with some extension, without observing significant cellular toxicity (<xref rid="B187" ref-type="bibr">Donskyi et al., 2021</xref>). These CBNs have been tested in other RNA+ viruses with biocompatibility and capacity to induce tissue regeneration, thereby representing promising nanotools for SARS-CoV-2 treatment. Moreover, and considering the antimicrobial effects reported for silver nanoparticles (AgNPs), thought to be associated with the positive charge of silver ions (Ag<sup>+</sup>), some works have explored the inhibition of SARS-CoV-2 infection with AgNPs (<xref rid="B313" ref-type="bibr">Jeremiah et al., 2020</xref>). These silver, metal nanoparticles have been assayed in clinical trial as Argovit<sup>&#174;</sup> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04894409" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04894409</ext-link>). The iron oxide nanoparticles (IONPs) Fe<sub>3</sub>O<sub>4</sub> and Fe<sub>2</sub>O3 have been reported to bind the S viral protein of SARS-CoV-2 (<xref rid="B1" ref-type="bibr">Abo-Zeid et al., 2020</xref>). Although there are not clinical studies initiated with these metal IONPs, molecular docking studies point to this possibility. Another metal nanoparticle made of Au-NP, ZnO-NP and ClO<sub>2</sub> (named TPNT1) has been assayed against SARS-CoV-2. TPNT1 blocks the SARS-CoV-2 viral entry in cells by inhibiting the binding of the S viral protein to the ACE2 receptor (<xref rid="B122" ref-type="bibr">Chang et al., 2021</xref>). Noteworthy, the poly (lactic-co-glycolic acid) (PLGA) forms biodegradable polymeric nanoparticles that have been used to deliver several antiviral drugs to treat ill patients suffering the COVID-19 disease, such as Ivermectin (i.e., Ivermectin-loaded PLGA-b-PEG-MAL nanoparticles). PLGA-derived nanoparticles allow to deliver a more potent antiviral dose of the drug and also impairs the S protein/ACE2 binding (<xref rid="B681" ref-type="bibr">Surnar et al., 2020</xref>). Several bionanoparticles made of polysaccharides and proteins (i.e., chitosan, alginate, gelatin, and albumin), have been tested or are developed to assay their anti-SARS-CoV-2 activity (reviewed in (<xref rid="B173" ref-type="bibr">Debnath and Srivastava, 2022</xref>)). The lack or low toxicity and the excellent biocompatibility showed by all the above-described nanomaterials provide great potential in the development of safe therapeutics based on nanoreagents and technology to prevent SARS-CoV-2 infection and cure the COVID-19 disease.</p><p>The use of nanomaterials and technology has reached the major relevance to combat COVID-19 pandemic with the development of nano-based vaccines. In this review, we have addressed the main vaccine designs, prototypes developments and commercial vaccines that have been used to immunize the whole population, in order to protect either individuals at risk or the rest of people. Vaccines have helped to reduce casualties and hospital distress during the last COVID-19 wave. However, these vaccines are not eliciting sterilizing immunity, and vaccinated people could be infected a reinfected by SARS-CoV-2, by the same variant and new evolving emerging variants. The virus could be transmitted between vaccinated people and naturally immunized individuals. Therefore, sterilizing vaccines to immunize at the mucosal, nasal tissues and NALT are a great challenge that nano-based vaccines would be able to achieve in a near future.</p><p>Nanotechnology and reagents based on next generation technologies for virus genomic sequencing have similarly achieved a historical milestone, allowing virus surveillance in real time, determining SARS-CoV-2 VOCs and identifying key viral mutations that confer virus resistance against natural- and vaccine-elicited cellular and humoral responses immune escape. This information has been key for making public health decisions for advising vaccine booster shots and wearing masks in public transport, plains, hospitals, schools, bars, companies, and administrations. These genomic sequencing technologies have also been useful in PoC facilities, as nanopore-based approaches have efficiently accomplished, even in low-resources regions. The rapid detection and characterization of new variants is therefore crucial to informing the potential efficacy of vaccines and drugs/treatments.</p><p>Altogether, nano-based vaccines and rapid, specific tests for diagnose and outbreak control would help to the efficient control of future COVID-19 epidemic or pandemic episodes. These COVID-19 tools, for sure, will help to the fast development of new and specific nanotools and treatments to challenge future emerging virus and associated crisis that would occur in this XXI century, associated with our global style of life, global warming, and the unsustainable manner we must exploit the resources and biodiversity of our planet.</p></sec></body><back><ack><p>We would like to thank BioRender (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://app.biorender.com/" ext-link-type="uri">https://app.biorender.com/</ext-link>) for offering online all outstanding designs and templates thar have allow to design all figures. We have the BioRender licensing rights for all figures.</p></ack><sec id="s4"><title>Author contributions</title><p>AV-F wrote the paper, conceived, designed the schemes, supervised and edited the manuscript, and equally contributed to this manuscript with conceptualization and literature research with JG-L and CF, RC-R and SP-Y designed all figures supervised and edited the manuscript. All authors have read and supervised the manuscript and agreed to the published version of the manuscript.</p></sec><sec id="s5"><title>Funding</title><p>This work was funded by the European Regional Development Fund (ERDF), PID2021-123031OB-I00 (&#8220;Ministerio de Ciencia e Innovaci&#243;n&#8221;, Spain), ProID2020010093 (&#8220;Agencia Canaria de Investigaci&#243;n, Innovaci&#243;n y Sociedad de la Informaci&#243;n&#8221; and the European Social Fund), UNLL10-3E-783 (ERDF and &#8220;Fundaci&#243;n CajaCa-narias&#8221;), &#8220;SEGAI-ULL&#8221;, and EU funding from the European Centre for Disease Prevention and Control (ECDC/HERA/2021/024 ECD.12241). SP-Y is funded by &#8220;Contrato Predoctoral Ministerio-ULL Formaci&#243;n de Doctores&#8221; (2019 Program) (&#8220;Ministerio de Ciencia, Innovaci&#243;n y Universidades&#8221;, Spain). RC-R is funded by RD16/0025/0011 and ProID2020010093 (&#8220;Agencia Canaria de Investigaci&#243;n, Innovaci&#243;n y Sociedad de la Informaci&#243;n&#8221; and European Social Fund). JG-L is funded by the &#8220;Juan de la Cierva de Incorporaci&#243;n&#8221; Spanish Program (IJC2019-038902-I) (&#8220;Ayudas Juan de la Cierva de incorporaci&#243;n; Agencia Estatal de Investigaci&#243;n. Ministerio de Ciencia e Innovaci&#243;n&#8221;).</p></sec><sec id="s6"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s7"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Zeid</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N. S. M.</given-names></name><name name-style="western"><surname>Mclean</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Hamdy</surname><given-names>N. M.</given-names></name></person-group> (<year>2020</year>). <article-title>A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection</article-title>. <source>Eur. J. Pharm. Sci.</source><volume>153</volume>, <fpage>105465</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105465</pub-id><pub-id pub-id-type="pmid">32668312</pub-id><pub-id pub-id-type="pmcid">PMC7354764</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abraham</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Kannangai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Nanotechnology: A new frontier in virus detection in clinical practice</article-title>. <source>Indian J. Med. Microbiol.</source><volume>26</volume>, <fpage>297</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.4103/0255-0857.43551</pub-id><pub-id pub-id-type="pmid">18974480</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Schrom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Coil</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Viral load among vaccinated and unvaccinated, asymptomatic and symptomatic persons infected with the SARS-CoV-2 Delta variant</article-title>. <source>Open Forum Infect. Dis.</source><volume>9</volume>, <fpage>ofac135</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofac135</pub-id><pub-id pub-id-type="pmid">35479304</pub-id><pub-id pub-id-type="pmcid">PMC8992250</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verleden</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Kuehnel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haverich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welte</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laenger</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>120</fpage>&#8211;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2015432</pub-id><pub-id pub-id-type="pmcid">PMC7412750</pub-id><pub-id pub-id-type="pmid">32437596</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Bharucha</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tumelty</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C. S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The role of viral genomics in understanding COVID-19 outbreaks in long-term care facilities</article-title>. <source>Lancet Microbe</source><volume>3</volume>, <fpage>e151</fpage>&#8211;<lpage>e158</lpage>. <pub-id pub-id-type="doi">10.1016/s2666-5247(21)00208-1</pub-id><pub-id pub-id-type="pmid">34608459</pub-id><pub-id pub-id-type="pmcid">PMC8480962</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>W.</given-names></name><name name-style="western"><surname>Angel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Edson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bibby</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bivins</surname><given-names>A.</given-names></name><name name-style="western"><surname>O'brien</surname><given-names>J. W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community</article-title>. <source>Sci. Total Environ.</source><volume>728</volume>, <fpage>138764</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138764</pub-id><pub-id pub-id-type="pmid">32387778</pub-id><pub-id pub-id-type="pmcid">PMC7165106</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahn</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Y. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19</article-title>. <source>J. Clin. Invest.</source><volume>131</volume>, <fpage>148517</fpage>. <pub-id pub-id-type="doi">10.1172/jci148517</pub-id><pub-id pub-id-type="pmid">34003804</pub-id><pub-id pub-id-type="pmcid">PMC8245175</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akhmetzhanov</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R. N.</given-names></name></person-group> (<year>2021</year>). <article-title>A hospital-related outbreak of SARS-CoV-2 associated with variant epsilon (B.1.429) in taiwan: Transmission potential and outbreak containment under intensified contact tracing, january-february 2021</article-title>. <source>Int. J. Infect. Dis.</source><volume>110</volume>, <fpage>15</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2021.06.028</pub-id><pub-id pub-id-type="pmid">34146689</pub-id><pub-id pub-id-type="pmcid">PMC8214728</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akilesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nicosia</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Alpers</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Tretiakova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hsiang</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>M.</given-names><suffix>Jr.</suffix></name><etal/></person-group> (<year>2021</year>). <article-title>Characterizing viral infection by electron microscopy: Lessons from the coronavirus disease 2019 pandemic</article-title>. <source>Am. J. Pathol.</source><volume>191</volume>, <fpage>222</fpage>&#8211;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2020.11.003</pub-id><pub-id pub-id-type="pmid">33227297</pub-id><pub-id pub-id-type="pmcid">PMC7678435</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Kaabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Al Qahtani</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Abdulrazzaq</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial</article-title>. <source>Jama</source><volume>326</volume>, <fpage>35</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.8565</pub-id><pub-id pub-id-type="pmid">34037666</pub-id><pub-id pub-id-type="pmcid">PMC8156175</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alafeef</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dighe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moitra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>17028</fpage>&#8211;<lpage>17045</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c06392</pub-id><pub-id pub-id-type="pmid">33079516</pub-id><pub-id pub-id-type="pmcid">PMC7586458</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Barwani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pelham</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>V. K.</given-names></name></person-group> (<year>2014a</year>). <article-title>Antigen delivery by virus-like particles for immunotherapeutic vaccination</article-title>. <source>Ther. Deliv.</source><volume>5</volume>, <fpage>1223</fpage>&#8211;<lpage>1240</lpage>. <pub-id pub-id-type="doi">10.4155/tde.14.74</pub-id><pub-id pub-id-type="pmid">25491672</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Barwani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Baird</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>V. K.</given-names></name></person-group> (<year>2014b</year>). <article-title>Mannosylation of virus-like particles enhances internalization by antigen presenting cells</article-title>. <source>Plos One</source><volume>9</volume>, <fpage>e104523</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0104523</pub-id><pub-id pub-id-type="pmid">25122183</pub-id><pub-id pub-id-type="pmcid">PMC4133192</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcoba-Florez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gil-Campesino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Artola</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Montelongo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Valenzuela-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciuffreda</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Sensitivity of different RT-qPCR solutions for SARS-CoV-2 detection</article-title>. <source>Int. J. Infect. Dis.</source><volume>99</volume>, <fpage>190</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.058</pub-id><pub-id pub-id-type="pmid">32745627</pub-id><pub-id pub-id-type="pmcid">PMC7395224</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcoba-Florez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Montelongo</surname><given-names>R.</given-names></name><name name-style="western"><surname>&#205;&#241;igo-Campos</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Artola</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Gil-Campesino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ciuffreda</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples</article-title>. <source>Int. J. Infect. Dis.</source><volume>97</volume>, <fpage>66</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.099</pub-id><pub-id pub-id-type="pmid">32492531</pub-id><pub-id pub-id-type="pmcid">PMC7833505</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alcoba-Florez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gil-Campesino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez De Artola</surname><given-names>D.</given-names></name><name name-style="western"><surname>D&#237;ez-Gil</surname><given-names>O.</given-names></name><name name-style="western"><surname>Valenzuela-Fern&#225;ndez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Montelongo</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Increasing SARS-CoV-2 RT-qPCR testing capacity by sample pooling</article-title>. <source>Int. J. Infect. Dis.</source><volume>103</volume>, <fpage>19</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.11.155</pub-id><pub-id pub-id-type="pmid">33220439</pub-id><pub-id pub-id-type="pmcid">PMC7674967</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbar Samad</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Slenker</surname><given-names>A. K.</given-names></name></person-group> (<year>2022</year>). &#8220;<article-title>Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)</article-title>,&#8221; in <source>StatPearls</source> (<publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing Copyright &#169; 2022, StatPearls Publishing LLC.</publisher-name>).<pub-id pub-id-type="pmid">34033342</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alejo-Cancho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gual-De-Torrella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gallego</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urrutikoetxea-Gutierrez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lejarraga</surname><given-names>C.</given-names></name><name name-style="western"><surname>L&#243;pez De Goikoetxea</surname><given-names>M. J.</given-names></name></person-group> (<year>2022</year>). <article-title>Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays</article-title>. <source>Arch. Virol.</source><volume>167</volume>, <fpage>1141</fpage>&#8211;<lpage>1144</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-022-05395-w</pub-id><pub-id pub-id-type="pmid">35194675</pub-id><pub-id pub-id-type="pmcid">PMC8863091</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cyster</surname><given-names>J. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Germinal-center organization and cellular dynamics</article-title>. <source>Immunity</source><volume>27</volume>, <fpage>190</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.07.009</pub-id><pub-id pub-id-type="pmid">17723214</pub-id><pub-id pub-id-type="pmcid">PMC2242846</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>G. Y.</given-names></name><name name-style="western"><surname>Hadas-Golan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brosh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Immunogenicity of sci-B-vac (a third-generation hepatitis B vaccine) in HIV-positive adults</article-title>. <source>Isr. Med. Assoc. J.</source><volume>19</volume>, <fpage>143</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="pmid">28457089</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsafar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Albreiki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Azman</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Vurivi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Waasia</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Genomic epidemiology and emergence of SARS-CoV-2 variants of concern in the United Arab Emirates</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>14669</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-16967-w</pub-id><pub-id pub-id-type="pmid">36038563</pub-id><pub-id pub-id-type="pmcid">PMC9421632</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Sharif</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strianese</surname><given-names>D.</given-names></name><name name-style="western"><surname>Almadhi</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>D'aponte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dell'omo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Benedetto</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Ocular tropism of coronavirus (CoVs): A comparison of the interaction between the animal-to-human transmitted coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS-CoV, CoV-229E, NL63, OC43, HKU1) and the eye</article-title>. <source>Int. Ophthalmol.</source><volume>41</volume>, <fpage>349</fpage>&#8211;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1007/s10792-020-01575-2</pub-id><pub-id pub-id-type="pmid">32880786</pub-id><pub-id pub-id-type="pmcid">PMC7471531</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsved</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nygren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thuresson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Medstrand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fraenkel</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Londahl</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 in exhaled aerosol particles from Covid-19 cases and its association to household transmission</article-title>. <source>Clin. Infect. Dis.</source><volume>75</volume>, <fpage>e50</fpage>&#8211;<lpage>e56</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciac202</pub-id><pub-id pub-id-type="pmid">35271734</pub-id><pub-id pub-id-type="pmcid">PMC8992237</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altmann</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Boyton</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Beale</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunity to SARS-CoV-2 variants of concern</article-title>. <source>Science</source><volume>371</volume>, <fpage>1103</fpage>&#8211;<lpage>1104</lpage>. <pub-id pub-id-type="doi">10.1126/science.abg7404</pub-id><pub-id pub-id-type="pmid">33707254</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alving</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Matyas</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Liposomal adjuvants for human vaccines</article-title>. <source>Expert Opin. Drug Deliv.</source><volume>13</volume>, <fpage>807</fpage>&#8211;<lpage>816</lpage>. <pub-id pub-id-type="doi">10.1517/17425247.2016.1151871</pub-id><pub-id pub-id-type="pmid">26866300</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alyautdin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khalin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nafeeza</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Haron</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Kuznetsov</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Nanoscale drug delivery systems and the blood-brain barrier</article-title>. <source>Int. J. Nanomedicine</source><volume>9</volume>, <fpage>795</fpage>&#8211;<lpage>811</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S52236</pub-id><pub-id pub-id-type="pmid">24550672</pub-id><pub-id pub-id-type="pmcid">PMC3926460</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amaechi</surname><given-names>U. A.</given-names></name><name name-style="western"><surname>Sodipo</surname><given-names>B. O.</given-names></name><name name-style="western"><surname>Nnaji</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Owoyemi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Omitiran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okedo-Alex</surname><given-names>I. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Social approaches to COVID-19 pandemic response: Effectiveness and practicality in sub-saharan africa</article-title>. <source>Pan Afr. Med. J.</source><volume>37</volume>, <fpage>2</fpage>. <pub-id pub-id-type="doi">10.11604/pamj.supp.2020.37.2.25183</pub-id><pub-id pub-id-type="pmcid">PMC7704349</pub-id><pub-id pub-id-type="pmid">33294103</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W. I.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The proximal origin of SARS-CoV-2</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>450</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Widge</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>2427</fpage>&#8211;<lpage>2438</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id><pub-id pub-id-type="pmid">32991794</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andries</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mc Cafferty</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>N. N.</given-names></name><name name-style="western"><surname>Kitada</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice</article-title>. <source>J. Control. Release</source><volume>217</volume>, <fpage>337</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2015.08.051</pub-id><pub-id pub-id-type="pmid">26342664</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anfinrud</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bax</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Stadnytskyi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bax</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Could SARS-CoV-2 be transmitted via speech droplets?</article-title><comment>medRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2020.04.02.20051177</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ansari</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Alhoshan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alsalhi</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Aldwayyan</surname><given-names>A. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Prospects of nanotechnology in clinical immunodiagnostics</article-title>. <source>Sensors (Basel)</source><volume>10</volume>, <fpage>6535</fpage>&#8211;<lpage>6581</lpage>. <pub-id pub-id-type="doi">10.3390/s100706535</pub-id><pub-id pub-id-type="pmid">22163566</pub-id><pub-id pub-id-type="pmcid">PMC3231125</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anselmo</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Mitragotri</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Nanoparticles in the clinic: An update</article-title>. <source>Bioeng. Transl. Med.</source><volume>4</volume>, <fpage>e10143</fpage>. <pub-id pub-id-type="doi">10.1002/btm2.10143</pub-id><pub-id pub-id-type="pmid">31572799</pub-id><pub-id pub-id-type="pmcid">PMC6764803</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thalhammer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tzakos</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Stojanovska</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Targeting antigens to dendritic cell receptors for vaccine development</article-title>. <source>J. Drug Deliv.</source><volume>2013</volume>, <fpage>1</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1155/2013/869718</pub-id><pub-id pub-id-type="pmcid">PMC3817681</pub-id><pub-id pub-id-type="pmid">24228179</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arons</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Hatfield</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>A.</given-names></name><name name-style="western"><surname>James</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>2081</fpage>&#8211;<lpage>2090</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2008457</pub-id><pub-id pub-id-type="pmcid">PMC7200056</pub-id><pub-id pub-id-type="pmid">32329971</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kempf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nehlmeier</surname><given-names>I.</given-names></name><name name-style="western"><surname>Graichen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>M. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency</article-title>. <source>Cell. Mol. Immunol.</source><volume>18</volume>, <fpage>2673</fpage>&#8211;<lpage>2675</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-021-00779-5</pub-id><pub-id pub-id-type="pmid">34697413</pub-id><pub-id pub-id-type="pmcid">PMC8543421</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arora</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kempf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nehlmeier</surname><given-names>I.</given-names></name><name name-style="western"><surname>Graichen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Lier</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination</article-title>. <source>Cell Rep.</source><volume>39</volume>, <fpage>110754</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2022.110754</pub-id><pub-id pub-id-type="pmid">35477025</pub-id><pub-id pub-id-type="pmcid">PMC9010234</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arslan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gamal El-Din</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Transmission of SARS-CoV-2 via fecal-oral and aerosols-borne routes: Environmental dynamics and implications for wastewater management in underprivileged societies</article-title>. <source>Sci. Total Environ.</source><volume>743</volume>, <fpage>140709</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.140709</pub-id><pub-id pub-id-type="pmid">32652357</pub-id><pub-id pub-id-type="pmcid">PMC7332911</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title>. <source>Nature</source><volume>594</volume>, <fpage>253</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascarateil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name></person-group> (<year>2006</year>). <article-title>Surfactants in vaccine adjuvants: Description and perspectives</article-title>. <source>Vaccine</source><volume>24</volume> (<issue>2</issue>), <fpage>S83</fpage>&#8211;<lpage>S8385</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.134</pub-id><pub-id pub-id-type="pmid">16823939</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ascarateil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Puget</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koziol</surname><given-names>M.-E.</given-names></name></person-group> (<year>2015</year>). <article-title>Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines</article-title>. <source>J. Immunother. Cancer</source><volume>3</volume>, <fpage>P428</fpage>. <pub-id pub-id-type="doi">10.1186/2051-1426-3-s2-p428</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asdaq</surname><given-names>S. M. B.</given-names></name><name name-style="western"><surname>Ikbal</surname><given-names>A. M. A.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deka</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanotechnology integration for SARS-CoV-2 diagnosis and treatment: An approach to preventing pandemic</article-title>. <source>Nanomater. (Basel)</source><volume>11</volume>, <fpage>1841</fpage>. <pub-id pub-id-type="doi">10.3390/nano11071841</pub-id><pub-id pub-id-type="pmcid">PMC8308419</pub-id><pub-id pub-id-type="pmid">34361227</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashraf</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bae</surname><given-names>Y. S.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 vaccines (revisited) and oral-mucosal vector system as a potential vaccine platform</article-title>. <source>Vaccines (Basel)</source><volume>9</volume>, <fpage>171</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9020171</pub-id><pub-id pub-id-type="pmid">33670630</pub-id><pub-id pub-id-type="pmcid">PMC7922043</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aydillo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gonzalez-Reiche</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van De Guchte</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Obla</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>2586</fpage>&#8211;<lpage>2588</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2031670</pub-id><pub-id pub-id-type="pmcid">PMC7722690</pub-id><pub-id pub-id-type="pmid">33259154</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>384</volume>, <fpage>403</fpage>&#8211;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id><pub-id pub-id-type="pmid">33378609</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badiola</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Otero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mar&#237;n</surname><given-names>B.</given-names></name><name name-style="western"><surname>Garc&#237;a Mart&#237;nez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Betancor</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 outbreak on a Spanish mink farm: Epidemiological, molecular, and pathological studies</article-title>. <source>Front. Vet. Sci.</source><volume>8</volume>, <fpage>805004</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2021.805004</pub-id><pub-id pub-id-type="pmid">35127883</pub-id><pub-id pub-id-type="pmcid">PMC8814420</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Yon</surname><given-names>D. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Asymptomatic transmission of SARS-CoV-2 on evacuation flight</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>2705</fpage>&#8211;<lpage>2708</lpage>. <pub-id pub-id-type="doi">10.3201/eid2611.203353</pub-id><pub-id pub-id-type="pmid">32822289</pub-id><pub-id pub-id-type="pmcid">PMC7588520</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Dynamics of viral shedding and symptoms in patients with asymptomatic or mild COVID-19</article-title>. <source>Viruses</source><volume>13</volume>, <fpage>2133</fpage>. <pub-id pub-id-type="doi">10.3390/v13112133</pub-id><pub-id pub-id-type="pmid">34834940</pub-id><pub-id pub-id-type="pmcid">PMC8625453</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Khaleeq</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>U.</given-names></name><name name-style="western"><surname>Syeda</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms</article-title>. <source>ACS Chem. Neurosci.</source><volume>11</volume>, <fpage>995</fpage>&#8211;<lpage>998</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.0c00122</pub-id><pub-id pub-id-type="pmid">32167747</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dolgin</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Coronapod: CureVac disappoints in COVID vaccine trial</article-title>. <source>Nature</source>. <pub-id pub-id-type="doi">10.1038/d41586-021-01694-5</pub-id><pub-id pub-id-type="pmid">34145414</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Congdon</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zwetsloot</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device</article-title>. <source>ACS Cent. Sci.</source><volume>6</volume>, <fpage>2046</fpage>&#8211;<lpage>2052</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.0c00855</pub-id><pub-id pub-id-type="pmid">33269329</pub-id><pub-id pub-id-type="pmcid">PMC7523238</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Destras</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaymard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stefic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marlet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eymieux</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020</article-title>. <source>Eurosurveillance</source><volume>26</volume>. <pub-id pub-id-type="doi">10.2807/1560-7917.es.2021.26.3.2100008</pub-id><pub-id pub-id-type="pmcid">PMC7848679</pub-id><pub-id pub-id-type="pmid">33478625</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balagna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Percivalle</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nepita</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Virucidal effect against coronavirus SARS-CoV-2 of a silver nanocluster/silica composite sputtered coating</article-title>. <source>Open Ceram.</source><volume>1</volume>, <fpage>100006</fpage>. <pub-id pub-id-type="doi">10.1016/j.oceram.2020.100006</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Kshirsagar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Spagnol</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sorgen</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Amphiphilic polyanhydride-based recombinant MUC4&#946;-nanovaccine activates dendritic cells</article-title>. <source>Genes Cancer</source><volume>10</volume>, <fpage>52</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.18632/genesandcancer.189</pub-id><pub-id pub-id-type="pmid">31258832</pub-id><pub-id pub-id-type="pmcid">PMC6584211</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangaru</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ozorowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Antanasijevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate</article-title>. <source>Science</source><volume>370</volume>, <fpage>1089</fpage>&#8211;<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1126/science.abe1502</pub-id><pub-id pub-id-type="pmid">33082295</pub-id><pub-id pub-id-type="pmcid">PMC7857404</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangash</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parekh</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 and the liver: Little cause for concern</article-title>. <source>Lancet Gastroenterol. Hepatol.</source><volume>5</volume>, <fpage>529</fpage>&#8211;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1016/s2468-1253(20)30084-4</pub-id><pub-id pub-id-type="pmid">32203680</pub-id><pub-id pub-id-type="pmcid">PMC7270582</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barb&#233;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Besnard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jousse</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wurtzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moulin</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 whole-genome sequencing using Oxford nanopore technology for variant monitoring in wastewaters</article-title>. <source>Front. Microbiol.</source><volume>13</volume>, <fpage>889811</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2022.889811</pub-id><pub-id pub-id-type="pmid">35756003</pub-id><pub-id pub-id-type="pmcid">PMC9218694</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar-On</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Flamholz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R.</given-names></name><name name-style="western"><surname>Milo</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 (COVID-19) by the numbers</article-title>. <source>Elife</source><volume>9</volume>, <fpage>e57309</fpage>. <pub-id pub-id-type="doi">10.7554/elife.57309</pub-id><pub-id pub-id-type="pmid">32228860</pub-id><pub-id pub-id-type="pmcid">PMC7224694</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barreiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prenafeta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bech-Sabat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Roca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Perozo Mur</surname><given-names>E.</given-names></name><name name-style="western"><surname>March</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Preclinical efficacy, safety, and immunogenicity of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2</article-title>. <comment>bioRxiv</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.isci.2023.106126</pub-id><pub-id pub-id-type="pmcid">PMC9893798</pub-id><pub-id pub-id-type="pmid">36748086</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barrett</surname><given-names>P. N.</given-names></name><name name-style="western"><surname>Mundt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>M. K.</given-names></name></person-group> (<year>2009</year>). <article-title>Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines</article-title>. <source>Expert Rev. Vaccines</source><volume>8</volume>, <fpage>607</fpage>&#8211;<lpage>618</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.19</pub-id><pub-id pub-id-type="pmid">19397417</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartik</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Glaeser</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Luca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stanton</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>The impact of COVID-19 on small business outcomes and expectations</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume>, <fpage>17656</fpage>&#8211;<lpage>17666</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2006991117</pub-id><pub-id pub-id-type="pmid">32651281</pub-id><pub-id pub-id-type="pmcid">PMC7395529</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barton</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Stroberg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 autopsies, Oklahoma, USA</article-title>. <source>Am. J. Clin. Pathol.</source><volume>153</volume>, <fpage>725</fpage>&#8211;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1093/ajcp/aqaa062</pub-id><pub-id pub-id-type="pmid">32275742</pub-id><pub-id pub-id-type="pmcid">PMC7184436</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartoszko</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Farooqi</surname><given-names>M. a. M.</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: A systematic review and meta-analysis of randomized trials</article-title>. <source>Influenza Other Respir. Viruses</source><volume>14</volume>, <fpage>365</fpage>&#8211;<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12745</pub-id><pub-id pub-id-type="pmid">32246890</pub-id><pub-id pub-id-type="pmcid">PMC7298295</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartsch</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>O'shea</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: A modelling study</article-title>. <source>Lancet Public Health</source><volume>7</volume>, <fpage>e356</fpage>&#8211;<lpage>e365</lpage>. <pub-id pub-id-type="doi">10.1016/s2468-2667(22)00040-8</pub-id><pub-id pub-id-type="pmid">35276093</pub-id><pub-id pub-id-type="pmcid">PMC8903840</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barycka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szarpak</surname><given-names>L.</given-names></name><name name-style="western"><surname>Filipiak</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Jaguszewski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smereka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ladny</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparative effectiveness of N95 respirators and surgical/face masks in preventing airborne infections in the era of SARS-CoV2 pandemic: A meta-analysis of randomized trials</article-title>. <source>Plos One</source><volume>15</volume>, <fpage>e0242901</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0242901</pub-id><pub-id pub-id-type="pmid">33320847</pub-id><pub-id pub-id-type="pmcid">PMC7737973</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Autoantibodies against type I IFNs in patients with life-threatening COVID-19</article-title>. <source>Science</source><volume>370</volume>, <fpage>eabd4585</fpage>. <pub-id pub-id-type="doi">10.1126/science.abd4585</pub-id><pub-id pub-id-type="pmid">32972996</pub-id><pub-id pub-id-type="pmcid">PMC7857397</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gervais</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le Voyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rosain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Philippot</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Manry</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Autoantibodies neutralizing type I IFNs are present in &#8764;4% of uninfected individuals over 70 years old and account for &#8764;20% of COVID-19 deaths</article-title>. <source>Sci. Immunol.</source><volume>6</volume>, <fpage>eabl4340</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abl4340</pub-id><pub-id pub-id-type="pmid">34413139</pub-id><pub-id pub-id-type="pmcid">PMC8521484</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauchner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fontanarosa</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>E. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Conserving supply of personal protective equipment&#8212;a call for ideas</article-title>. <source>JAMA</source><volume>323</volume>, <fpage>1911</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.4770</pub-id><pub-id pub-id-type="pmid">32196543</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baz Morelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koernig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Drane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maraskovsky</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>). <article-title>Iscomatrix: A novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases</article-title>. <source>J. Med. Microbiol.</source><volume>61</volume>, <fpage>935</fpage>&#8211;<lpage>943</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.040857-0</pub-id><pub-id pub-id-type="pmid">22442293</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becerra-Flores</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardozo</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate</article-title>. <source>Int. J. Clin. Pract.</source><volume>74</volume>, <fpage>e13525</fpage>. <pub-id pub-id-type="doi">10.1111/ijcp.13525</pub-id><pub-id pub-id-type="pmid">32374903</pub-id><pub-id pub-id-type="pmcid">PMC7267315</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beech</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anseel</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 and its impact on management research and education: Threats, opportunities and a manifesto</article-title>. <source>Brit. J. Manage.</source><volume>31</volume>, <fpage>447</fpage>&#8211;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12421</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beesoon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Behary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Perwuelz</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Universal masking during COVID-19 pandemic: Can textile engineering help public health? Narrative review of the evidence</article-title>. <source>Prev. Med.</source><volume>139</volume>, <fpage>106236</fpage>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2020.106236</pub-id><pub-id pub-id-type="pmid">32795645</pub-id><pub-id pub-id-type="pmcid">PMC7418702</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bengtsson</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Magnusson</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Reimer</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>). <article-title>Matrix-M adjuvant: Enhancing immune responses by 'setting the stage' for the antigen</article-title>. <source>Expert Rev. Vaccines</source><volume>12</volume>, <fpage>821</fpage>&#8211;<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2013.814822</pub-id><pub-id pub-id-type="pmid">23984954</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergamaschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mescia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Kotagiri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dunmore</surname><given-names>B. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease</article-title>. <source>Immunity</source><volume>54</volume>, <fpage>1257</fpage>&#8211;<lpage>1275</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2021.05.010</pub-id><pub-id pub-id-type="pmid">34051148</pub-id><pub-id pub-id-type="pmcid">PMC8125900</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergwerk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lustig</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Amit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Covid-19 breakthrough infections in vaccinated health care workers</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>385</volume>, <fpage>1474</fpage>&#8211;<lpage>1484</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2109072</pub-id><pub-id pub-id-type="pmcid">PMC8362591</pub-id><pub-id pub-id-type="pmid">34320281</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bestle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heindl</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Limburg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Lam Van</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pilgram</surname><given-names>O.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells</article-title>. <source>Life Sci. Alliance</source><volume>3</volume>, <fpage>e202000786</fpage>. <pub-id pub-id-type="doi">10.26508/lsa.202000786</pub-id><pub-id pub-id-type="pmid">32703818</pub-id><pub-id pub-id-type="pmcid">PMC7383062</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies</article-title>. <source>Expert Rev. Vaccines</source><volume>20</volume>, <fpage>365</fpage>&#8211;<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2021.1903879</pub-id><pub-id pub-id-type="pmid">33851875</pub-id><pub-id pub-id-type="pmcid">PMC8054487</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binder</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Alarja</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Robie</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Kochek</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Xiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rocha-Melogno</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Environmental and aerosolized severe acute respiratory syndrome coronavirus 2 among hospitalized coronavirus disease 2019 patients</article-title>. <source>J. Infect. Dis.</source><volume>222</volume>, <fpage>1798</fpage>&#8211;<lpage>1806</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiaa575</pub-id><pub-id pub-id-type="pmid">32905595</pub-id><pub-id pub-id-type="pmcid">PMC7499634</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkhead</surname><given-names>M.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Allan-Gould</surname><given-names>H.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>C. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Ultrastructural evidence for vertical transmission of SARS-CoV-2</article-title>. <source>Int. J. Infect. Dis.</source><volume>111</volume>, <fpage>10</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2021.08.020</pub-id><pub-id pub-id-type="pmid">34403782</pub-id><pub-id pub-id-type="pmcid">PMC8364418</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Decastro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kataoka</surname><given-names>H.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily</article-title>. <source>Cancer Res.</source><volume>55</volume>, <fpage>434</fpage>&#8211;<lpage>439</lpage>.<pub-id pub-id-type="pmid">7812975</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bizzarro</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Rycus</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults</article-title>. <source>Pediatr. Crit. Care Med.</source><volume>12</volume>, <fpage>277</fpage>&#8211;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1097/pcc.0b013e3181e28894</pub-id><pub-id pub-id-type="pmid">20495508</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sattler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Giacoletti</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>C. D.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women</article-title>. <source>Pediatrics</source><volume>118</volume>, <fpage>2135</fpage>&#8211;<lpage>2145</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2006-0461</pub-id><pub-id pub-id-type="pmid">17079588</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kronig</surname><given-names>I.</given-names></name><name name-style="western"><surname>Neher</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Eckerle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Novel SARS-CoV-2 variants: The pandemics within the pandemic</article-title>. <source>Clin. Microbiol. Infect.</source><volume>27</volume>, <fpage>1109</fpage>&#8211;<lpage>1117</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2021.05.022</pub-id><pub-id pub-id-type="pmid">34015535</pub-id><pub-id pub-id-type="pmcid">PMC8127517</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bollavaram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leeman</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Upshaw</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V</article-title>. <source>Protein Sci.</source><volume>30</volume>, <fpage>1131</fpage>&#8211;<lpage>1143</lpage>. <pub-id pub-id-type="doi">10.1002/pro.4073</pub-id><pub-id pub-id-type="pmid">33786919</pub-id><pub-id pub-id-type="pmcid">PMC8138523</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dioscoridi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mutignani</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Fecal-oral transmission of SARS-COV-2: Practical implications</article-title>. <source>Gastroenterology</source><volume>159</volume>, <fpage>1621</fpage>&#8211;<lpage>1622</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.066</pub-id><pub-id pub-id-type="pmid">32247692</pub-id><pub-id pub-id-type="pmcid">PMC7194731</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rutten</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Der Lubbe</surname><given-names>J. E. M.</given-names></name><name name-style="western"><surname>Bakkers</surname><given-names>M. J. G.</given-names></name><name name-style="western"><surname>Hardenberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses</article-title>. <source>NPJ Vaccines</source><volume>5</volume>, <fpage>91</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-020-00243-x</pub-id><pub-id pub-id-type="pmid">33083026</pub-id><pub-id pub-id-type="pmcid">PMC7522255</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougakov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Podell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Multiple neuroinvasive pathways in COVID-19</article-title>. <source>Mol. Neurobiol.</source><volume>58</volume>, <fpage>564</fpage>&#8211;<lpage>575</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-020-02152-5</pub-id><pub-id pub-id-type="pmid">32990925</pub-id><pub-id pub-id-type="pmcid">PMC7523266</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourouiba</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Turbulent gas clouds and respiratory pathogen emissions: Potential implications for reducing transmission of COVID-19</article-title>. <source>JAMA</source><volume>323</volume>, <fpage>1837</fpage>&#8211;<lpage>1838</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.4756</pub-id><pub-id pub-id-type="pmid">32215590</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brainard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Lake</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>P. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Community use of face masks and similar barriers to prevent respiratory illness such as COVID-19: A rapid scoping review</article-title>. <source>Eurosurveillance</source><volume>25</volume> (<issue>49</issue>), <fpage>2000725</fpage>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.49.2000725</pub-id><pub-id pub-id-type="pmid">33303066</pub-id><pub-id pub-id-type="pmcid">PMC7730486</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brammer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 and management education: Reflections on challenges, opportunities, and potential futures</article-title>. <source>Brit. J. Manage.</source><volume>31</volume>, <fpage>453</fpage>&#8211;<lpage>456</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12425</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brann</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Tsukahara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weinreb</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lipovsek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Den Berge</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia</article-title>. <source>Sci. Adv.</source><volume>6</volume>, <fpage>eabc5801</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abc5801</pub-id><pub-id pub-id-type="pmid">32937591</pub-id><pub-id pub-id-type="pmcid">PMC10715684</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brejov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bor&#353;ov&#225;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hodorov&#225;</surname><given-names>V.</given-names></name><name name-style="western"><surname>&#268;abanov&#225;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gafurov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fri&#269;ov&#225;</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanopore sequencing of SARS-CoV-2: Comparison of short and long PCR-tiling amplicon protocols</article-title>. <source>Plos One</source><volume>16</volume>, <fpage>e0259277</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0259277</pub-id><pub-id pub-id-type="pmid">34714886</pub-id><pub-id pub-id-type="pmcid">PMC8555800</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brouwer</surname><given-names>P. J. M.</given-names></name><name name-style="western"><surname>Caniels</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Van Der Straten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Snitselaar</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Aldon</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bangaru</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability</article-title>. <source>Science</source><volume>369</volume>, <fpage>643</fpage>&#8211;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc5902</pub-id><pub-id pub-id-type="pmid">32540902</pub-id><pub-id pub-id-type="pmcid">PMC7299281</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Br&#252;ssow</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zuber</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?</article-title><source>Microb. Biotechnol.</source><volume>15</volume>, <fpage>721</fpage>&#8211;<lpage>737</lpage>. <pub-id pub-id-type="doi">10.1111/1751-7915.13997</pub-id><pub-id pub-id-type="pmid">34962710</pub-id><pub-id pub-id-type="pmcid">PMC8913850</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buckeridge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cadieux</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>Surveillance for newly emerging viruses</article-title>. <source>Perspect. Med. Virol.</source><volume>16</volume>, <fpage>325</fpage>&#8211;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1016/S0168-7069(06)16013-9</pub-id><pub-id pub-id-type="pmid">32287587</pub-id><pub-id pub-id-type="pmcid">PMC7114643</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bueckert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazumder</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Infectivity of SARS-CoV-2 and other coronaviruses on dry surfaces: Potential for indirect transmission</article-title>. <source>Mater. (Basel)</source><volume>13</volume>, <fpage>5211</fpage>. <pub-id pub-id-type="doi">10.3390/ma13225211</pub-id><pub-id pub-id-type="pmcid">PMC7698891</pub-id><pub-id pub-id-type="pmid">33218120</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bulbake</surname><given-names>U.</given-names></name><name name-style="western"><surname>Doppalapudi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kommineni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Liposomal formulations in clinical use: An updated review</article-title>. <source>Pharmaceutics</source><volume>9</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics9020012</pub-id><pub-id pub-id-type="pmid">28346375</pub-id><pub-id pub-id-type="pmcid">PMC5489929</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Adikari</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Stevanovski</surname><given-names>I.</given-names></name><name name-style="western"><surname>Beukers</surname><given-names>A. G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>6272</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20075-6</pub-id><pub-id pub-id-type="pmid">33298935</pub-id><pub-id pub-id-type="pmcid">PMC7726558</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group> (<year>2019</year>). <article-title>Preventing viral disease by ZnONPs through directly deactivating TMV and activating plant immunity in Nicotiana benthamiana</article-title>. <source>Environ. Sci. Nano</source><volume>6</volume>, <fpage>3653</fpage>&#8211;<lpage>3669</lpage>. <pub-id pub-id-type="doi">10.1039/c9en00850k</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldas</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>F. A.</given-names></name><name name-style="western"><surname>Higa</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Da Costa</surname><given-names>L. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Ultrastructural analysis of SARS-CoV-2 interactions with the host cell via high resolution scanning electron microscopy</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>16099</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-73162-5</pub-id><pub-id pub-id-type="pmid">32999356</pub-id><pub-id pub-id-type="pmcid">PMC7528159</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group> (<year>2020</year>). <article-title>The race for coronavirus vaccines: A graphical guide</article-title>. <source>Nature</source><volume>580</volume>, <fpage>576</fpage>&#8211;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-01221-y</pub-id><pub-id pub-id-type="pmid">32346146</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camp</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Buchta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puchhammer-Stockl</surname><given-names>E.</given-names></name><name name-style="western"><surname>Benka</surname><given-names>B.</given-names></name><name name-style="western"><surname>Griesmacher</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>RT-PCR based SARS-CoV-2 variant screening assays require careful quality control</article-title>. <source>J. Clin. Virol.</source><volume>141</volume>, <fpage>104905</fpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2021.104905</pub-id><pub-id pub-id-type="pmid">34273859</pub-id><pub-id pub-id-type="pmcid">PMC8262392</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>E. V. R.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A. E. S.</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Guilger-Casagrande</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Lima</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>How can nanotechnology help to combat COVID-19? Opportunities and urgent need</article-title>. <source>J. Nanobiotechnology</source><volume>18</volume>, <fpage>125</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-020-00685-4</pub-id><pub-id pub-id-type="pmid">32891146</pub-id><pub-id pub-id-type="pmcid">PMC7474329</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caniels</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Bontjer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Van Der Straten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Poniman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burger</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Appelman</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination</article-title>. <source>Sci. Adv.</source><volume>7</volume>, <fpage>eabj5365</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abj5365</pub-id><pub-id pub-id-type="pmid">34516917</pub-id><pub-id pub-id-type="pmcid">PMC8442901</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantuti-Castelvetri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pedro</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Djannatian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuivanen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title>. <source>Science</source><volume>370</volume>, <fpage>856</fpage>&#8211;<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1126/science.abd2985</pub-id><pub-id pub-id-type="pmid">33082293</pub-id><pub-id pub-id-type="pmcid">PMC7857391</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Gold nanoparticle-based signal amplification for biosensing</article-title>. <source>Anal. Biochem.</source><volume>417</volume>, <fpage>1</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2011.05.027</pub-id><pub-id pub-id-type="pmid">21703222</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells</article-title>. <source>Cell</source><volume>182</volume>, <fpage>73</fpage>&#8211;<lpage>84.e16</lpage>. <comment>e16</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.025</pub-id><pub-id pub-id-type="pmid">32425270</pub-id><pub-id pub-id-type="pmcid">PMC7231725</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yisimayi</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies</article-title>. <source>Nature</source><volume>602</volume>, <fpage>657</fpage>&#8211;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04385-3</pub-id><pub-id pub-id-type="pmid">35016194</pub-id><pub-id pub-id-type="pmcid">PMC8866119</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carraturo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>C.</given-names></name><name name-style="western"><surname>Morelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cerullo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Libralato</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galdiero</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Persistence of SARS-CoV-2 in the environment and COVID-19 transmission risk from environmental matrices and surfaces</article-title>. <source>Environ. Pollut.</source><volume>265</volume>, <fpage>115010</fpage>. <pub-id pub-id-type="doi">10.1016/j.envpol.2020.115010</pub-id><pub-id pub-id-type="pmid">32570023</pub-id><pub-id pub-id-type="pmcid">PMC7280109</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alqusairi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kothari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 gastrointestinal infection causing hemorrhagic colitis: Implications for detection and transmission of COVID-19 disease</article-title>. <source>Am. J. Gastroenterol.</source><volume>115</volume>, <fpage>942</fpage>&#8211;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.14309/ajg.0000000000000667</pub-id><pub-id pub-id-type="pmid">32496741</pub-id><pub-id pub-id-type="pmcid">PMC7172485</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castano-Jaramillo</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Yamazaki-Nakashimada</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>O'farrill-Romanillos</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Muzquiz Zerme&#241;o</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scheffler Mendoza</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Venegas Montoya</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 in the context of inborn errors of immunity: A case series of 31 patients from Mexico</article-title>. <source>J. Clin. Immunol.</source><volume>41</volume>, <fpage>1463</fpage>&#8211;<lpage>1478</lpage>. <pub-id pub-id-type="doi">10.1007/s10875-021-01077-5</pub-id><pub-id pub-id-type="pmid">34114122</pub-id><pub-id pub-id-type="pmcid">PMC8191444</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catching</surname><given-names>A.</given-names></name><name name-style="western"><surname>Capponi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Bianco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Examining the interplay between face mask usage, asymptomatic transmission, and social distancing on the spread of COVID-19</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>15998</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-94960-5</pub-id><pub-id pub-id-type="pmid">34362936</pub-id><pub-id pub-id-type="pmcid">PMC8346500</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavalcanti</surname><given-names>I. D. L.</given-names></name><name name-style="western"><surname>Cajub&#225; De Britto Lira Nogueira</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Pharmaceutical nanotechnology: Which products are been designed against COVID-19?</article-title><source>J. Nanopart. Res.</source><volume>22</volume>, <fpage>276</fpage>. <pub-id pub-id-type="doi">10.1007/s11051-020-05010-6</pub-id><pub-id pub-id-type="pmid">32922162</pub-id><pub-id pub-id-type="pmcid">PMC7480001</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cavanagh</surname><given-names>D.</given-names></name></person-group> (<year>1995</year>). &#8220;<article-title>The coronavirus surface glycoprotein</article-title>,&#8221; in <source>The coronaviridae</source>. Editor <person-group person-group-type="editor"><name name-style="western"><surname>Siddell</surname><given-names>S. G.</given-names></name></person-group> (<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Springer US</publisher-name>), <fpage>73</fpage>&#8211;<lpage>113</lpage>.</mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cevik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>O.</given-names></name><name name-style="western"><surname>Maraolo</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Schafers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis</article-title>. <source>Lancet Microbe</source><volume>2</volume>, <fpage>e13</fpage>&#8211;<lpage>e22</lpage>. <pub-id pub-id-type="doi">10.1016/s2666-5247(20)30172-5</pub-id><pub-id pub-id-type="pmid">33521734</pub-id><pub-id pub-id-type="pmcid">PMC7837230</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chac&#243;n-Torres</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Reinoso</surname><given-names>C.</given-names></name><name name-style="western"><surname>Navas-Le&#243;n</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Brice&#241;o</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Optimized and scalable synthesis of magnetic nanoparticles for RNA extraction in response to developing countries' needs in the detection and control of SARS-CoV-2</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>19004</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-75798-9</pub-id><pub-id pub-id-type="pmid">33149153</pub-id><pub-id pub-id-type="pmcid">PMC7642403</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chahal</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>O. F.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Mcpartlan</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Tsosie</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Tilley</surname><given-names>L. D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>113</volume>, <fpage>E4133</fpage>&#8211;<lpage>E4142</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1600299113</pub-id><pub-id pub-id-type="pmid">27382155</pub-id><pub-id pub-id-type="pmcid">PMC4961123</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title>. <source>Emerg. Microbes Infect.</source><volume>9</volume>, <fpage>221</fpage>&#8211;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmid">31987001</pub-id><pub-id pub-id-type="pmcid">PMC7067204</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klaus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meli</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Hofmann-Lehmann</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 infections in cats, dogs, and other animal species: Findings on infection and data from Switzerland</article-title>. <source>Schweiz Arch. Tierheilkd</source><volume>163</volume>, <fpage>821</fpage>&#8211;<lpage>835</lpage>. <pub-id pub-id-type="doi">10.17236/sat00329</pub-id><pub-id pub-id-type="pmid">34881715</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A. W.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Probable animal-to-human transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant AY.127 causing a pet shop-related coronavirus disease 2019 (COVID-19) outbreak in Hong Kong</article-title>. <source>Clin. Infect. Dis.</source><volume>75</volume>, <fpage>e76</fpage>&#8211;<lpage>e81</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciac171</pub-id><pub-id pub-id-type="pmid">35234870</pub-id><pub-id pub-id-type="pmcid">PMC8903450</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>1631</fpage>&#8211;<lpage>1633</lpage>. <pub-id pub-id-type="doi">10.3201/eid2607.200839</pub-id><pub-id pub-id-type="pmid">32243255</pub-id><pub-id pub-id-type="pmcid">PMC7323524</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K. Y.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>T. L.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>8692</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-87254-3</pub-id><pub-id pub-id-type="pmid">33888738</pub-id><pub-id pub-id-type="pmcid">PMC8062499</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K. J. K.</given-names></name></person-group> (<year>2022</year>). <article-title>The determinants of COVID-19 morbidity and mortality across countries</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>5888</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-09783-9</pub-id><pub-id pub-id-type="pmid">35393471</pub-id><pub-id pub-id-type="pmcid">PMC8989117</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chau</surname><given-names>N. V. V.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>N. T. T.</given-names></name><name name-style="western"><surname>Ngoc</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Thanh</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Khanh</surname><given-names>P. N. Q.</given-names></name><name name-style="western"><surname>Nguyet</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Superspreading event of SARS-CoV-2 infection at a bar, Ho chi minh city, vietnam</article-title>. <source>Emerg. Infect. Dis.</source><volume>27</volume>, <fpage>310</fpage>&#8211;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.3201/eid2701.203480</pub-id><pub-id pub-id-type="pmid">33063657</pub-id><pub-id pub-id-type="pmcid">PMC7774544</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaubey</surname><given-names>I.</given-names></name><name name-style="western"><surname>Vignesh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Babu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wagoner</surname><given-names>I.</given-names></name><name name-style="western"><surname>Govindaraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Velu</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 in pregnant women: Consequences of vertical transmission</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>11</volume>, <fpage>717104</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2021.717104</pub-id><pub-id pub-id-type="pmid">34568094</pub-id><pub-id pub-id-type="pmcid">PMC8458876</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>V.</given-names></name><name name-style="western"><surname>Royal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chavali</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Advancements in research and development to combat COVID-19 using nanotechnology</article-title>. <source>Nanotechnol. Environ. Eng.</source><volume>6</volume>, <fpage>8</fpage>. <pub-id pub-id-type="doi">10.1007/s41204-021-00102-7</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Madou</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Kalra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martinez-Chapa</surname><given-names>S. O.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanotechnology for COVID-19: Therapeutics and vaccine research</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>7760</fpage>&#8211;<lpage>7782</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c04006</pub-id><pub-id pub-id-type="pmid">32571007</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Kulaga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hillel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>M.</given-names><suffix>Jr.</suffix></name><etal/></person-group> (<year>2020</year>). <article-title>Elevated ACE-2 expression in the olfactory neuroepithelium: Implications for anosmia and upper respiratory SARS-CoV-2 entry and replication</article-title>. <source>Eur. Respir. J.</source><volume>56</volume>, <fpage>2001948</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01948-2020</pub-id><pub-id pub-id-type="pmid">32817004</pub-id><pub-id pub-id-type="pmcid">PMC7439429</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilby</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>G. W.</given-names></name></person-group> (<year>2021a</year>). <article-title>Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance</article-title>. <source>ArXiv</source><volume>62</volume> (<issue>2</issue>), <fpage>412</fpage>&#8211;<lpage>422</lpage>. <comment>arXiv:2112.01318v1</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.1c01451</pub-id><pub-id pub-id-type="pmcid">PMC8751645</pub-id><pub-id pub-id-type="pmid">34989238</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Safety of SARS-CoV-2 vaccines: A systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Infect. Dis. Poverty</source><volume>10</volume>, <fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/s40249-021-00878-5</pub-id><pub-id pub-id-type="pmid">34225791</pub-id><pub-id pub-id-type="pmcid">PMC8256217</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021c</year>). <article-title>Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate</article-title>. <source>Biochimica Biophysica Acta - General Subj.</source><volume>1865</volume>, <fpage>129893</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2021.129893</pub-id><pub-id pub-id-type="pmcid">PMC7955913</pub-id><pub-id pub-id-type="pmid">33731300</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Papenburg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Desjardins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanjilal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libman</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: A narrative review</article-title>. <source>Ann. Intern. Med.</source><volume>172</volume>, <fpage>726</fpage>&#8211;<lpage>734</lpage>. <pub-id pub-id-type="doi">10.7326/m20-1301</pub-id><pub-id pub-id-type="pmid">32282894</pub-id><pub-id pub-id-type="pmcid">PMC7170415</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Kidney disease is associated with in-hospital death of patients with COVID-19</article-title>. <source>Kidney Int.</source><volume>97</volume>, <fpage>829</fpage>&#8211;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1016/j.kint.2020.03.005</pub-id><pub-id pub-id-type="pmid">32247631</pub-id><pub-id pub-id-type="pmcid">PMC7110296</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chenthamara</surname><given-names>D.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Essa</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F. H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Therapeutic efficacy of nanoparticles and routes of administration</article-title>. <source>Biomater. Res.</source><volume>23</volume>, <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s40824-019-0166-x</pub-id><pub-id pub-id-type="pmid">31832232</pub-id><pub-id pub-id-type="pmcid">PMC6869321</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I. F. N.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P. P. Y.</given-names></name><name name-style="western"><surname>Lung</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Tso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: Systematic review and meta-analysis</article-title>. <source>Gastroenterology</source><volume>159</volume>, <fpage>81</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.065</pub-id><pub-id pub-id-type="pmid">32251668</pub-id><pub-id pub-id-type="pmcid">PMC7194936</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Zuniga</surname><given-names>E. I.</given-names></name></person-group> (<year>2022</year>). <article-title>Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection</article-title>. <source>Immunol. Rev.</source><volume>309</volume>, <fpage>12</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/imr.13113</pub-id><pub-id pub-id-type="pmid">35775361</pub-id><pub-id pub-id-type="pmcid">PMC9350402</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="book"><collab>China-National-Health-Commission-(Beijing)</collab> (<year>2020</year>). <source>Announcement from the Headquarter for novel coronavirus pneumonia prevention and control</source>.</mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Akl</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Duda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yaacoub</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sch&#252;nemann</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>1973</fpage>&#8211;<lpage>1987</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31142-9</pub-id><pub-id pub-id-type="pmid">32497510</pub-id><pub-id pub-id-type="pmcid">PMC7263814</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N. F.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 vaccine frontrunners and their nanotechnology design</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>12522</fpage>&#8211;<lpage>12537</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c07197</pub-id><pub-id pub-id-type="pmid">33034449</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cibulski</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Mourglia-Ettlin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Quirici</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roehe</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake</article-title>. <source>Vaccine</source><volume>34</volume>, <fpage>1162</fpage>&#8211;<lpage>1171</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.029</pub-id><pub-id pub-id-type="pmid">26826546</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciuffreda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lorenzo-Salazar</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Alcoba-Florez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodriguez-Perez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gil-Campesino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Inigo-Campos</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia</article-title>. <source>J. Infect.</source><volume>83</volume>, <fpage>607</fpage>&#8211;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2021.07.028</pub-id><pub-id pub-id-type="pmcid">PMC8316714</pub-id><pub-id pub-id-type="pmid">34329678</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciuffreda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodriguez-Perez</surname><given-names>H.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>C.</given-names></name></person-group> (<year>2021b</year>). <article-title>Nanopore sequencing and its application to the study of microbial communities</article-title>. <source>Comput. Struct. Biotechnol. J.</source><volume>19</volume>, <fpage>1497</fpage>&#8211;<lpage>1511</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2021.02.020</pub-id><pub-id pub-id-type="pmid">33815688</pub-id><pub-id pub-id-type="pmcid">PMC7985215</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciuffreda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alcoba-Florez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lorenzo-Salazar</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Gil-Campesino</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garcia-Martinez De Artola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diez-Gil</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Association of the Delta SARS-CoV-2 variant with 28-day hospital mortality between december 2020 and september 2021</article-title>. <source>J. Infect.</source><volume>85</volume>, <fpage>90</fpage>&#8211;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2022.04.030</pub-id><pub-id pub-id-type="pmcid">PMC9023377</pub-id><pub-id pub-id-type="pmid">35461907</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleary</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamandjou Tchuem</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Docrat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solanki</surname><given-names>G. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Cost-effectiveness of intensive care for hospitalized COVID-19 patients: Experience from south Africa</article-title>. <source>BMC Health Serv. Res.</source><volume>21</volume>, <fpage>82</fpage>. <pub-id pub-id-type="doi">10.1186/s12913-021-06081-4</pub-id><pub-id pub-id-type="pmid">33482807</pub-id><pub-id pub-id-type="pmcid">PMC7820836</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clinkard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mashari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karkouti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fedorko</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Evaluation of N95 respirators, modified snorkel masks and low-cost powered air-purifying respirators: A prospective observational cohort study in healthcare workers</article-title>. <source>Anaesthesia</source><volume>76</volume>, <fpage>617</fpage>&#8211;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1111/anae.15392</pub-id><pub-id pub-id-type="pmid">33470422</pub-id><pub-id pub-id-type="pmcid">PMC8014823</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coloma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajashankar</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>A. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Structures of NS5 methyltransferase from Zika virus</article-title>. <source>Cell Rep.</source><volume>16</volume>, <fpage>3097</fpage>&#8211;<lpage>3102</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.091</pub-id><pub-id pub-id-type="pmid">27633330</pub-id><pub-id pub-id-type="pmcid">PMC5074680</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comber</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Philip</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines</article-title>. <source>Ther. Adv. Vaccines</source><volume>2</volume>, <fpage>77</fpage>&#8211;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1177/2051013614525375</pub-id><pub-id pub-id-type="pmid">24790732</pub-id><pub-id pub-id-type="pmcid">PMC3991156</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Constantin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pisani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bardi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Neagu</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Nano-carriers of COVID-19 vaccines: The main pillars of efficacy</article-title>. <source>Nanomedicine (Lond)</source><volume>16</volume>, <fpage>2377</fpage>&#8211;<lpage>2387</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2021-0250</pub-id><pub-id pub-id-type="pmid">34632802</pub-id><pub-id pub-id-type="pmcid">PMC8544481</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Terreri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piano Mortari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Albano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Natale</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boscarino</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Immune response of neonates born to mothers infected with SARS-CoV-2</article-title>. <source>JAMA Netw. Open</source><volume>4</volume>, <fpage>e2132563</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.32563</pub-id><pub-id pub-id-type="pmid">34730817</pub-id><pub-id pub-id-type="pmcid">PMC8567114</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>R. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title>. <source>Nature</source><volume>586</volume>, <fpage>567</fpage>&#8211;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmid">32756549</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Nason</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Flach</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gagne</surname><given-names>M.</given-names></name><name name-style="western"><surname>O'connell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>T. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates</article-title>. <source>Science</source><volume>373</volume>, <fpage>eabj0299</fpage>. <pub-id pub-id-type="doi">10.1126/science.abj0299</pub-id><pub-id pub-id-type="pmid">34529476</pub-id><pub-id pub-id-type="pmcid">PMC8449013</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Landt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>. <source>Eurosurveillance</source><volume>25</volume>. <pub-id pub-id-type="doi">10.2807/1560-7917.es.2020.25.3.2000045</pub-id><pub-id pub-id-type="pmcid">PMC6988269</pub-id><pub-id pub-id-type="pmid">31992387</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corominas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garriga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prenafeta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ca&#241;ete</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: A multicentre, randomised, double-blind, non-inferiority phase IIb trial</article-title>. <comment>medRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2022.07.05.22277210</pub-id><pub-id pub-id-type="pmcid">PMC10102678</pub-id><pub-id pub-id-type="pmid">37131861</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bottoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiberi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fattore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Vertical transmission of SARS-CoV-2 during pregnancy: A prospective Italian cohort study</article-title>. <source>Am. J. Perinatol.</source><pub-id pub-id-type="doi">10.1055/a-1792-4535</pub-id><pub-id pub-id-type="pmid">35263767</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><collab>Covid-19-Host-Genetics-Initiative</collab> (<year>2021</year>). <article-title>The mutation that helps Delta spread like wildfire</article-title>. <source>Nature</source><volume>600</volume>, <fpage>472</fpage>&#8211;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1038/d41586-021-02275-2</pub-id><pub-id pub-id-type="pmid">34417582</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creech</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>R. J.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 vaccines</article-title>. <source>Jama</source><volume>325</volume>, <fpage>1318</fpage>&#8211;<lpage>1320</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.3199</pub-id><pub-id pub-id-type="pmid">33635317</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cucinotta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vanelli</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>WHO declares COVID-19 a pandemic</article-title>. <source>Acta Biomed.</source><volume>91</volume>, <fpage>157</fpage>&#8211;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.23750/abm.v91i1.9397</pub-id><pub-id pub-id-type="pmid">32191675</pub-id><pub-id pub-id-type="pmcid">PMC7569573</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuicchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lazzarotto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Poggioli</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Fecal-oral transmission of SARS-CoV-2: Review of laboratory-confirmed virus in gastrointestinal system</article-title>. <source>Int. J. Colorectal Dis.</source><volume>36</volume>, <fpage>437</fpage>&#8211;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1007/s00384-020-03785-7</pub-id><pub-id pub-id-type="pmid">33057894</pub-id><pub-id pub-id-type="pmcid">PMC7556558</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cyster</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C. D. C.</given-names></name></person-group> (<year>2019</year>). <article-title>B cell responses: Cell interaction dynamics and decisions</article-title>. <source>Cell</source><volume>177</volume>, <fpage>524</fpage>&#8211;<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.03.016</pub-id><pub-id pub-id-type="pmid">31002794</pub-id><pub-id pub-id-type="pmcid">PMC6538279</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2021</year>). <article-title>Viral targets for vaccines against COVID-19</article-title>. <source>Nat. Rev. Immunol.</source><volume>21</volume>, <fpage>73</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-00480-0</pub-id><pub-id pub-id-type="pmid">33340022</pub-id><pub-id pub-id-type="pmcid">PMC7747004</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS</article-title>. <source>Cell</source><volume>182</volume>, <fpage>722</fpage>&#8211;<lpage>733.e11</lpage>. <comment>e711</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.035</pub-id><pub-id pub-id-type="pmid">32645327</pub-id><pub-id pub-id-type="pmcid">PMC7321023</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalvie</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Rodriguez-Aponte</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Hartwell</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Biedermann</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Crowell</surname><given-names>L. E.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>e2106845118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2106845118</pub-id><pub-id pub-id-type="pmid">34493582</pub-id><pub-id pub-id-type="pmcid">PMC8463846</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalvie</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Rodriguez-Aponte</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bajoria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumru</surname><given-names>O. S.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates</article-title>. <source>bioRxiv.</source>, <fpage>452251</fpage>. <pub-id pub-id-type="doi">10.1101/2021.07.13.452251</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Simonetti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Ant&#243;n-Pl&#225;garo</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neuropilin-1 is a host factor for SARS-CoV-2 infection</article-title>. <source>Science</source><volume>370</volume>, <fpage>861</fpage>&#8211;<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1126/science.abd3072</pub-id><pub-id pub-id-type="pmid">33082294</pub-id><pub-id pub-id-type="pmcid">PMC7612957</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniloski</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>T. X.</given-names></name><name name-style="western"><surname>Ilmain</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bhabha</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tenoever</surname><given-names>B. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types</article-title>. <source>eLife</source><volume>10</volume>, <fpage>e65365</fpage>. <pub-id pub-id-type="doi">10.7554/elife.65365</pub-id><pub-id pub-id-type="pmid">33570490</pub-id><pub-id pub-id-type="pmcid">PMC7891930</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Day</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Covid-19: Four fifths of cases are asymptomatic, China figures indicate</article-title>. <source>BMJ</source><volume>369</volume>, <fpage>m1375</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1375</pub-id><pub-id pub-id-type="pmid">32241884</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Alwis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice</article-title>. <source>Mol. Ther.</source><volume>29</volume>, <fpage>1970</fpage>&#8211;<lpage>1983</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2021.04.001</pub-id><pub-id pub-id-type="pmid">33823303</pub-id><pub-id pub-id-type="pmcid">PMC8019652</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Luytjes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Horzinek</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Van Der Zeijst</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Spaan</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Lenstra</surname><given-names>J. A.</given-names></name></person-group> (<year>1987</year>). <article-title>Evidence for a coiled-coil structure in the spike proteins of coronaviruses</article-title>. <source>J. Mol. Biol.</source><volume>196</volume>, <fpage>963</fpage>&#8211;<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1016/0022-2836(87)90422-0</pub-id><pub-id pub-id-type="pmid">3681988</pub-id><pub-id pub-id-type="pmcid">PMC7131189</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Nardo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gentilotti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mazzaferri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cremonini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Multi-Criteria Decision Analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage</article-title>. <source>Int. J. Infect. Dis.</source><volume>98</volume>, <fpage>494</fpage>&#8211;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.06.082</pub-id><pub-id pub-id-type="pmid">32619766</pub-id><pub-id pub-id-type="pmcid">PMC7326449</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Oliveira-Filho</surname><given-names>E. F.</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>I. O.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>F. D.</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Pedroso</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Frequent infection of cats with SARS-CoV-2 irrespective of pre-existing enzootic coronavirus immunity, Brazil 2020</article-title>. <source>Front. Immunol.</source><volume>13</volume>, <fpage>857322</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.857322</pub-id><pub-id pub-id-type="pmid">35450070</pub-id><pub-id pub-id-type="pmcid">PMC9016337</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deamer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Akeson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Branton</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Three decades of nanopore sequencing</article-title>. <source>Nat. Biotechnol.</source><volume>34</volume>, <fpage>518</fpage>&#8211;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3423</pub-id><pub-id pub-id-type="pmid">27153285</pub-id><pub-id pub-id-type="pmcid">PMC6733523</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debnath</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>Potential application of bionanoparticles to treat severe acute respiratory syndrome coronavirus-2 infection</article-title>. <source>Front. Nanotechnol.</source><volume>3</volume>. <pub-id pub-id-type="doi">10.3389/fnano.2021.813847</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Della Cioppa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nicolay</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lindert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castellino</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: Results from a dose-finding clinical trial in older adults</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>8</volume>, <fpage>216</fpage>&#8211;<lpage>227</lpage>. <pub-id pub-id-type="doi">10.4161/hv.18445</pub-id><pub-id pub-id-type="pmid">22426371</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Della Cioppa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nicolay</surname><given-names>U.</given-names></name><name name-style="western"><surname>Lindert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castellino</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59&#174;-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>10</volume>, <fpage>1701</fpage>&#8211;<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.4161/hv.28618</pub-id><pub-id pub-id-type="pmid">24732325</pub-id><pub-id pub-id-type="pmcid">PMC5396251</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boursiquot</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>E. Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Long-term complications of COVID-19</article-title>. <source>Am. J. Physiology-Cell Physiology</source><volume>322</volume>, <fpage>C1</fpage>&#8211;<lpage>c11</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00375.2021</pub-id><pub-id pub-id-type="pmcid">PMC8721906</pub-id><pub-id pub-id-type="pmid">34817268</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devaux</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Rolain</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Raoult</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome</article-title>. <source>J. Microbiol. Immunol. Infect.</source><volume>53</volume>, <fpage>425</fpage>&#8211;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmii.2020.04.015</pub-id><pub-id pub-id-type="pmid">32414646</pub-id><pub-id pub-id-type="pmcid">PMC7201239</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Masand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yatoo</surname><given-names>M. I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The role of disinfectants and sanitizers during COVID-19 pandemic: Advantages and deleterious effects on humans and the environment</article-title>. <source>Environ. Sci. Pollut. Res.</source><volume>28</volume>, <fpage>34211</fpage>&#8211;<lpage>34228</lpage>. <pub-id pub-id-type="doi">10.1007/s11356-021-14429-w</pub-id><pub-id pub-id-type="pmcid">PMC8122186</pub-id><pub-id pub-id-type="pmid">33991301</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dheda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Charalambous</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karat</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Von Delft</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>U. G.</given-names></name><name name-style="western"><surname>Van Zyl Smit</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A position statement and practical guide to the use of particulate filtering facepiece respirators (N95, FFP2, or equivalent) for South African health workers exposed to respiratory pathogens including <italic toggle="yes">Mycobacterium tuberculosis</italic> and SARS-CoV-2</article-title>. <source>Afr. J. Thorac. Crit. Care Med.</source><volume>27</volume>. <pub-id pub-id-type="doi">10.7196/ajtccm.2021.v27i4.173</pub-id><pub-id pub-id-type="pmcid">PMC8545268</pub-id><pub-id pub-id-type="pmid">34734176</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Fusco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Angulo</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Benigno</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Health outcomes and economic burden of hospitalized COVID-19 patients in the United States</article-title>. <source>J. Med. Econ.</source><volume>24</volume>, <fpage>308</fpage>&#8211;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1080/13696998.2021.1886109</pub-id><pub-id pub-id-type="pmid">33555956</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title>. <source>Front. Immunol.</source><volume>11</volume>, <fpage>827</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>H. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Toilets dominate environmental detection of severe acute respiratory syndrome coronavirus 2 in a hospital</article-title>. <source>Sci. Total Environ.</source><volume>753</volume>, <fpage>141710</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.141710</pub-id><pub-id pub-id-type="pmid">32891988</pub-id><pub-id pub-id-type="pmcid">PMC7428758</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinnes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Adriano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berhane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dittrich</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection</article-title>. <source>Cochrane Database Syst. Rev.</source><volume>8</volume>, <fpage>Cd013705</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD013705</pub-id><pub-id pub-id-type="pmid">32845525</pub-id><pub-id pub-id-type="pmcid">PMC8078202</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolgin</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>CureVac COVID vaccine let-down spotlights mRNA design challenges</article-title>. <source>Nature</source><volume>594</volume>, <fpage>483</fpage>. <pub-id pub-id-type="doi">10.1038/d41586-021-01661-0</pub-id><pub-id pub-id-type="pmid">34145413</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dona</surname><given-names>D.</given-names></name><name name-style="western"><surname>Minotti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costenaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Da Dalt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Giaquinto</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Fecal-oral transmission of SARS-CoV-2 in children: Is it time to change our approach?</article-title><source>Pediatr. Infect. Dis. J.</source><volume>39</volume>, <fpage>e133</fpage>&#8211;<lpage>e134</lpage>. <pub-id pub-id-type="doi">10.1097/inf.0000000000002704</pub-id><pub-id pub-id-type="pmid">32304466</pub-id><pub-id pub-id-type="pmcid">PMC7279053</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lateef</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>V. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Virus-like particle vaccines: Immunology and formulation for clinical translation</article-title>. <source>Expert Rev. Vaccines</source><volume>17</volume>, <fpage>833</fpage>&#8211;<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2018.1516552</pub-id><pub-id pub-id-type="pmid">30173619</pub-id><pub-id pub-id-type="pmcid">PMC7103734</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donskyi</surname><given-names>I. S.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Trimpert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Quaas</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS&#8208;CoV&#8208;2 inhibitors: Graphene sheets with defined dual functionalities for the strong SARS&#8208;CoV&#8208;2 interactions (small 11/2021)</article-title>. <source>Small</source><volume>17</volume>, <fpage>2170046</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202170046</pub-id><pub-id pub-id-type="pmcid">PMC7995151</pub-id><pub-id pub-id-type="pmid">33533178</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dro&#380;d&#380;al</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lechowicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Machaj</surname><given-names>F.</given-names></name><name name-style="western"><surname>Szostak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Przybyci&#324;ski</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment</article-title>. <source>Drug resist. updat.</source><volume>59</volume>, <fpage>100794</fpage>. <pub-id pub-id-type="doi">10.1016/j.drup.2021.100794</pub-id><pub-id pub-id-type="pmid">34991982</pub-id><pub-id pub-id-type="pmcid">PMC8654464</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection</article-title>. <source>J. Immunol.</source><volume>180</volume>, <fpage>948</fpage>&#8211;<lpage>956</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.180.2.948</pub-id><pub-id pub-id-type="pmid">18178835</pub-id><pub-id pub-id-type="pmcid">PMC2603051</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumitriu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Emeruwa</surname><given-names>U. N.</given-names></name><name name-style="western"><surname>Hanft</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G. V.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>E.</given-names></name><name name-style="western"><surname>Walzer</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 infection at a large medical center in New York city</article-title>. <source>JAMA Pediatr.</source><volume>175</volume>, <fpage>157</fpage>&#8211;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.4298</pub-id><pub-id pub-id-type="pmid">33044493</pub-id><pub-id pub-id-type="pmcid">PMC7551222</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkle</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>&#193;&#241;ez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Adelglass</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Barrat Hern&#225;ndez</surname><given-names>A. Q.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>386</volume>, <fpage>531</fpage>&#8211;<lpage>543</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2116185</pub-id><pub-id pub-id-type="pmcid">PMC8693692</pub-id><pub-id pub-id-type="pmid">34910859</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Naiyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mansuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>COVID-19 diagnosis: A comprehensive review of the RT-qPCR method for detection of SARS-CoV-2</article-title>. <source>Diagn. (Basel)</source><volume>12</volume>, <fpage>1503</fpage>. <pub-id pub-id-type="doi">10.3390/diagnostics12061503</pub-id><pub-id pub-id-type="pmcid">PMC9221722</pub-id><pub-id pub-id-type="pmid">35741313</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eaaswarkhanth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al Madhoun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Mulla</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?</article-title><source>Int. J. Infect. Dis.</source><volume>96</volume>, <fpage>459</fpage>&#8211;<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.071</pub-id><pub-id pub-id-type="pmid">32464271</pub-id><pub-id pub-id-type="pmcid">PMC7247990</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Earle</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Ambrosino</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Siber</surname><given-names>G. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Evidence for antibody as a protective correlate for COVID-19 vaccines</article-title>. <source>Vaccine</source><volume>39</volume>, <fpage>4423</fpage>&#8211;<lpage>4428</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.05.063</pub-id><pub-id pub-id-type="pmid">34210573</pub-id><pub-id pub-id-type="pmcid">PMC8142841</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Buckland-Merrett</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Data, disease and diplomacy: GISAID's innovative contribution to global health</article-title>. <source>Glob. Chall.</source><volume>1</volume>, <fpage>33</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1002/gch2.1018</pub-id><pub-id pub-id-type="pmid">31565258</pub-id><pub-id pub-id-type="pmcid">PMC6607375</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>W.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial</article-title>. <source>Lancet</source><volume>398</volume>, <fpage>2173</fpage>&#8211;<lpage>2184</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)02000-6</pub-id><pub-id pub-id-type="pmid">34774196</pub-id><pub-id pub-id-type="pmcid">PMC8584828</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>950</fpage>&#8211;<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmid">33705727</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellinghaus</surname><given-names>D.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bujanda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Albillos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Invernizzi</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Genomewide association study of severe covid-19 with respiratory failure</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>1522</fpage>&#8211;<lpage>1534</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2020283</pub-id><pub-id pub-id-type="pmcid">PMC7315890</pub-id><pub-id pub-id-type="pmid">32558485</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erasmus</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Khandhar</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>O'connor</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hemann</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Murapa</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates</article-title>. <source>Sci. Transl. Med.</source><volume>12</volume>, <fpage>eabc9396</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abc9396</pub-id><pub-id pub-id-type="pmid">32690628</pub-id><pub-id pub-id-type="pmcid">PMC7402629</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eslami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jalili</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>The role of environmental factors to transmission of SARS-CoV-2 (COVID-19)</article-title>. <source>Amb. Express</source><volume>10</volume>, <fpage>92</fpage>. <pub-id pub-id-type="doi">10.1186/s13568-020-01028-0</pub-id><pub-id pub-id-type="pmid">32415548</pub-id><pub-id pub-id-type="pmcid">PMC7226715</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Principi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Migliori</surname><given-names>G. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Universal use of face masks for success against COVID-19: Evidence and implications for prevention policies</article-title>. <source>Eur. Respir. J.</source><volume>55</volume>, <fpage>2001260</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.01260-2020</pub-id><pub-id pub-id-type="pmid">32350103</pub-id><pub-id pub-id-type="pmcid">PMC7191114</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eugenia Toledo-Roman&#237;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Carmenate</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valenzuela-Silva</surname><given-names>C.</given-names></name><name name-style="western"><surname>Baldoqu&#237;n-Rodr&#237;guez</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mart&#237;nez-P&#233;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gonz&#225;lez</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: Double-blind, randomised, placebo-controlled phase 3 clinical trial</article-title>. <comment>medRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2021.10.31.21265703</pub-id><pub-id pub-id-type="pmcid">PMC9803910</pub-id><pub-id pub-id-type="pmid">36618081</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharpe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Makinson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morter</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>270</fpage>&#8211;<lpage>278</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezoe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palacpac</surname><given-names>N. M. Q.</given-names></name><name name-style="western"><surname>Tetsutani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Taira</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)</article-title>. <source>Vaccine</source><volume>38</volume>, <fpage>7246</fpage>&#8211;<lpage>7257</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.09.056</pub-id><pub-id pub-id-type="pmid">33012605</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakhruddin</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Haiat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Panduwawala</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J. W. W.</given-names></name><name name-style="western"><surname>Samaranayake</surname><given-names>L. P.</given-names></name></person-group> (<year>2022</year>). <article-title>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) viral positivity and their burden in saliva of asymptomatic carriers - a systematic review and meta-analysis</article-title>. <source>Acta Odontol. Scand.</source><volume>80</volume>, <fpage>182</fpage>&#8211;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1080/00016357.2021.1977385</pub-id><pub-id pub-id-type="pmid">34689688</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallerini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picchiotti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Francisci</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study</article-title>. <source>Elife</source><volume>10</volume>, <fpage>e67569</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.67569</pub-id><pub-id pub-id-type="pmid">33650967</pub-id><pub-id pub-id-type="pmcid">PMC7987337</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gattuso</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spandidos</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Libra</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Current and innovative methods for the diagnosis of COVID-19 infection (Review)</article-title>. <source>Int. J. Mol. Med.</source><volume>47</volume>, <fpage>100</fpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2021.4933</pub-id><pub-id pub-id-type="pmid">33846767</pub-id><pub-id pub-id-type="pmcid">PMC8043662</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fauziah</surname><given-names>N.</given-names></name><name name-style="western"><surname>Koesoemadinata</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Andriyoko</surname><given-names>B.</given-names></name><name name-style="western"><surname>Faridah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Riswari</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Widyatmoko</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The performance of point-of-care antibody test for COVID-19 diagnosis in a tertiary hospital in Bandung, Indonesia</article-title>. <source>J. Infect. Dev. Ctries.</source><volume>15</volume>, <fpage>237</fpage>&#8211;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.3855/jidc.13370</pub-id><pub-id pub-id-type="pmid">33690206</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenizia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galbiati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vanetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vago</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clerici</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tacchetti</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 entry: At the crossroads of CD147 and ACE2</article-title>. <source>Cells</source><volume>10</volume>, <fpage>1434</fpage>. <pub-id pub-id-type="doi">10.3390/cells10061434</pub-id><pub-id pub-id-type="pmid">34201214</pub-id><pub-id pub-id-type="pmcid">PMC8226513</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenton</surname><given-names>O. S.</given-names></name><name name-style="western"><surname>Olafson</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group> (<year>2018</year>). <article-title>Advances in biomaterials for drug delivery</article-title>. <source>Adv. Mat.</source><volume>30</volume>, <fpage>e1705328</fpage>. <pub-id pub-id-type="doi">10.1002/adma.201705328</pub-id><pub-id pub-id-type="pmcid">PMC6261797</pub-id><pub-id pub-id-type="pmid">29736981</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferretti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wymant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nurtay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abeler-Dorner</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing</article-title>. <source>Science</source><volume>368</volume>, <fpage>eabb6936</fpage>. <pub-id pub-id-type="doi">10.1126/science.abb6936</pub-id><pub-id pub-id-type="pmid">32234805</pub-id><pub-id pub-id-type="pmcid">PMC7164555</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flemming</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Omicron, the great escape artist</article-title>. <source>Nat. Rev. Immunol.</source><volume>22</volume>, <fpage>75</fpage>. <pub-id pub-id-type="doi">10.1038/s41577-022-00676-6</pub-id><pub-id pub-id-type="pmid">35017722</pub-id><pub-id pub-id-type="pmcid">PMC8749340</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Focosi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence</article-title>. <source>Viruses</source><volume>14</volume>, <fpage>187</fpage>. <pub-id pub-id-type="doi">10.3390/v14020187</pub-id><pub-id pub-id-type="pmid">35215783</pub-id><pub-id pub-id-type="pmcid">PMC8878800</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title>. <source>Lancet</source><volume>396</volume>, <fpage>467</fpage>&#8211;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fonseca-Santos</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gremi&#227;o</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Chorilli</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease</article-title>. <source>Int. J. Nanomedicine</source><volume>10</volume>, <fpage>4981</fpage>&#8211;<lpage>5003</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S87148</pub-id><pub-id pub-id-type="pmid">26345528</pub-id><pub-id pub-id-type="pmcid">PMC4531021</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Formica</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>R.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plested</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial</article-title>. <source>PLoS Med.</source><volume>18</volume>, <fpage>e1003769</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1003769</pub-id><pub-id pub-id-type="pmid">34597298</pub-id><pub-id pub-id-type="pmcid">PMC8486115</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Forum</surname><given-names>W. E.</given-names></name></person-group> (<year>2020</year>). <source>These are the occupations with the highest COVID-19 risk</source>.</mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Choudhari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Perazzelli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Storm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response</article-title>. <source>Hum. Gene Ther.</source><volume>30</volume>, <fpage>168</fpage>&#8211;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1089/hum.2018.145</pub-id><pub-id pub-id-type="pmid">30024272</pub-id><pub-id pub-id-type="pmcid">PMC6383579</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fougeroux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goks&#248;yr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Idorn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soroka</surname><given-names>V.</given-names></name><name name-style="western"><surname>Myeni</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Dagil</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>324</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20251-8</pub-id><pub-id pub-id-type="pmid">33436573</pub-id><pub-id pub-id-type="pmcid">PMC7804149</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraser</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Beldar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seitova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mannar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation</article-title>. <source>Nat. Chem. Biol.</source><volume>18</volume>, <fpage>963</fpage>&#8211;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-022-01059-7</pub-id><pub-id pub-id-type="pmid">35676539</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuya-Kanamori</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yakob</surname><given-names>L.</given-names></name></person-group> (<year>2018</year>). <article-title>Heterogeneous and dynamic prevalence of asymptomatic influenza virus infections</article-title>. <source>Emerg. Infect. Dis.</source><volume>24</volume>, <fpage>951</fpage>. <pub-id pub-id-type="doi">10.3201/eid2405.180075</pub-id><pub-id pub-id-type="pmcid">PMC5938779</pub-id><pub-id pub-id-type="pmid">29664719</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Locatello</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Mazzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Novelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Annunziato</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection</article-title>. <source>Mucosal Immunol.</source><volume>14</volume>, <fpage>305</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1038/s41385-020-00359-2</pub-id><pub-id pub-id-type="pmid">33244161</pub-id><pub-id pub-id-type="pmcid">PMC7690066</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>G. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Facial masking for covid-19 - potential for "variolation" as we await a vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>e101</fpage>. <pub-id pub-id-type="doi">10.1056/nejmp2026913</pub-id><pub-id pub-id-type="pmcid">PMC7890559</pub-id><pub-id pub-id-type="pmid">32897661</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gangapurwala</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vollrath</surname><given-names>A.</given-names></name><name name-style="western"><surname>De San Luis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>U. S.</given-names></name></person-group> (<year>2020</year>). <article-title>PLA/PLGA-Based drug delivery systems produced with supercritical CO(2)-A green future for particle formulation?</article-title><source>Pharmaceutics</source><volume>12</volume>, <fpage>1118</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics12111118</pub-id><pub-id pub-id-type="pmid">33233637</pub-id><pub-id pub-id-type="pmcid">PMC7699691</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title>. <source>Science</source><volume>369</volume>, <fpage>77</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>A cluster of the Corona Virus Disease 2019 caused by incubation period transmission in Wuxi, China</article-title>. <source>J. Infect.</source><volume>80</volume>, <fpage>666</fpage>&#8211;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.042</pub-id><pub-id pub-id-type="pmid">32283165</pub-id><pub-id pub-id-type="pmcid">PMC7195026</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcea</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Gissmann</surname><given-names>L.</given-names></name></person-group> (<year>2004</year>). <article-title>Virus-like particles as vaccines and vessels for the delivery of small molecules</article-title>. <source>Curr. Opin. Biotechnol.</source><volume>15</volume>, <fpage>513</fpage>&#8211;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2004.10.002</pub-id><pub-id pub-id-type="pmid">15560977</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loman</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Real-time digital pathogen surveillance - the time is now</article-title>. <source>Genome Biol.</source><volume>16</volume>, <fpage>155</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-015-0726-x</pub-id><pub-id pub-id-type="pmid">27391693</pub-id><pub-id pub-id-type="pmcid">PMC4531805</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavriatopoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korompoki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fotiou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ntanasis-Stathopoulos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Psaltopoulou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kastritis</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Organ-specific manifestations of COVID-19 infection</article-title>. <source>Clin. Exp. Med.</source><volume>20</volume>, <fpage>493</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1007/s10238-020-00648-x</pub-id><pub-id pub-id-type="pmid">32720223</pub-id><pub-id pub-id-type="pmcid">PMC7383117</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection</article-title>. <source>PLoS Pathog.</source><volume>17</volume>, <fpage>e1009897</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1009897</pub-id><pub-id pub-id-type="pmid">34492082</pub-id><pub-id pub-id-type="pmcid">PMC8448314</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gengler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Speth</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Sedaghat</surname><given-names>A. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Sinonasal pathophysiology of SARS-CoV-2 and COVID-19: A systematic review of the current evidence</article-title>. <source>Laryngoscope Investig. Otolaryngol.</source><volume>5</volume>, <fpage>354</fpage>&#8211;<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1002/lio2.384</pub-id><pub-id pub-id-type="pmcid">PMC7262250</pub-id><pub-id pub-id-type="pmid">32587887</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Kasperbauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eddy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Magin</surname><given-names>C. M.</given-names></name></person-group> (<year>2020</year>). <article-title>How to leverage collaborations between the BME community and local hospitals to address critical personal protective equipment shortages during the COVID-19 pandemic</article-title>. <source>Ann. Biomed. Eng.</source><volume>48</volume>, <fpage>2281</fpage>&#8211;<lpage>2284</lpage>. <pub-id pub-id-type="doi">10.1007/s10439-020-02580-3</pub-id><pub-id pub-id-type="pmid">32710248</pub-id><pub-id pub-id-type="pmcid">PMC7380659</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fawad</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shadan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rowaiee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghanem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hassan Khamis</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 and healthcare workers: A systematic review and meta-analysis</article-title>. <source>Int. J. Infect. Dis.</source><volume>104</volume>, <fpage>335</fpage>&#8211;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2021.01.013</pub-id><pub-id pub-id-type="pmid">33444754</pub-id><pub-id pub-id-type="pmcid">PMC7798435</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibson</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Puah</surname><given-names>S. H.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS</article-title>. <source>Med. J. Aust.</source><volume>213</volume>, <fpage>54</fpage>&#8211;<lpage>56</lpage>. <comment>e51</comment>. <pub-id pub-id-type="doi">10.5694/mja2.50674</pub-id><pub-id pub-id-type="pmid">32572965</pub-id><pub-id pub-id-type="pmcid">PMC7361309</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lebreil</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>L.</given-names></name><name name-style="western"><surname>N'guyen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Andreoletti</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Asymptomatic COVID-19 adult outpatients identified as significant viable SARS-CoV-2 shedders</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>20615</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-00142-8</pub-id><pub-id pub-id-type="pmid">34663858</pub-id><pub-id pub-id-type="pmcid">PMC8523690</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="webpage"><collab>Global-Preparedness-Monitoring-Board-(Gpmb)</collab> (<year>2019</year>). <article-title>A world at risk: Annual report on global preparedness for health emergencies</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf?utm_source=mandiner&amp;utm_medium=link&amp;utm_campaign=mandiner_202004" ext-link-type="uri">https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf?utm_source=mandiner&amp;utm_medium=link&amp;utm_campaign=mandiner_202004</ext-link></comment>.</mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goepfert</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chabanon</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Bonaparte</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: Interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>1257</fpage>&#8211;<lpage>1270</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00147-x</pub-id><pub-id pub-id-type="pmid">33887209</pub-id><pub-id pub-id-type="pmcid">PMC8055206</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goharshadi</surname><given-names>E. K.</given-names></name><name name-style="western"><surname>Goharshadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moghayedi</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>The use of nanotechnology in the fight against viruses: A critical review</article-title>. <source>Coord. Chem. Rev.</source><volume>464</volume>, <fpage>214559</fpage>. <pub-id pub-id-type="doi">10.1016/j.ccr.2022.214559</pub-id></mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohl</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grady</surname><given-names>P.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R. H. B.</given-names></name><name name-style="western"><surname>Auch</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A rapid, cost-effective tailed amplicon method for sequencing SARS-CoV-2</article-title>. <source>BMC Genomics</source><volume>21</volume>, <fpage>863</fpage>. <pub-id pub-id-type="doi">10.1186/s12864-020-07283-6</pub-id><pub-id pub-id-type="pmid">33276717</pub-id><pub-id pub-id-type="pmcid">PMC7716288</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aboubakr</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Brockgreitens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Durable nanocomposite face masks with high particulate filtration and rapid inactivation of coronaviruses</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>24318</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-03771-1</pub-id><pub-id pub-id-type="pmid">34934121</pub-id><pub-id pub-id-type="pmcid">PMC8692499</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Recio</surname><given-names>O.</given-names></name><name name-style="western"><surname>Guti&#233;rrez-Rivas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peir&#243;-Pastor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aguilera-Sep&#250;lveda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cano-G&#243;mez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jim&#233;nez-Clavero</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Sequencing of SARS-CoV-2 genome using different nanopore chemistries</article-title>. <source>Appl. Microbiol. Biotechnol.</source><volume>105</volume>, <fpage>3225</fpage>&#8211;<lpage>3234</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-021-11250-w</pub-id><pub-id pub-id-type="pmid">33792750</pub-id><pub-id pub-id-type="pmcid">PMC8014908</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Pinheiro</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Schenck</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jabri</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of covid-19 in New York city</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>2372</fpage>&#8211;<lpage>2374</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2010419</pub-id><pub-id pub-id-type="pmcid">PMC7182018</pub-id><pub-id pub-id-type="pmid">32302078</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grasselli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zanella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Albano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bellani</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy</article-title>. <source>JAMA Intern. Med.</source><volume>180</volume>, <fpage>1345</fpage>&#8211;<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.3539</pub-id><pub-id pub-id-type="pmid">32667669</pub-id><pub-id pub-id-type="pmcid">PMC7364371</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grassia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Testa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>C. B.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 and gastrointestinal tract: The dark side of the pandemic</article-title>. <source>Dig. Liver Dis.</source><volume>52</volume>, <fpage>700</fpage>&#8211;<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1016/j.dld.2020.04.028</pub-id><pub-id pub-id-type="pmid">32423849</pub-id><pub-id pub-id-type="pmcid">PMC7188635</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grau-Exposito</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanchez-Gaona</surname><given-names>N.</given-names></name><name name-style="western"><surname>Massana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Suppi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Astorga-Gamaza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perea</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Peripheral and lung resident memory T cell responses against SARS-CoV-2</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>3010</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-23333-3</pub-id><pub-id pub-id-type="pmid">34021148</pub-id><pub-id pub-id-type="pmcid">PMC8140108</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>C. Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>J. X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1708</fpage>&#8211;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2002032</pub-id><pub-id pub-id-type="pmcid">PMC7092819</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guebre-Xabier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maciejewski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge</article-title>. <source>Vaccine</source><volume>38</volume>, <fpage>7892</fpage>&#8211;<lpage>7896</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2020.10.064</pub-id><pub-id pub-id-type="pmid">33139139</pub-id><pub-id pub-id-type="pmcid">PMC7584426</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Magr&#236;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gioria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Medaglini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Calzolai</surname><given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Characterization of nanoparticles-based vaccines for COVID-19</article-title>. <source>Nat. Nanotechnol.</source><volume>17</volume>, <fpage>570</fpage>&#8211;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-022-01129-w</pub-id><pub-id pub-id-type="pmid">35710950</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Highly sensitive fluorescence-linked immunosorbent assay for the determination of human IgG in serum using quantum dot nanobeads and magnetic Fe(3)O(4) nanospheres</article-title>. <source>ACS Omega</source><volume>5</volume>, <fpage>23229</fpage>&#8211;<lpage>23236</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.0c02987</pub-id><pub-id pub-id-type="pmid">32954173</pub-id><pub-id pub-id-type="pmcid">PMC7495760</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M.</given-names></name><name name-style="western"><surname>ChangYang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dela Cruz</surname><given-names>C. S.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume>, <fpage>778</fpage>&#8211;<lpage>785</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa310</pub-id><pub-id pub-id-type="pmid">32198501</pub-id><pub-id pub-id-type="pmcid">PMC7184472</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Z. D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z. Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, wuhan, China, 2020</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>1583</fpage>&#8211;<lpage>1591</lpage>. <pub-id pub-id-type="doi">10.3201/eid2607.200885</pub-id><pub-id pub-id-type="pmid">32275497</pub-id><pub-id pub-id-type="pmcid">PMC7323510</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sagar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Priyadarshi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandhir</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rishi</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanotechnology-based approaches for the detection of SARS-CoV-2</article-title>. <source>Front. Nanotechnol.</source><volume>2</volume>. <pub-id pub-id-type="doi">10.3389/fnano.2020.589832</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Augustine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>T.</given-names></name><name name-style="western"><surname>O'riordan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Point-of-Care PCR assays for COVID-19 detection</article-title>. <source>Biosens. (Basel)</source><volume>11</volume>, <fpage>141</fpage>. <pub-id pub-id-type="doi">10.3390/bios11050141</pub-id><pub-id pub-id-type="pmcid">PMC8147281</pub-id><pub-id pub-id-type="pmid">34062874</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhoyar</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name><name name-style="western"><surname>Upadhayay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Imran</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Asymptomatic reinfection in 2 healthcare workers from India with genetically distinct severe acute respiratory syndrome coronavirus 2</article-title>. <source>Clin. Infect. Dis.</source><volume>73</volume>, <fpage>e2823</fpage>&#8211;<lpage>e2825</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1451</pub-id><pub-id pub-id-type="pmcid">PMC7543380</pub-id><pub-id pub-id-type="pmid">32964927</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hachmann</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>387</volume>, <fpage>86</fpage>&#8211;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2206576</pub-id><pub-id pub-id-type="pmcid">PMC9258748</pub-id><pub-id pub-id-type="pmid">35731894</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadas</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sultana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Youssef</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sharkar</surname><given-names>M. T. K.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chepurko</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Optimizing modified mRNA <italic toggle="yes">in vitro</italic> synthesis protocol for heart gene therapy</article-title>. <source>Mol. Ther. - Methods &amp; Clin. Dev.</source><volume>14</volume>, <fpage>300</fpage>&#8211;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.omtm.2019.07.006</pub-id><pub-id pub-id-type="pmid">31508439</pub-id><pub-id pub-id-type="pmcid">PMC6722299</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadfield</surname><given-names>J.</given-names></name><name name-style="western"><surname>Megill</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Huddleston</surname><given-names>J.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Callender</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Nextstrain: Real-time tracking of pathogen evolution</article-title>. <source>Bioinformatics</source><volume>34</volume>, <fpage>4121</fpage>&#8211;<lpage>4123</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty407</pub-id><pub-id pub-id-type="pmid">29790939</pub-id><pub-id pub-id-type="pmcid">PMC6247931</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Mccormick</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sleweon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nicolae</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant infections among incarcerated persons in a federal prison - Texas, july-august 2021</article-title>. <source>MMWR. Morb. Mortal. Wkly. Rep.</source><volume>70</volume>, <fpage>1349</fpage>&#8211;<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7038e3</pub-id><pub-id pub-id-type="pmid">34555009</pub-id><pub-id pub-id-type="pmcid">PMC8459894</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamming</surname><given-names>I.</given-names></name><name name-style="western"><surname>Timens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bulthuis</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Lely</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Navis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Goor</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>). <article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title>. <source>J. Pathol.</source><volume>203</volume>, <fpage>631</fpage>&#8211;<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1002/path.1570</pub-id><pub-id pub-id-type="pmid">15141377</pub-id><pub-id pub-id-type="pmcid">PMC7167720</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamza</surname><given-names>R. Z.</given-names></name><name name-style="western"><surname>Gobouri</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Al-Yasi</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Al-Talhi</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>El-Megharbel</surname><given-names>S. M.</given-names></name></person-group> (<year>2021</year>). <article-title>A new sterilization strategy using TiO2 nanotubes for production of free radicals that eliminate viruses and application of a treatment strategy to combat infections caused by emerging SARS-CoV-2 during the COVID-19 pandemic</article-title>. <source>Coatings</source><volume>11</volume>, <fpage>680</fpage>. <pub-id pub-id-type="doi">10.3390/coatings11060680</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>1645</fpage>&#8211;<lpage>1653</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00319-4</pub-id><pub-id pub-id-type="pmid">34197764</pub-id><pub-id pub-id-type="pmcid">PMC8238449</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Reconstruction of the full transmission dynamics of COVID-19 in Wuhan</article-title>. <source>Nature</source><volume>584</volume>, <fpage>420</fpage>&#8211;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2554-8</pub-id><pub-id pub-id-type="pmid">32674112</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hariri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hardin</surname><given-names>C. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Covid-19, angiogenesis, and ARDS endotypes</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>182</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1056/nejme2018629</pub-id><pub-id pub-id-type="pmid">32437597</pub-id></mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrigan</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>H. V.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Clinical severity of omicron SARS-CoV-2 variant relative to delta in British columbia, Canada: A retrospective analysis of whole genome sequenced cases</article-title>. <source>Clin. Infect. Dis.</source><volume>30</volume>, <fpage>ciac705</fpage>. <pub-id pub-id-type="doi">10.1093/cid/ciac705</pub-id><pub-id pub-id-type="pmcid">PMC9452171</pub-id><pub-id pub-id-type="pmid">36041009</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasanoglu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Korukluoglu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Asilturk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cosgun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kalem</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Altas</surname><given-names>A. B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg</article-title>. <source>Infection</source><volume>49</volume>, <fpage>117</fpage>&#8211;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-020-01548-8</pub-id><pub-id pub-id-type="pmid">33231841</pub-id><pub-id pub-id-type="pmcid">PMC7685188</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasanzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alamdaran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nourizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bagherzadeh</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Mofazzal Jahromi</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies</article-title>. <source>J. Control. Release</source><volume>336</volume>, <fpage>354</fpage>&#8211;<lpage>374</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.06.036</pub-id><pub-id pub-id-type="pmid">34175366</pub-id><pub-id pub-id-type="pmcid">PMC8226031</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hirschenberger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koepke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nchioua</surname><given-names>R.</given-names></name><name name-style="western"><surname>Straub</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Klute</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities</article-title>. <source>Cell Rep.</source><volume>35</volume>, <fpage>109126</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109126</pub-id><pub-id pub-id-type="pmid">33974846</pub-id><pub-id pub-id-type="pmcid">PMC8078906</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>E. H. Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Temporal dynamics in viral shedding and transmissibility of COVID-19</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>672</fpage>&#8211;<lpage>675</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0869-5</pub-id><pub-id pub-id-type="pmid">32296168</pub-id></mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ngo</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates</article-title>. <source>Sci. Adv.</source><volume>7</volume>, <fpage>eabf1591</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abf1591</pub-id><pub-id pub-id-type="pmid">33741598</pub-id><pub-id pub-id-type="pmcid">PMC7978432</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>P. T.</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and efficacy of NVX-CoV2373 covid-19 vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>385</volume>, <fpage>1172</fpage>&#8211;<lpage>1183</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2107659</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id><pub-id pub-id-type="pmid">34192426</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heida</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hinrichs</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Frijlink</surname><given-names>H. W.</given-names></name></person-group> (<year>2022</year>). <article-title>Inhaled vaccine delivery in the combat against respiratory viruses: A 2021 overview of recent developments and implications for COVID-19</article-title>. <source>Expert Rev. Vaccines</source><volume>21</volume>, <fpage>957</fpage>&#8211;<lpage>974</lpage>. <pub-id pub-id-type="doi">10.1080/14760584.2021.1903878</pub-id><pub-id pub-id-type="pmid">33749491</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinberg</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Social isolation and loneliness during the COVID-19 pandemic: Impact on weight</article-title>. <source>Curr. Obes. Rep.</source><volume>10</volume>, <fpage>365</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1007/s13679-021-00447-9</pub-id><pub-id pub-id-type="pmid">34297344</pub-id><pub-id pub-id-type="pmcid">PMC8300081</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinz</surname><given-names>F. X.</given-names></name><name name-style="western"><surname>Stiasny</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action</article-title>. <source>NPJ Vaccines</source><volume>6</volume>, <fpage>104</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-021-00369-6</pub-id><pub-id pub-id-type="pmid">34400651</pub-id><pub-id pub-id-type="pmcid">PMC8368295</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helms</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Merdji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Clere-Jehl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schenck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kummerlen</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neurologic features in severe SARS-CoV-2 infection</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>2268</fpage>&#8211;<lpage>2270</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2008597</pub-id><pub-id pub-id-type="pmcid">PMC7179967</pub-id><pub-id pub-id-type="pmid">32294339</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fortunak</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Minimum costs to manufacture new treatments for COVID-19</article-title>. <source>J. Virus Erad.</source><volume>6</volume>, <fpage>61</fpage>&#8211;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/s2055-6640(20)30018-2</pub-id><pub-id pub-id-type="pmid">32405423</pub-id><pub-id pub-id-type="pmcid">PMC7331548</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirotsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Omata</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan</article-title>. <source>J. Infect.</source><volume>82</volume>, <fpage>276</fpage>&#8211;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2021.03.013</pub-id><pub-id pub-id-type="pmcid">PMC7985610</pub-id><pub-id pub-id-type="pmid">33766552</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoang</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T. T. H.</given-names></name><name name-style="western"><surname>Le</surname><given-names>Q. D.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>K. V.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam</article-title>. <source>BMC Infect. Dis.</source><volume>22</volume>, <fpage>558</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-022-07415-1</pub-id><pub-id pub-id-type="pmid">35718768</pub-id><pub-id pub-id-type="pmcid">PMC9206857</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Mansatta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V.</given-names></name><name name-style="western"><surname>Emary</surname><given-names>K. R. W.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A. J.</given-names></name></person-group> (<year>2021</year>). <article-title>What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>e26</fpage>&#8211;<lpage>e35</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30773-8</pub-id><pub-id pub-id-type="pmid">33125914</pub-id><pub-id pub-id-type="pmcid">PMC7837315</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoehl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rabenau</surname><given-names>H.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kortenbusch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cinatl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bojkova</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Evidence of SARS-CoV-2 infection in returning travelers from wuhan, China</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1278</fpage>&#8211;<lpage>1280</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2001899</pub-id><pub-id pub-id-type="pmcid">PMC7121749</pub-id><pub-id pub-id-type="pmid">32069388</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>S.</given-names></name></person-group> (<year>2020a</year>). <article-title>A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells</article-title>. <source>Mol. Cell</source><volume>78</volume>, <fpage>779</fpage>&#8211;<lpage>784.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.04.022</pub-id><pub-id pub-id-type="pmid">32362314</pub-id><pub-id pub-id-type="pmcid">PMC7194065</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source><volume>181</volume>, <fpage>271</fpage>&#8211;<lpage>280.e8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arora</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornich</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies</article-title>. <source>Cell</source><volume>184</volume>, <fpage>2384</fpage>&#8211;<lpage>2393.e12</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.036</pub-id><pub-id pub-id-type="pmid">33794143</pub-id><pub-id pub-id-type="pmcid">PMC7980144</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pyrc</surname><given-names>K.</given-names></name><name name-style="western"><surname>Van Der Hoek</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berkhout</surname><given-names>B.</given-names></name><name name-style="western"><surname>P&#246;hlmann</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>102</volume>, <fpage>7988</fpage>&#8211;<lpage>7993</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0409465102</pub-id><pub-id pub-id-type="pmid">15897467</pub-id><pub-id pub-id-type="pmcid">PMC1142358</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le Goff</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cosnier</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Nanomaterials for biosensing applications: A review</article-title>. <source>Front. Chem.</source><volume>2</volume>, <fpage>63</fpage>. <pub-id pub-id-type="doi">10.3389/fchem.2014.00063</pub-id><pub-id pub-id-type="pmid">25221775</pub-id><pub-id pub-id-type="pmcid">PMC4145256</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horejs</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Artificially intelligent nanopore for rapid SARS-CoV-2 testing</article-title>. <source>Nat. Rev. Mat.</source><volume>6</volume>, <fpage>650</fpage>. <pub-id pub-id-type="doi">10.1038/s41578-021-00346-4</pub-id><pub-id pub-id-type="pmcid">PMC8244452</pub-id><pub-id pub-id-type="pmid">34226850</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Behzadinasab</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benmamoun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ducker</surname><given-names>W. A.</given-names></name></person-group> (<year>2021</year>). <article-title>The viability of SARS-CoV-2 on solid surfaces</article-title>. <source>Curr. Opin. Colloid Interface Sci.</source><volume>55</volume>, <fpage>101481</fpage>. <pub-id pub-id-type="doi">10.1016/j.cocis.2021.101481</pub-id><pub-id pub-id-type="pmid">34149298</pub-id><pub-id pub-id-type="pmcid">PMC8205552</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Asakura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K. H.</given-names><suffix>3rd</suffix></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract</article-title>. <source>Cell</source><volume>182</volume>, <fpage>429</fpage>&#8211;<lpage>446.e14</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.05.042</pub-id><pub-id pub-id-type="pmid">32526206</pub-id><pub-id pub-id-type="pmcid">PMC7250779</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tufekci</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zdimal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Van Der Westhuizen</surname><given-names>H. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An evidence review of face masks against COVID-19</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>e2014564118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2014564118</pub-id><pub-id pub-id-type="pmid">33431650</pub-id><pub-id pub-id-type="pmcid">PMC7848583</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Schaub</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Divenere</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Javanmardi</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Structure-based design of prefusion-stabilized SARS-CoV-2 spikes</article-title>. <source>Science</source><volume>369</volume>, <fpage>1501</fpage>&#8211;<lpage>1505</lpage>. <pub-id pub-id-type="doi">10.1126/science.abd0826</pub-id><pub-id pub-id-type="pmid">32703906</pub-id><pub-id pub-id-type="pmcid">PMC7402631</pub-id></mixed-citation></ref><ref id="B290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Wilen</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Cresswell</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>e2101161118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2101161118</pub-id><pub-id pub-id-type="pmid">34045361</pub-id><pub-id pub-id-type="pmcid">PMC8214666</pub-id></mixed-citation></ref><ref id="B291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>C. Z.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Z. P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q. F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epidemiological features and viral shedding in children with SARS-CoV-2 infection</article-title>. <source>J. Med. Virol.</source><volume>92</volume>, <fpage>2804</fpage>&#8211;<lpage>2812</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.26180</pub-id><pub-id pub-id-type="pmid">32542750</pub-id><pub-id pub-id-type="pmcid">PMC7323101</pub-id></mixed-citation></ref><ref id="B292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>497</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></mixed-citation></ref><ref id="B293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Y. J.</given-names></name></person-group> (<year>2020b</year>). <article-title>Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay</article-title>. <source>ACS Omega</source><volume>5</volume>, <fpage>12550</fpage>&#8211;<lpage>12556</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.0c01554</pub-id><pub-id pub-id-type="pmid">32542208</pub-id><pub-id pub-id-type="pmcid">PMC7241732</pub-id></mixed-citation></ref><ref id="B294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X. F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S. W.</given-names></name></person-group> (<year>2020c</year>). <article-title>Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19</article-title>. <source>Acta Pharmacol. Sin.</source><volume>41</volume>, <fpage>1141</fpage>&#8211;<lpage>1149</lpage>. <pub-id pub-id-type="doi">10.1038/s41401-020-0485-4</pub-id><pub-id pub-id-type="pmid">32747721</pub-id><pub-id pub-id-type="pmcid">PMC7396720</pub-id></mixed-citation></ref><ref id="B295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>R. C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 infection of the oral cavity and saliva</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>892</fpage>&#8211;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-021-01296-8</pub-id><pub-id pub-id-type="pmid">33767405</pub-id><pub-id pub-id-type="pmcid">PMC8240394</pub-id></mixed-citation></ref><ref id="B296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Developing RT-LAMP assays for rapid diagnosis of SARS-CoV-2 in saliva</article-title>. <source>EBioMedicine</source><volume>75</volume>, <fpage>103736</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103736</pub-id><pub-id pub-id-type="pmid">34922321</pub-id><pub-id pub-id-type="pmcid">PMC8674011</pub-id></mixed-citation></ref><ref id="B297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iannaccone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alemanno</surname><given-names>F.</given-names></name><name name-style="western"><surname>Houdayer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brugliera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Castellazzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cianflone</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 rehabilitation units are twice as expensive as regular rehabilitation units</article-title>. <source>J. Rehabil. Med.</source><volume>52</volume>, <fpage>jrm00073</fpage>. <pub-id pub-id-type="doi">10.2340/16501977-2704</pub-id><pub-id pub-id-type="pmid">32516421</pub-id></mixed-citation></ref><ref id="B298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Idris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Supramaniam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tayyar</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19</article-title>. <source>Mol. Ther.</source><volume>29</volume>, <fpage>2219</fpage>&#8211;<lpage>2226</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2021.05.004</pub-id><pub-id pub-id-type="pmid">33992805</pub-id><pub-id pub-id-type="pmcid">PMC8118699</pub-id></mixed-citation></ref><ref id="B299"><mixed-citation publication-type="journal"><collab>Ifc</collab> (<year>2021</year>). <article-title>Innovation in manufacturing personal protective equipment: Toward sustainability and circularity</article-title>. <source>Int. Finance Corp.</source>, <fpage>1</fpage>&#8211;<lpage>57</lpage>.</mixed-citation></ref><ref id="B300"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilyas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Disinfection technology and strategies for COVID-19 hospital and bio-medical waste management</article-title>. <source>Sci. Total Environ.</source><volume>749</volume>, <fpage>141652</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.141652</pub-id><pub-id pub-id-type="pmid">32822917</pub-id><pub-id pub-id-type="pmcid">PMC7419320</pub-id></mixed-citation></ref><ref id="B301"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ingram</surname><given-names>C.</given-names></name><name name-style="western"><surname>Downey</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Archibald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kallas</surname><given-names>K. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 prevention and control measures in workplace settings: A rapid review and meta-analysis</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>18</volume>, <fpage>7847</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph18157847</pub-id><pub-id pub-id-type="pmid">34360142</pub-id><pub-id pub-id-type="pmcid">PMC8345343</pub-id></mixed-citation></ref><ref id="B302"><mixed-citation publication-type="journal"><collab>International-Committee-on-Taxonomy-of-Viruses</collab> (<year>2020</year>). <article-title>The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2</article-title>. <source>Nat. Microbiol.</source><volume>5</volume>, <fpage>536</fpage>&#8211;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></mixed-citation></ref><ref id="B303"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ip</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Viral shedding and transmission potential of asymptomatic and paucisymptomatic influenza virus infections in the community</article-title>. <source>Clin. Infect. Dis.</source><volume>64</volume>, <fpage>736</fpage>&#8211;<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw841</pub-id><pub-id pub-id-type="pmid">28011603</pub-id><pub-id pub-id-type="pmcid">PMC5967351</pub-id></mixed-citation></ref><ref id="B304"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>An mRNA vaccine against SARS-CoV-2 - preliminary report</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>1920</fpage>&#8211;<lpage>1931</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id><pub-id pub-id-type="pmid">32663912</pub-id></mixed-citation></ref><ref id="B305"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name></person-group> (<year>2022</year>). <article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source><volume>23</volume>, <fpage>3</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id></mixed-citation></ref><ref id="B306"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacofsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jacofsky</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Jacofsky</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Understanding antibody testing for COVID-19</article-title>. <source>J. Arthroplasty</source><volume>35</volume>, <fpage>S74</fpage>&#8211;<lpage>s81</lpage>. <pub-id pub-id-type="doi">10.1016/j.arth.2020.04.055</pub-id><pub-id pub-id-type="pmid">32389405</pub-id><pub-id pub-id-type="pmcid">PMC7184973</pub-id></mixed-citation></ref><ref id="B307"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagannathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunity after SARS-CoV-2 infections</article-title>. <source>Nat. Immunol.</source><volume>22</volume>, <fpage>539</fpage>&#8211;<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-00923-3</pub-id><pub-id pub-id-type="pmid">33875881</pub-id><pub-id pub-id-type="pmcid">PMC9832995</pub-id></mixed-citation></ref><ref id="B308"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaimes</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Millet</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site</article-title>. <source>iScience</source><volume>23</volume>, <fpage>101212</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2020.101212</pub-id><pub-id pub-id-type="pmid">32512386</pub-id><pub-id pub-id-type="pmcid">PMC7255728</pub-id></mixed-citation></ref><ref id="B309"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>V.</given-names></name><name name-style="western"><surname>Duse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bausch</surname><given-names>D. G.</given-names></name></person-group> (<year>2018</year>). <article-title>Planning for large epidemics and pandemics: Challenges from a policy perspective</article-title>. <source>Curr. Opin. Infect. Dis.</source><volume>31</volume>, <fpage>316</fpage>&#8211;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1097/qco.0000000000000462</pub-id><pub-id pub-id-type="pmid">29846209</pub-id></mixed-citation></ref><ref id="B310"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jairak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chamsai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Udom</surname><given-names>K.</given-names></name><name name-style="western"><surname>Charoenkul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chaiyawong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Techakriengkrai</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 delta variant infection in domestic dogs and cats, Thailand</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>8403</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-12468-y</pub-id><pub-id pub-id-type="pmid">35589808</pub-id><pub-id pub-id-type="pmcid">PMC9117851</pub-id></mixed-citation></ref><ref id="B311"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stoddart</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Beaulaurier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>S. W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>LamPORE: Rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing</article-title>. <comment>medRxiv 2020.08.07.20161737</comment>. <pub-id pub-id-type="doi">10.1101/2020.08.07.20161737</pub-id></mixed-citation></ref><ref id="B312"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jefferson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Brassey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heneghan</surname><given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Viral cultures for coronavirus disease 2019 infectivity assessment: A systematic review</article-title>. <source>Clin. Infect. Dis.</source><volume>73</volume>, <fpage>e3884</fpage>&#8211;<lpage>e3899</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1764</pub-id><pub-id pub-id-type="pmid">33270107</pub-id><pub-id pub-id-type="pmcid">PMC7799320</pub-id></mixed-citation></ref><ref id="B313"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeremiah</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Miyakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamaoka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ryo</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Potent antiviral effect of silver nanoparticles on SARS-CoV-2</article-title>. <source>Biochem. Biophys. Res. Commun.</source><volume>533</volume>, <fpage>195</fpage>&#8211;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.09.018</pub-id><pub-id pub-id-type="pmid">32958250</pub-id><pub-id pub-id-type="pmcid">PMC7486059</pub-id></mixed-citation></ref><ref id="B314"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jh</surname><given-names>V.</given-names></name><name name-style="western"><surname>B</surname><given-names>R.</given-names></name><name name-style="western"><surname>S</surname><given-names>J.</given-names></name><name name-style="western"><surname>R</surname><given-names>S.</given-names></name><name name-style="western"><surname>E</surname><given-names>T.</given-names></name><name name-style="western"><surname>B</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff</article-title>. <source>Cochrane Database Syst. Rev.</source><volume>5</volume>, <fpage>CD011621</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD011621.pub5</pub-id><pub-id pub-id-type="pmid">32412096</pub-id><pub-id pub-id-type="pmcid">PMC8785899</pub-id></mixed-citation></ref><ref id="B315"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Serological antibody testing in the COVID-19 pandemic: Their molecular basis and applications</article-title>. <source>Biochem. Soc. Trans.</source><volume>48</volume>, <fpage>2851</fpage>&#8211;<lpage>2863</lpage>. <pub-id pub-id-type="doi">10.1042/bst20200744</pub-id><pub-id pub-id-type="pmid">33170924</pub-id></mixed-citation></ref><ref id="B316"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X. N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z. Q.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: A 3-family cluster study in China</article-title>. <source>J. Infect. Dis.</source><volume>221</volume>, <fpage>1948</fpage>&#8211;<lpage>1952</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiaa206</pub-id><pub-id pub-id-type="pmid">32319519</pub-id><pub-id pub-id-type="pmcid">PMC7188140</pub-id></mixed-citation></ref><ref id="B317"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms</article-title>. <source>Gut</source><volume>69</volume>, <fpage>1002</fpage>&#8211;<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2020-320926</pub-id><pub-id pub-id-type="pmid">32213556</pub-id><pub-id pub-id-type="pmcid">PMC7133387</pub-id></mixed-citation></ref><ref id="B318"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kalveram</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Muruato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Furin cleavage site is key to SARS-CoV-2 pathogenesis</article-title>. <comment>bioRxiv 2020.08.26.268854</comment>. <pub-id pub-id-type="doi">10.1101/2020.08.26.268854</pub-id><pub-id pub-id-type="pmcid">PMC8175039</pub-id><pub-id pub-id-type="pmid">33494095</pub-id></mixed-citation></ref><ref id="B319"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Kalveram</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Muruato</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis</article-title>. <source>Nature</source><volume>591</volume>, <fpage>293</fpage>&#8211;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03237-4</pub-id><pub-id pub-id-type="pmid">33494095</pub-id><pub-id pub-id-type="pmcid">PMC8175039</pub-id></mixed-citation></ref><ref id="B320"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Nishida</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Sonpar</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S. W.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Viral load of SARS-CoV-2 in droplets and bioaerosols directly captured during breathing, speaking and coughing</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>3484</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-07301-5</pub-id><pub-id pub-id-type="pmid">35241703</pub-id><pub-id pub-id-type="pmcid">PMC8894466</pub-id></mixed-citation></ref><ref id="B321"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Adhya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>V. P. S.</given-names></name><name name-style="western"><surname>Pani</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Spread of COVID-19 by asymptomatic cases: Evidence from military quarantine facilities</article-title>. <source>BMJ Mil. Health</source><volume>167</volume>, <fpage>217</fpage>&#8211;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1136/bmjmilitary-2020-001669</pub-id><pub-id pub-id-type="pmid">33122402</pub-id></mixed-citation></ref><ref id="B322"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>J. T. J.</given-names></name><name name-style="western"><surname>Boisvert</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Y. Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Face masks against COVID-19: Standards, efficacy, testing and decontamination methods</article-title>. <source>Adv. Colloid Interface Sci.</source><volume>292</volume>, <fpage>102435</fpage>. <pub-id pub-id-type="doi">10.1016/j.cis.2021.102435</pub-id><pub-id pub-id-type="pmid">33971389</pub-id><pub-id pub-id-type="pmcid">PMC8084286</pub-id></mixed-citation></ref><ref id="B323"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Nanopore electrochemistry for pathogen detection</article-title>. <source>Chem. Asian J.</source><volume>7</volume>, <fpage>e202200774</fpage>. <pub-id pub-id-type="doi">10.1002/asia.202200774</pub-id><pub-id pub-id-type="pmid">36069587</pub-id></mixed-citation></ref><ref id="B324"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rajapakshe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Julien</surname><given-names>C.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Analytical and clinical performance of cPass neutralizing antibodies assay</article-title>. <source>Clin. Biochem.</source><volume>98</volume>, <fpage>70</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2021.09.008</pub-id><pub-id pub-id-type="pmid">34560062</pub-id><pub-id pub-id-type="pmcid">PMC8453782</pub-id></mixed-citation></ref><ref id="B325"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E. O.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name></person-group> (<year>2022</year>). <article-title>Risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission among healthcare workers dining in hospital staff cafeterias</article-title>. <source>J. Korean Med. Sci.</source><volume>37</volume>, <fpage>e14</fpage>. <pub-id pub-id-type="doi">10.3346/jkms.2022.37.e14</pub-id><pub-id pub-id-type="pmid">35014226</pub-id><pub-id pub-id-type="pmcid">PMC8748669</pub-id></mixed-citation></ref><ref id="B326"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>Y. B.</given-names></name><name name-style="western"><surname>Schutz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kyratzis</surname><given-names>I. L.</given-names></name><name name-style="western"><surname>Padhye</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Gelatin/&#946;&#8211;Cyclodextrin Bio&#8211;Nanofibers as respiratory filter media for filtration of aerosols and volatile organic compounds at low air resistance</article-title>. <source>J. Hazard. Mater.</source><volume>403</volume>, <fpage>123841</fpage>. <pub-id pub-id-type="doi">10.1016/j.jhazmat.2020.123841</pub-id><pub-id pub-id-type="pmid">33264922</pub-id><pub-id pub-id-type="pmcid">PMC7467901</pub-id></mixed-citation></ref><ref id="B327"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kaba</surname><given-names>H. E. J.</given-names></name><name name-style="western"><surname>Steinmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pfaender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scheithauer</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2</article-title>. <source>J. Hosp. Infect.</source><volume>106</volume>, <fpage>678</fpage>&#8211;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2020.09.022</pub-id><pub-id pub-id-type="pmid">32956786</pub-id><pub-id pub-id-type="pmcid">PMC7500278</pub-id></mixed-citation></ref><ref id="B328"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampf</surname><given-names>G.</given-names></name><name name-style="western"><surname>Todt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pfaender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steinmann</surname><given-names>E.</given-names></name></person-group> (<year>2020b</year>). <article-title>Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents</article-title>. <source>J. Hosp. Infect.</source><volume>104</volume>, <fpage>246</fpage>&#8211;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2020.01.022</pub-id><pub-id pub-id-type="pmid">32035997</pub-id><pub-id pub-id-type="pmcid">PMC7132493</pub-id></mixed-citation></ref><ref id="B329"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaname</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyauchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuwano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kajii</surname><given-names>T.</given-names></name></person-group> (<year>1993</year>). <article-title>Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3</article-title>. <source>Cytogenet. Genome Res.</source><volume>64</volume>, <fpage>195</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1159/000133573</pub-id><pub-id pub-id-type="pmid">8404035</pub-id></mixed-citation></ref><ref id="B330"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneko</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Boucau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Allard-Chamard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>V. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Pillai, S., and Massachusetts consortium on pathogen readiness specimen working, GLoss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19</article-title>. <source>Cell</source><volume>183</volume>, <fpage>143</fpage>&#8211;<lpage>157.e13</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.025</pub-id><pub-id pub-id-type="pmid">32877699</pub-id><pub-id pub-id-type="pmcid">PMC7437499</pub-id></mixed-citation></ref><ref id="B331"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Plaxco</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>White</surname><given-names>R. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Comparing the properties of electrochemical-based DNA sensors employing different redox tags</article-title>. <source>Anal. Chem.</source><volume>81</volume>, <fpage>9109</fpage>&#8211;<lpage>9113</lpage>. <pub-id pub-id-type="doi">10.1021/ac901811n</pub-id><pub-id pub-id-type="pmid">19810694</pub-id><pub-id pub-id-type="pmcid">PMC2783686</pub-id></mixed-citation></ref><ref id="B332"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y. F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates</article-title>. <source>ACS Nano</source><volume>15</volume>, <fpage>2738</fpage>&#8211;<lpage>2752</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c08379</pub-id><pub-id pub-id-type="pmid">33464829</pub-id></mixed-citation></ref><ref id="B333"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K. J.</given-names></name></person-group> (<year>2022</year>). <article-title>Detection of SARS-CoV-2 B.1.617.2 (Delta) variant in three cats owned by a confirmed COVID-19 patient in Harbin, China</article-title>. <source>Vet. Med. Sci.</source><volume>8</volume>, <fpage>945</fpage>&#8211;<lpage>946</lpage>. <pub-id pub-id-type="doi">10.1002/vms3.715</pub-id><pub-id pub-id-type="pmid">34958181</pub-id><pub-id pub-id-type="pmcid">PMC9122386</pub-id></mixed-citation></ref><ref id="B334"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannan</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Nance</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomalia</surname><given-names>D. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Emerging concepts in dendrimer-based nanomedicine: From design principles to clinical applications</article-title>. <source>J. Intern. Med.</source><volume>276</volume>, <fpage>579</fpage>&#8211;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12280</pub-id><pub-id pub-id-type="pmid">24995512</pub-id></mixed-citation></ref><ref id="B335"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantipakala</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Vemireddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miryala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>M. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Squalane-based emulsion vaccine delivery system: Composition with murabutide activate Th1 response</article-title>. <source>Pharm. Dev. Technol.</source><volume>24</volume>, <fpage>269</fpage>&#8211;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1080/10837450.2018.1469150</pub-id><pub-id pub-id-type="pmid">29688119</pub-id></mixed-citation></ref><ref id="B336"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karik&#243;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Buckstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group> (<year>2005</year>). <article-title>Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA</article-title>. <source>Immunity</source><volume>23</volume>, <fpage>165</fpage>&#8211;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2005.06.008</pub-id><pub-id pub-id-type="pmid">16111635</pub-id></mixed-citation></ref><ref id="B337"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Afroj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oaten</surname><given-names>L. C.</given-names></name><name name-style="western"><surname>Andreeva</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Sustainable personal protective clothing for healthcare applications: A review</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>12313</fpage>&#8211;<lpage>12340</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c05537</pub-id><pub-id pub-id-type="pmid">32866368</pub-id><pub-id pub-id-type="pmcid">PMC7518242</pub-id></mixed-citation></ref><ref id="B338"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karlsen</surname><given-names>T. H.</given-names></name></person-group> (<year>2022</year>). <article-title>Understanding COVID-19 through genome-wide association studies</article-title>. <source>Nat. Genet.</source><volume>54</volume>, <fpage>368</fpage>&#8211;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-021-00985-x</pub-id><pub-id pub-id-type="pmid">35410380</pub-id></mixed-citation></ref><ref id="B339"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katona</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kullar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name></person-group> (<year>2022</year>). <article-title>Bringing transmission of SARS-CoV-2 to the surface: Is there a role for fomites?</article-title><source>Clin. Infect. Dis.</source><volume>75</volume>, <fpage>910</fpage>&#8211;<lpage>916</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciac157</pub-id><pub-id pub-id-type="pmid">35218181</pub-id><pub-id pub-id-type="pmcid">PMC8903442</pub-id></mixed-citation></ref><ref id="B340"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>2320</fpage>&#8211;<lpage>2332</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id><pub-id pub-id-type="pmid">32877576</pub-id></mixed-citation></ref><ref id="B341"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khabazzadeh Tehrani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maleki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zarrati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tabatabaie</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine</article-title>. <source>J. Parasit. Dis.</source><volume>40</volume>, <fpage>760</fpage>&#8211;<lpage>767</lpage>. <pub-id pub-id-type="doi">10.1007/s12639-014-0574-8</pub-id><pub-id pub-id-type="pmid">27605780</pub-id><pub-id pub-id-type="pmcid">PMC4996187</pub-id></mixed-citation></ref><ref id="B342"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khademi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Momtazi-Borojeni</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Farnoosh</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Potential of cationic liposomes as adjuvants/delivery systems for tuberculosis subunit vaccines</article-title>. <source>Rev. Physiol. Biochem. Pharmacol.</source><volume>175</volume>, <fpage>47</fpage>&#8211;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1007/112_2018_9</pub-id><pub-id pub-id-type="pmid">29700609</pub-id></mixed-citation></ref><ref id="B343"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khailany</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Safdar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ozaslan</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Genomic characterization of a novel SARS-CoV-2</article-title>. <source>Gene Rep.</source><volume>19</volume>, <fpage>100682</fpage>. <pub-id pub-id-type="doi">10.1016/j.genrep.2020.100682</pub-id><pub-id pub-id-type="pmid">32300673</pub-id><pub-id pub-id-type="pmcid">PMC7161481</pub-id></mixed-citation></ref><ref id="B344"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanh</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>P. Q.</given-names></name><name name-style="western"><surname>Quach</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Thi</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>T. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Transmission of SARS-CoV 2 during long-haul flight</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>2617</fpage>&#8211;<lpage>2624</lpage>. <pub-id pub-id-type="doi">10.3201/eid2611.203299</pub-id><pub-id pub-id-type="pmid">32946369</pub-id><pub-id pub-id-type="pmcid">PMC7588538</pub-id></mixed-citation></ref><ref id="B345"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gurry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Bach</surname><given-names>G.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>GISAID's role in pandemic response</article-title>. <source>China CDC Wkly.</source><volume>3</volume>, <fpage>1049</fpage>&#8211;<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.46234/ccdcw2021.255</pub-id><pub-id pub-id-type="pmid">34934514</pub-id><pub-id pub-id-type="pmcid">PMC8668406</pub-id></mixed-citation></ref><ref id="B346"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Cromer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reynaldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schlub</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Juno</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>1205</fpage>&#8211;<lpage>1211</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-021-01377-8</pub-id><pub-id pub-id-type="pmid">34002089</pub-id></mixed-citation></ref><ref id="B347"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kianpour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akbarian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V. N.</given-names></name></person-group> (<year>2022</year>). <article-title>Nanoparticles for coronavirus control</article-title>. <source>Nanomater. (Basel)</source><volume>12</volume>, <fpage>1602</fpage>. <pub-id pub-id-type="doi">10.3390/nano12091602</pub-id><pub-id pub-id-type="pmcid">PMC9104235</pub-id><pub-id pub-id-type="pmid">35564311</pub-id></mixed-citation></ref><ref id="B348"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiesslich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamen</surname><given-names>A. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Vero cell upstream bioprocess development for the production of viral vectors and vaccines</article-title>. <source>Biotechnol. Adv.</source><volume>44</volume>, <fpage>107608</fpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2020.107608</pub-id><pub-id pub-id-type="pmid">32768520</pub-id><pub-id pub-id-type="pmcid">PMC7405825</pub-id></mixed-citation></ref><ref id="B349"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weissleder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Molecular and immunological diagnostic tests of COVID-19: Current status and challenges</article-title>. <source>iScience</source><volume>23</volume>, <fpage>101406</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2020.101406</pub-id><pub-id pub-id-type="pmid">32771976</pub-id><pub-id pub-id-type="pmcid">PMC7381402</pub-id></mixed-citation></ref><ref id="B350"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.</given-names></name></person-group> (<year>2020a</year>). <article-title>The architecture of SARS-CoV-2 transcriptome</article-title>. <source>Cell</source><volume>181</volume>, <fpage>914</fpage>&#8211;<lpage>921.e10</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.011</pub-id><pub-id pub-id-type="pmid">32330414</pub-id><pub-id pub-id-type="pmcid">PMC7179501</pub-id></mixed-citation></ref><ref id="B351"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>S. U.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>T. H.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients</article-title>. <source>Int. J. Infect. Dis.</source><volume>95</volume>, <fpage>441</fpage>&#8211;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.04.083</pub-id><pub-id pub-id-type="pmid">32376309</pub-id><pub-id pub-id-type="pmcid">PMC7196533</pub-id></mixed-citation></ref><ref id="B352"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eygeris</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>G.</given-names></name></person-group> (<year>2021a</year>). <article-title>Self-assembled mRNA vaccines</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>170</volume>, <fpage>83</fpage>&#8211;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2020.12.014</pub-id><pub-id pub-id-type="pmid">33400957</pub-id><pub-id pub-id-type="pmcid">PMC7837307</pub-id></mixed-citation></ref><ref id="B353"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y. I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Casel</surname><given-names>M. a. B.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets</article-title>. <source>mBio</source><volume>12</volume> (<issue>2</issue>), <fpage>e00230-21</fpage>. <pub-id pub-id-type="doi">10.1128/mBio.00230-21</pub-id><pub-id pub-id-type="pmid">33653891</pub-id><pub-id pub-id-type="pmcid">PMC8092224</pub-id></mixed-citation></ref><ref id="B354"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hatfield</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Arons</surname><given-names>M.</given-names></name><name name-style="western"><surname>James</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spicer</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility - king county, Washington, march 2020</article-title>. <source>MMWR. Morb. Mortal. Wkly. Rep.</source><volume>69</volume>, <fpage>377</fpage>&#8211;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6913e1</pub-id><pub-id pub-id-type="pmid">32240128</pub-id><pub-id pub-id-type="pmcid">PMC7119514</pub-id></mixed-citation></ref><ref id="B355"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Konno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uriu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hopfensperger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Sarbecovirus ORF6 proteins hamper induction of interferon signaling</article-title>. <source>Cell Rep.</source><volume>34</volume>, <fpage>108916</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2021.108916</pub-id><pub-id pub-id-type="pmid">33765414</pub-id><pub-id pub-id-type="pmcid">PMC7953434</pub-id></mixed-citation></ref><ref id="B356"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>H. a. D.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Lakhal-Naouar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cincotta</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Subra</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>e2106433118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2106433118</pub-id><pub-id pub-id-type="pmid">34470866</pub-id><pub-id pub-id-type="pmcid">PMC8463842</pub-id></mixed-citation></ref><ref id="B357"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kahre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blankenburg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schumm</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haag</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galow</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Seroprevalence of SARS-CoV-2 in German secondary schools from october 2020 to july 2021: A longitudinal study</article-title>. <source>Infection</source><volume>23</volume>, <fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-022-01824-9</pub-id><pub-id pub-id-type="pmcid">PMC9034260</pub-id><pub-id pub-id-type="pmid">35460495</pub-id></mixed-citation></ref><ref id="B358"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleanthous</surname><given-names>H.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Makar</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I. K.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D. W.</given-names></name></person-group> (<year>2021</year>). <article-title>Scientific rationale for developing potent RBD-based vaccines targeting COVID-19</article-title>. <source>NPJ Vaccines</source><volume>6</volume>, <fpage>128</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-021-00393-6</pub-id><pub-id pub-id-type="pmid">34711846</pub-id><pub-id pub-id-type="pmcid">PMC8553742</pub-id></mixed-citation></ref><ref id="B359"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klebe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Felfe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klug</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Healthy leadership in turbulent times: The effectiveness of health-oriented leadership in crisis</article-title>. <source>Brit. J. Manage.</source><volume>32</volume>, <fpage>1203</fpage>&#8211;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12498</pub-id></mixed-citation></ref><ref id="B360"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinman</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Klaschik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tross</surname><given-names>D.</given-names></name></person-group> (<year>2009</year>). <article-title>CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>61</volume>, <fpage>248</fpage>&#8211;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2008.12.012</pub-id><pub-id pub-id-type="pmid">19272313</pub-id></mixed-citation></ref><ref id="B361"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klompas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>C.</given-names></name></person-group> (<year>2020a</year>). <article-title>Airborne transmission of SARS-CoV-2: Theoretical considerations and available evidence</article-title>. <source>JAMA</source><volume>324</volume>, <fpage>441</fpage>&#8211;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.12458</pub-id><pub-id pub-id-type="pmid">32749495</pub-id></mixed-citation></ref><ref id="B362"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klompas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>E. S.</given-names></name></person-group> (<year>2020b</year>). <article-title>Universal masking in the covid-19 era</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>e9</fpage>. <pub-id pub-id-type="doi">10.1056/nejmc2020836</pub-id><pub-id pub-id-type="pmid">32492295</pub-id></mixed-citation></ref><ref id="B363"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluge</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mart&#237;n-Moreno</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Emiroglu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodier</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vujnovic</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Strengthening global health security by embedding the International Health Regulations requirements into national health systems</article-title>. <source>BMJ Glob. Health</source><volume>3</volume>, <fpage>e000656</fpage>. <pub-id pub-id-type="doi">10.1136/bmjgh-2017-000656</pub-id><pub-id pub-id-type="pmcid">PMC5783036</pub-id><pub-id pub-id-type="pmid">29379650</pub-id></mixed-citation></ref><ref id="B364"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8(+) lung-resident memory T cells</article-title>. <source>ACS Nano</source><volume>13</volume>, <fpage>10939</fpage>&#8211;<lpage>10960</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b00326</pub-id><pub-id pub-id-type="pmid">31553872</pub-id><pub-id pub-id-type="pmcid">PMC6832804</pub-id></mixed-citation></ref><ref id="B365"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kociolek</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dien Bard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Revell</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparison of upper respiratory viral load distributions in asymptomatic and symptomatic children diagnosed with SARS-CoV-2 infection in pediatric hospital testing programs</article-title>. <source>J. Clin. Microbiol.</source><volume>59</volume> (<issue>1</issue>), <fpage>e02593-20</fpage>. <pub-id pub-id-type="doi">10.1128/JCM.02593-20</pub-id><pub-id pub-id-type="pmid">33093026</pub-id><pub-id pub-id-type="pmcid">PMC7771452</pub-id></mixed-citation></ref><ref id="B366"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kompaniyets</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agathis</surname><given-names>N. T.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Preston</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Belay</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Underlying medical conditions associated with severe COVID-19 illness among children</article-title>. <source>JAMA Netw. Open</source><volume>4</volume>, <fpage>e2111182</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.11182</pub-id><pub-id pub-id-type="pmid">34097050</pub-id><pub-id pub-id-type="pmcid">PMC8185607</pub-id></mixed-citation></ref><ref id="B367"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Schmoldt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Guha</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Aerosol filtration efficiency of common fabrics used in respiratory cloth masks</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>6339</fpage>&#8211;<lpage>6347</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c03252</pub-id><pub-id pub-id-type="pmid">32329337</pub-id></mixed-citation></ref><ref id="B368"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abfalterer</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus</article-title>. <source>Cell</source><volume>182</volume>, <fpage>812</fpage>&#8211;<lpage>827.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id><pub-id pub-id-type="pmcid">PMC7332439</pub-id></mixed-citation></ref><ref id="B369"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#228;utler</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Suan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hermes</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T. D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells</article-title>. <source>J. Exp. Med.</source><volume>214</volume>, <fpage>1259</fpage>&#8211;<lpage>1267</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20161533</pub-id><pub-id pub-id-type="pmid">28363897</pub-id><pub-id pub-id-type="pmcid">PMC5413338</pub-id></mixed-citation></ref><ref id="B370"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kremsner</surname><given-names>P. G.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kroidl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schindler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gabor</surname><given-names>J. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial</article-title>. <source>Wien. Klin. Wochenschr.</source><volume>133</volume>, <fpage>931</fpage>&#8211;<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1007/s00508-021-01922-y</pub-id><pub-id pub-id-type="pmid">34378087</pub-id><pub-id pub-id-type="pmcid">PMC8354521</pub-id></mixed-citation></ref><ref id="B371"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuhlmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maponga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Burgers</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Keeton</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose</article-title>. <source>Lancet</source><volume>399</volume>, <fpage>625</fpage>&#8211;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(22)00090-3</pub-id><pub-id pub-id-type="pmid">35063123</pub-id><pub-id pub-id-type="pmcid">PMC8765759</pub-id></mixed-citation></ref><ref id="B372"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>FadilaPrasad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>L. K.</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Vertical transmission and clinical outcome of the neonates born to SARS-CoV-2-positive mothers: A tertiary care hospital-based observational study</article-title>. <source>BMJ Paediatr. Open</source><volume>5</volume>, <fpage>e001193</fpage>. <pub-id pub-id-type="doi">10.1136/bmjpo-2021-001193</pub-id><pub-id pub-id-type="pmcid">PMC8526519</pub-id><pub-id pub-id-type="pmid">34697599</pub-id></mixed-citation></ref><ref id="B373"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ghoshal</surname><given-names>U.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Development of RNA-based assay for rapid detection of SARS-CoV-2 in clinical samples</article-title>. <source>Intervirology</source><volume>65</volume>, <fpage>181</fpage>&#8211;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1159/000522337</pub-id><pub-id pub-id-type="pmid">35193136</pub-id><pub-id pub-id-type="pmcid">PMC9393769</pub-id></mixed-citation></ref><ref id="B374"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumari</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mittra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bajpai</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Pregnancy outcomes and vertical transmission capability of SARS-CoV-2 infection among asymptomatic females: A cross-sectional study in a tertiary care rural hospital</article-title>. <source>J. Fam. Med. Prim. Care</source><volume>10</volume>, <fpage>3247</fpage>&#8211;<lpage>3251</lpage>. <pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_23_21</pub-id><pub-id pub-id-type="pmcid">PMC8565111</pub-id><pub-id pub-id-type="pmid">34760738</pub-id></mixed-citation></ref><ref id="B375"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuster</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Pfister</surname><given-names>O.</given-names></name><name name-style="western"><surname>Burkard</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Twerenbold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haaf</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?</article-title><source>Eur. Heart J.</source><volume>41</volume>, <fpage>1801</fpage>&#8211;<lpage>1803</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehaa235</pub-id><pub-id pub-id-type="pmid">32196087</pub-id><pub-id pub-id-type="pmcid">PMC7184407</pub-id></mixed-citation></ref><ref id="B376"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutter</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>De Meulder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Lexmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mulders</surname><given-names>A.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>1653</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-21918-6</pub-id><pub-id pub-id-type="pmid">33712573</pub-id><pub-id pub-id-type="pmcid">PMC7955093</pub-id></mixed-citation></ref><ref id="B377"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyle</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saltz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mollicone</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bence</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dumitriu</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>Vertical transmission and neonatal outcomes following maternal SARS-CoV-2 infection during pregnancy</article-title>. <source>Clin. Obstet. Gynecol.</source><volume>65</volume>, <fpage>195</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1097/grf.0000000000000667</pub-id><pub-id pub-id-type="pmid">35045041</pub-id><pub-id pub-id-type="pmcid">PMC8767921</pub-id></mixed-citation></ref><ref id="B378"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriakidis</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>L&#243;pez-Cort&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Grimaldos</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Prado</surname><given-names>E. O.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates</article-title>. <source>NPJ Vaccines</source><volume>6</volume>, <fpage>28</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-021-00292-w</pub-id><pub-id pub-id-type="pmid">33619260</pub-id><pub-id pub-id-type="pmcid">PMC7900244</pub-id></mixed-citation></ref><ref id="B379"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>La Rosa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brandtner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Veneri</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonanno Ferraro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonadonna</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Key SARS-CoV-2 mutations of alpha, gamma, and eta variants detected in urban wastewaters in Italy by long-read amplicon sequencing based on nanopore technology</article-title>. <source>Water</source><volume>13</volume>, <fpage>2503</fpage>. <pub-id pub-id-type="doi">10.3390/w13182503</pub-id></mixed-citation></ref><ref id="B380"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ladhani</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Ireland</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baawuah</surname><given-names>F.</given-names></name><name name-style="western"><surname>Beckmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Okike</surname><given-names>I. O.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Emergence of the delta variant and risk of SARS-CoV-2 infection in secondary school students and staff: Prospective surveillance in 18 schools, England</article-title>. <source>EClinicalMedicine</source><volume>45</volume>, <fpage>101319</fpage>. <pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101319</pub-id><pub-id pub-id-type="pmid">35233517</pub-id><pub-id pub-id-type="pmcid">PMC8882000</pub-id></mixed-citation></ref><ref id="B381"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laidlaw</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Ellebedy</surname><given-names>A. H.</given-names></name></person-group> (<year>2022</year>). <article-title>The germinal centre B cell response to SARS-CoV-2</article-title>. <source>Nat. Rev. Immunol.</source><volume>22</volume>, <fpage>7</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-021-00657-1</pub-id><pub-id pub-id-type="pmid">34873279</pub-id><pub-id pub-id-type="pmcid">PMC8647067</pub-id></mixed-citation></ref><ref id="B382"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>. <source>Nature</source><volume>581</volume>, <fpage>215</fpage>&#8211;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id><pub-id pub-id-type="pmid">32225176</pub-id></mixed-citation></ref><ref id="B383"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>B. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction</article-title>. <source>Emerg. Microbes Infect.</source><volume>9</volume>, <fpage>837</fpage>&#8211;<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1080/22221751.2020.1756700</pub-id><pub-id pub-id-type="pmid">32301390</pub-id><pub-id pub-id-type="pmcid">PMC7241555</pub-id></mixed-citation></ref><ref id="B384"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Bert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clapham</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>W. N.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>C. Y. L.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection</article-title>. <source>J. Exp. Med.</source><volume>218</volume>, <fpage>e20202617</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20202617</pub-id><pub-id pub-id-type="pmid">33646265</pub-id><pub-id pub-id-type="pmcid">PMC7927662</pub-id></mixed-citation></ref><ref id="B385"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>T. Q. M.</given-names></name><name name-style="western"><surname>Takemura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moi</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Nabeshima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L. K. H.</given-names></name><name name-style="western"><surname>Hoang</surname><given-names>V. M. P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Severe acute respiratory syndrome coronavirus 2 shedding by travelers, vietnam, 2020</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>1624</fpage>&#8211;<lpage>1626</lpage>. <pub-id pub-id-type="doi">10.3201/eid2607.200591</pub-id><pub-id pub-id-type="pmid">32240079</pub-id><pub-id pub-id-type="pmcid">PMC7323563</pub-id></mixed-citation></ref><ref id="B386"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Leal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nava</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mart&#237;-Lluch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2: Preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://org.medRxiv/abs/200822278560" ext-link-type="uri">https://org.medRxiv/abs/200822278560</ext-link></comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-023-00736-5</pub-id><pub-id pub-id-type="pmcid">PMC10541407</pub-id><pub-id pub-id-type="pmid">37775521</pub-id></mixed-citation></ref><ref id="B387"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lechien</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Chiesa-Estomba</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>De Siati</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Horoi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le Bon</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): A multicenter European study</article-title>. <source>Eur. Arch. Otorhinolaryngol.</source><volume>277</volume>, <fpage>2251</fpage>&#8211;<lpage>2261</lpage>. <pub-id pub-id-type="doi">10.1007/s00405-020-05965-1</pub-id><pub-id pub-id-type="pmid">32253535</pub-id><pub-id pub-id-type="pmcid">PMC7134551</pub-id></mixed-citation></ref><ref id="B388"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lederer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Casta&#241;o</surname><given-names>D.</given-names></name><name name-style="western"><surname>G&#243;mez Atria</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oguin</surname><given-names>T. H.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>T. B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation</article-title>. <source>Immunity</source><volume>53</volume>, <fpage>1281</fpage>&#8211;<lpage>1295.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.009</pub-id><pub-id pub-id-type="pmid">33296685</pub-id><pub-id pub-id-type="pmcid">PMC7680029</pub-id></mixed-citation></ref><ref id="B389"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus breakthrough: Dexamethasone is first drug shown to save lives</article-title>. <source>Nature</source><volume>582</volume>, <fpage>469</fpage>. <pub-id pub-id-type="doi">10.1038/d41586-020-01824-5</pub-id><pub-id pub-id-type="pmid">32546811</pub-id></mixed-citation></ref><ref id="B390"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lednicky</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Lauzardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Z. H.</given-names></name><name name-style="western"><surname>Jutla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tilly</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Gangwar</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients</article-title>. <source>Int. J. Infect. Dis.</source><volume>100</volume>, <fpage>476</fpage>&#8211;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.09.025</pub-id><pub-id pub-id-type="pmid">32949774</pub-id><pub-id pub-id-type="pmcid">PMC7493737</pub-id></mixed-citation></ref><ref id="B391"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Hur</surname><given-names>W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Liver-specific gene delivery using engineered virus-like particles of hepatitis E virus</article-title>. <source>Sci. Rep.</source><volume>9</volume>, <fpage>1616</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-38533-7</pub-id><pub-id pub-id-type="pmid">30733562</pub-id><pub-id pub-id-type="pmcid">PMC6367430</pub-id></mixed-citation></ref><ref id="B392"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I. T.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Goltsev</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gall</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>5453</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19145-6</pub-id><pub-id pub-id-type="pmid">33116139</pub-id><pub-id pub-id-type="pmcid">PMC7595232</pub-id></mixed-citation></ref><ref id="B393"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the republic of Korea</article-title>. <source>JAMA Intern. Med.</source><volume>180</volume>, <fpage>1447</fpage>&#8211;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.3862</pub-id><pub-id pub-id-type="pmid">32780793</pub-id><pub-id pub-id-type="pmcid">PMC7411944</pub-id></mixed-citation></ref><ref id="B394"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Aguilera</surname><given-names>X.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aguilera</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Preparedness for emerging epidemic threats: A lancet infectious diseases commission</article-title>. <source>Lancet Infect. Dis.</source><volume>20</volume>, <fpage>17</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(19)30674-7</pub-id><pub-id pub-id-type="pmid">31876487</pub-id><pub-id pub-id-type="pmcid">PMC7158988</pub-id></mixed-citation></ref><ref id="B395"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1</article-title>. <source>Appl. Microbiol. Biotechnol.</source><volume>105</volume>, <fpage>4153</fpage>&#8211;<lpage>4165</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-021-11281-3</pub-id><pub-id pub-id-type="pmid">33959781</pub-id><pub-id pub-id-type="pmcid">PMC8102132</pub-id></mixed-citation></ref><ref id="B396"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leeman</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Pathiraja</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Adnan</surname><given-names>T. Z.</given-names></name><name name-style="western"><surname>Baltas</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) nosocomial transmission dynamics, a retrospective cohort study of two healthcare-associated coronavirus disease 2019 (COVID-19) clusters in a district hospital in England during March and April 2020</article-title>. <source>Infect. Control Hosp. Epidemiol.</source><volume>43</volume><issue>(11)</issue>, <fpage>1618</fpage>&#8211;<lpage>1624</lpage>. <pub-id pub-id-type="doi">10.1017/ice.2021.483</pub-id><pub-id pub-id-type="pmid">34802481</pub-id><pub-id pub-id-type="pmcid">PMC8674194</pub-id></mixed-citation></ref><ref id="B397"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Activation and evasion of type I interferon responses by SARS-CoV-2</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>3810</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17665-9</pub-id><pub-id pub-id-type="pmid">32733001</pub-id><pub-id pub-id-type="pmcid">PMC7392898</pub-id></mixed-citation></ref><ref id="B398"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemmin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kalbermatter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Plattet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fotiadis</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein</article-title>. <source>J. Struct. Biol. X</source><volume>4</volume>, <fpage>100038</fpage>. <pub-id pub-id-type="doi">10.1016/j.yjsbx.2020.100038</pub-id><pub-id pub-id-type="pmid">33043289</pub-id><pub-id pub-id-type="pmcid">PMC7534663</pub-id></mixed-citation></ref><ref id="B399"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Southall</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Tildesley</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Quantifying pupil-to-pupil SARS-CoV-2 transmission and the impact of lateral flow testing in English secondary schools</article-title>. <source>Nat. Commun.</source><volume>13</volume>, <fpage>1106</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-28731-9</pub-id><pub-id pub-id-type="pmid">35232987</pub-id><pub-id pub-id-type="pmcid">PMC8888696</pub-id></mixed-citation></ref><ref id="B400"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lerner</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Folkers</surname><given-names>G. K.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Preventing the spread of SARS-CoV-2 with masks and other "Low-tech" interventions</article-title>. <source>Jama</source><volume>324</volume>, <fpage>1935</fpage>&#8211;<lpage>1936</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.21946</pub-id><pub-id pub-id-type="pmid">33104157</pub-id></mixed-citation></ref><ref id="B401"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lescure</surname><given-names>F. X.</given-names></name><name name-style="western"><surname>Bouadma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parisey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wicky</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Behillil</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Clinical and virological data of the first cases of COVID-19 in europe: A case series</article-title>. <source>Lancet Infect. Dis.</source><volume>20</volume>, <fpage>697</fpage>&#8211;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30200-0</pub-id><pub-id pub-id-type="pmid">32224310</pub-id><pub-id pub-id-type="pmcid">PMC7156120</pub-id></mixed-citation></ref><ref id="B402"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lessler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grabowski</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Grantz</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Badillo-Goicoechea</surname><given-names>E.</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>C. J. E.</given-names></name><name name-style="western"><surname>Lupton-Smith</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Household COVID-19 risk and in-person schooling</article-title>. <source>Science</source><volume>372</volume>, <fpage>1092</fpage>&#8211;<lpage>1097</lpage>. <pub-id pub-id-type="doi">10.1126/science.abh2939</pub-id><pub-id pub-id-type="pmid">33927057</pub-id><pub-id pub-id-type="pmcid">PMC8168618</pub-id></mixed-citation></ref><ref id="B403"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hafez</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P. R.</given-names></name></person-group> (<year>2015a</year>). <article-title>Microfluidic mixing: A general method for encapsulating macromolecules in lipid nanoparticle systems</article-title>. <source>J. Phys. Chem. B</source><volume>119</volume>, <fpage>8698</fpage>&#8211;<lpage>8706</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jpcb.5b02891</pub-id><pub-id pub-id-type="pmid">26087393</pub-id></mixed-citation></ref><ref id="B404"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>B. J.</given-names></name></person-group> (<year>2015b</year>). <article-title>Review article: The fraction of influenza virus infections that are asymptomatic: A systematic review and meta-analysis</article-title>. <source>Epidemiology</source><volume>26</volume>, <fpage>862</fpage>&#8211;<lpage>872</lpage>. <pub-id pub-id-type="doi">10.1097/ede.0000000000000340</pub-id><pub-id pub-id-type="pmid">26133025</pub-id><pub-id pub-id-type="pmcid">PMC4586318</pub-id></mixed-citation></ref><ref id="B405"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Migliori</surname><given-names>G. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Mask wearing to complement social distancing and save lives during COVID-19</article-title>. <source>Int. J. Tuberc. lung Dis.</source><volume>24</volume>, <fpage>556</fpage>&#8211;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.20.0244</pub-id><pub-id pub-id-type="pmid">32553007</pub-id></mixed-citation></ref><ref id="B406"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thachil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>J. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Coagulation abnormalities and thrombosis in patients with COVID-19</article-title>. <source>Lancet Haematol.</source><volume>7</volume>, <fpage>e438</fpage>&#8211;<lpage>e440</lpage>. <pub-id pub-id-type="doi">10.1016/s2352-3026(20)30145-9</pub-id><pub-id pub-id-type="pmid">32407672</pub-id><pub-id pub-id-type="pmcid">PMC7213964</pub-id></mixed-citation></ref><ref id="B407"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Immunologic testing for SARS-CoV-2 infection from the antigen perspective</article-title>. <source>J. Clin. Microbiol.</source><volume>59</volume>, <fpage>021600</fpage>&#8211;<lpage>e2220</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.02160-20</pub-id><pub-id pub-id-type="pmcid">PMC8091849</pub-id><pub-id pub-id-type="pmid">33318065</pub-id></mixed-citation></ref><ref id="B408"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Berne</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature</source><volume>426</volume>, <fpage>450</fpage>&#8211;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id><pub-id pub-id-type="pmcid">PMC7095016</pub-id></mixed-citation></ref><ref id="B409"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S. C.</given-names></name></person-group> (<year>2005</year>). <article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title>. <source>Science</source><volume>309</volume>, <fpage>1864</fpage>&#8211;<lpage>1868</lpage>. <pub-id pub-id-type="doi">10.1126/science.1116480</pub-id><pub-id pub-id-type="pmid">16166518</pub-id></mixed-citation></ref><ref id="B410"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thoon</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Maiwald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>K. Q.</given-names></name><name name-style="western"><surname>Nadua</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children</article-title>. <source>Ann. Acad. Med. Singap.</source><volume>49</volume>, <fpage>530</fpage>&#8211;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.47102/annals-acadmedsg.2020257</pub-id><pub-id pub-id-type="pmid">33164022</pub-id></mixed-citation></ref><ref id="B411"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>W. Z.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2</article-title>. <source>Clin. Microbiol. Infect.</source><volume>26</volume>, <fpage>1556.e1</fpage>&#8211;<lpage>1556.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.008</pub-id><pub-id pub-id-type="pmcid">PMC7346822</pub-id><pub-id pub-id-type="pmid">32653662</pub-id></mixed-citation></ref><ref id="B412"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Development of a colloidal gold-based immunochromatographic strip for rapid detection of severe acute respiratory syndrome coronavirus 2 spike protein</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>635677</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.635677</pub-id><pub-id pub-id-type="pmid">33777026</pub-id><pub-id pub-id-type="pmcid">PMC7992422</pub-id></mixed-citation></ref><ref id="B413"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ayaz Ahmed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uy</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis</article-title>. <source>Am. J. Infect. Control</source><volume>49</volume>, <fpage>900</fpage>&#8211;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajic.2020.12.007</pub-id><pub-id pub-id-type="pmid">33347937</pub-id><pub-id pub-id-type="pmcid">PMC7748970</pub-id></mixed-citation></ref><ref id="B414"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.-X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Du</surname><given-names>P.-C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.-Q.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Rapid and accurate detection of SARS coronavirus 2 by nanopore amplicon sequencing</article-title>. <source>Front. Microbiol.</source><volume>13</volume>, <fpage>735363</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2022.735363</pub-id><pub-id pub-id-type="pmid">35464969</pub-id><pub-id pub-id-type="pmcid">PMC9019561</pub-id></mixed-citation></ref><ref id="B415"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liefting</surname><given-names>L. W.</given-names></name><name name-style="western"><surname>Waite</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Application of Oxford nanopore technology to plant virus detection</article-title>. <source>Viruses</source><volume>13</volume>, <fpage>1424</fpage>. <pub-id pub-id-type="doi">10.3390/v13081424</pub-id><pub-id pub-id-type="pmid">34452290</pub-id><pub-id pub-id-type="pmcid">PMC8402922</pub-id></mixed-citation></ref><ref id="B416"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mario</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). &#8220;<article-title>Poly(Lactic acid)-based biomaterials: Synthesis, modification and applications</article-title>,&#8221; in <source>Biomedical science, engineering and technology</source>. Editor <person-group person-group-type="editor"><name name-style="western"><surname>Dhanjoo</surname><given-names>N. G.</given-names></name></person-group>. <comment>(Rijeka: IntechOpen), Ch. 11</comment>.</mixed-citation></ref><ref id="B417"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Nanopore technology and its applications in gene sequencing</article-title>. <source>Biosens. (Basel)</source><volume>11</volume>, <fpage>214</fpage>. <pub-id pub-id-type="doi">10.3390/bios11070214</pub-id><pub-id pub-id-type="pmcid">PMC8301755</pub-id><pub-id pub-id-type="pmid">34208844</pub-id></mixed-citation></ref><ref id="B418"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Finelli</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Defining the epidemiology of covid-19 - studies needed</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1194</fpage>&#8211;<lpage>1196</lpage>. <pub-id pub-id-type="doi">10.1056/nejmp2002125</pub-id><pub-id pub-id-type="pmid">32074416</pub-id></mixed-citation></ref><ref id="B419"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>A facile assay for rapid detection of COVID-19 antibodies</article-title>. <source>RSC Adv.</source><volume>10</volume>, <fpage>28041</fpage>&#8211;<lpage>28048</lpage>. <pub-id pub-id-type="doi">10.1039/d0ra04107f</pub-id><pub-id pub-id-type="pmid">35519100</pub-id><pub-id pub-id-type="pmcid">PMC9055646</pub-id></mixed-citation></ref><ref id="B420"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by cryo-EM and cryo-ET</article-title>. <source>Structure</source><volume>28</volume>, <fpage>1218</fpage>&#8211;<lpage>1224</lpage>. <comment>e4e1214</comment>. <pub-id pub-id-type="doi">10.1016/j.str.2020.10.001</pub-id><pub-id pub-id-type="pmid">33058760</pub-id><pub-id pub-id-type="pmcid">PMC7557167</pub-id></mixed-citation></ref><ref id="B421"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>Viral architecture of SARS-CoV-2 with post-fusion spike revealed by cryo-EM</article-title>. <comment>bioRxiv</comment>, <comment>2020.2003.2002.972927</comment>. <pub-id pub-id-type="doi">10.1101/2020.03.02.972927</pub-id></mixed-citation></ref><ref id="B422"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020d</year>). <article-title>Detection of covid-19 in children in early january 2020 in wuhan, China</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1370</fpage>&#8211;<lpage>1371</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2003717</pub-id><pub-id pub-id-type="pmcid">PMC7121643</pub-id><pub-id pub-id-type="pmid">32163697</pub-id></mixed-citation></ref><ref id="B423"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gayle</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rockl&#246;v</surname><given-names>J.</given-names></name></person-group> (<year>2020e</year>). <article-title>The reproductive number of COVID-19 is higher compared to SARS coronavirus</article-title>. <source>J. Travel Med.</source><volume>27</volume>, <fpage>taaa021</fpage>. <pub-id pub-id-type="doi">10.1093/jtm/taaa021</pub-id><pub-id pub-id-type="pmid">32052846</pub-id><pub-id pub-id-type="pmcid">PMC7074654</pub-id></mixed-citation></ref><ref id="B424"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gali</surname><given-names>N. K.</given-names></name><etal/></person-group> (<year>2020f</year>). <article-title>Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals</article-title>. <source>Nature</source><volume>582</volume>, <fpage>557</fpage>&#8211;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2271-3</pub-id><pub-id pub-id-type="pmid">32340022</pub-id></mixed-citation></ref><ref id="B425"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips</article-title>. <source>Mol. Immunol.</source><volume>131</volume>, <fpage>6</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2021.01.005</pub-id><pub-id pub-id-type="pmid">33450670</pub-id><pub-id pub-id-type="pmcid">PMC7833923</pub-id></mixed-citation></ref><ref id="B426"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kshirsagar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Aithal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4&#946;</article-title>. <source>J. Biomed. Mat. Res. A</source><volume>109</volume>, <fpage>893</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.a.37080</pub-id><pub-id pub-id-type="pmcid">PMC8100985</pub-id><pub-id pub-id-type="pmid">32776461</pub-id></mixed-citation></ref><ref id="B427"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group> (<year>2021c</year>). <article-title>Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis</article-title>. <source>Infect. Dis. Poverty</source><volume>10</volume>, <fpage>132</fpage>. <pub-id pub-id-type="doi">10.1186/s40249-021-00915-3</pub-id><pub-id pub-id-type="pmid">34776011</pub-id><pub-id pub-id-type="pmcid">PMC8590867</pub-id></mixed-citation></ref><ref id="B428"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vanblargan</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Bloyet</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Rothlauf</surname><given-names>P. W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Stumpf</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021d</year>). <article-title>Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>. <source>Cell Host Microbe</source><volume>29</volume>, <fpage>477</fpage>&#8211;<lpage>488</lpage>. <comment>e4e474</comment>. <pub-id pub-id-type="doi">10.1016/j.chom.2021.01.014</pub-id><pub-id pub-id-type="pmid">33535027</pub-id><pub-id pub-id-type="pmcid">PMC7839837</pub-id></mixed-citation></ref><ref id="B429"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I. V.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Tukhvatullin</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia</article-title>. <source>Lancet</source><volume>396</volume>, <fpage>887</fpage>&#8211;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></mixed-citation></ref><ref id="B430"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D. Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I. V.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>A. I.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O. V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>671</fpage>&#8211;<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></mixed-citation></ref><ref id="B431"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><name name-style="western"><surname>Hage</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Vries</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valero-Jimenez</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Schindewolf</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dittmann</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV</article-title>. <source>J. Virol.</source><volume>94</volume>, <fpage>e01410</fpage>&#8211;<lpage>e01420</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.01410-20</pub-id><pub-id pub-id-type="pmcid">PMC7654262</pub-id><pub-id pub-id-type="pmid">32938761</pub-id></mixed-citation></ref><ref id="B432"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Vanover</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beyersdorf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hatit</surname><given-names>M. Z. C.</given-names></name><name name-style="western"><surname>Rotolo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Echeverri</surname><given-names>E. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs</article-title>. <source>Nat. Biomed. Eng.</source><volume>5</volume>, <fpage>1059</fpage>&#8211;<lpage>1068</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-021-00786-x</pub-id><pub-id pub-id-type="pmid">34616046</pub-id><pub-id pub-id-type="pmcid">PMC10197923</pub-id></mixed-citation></ref><ref id="B433"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kiselev</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Caccamo</surname><given-names>M. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in Biotechnology and nanomedicine</article-title>. <source>J. Nanomater.</source><volume>2019</volume>, <fpage>1</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1155/2019/3702518</pub-id></mixed-citation></ref><ref id="B434"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Q.-X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.-Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.-C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-K.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>. <source>Nat. Med.</source><volume>26</volume>, <fpage>845</fpage>&#8211;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0897-1</pub-id><pub-id pub-id-type="pmid">32350462</pub-id></mixed-citation></ref><ref id="B435"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Redondo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Simons</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways</article-title>. <source>EBioMedicine</source><volume>62</volume>, <fpage>103112</fpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103112</pub-id><pub-id pub-id-type="pmid">33186810</pub-id><pub-id pub-id-type="pmcid">PMC7655495</pub-id></mixed-citation></ref><ref id="B436"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loucera</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perez-Florido</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casimiro-Soriguer</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Ortu&#241;o</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Carmona</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bostelmann</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Assessing the impact of SARS-CoV-2 lineages and mutations on patient survival</article-title>. <source>Viruses</source><volume>14</volume>, <fpage>1893</fpage>. <pub-id pub-id-type="doi">10.3390/v14091893</pub-id><pub-id pub-id-type="pmid">36146700</pub-id><pub-id pub-id-type="pmcid">PMC9500738</pub-id></mixed-citation></ref><ref id="B437"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#248;vestad</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>J&#248;rgensen</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Handal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ambur</surname><given-names>O. H.</given-names></name><name name-style="western"><surname>Aamot</surname><given-names>H. V.</given-names></name></person-group> (<year>2021</year>). <article-title>Investigation of intra-hospital SARS-CoV-2 transmission using nanopore whole-genome sequencing</article-title>. <source>J. Hosp. Infect.</source><volume>111</volume>, <fpage>107</fpage>&#8211;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhin.2021.02.022</pub-id><pub-id pub-id-type="pmid">33647375</pub-id><pub-id pub-id-type="pmcid">PMC7908852</pub-id></mixed-citation></ref><ref id="B438"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>De Alwis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kalimuddin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>Y. S.</given-names></name><name name-style="western"><surname>Mah</surname><given-names>T. K. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess the safety, tolerability and immunogenicity of ARCT-021 in healthy adults</article-title>. <comment>medRxiv</comment>, <comment>2021.2007.2001.21259831</comment>. <pub-id pub-id-type="doi">10.1101/2021.07.01.21259831</pub-id></mixed-citation></ref><ref id="B439"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>565</fpage>&#8211;<lpage>574</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id></mixed-citation></ref><ref id="B440"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lua</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Connors</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Sainsbury</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>Y. P.</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Bioengineering virus-like particles as vaccines</article-title>. <source>Biotechnol. Bioeng.</source><volume>111</volume>, <fpage>425</fpage>&#8211;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1002/bit.25159</pub-id><pub-id pub-id-type="pmid">24347238</pub-id></mixed-citation></ref><ref id="B441"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubinski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M. H. V.</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diel</surname><given-names>D. G.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike</article-title>. <source>iScience</source><volume>25</volume>, <fpage>103589</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2021.103589</pub-id><pub-id pub-id-type="pmid">34909610</pub-id><pub-id pub-id-type="pmcid">PMC8662955</pub-id></mixed-citation></ref><ref id="B442"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Kinetics of antibody responses dictate COVID-19 outcome</article-title>. <comment>medRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2020.12.18.20248331</pub-id></mixed-citation></ref><ref id="B443"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>T. B. R.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Longitudinal analyses reveal immunological misfiring in severe COVID-19</article-title>. <source>Nature</source><volume>584</volume>, <fpage>463</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2588-y</pub-id><pub-id pub-id-type="pmid">32717743</pub-id><pub-id pub-id-type="pmcid">PMC7477538</pub-id></mixed-citation></ref><ref id="B444"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lucas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Delayed production of neutralizing antibodies correlates with fatal COVID-19</article-title>. <source>Nat. Med.</source><volume>27</volume>, <fpage>1178</fpage>&#8211;<lpage>1186</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-021-01355-0</pub-id><pub-id pub-id-type="pmid">33953384</pub-id><pub-id pub-id-type="pmcid">PMC8785364</pub-id></mixed-citation></ref><ref id="B445"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyngse</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Kirkeby</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Denwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>M&#248;lbak</surname><given-names>K.</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>C. H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households</article-title>. <comment>medRxiv</comment>, <comment>2022.2001.2028.22270044</comment>. <pub-id pub-id-type="doi">10.1101/2022.01.28.22270044</pub-id></mixed-citation></ref><ref id="B446"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nanoparticle vaccines based on the receptor binding domain (RBD) and Heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses</article-title>. <source>Immunity</source><volume>53</volume>, <fpage>1315</fpage>&#8211;<lpage>1330</lpage>. <comment>e9. e1319</comment>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.015</pub-id><pub-id pub-id-type="pmid">33275896</pub-id><pub-id pub-id-type="pmcid">PMC7687490</pub-id></mixed-citation></ref><ref id="B447"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shahjin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelmoaty</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J. D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanocarrier vaccines for SARS-CoV-2</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>171</volume>, <fpage>215</fpage>&#8211;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2021.01.002</pub-id><pub-id pub-id-type="pmid">33428995</pub-id><pub-id pub-id-type="pmcid">PMC7794055</pub-id></mixed-citation></ref><ref id="B448"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macintyre</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Ananda-Rajah</surname><given-names>M. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Scientific evidence supports aerosol transmission of SARS-COV-2</article-title>. <source>Antimicrob. Resist. Infect. Control</source><volume>9</volume>, <fpage>202</fpage>. <pub-id pub-id-type="doi">10.1186/s13756-020-00868-6</pub-id><pub-id pub-id-type="pmid">33339522</pub-id><pub-id pub-id-type="pmcid">PMC7747188</pub-id></mixed-citation></ref><ref id="B449"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madden</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group> (<year>2022</year>). <article-title>Host cell-intrinsic innate immune recognition of SARS-CoV-2</article-title>. <source>Curr. Opin. Virol.</source><volume>52</volume>, <fpage>30</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2021.11.002</pub-id><pub-id pub-id-type="pmid">34814102</pub-id><pub-id pub-id-type="pmcid">PMC8580835</pub-id></mixed-citation></ref><ref id="B450"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahapatra</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>R.</given-names></name><name name-style="western"><surname>Megaridis</surname><given-names>C. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Surface treatments to enhance the functionality of PPEs</article-title>. <source>Trans. Indian Natl. Acad. Eng.</source><volume>5</volume>, <fpage>333</fpage>&#8211;<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1007/s41403-020-00110-0</pub-id><pub-id pub-id-type="pmcid">PMC7257351</pub-id><pub-id pub-id-type="pmid">38624344</pub-id></mixed-citation></ref><ref id="B451"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant</article-title>. <source>Bmj</source><volume>372</volume>, <fpage>n296</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.n296</pub-id><pub-id pub-id-type="pmid">33526412</pub-id></mixed-citation></ref><ref id="B452"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Bahmer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Herget-Rosenthal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2: Viral loads of exhaled breath and oronasopharyngeal specimens in hospitalized patients with COVID-19</article-title>. <source>Int. J. Infect. Dis.</source><volume>110</volume>, <fpage>105</fpage>&#8211;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2021.07.012</pub-id><pub-id pub-id-type="pmid">34242768</pub-id><pub-id pub-id-type="pmcid">PMC8260556</pub-id></mixed-citation></ref><ref id="B453"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malladi</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>U. R.</given-names></name><name name-style="western"><surname>Rajmani</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Immunogenicity and protective efficacy of a highly thermotolerant, trimeric SARS-CoV-2 receptor binding domain derivative</article-title>. <source>ACS Infect. Dis.</source><volume>7</volume>, <fpage>2546</fpage>&#8211;<lpage>2564</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00276</pub-id><pub-id pub-id-type="pmid">34260218</pub-id><pub-id pub-id-type="pmcid">PMC8996237</pub-id></mixed-citation></ref><ref id="B454"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malladi</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gayathri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanjo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment</article-title>. <source>J. Biol. Chem.</source><volume>296</volume>, <fpage>100025</fpage>. <pub-id pub-id-type="doi">10.1074/jbc.ra120.016284</pub-id><pub-id pub-id-type="pmid">33154165</pub-id><pub-id pub-id-type="pmcid">PMC7832000</pub-id></mixed-citation></ref><ref id="B455"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansbach</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>The SARS-CoV-2 Spike variant D614G favors an open conformational state</article-title>. <source>Sci. Adv.</source><volume>7</volume>, <fpage>eabf3671</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.abf3671</pub-id><pub-id pub-id-type="pmid">33863729</pub-id><pub-id pub-id-type="pmcid">PMC8051874</pub-id></mixed-citation></ref><ref id="B456"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcenac</surname><given-names>P.</given-names></name><name name-style="western"><surname>Park</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Duca</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Detection of SARS-CoV-2 on surfaces in households of persons with COVID-19</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>18</volume>, <fpage>8184</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph18158184</pub-id><pub-id pub-id-type="pmid">34360477</pub-id><pub-id pub-id-type="pmcid">PMC8345969</pub-id></mixed-citation></ref><ref id="B457"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchese</surname><given-names>V.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cola</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gregori</surname><given-names>N.</given-names></name><name name-style="western"><surname>Albini</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Palma</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Importance of mitigation measures for hospital transmission of SARS-CoV-2 at the onset of the epidemic: The experience of brescia, northern Italy</article-title>. <source>Infection</source><volume>49</volume>, <fpage>1241</fpage>&#8211;<lpage>1248</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-021-01692-9</pub-id><pub-id pub-id-type="pmid">34524648</pub-id><pub-id pub-id-type="pmcid">PMC8441227</pub-id></mixed-citation></ref><ref id="B458"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mardian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kosasih</surname><given-names>H.</given-names></name><name name-style="western"><surname>Karyana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C. Y.</given-names></name></person-group> (<year>2021</year>). <article-title>Review of current COVID-19 diagnostics and opportunities for further development</article-title>. <source>Front. Med.</source><volume>8</volume>, <fpage>615099</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2021.615099</pub-id><pub-id pub-id-type="pmcid">PMC8138031</pub-id><pub-id pub-id-type="pmid">34026773</pub-id></mixed-citation></ref><ref id="B459"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Flores</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zepeda-Cervantes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruz-Resendiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aguirre-Sampieri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sampieri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants</article-title>. <source>Front. Immunol.</source><volume>12</volume>, <fpage>701501</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.701501</pub-id><pub-id pub-id-type="pmid">34322129</pub-id><pub-id pub-id-type="pmcid">PMC8311925</pub-id></mixed-citation></ref><ref id="B460"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giles</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Oldridge</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Greenplate</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J. E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>. <source>Science</source><volume>369</volume>, <fpage>eabc8511</fpage>. <pub-id pub-id-type="doi">10.1126/science.abc8511</pub-id><pub-id pub-id-type="pmid">32669297</pub-id><pub-id pub-id-type="pmcid">PMC7402624</pub-id></mixed-citation></ref><ref id="B461"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauger</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Presnyak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Su</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>mRNA structure regulates protein expression through changes in functional half-life</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume>, <fpage>24075</fpage>&#8211;<lpage>24083</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1908052116</pub-id><pub-id pub-id-type="pmid">31712433</pub-id><pub-id pub-id-type="pmcid">PMC6883848</pub-id></mixed-citation></ref><ref id="B462"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maurin</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mentek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verhoeven</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pillet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bourlet</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Exploration of the ocular surface infection by SARS-CoV-2 and implications for corneal donation: An <italic toggle="yes">ex vivo</italic> study</article-title>. <source>PLoS Med.</source><volume>19</volume>, <fpage>e1003922</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pmed.1003922</pub-id><pub-id pub-id-type="pmid">35231027</pub-id><pub-id pub-id-type="pmcid">PMC8887728</pub-id></mixed-citation></ref><ref id="B463"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salvati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Maggi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vanni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spinicci</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent</article-title>. <source>J. Clin. Invest.</source><volume>130</volume>, <fpage>4694</fpage>&#8211;<lpage>4703</lpage>. <pub-id pub-id-type="doi">10.1172/jci138554</pub-id><pub-id pub-id-type="pmid">32463803</pub-id><pub-id pub-id-type="pmcid">PMC7456250</pub-id></mixed-citation></ref><ref id="B464"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcaloon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Incubation period of COVID-19: A rapid systematic review and meta-analysis of observational research</article-title>. <source>BMJ Open</source><volume>10</volume>, <fpage>e039652</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2020-039652</pub-id><pub-id pub-id-type="pmcid">PMC7430485</pub-id><pub-id pub-id-type="pmid">32801208</pub-id></mixed-citation></ref><ref id="B465"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mccloskey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heymann</surname><given-names>D. L.</given-names></name></person-group> (<year>2014</year>). <article-title>Emerging infectious diseases and pandemic potential: Status quo and reducing risk of global spread</article-title>. <source>Lancet Infect. Dis.</source><volume>14</volume>, <fpage>1001</fpage>&#8211;<lpage>1010</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(14)70846-1</pub-id><pub-id pub-id-type="pmid">25189351</pub-id><pub-id pub-id-type="pmcid">PMC7106439</pub-id></mixed-citation></ref><ref id="B466"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mckay</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Samnuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Penn</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>3523</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17409-9</pub-id><pub-id pub-id-type="pmid">32647131</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id></mixed-citation></ref><ref id="B467"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcmahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature</source><volume>590</volume>, <fpage>630</fpage>&#8211;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-03041-6</pub-id><pub-id pub-id-type="pmid">33276369</pub-id><pub-id pub-id-type="pmcid">PMC7906955</pub-id></mixed-citation></ref><ref id="B468"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meinhardt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Radke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dittmayer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Franz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mothes</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</article-title>. <source>Nat. Neurosci.</source><volume>24</volume>, <fpage>168</fpage>&#8211;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-020-00758-5</pub-id><pub-id pub-id-type="pmid">33257876</pub-id></mixed-citation></ref><ref id="B469"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melk</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>El-Hawary</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Melek</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>D. O.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>El Raey</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Antiviral activity of zinc oxide nanoparticles mediated by plumbago indica L. Extract against herpes simplex virus type 1 (HSV-1)</article-title>. <source>Int. J. Nanomedicine</source><volume>16</volume>, <fpage>8221</fpage>&#8211;<lpage>8233</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s339404</pub-id><pub-id pub-id-type="pmid">34955639</pub-id><pub-id pub-id-type="pmcid">PMC8694278</pub-id></mixed-citation></ref><ref id="B470"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mello</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Eller</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Salvio</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>F. F.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Effectiveness of face masks in blocking the transmission of SARS-CoV-2: A preliminary evaluation of masks used by SARS-CoV-2-infected individuals</article-title>. <source>PLoS One</source><volume>17</volume>, <fpage>e0264389</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0264389</pub-id><pub-id pub-id-type="pmid">35196363</pub-id><pub-id pub-id-type="pmcid">PMC8865648</pub-id></mixed-citation></ref><ref id="B471"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendes</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Dilarri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Forsan</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Sapata</surname><given-names>V. D. M. R.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>P. R. M.</given-names></name><name name-style="western"><surname>De Moraes</surname><given-names>P. B.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Antibacterial action and target mechanisms of zinc oxide nanoparticles against bacterial pathogens</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>2658</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-06657-y</pub-id><pub-id pub-id-type="pmid">35173244</pub-id><pub-id pub-id-type="pmcid">PMC8850488</pub-id></mixed-citation></ref><ref id="B472"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menter</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haslbauer</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Nienhold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Savic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hopfer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deigendesch</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction</article-title>. <source>Histopathology</source><volume>77</volume>, <fpage>198</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1111/his.14134</pub-id><pub-id pub-id-type="pmid">32364264</pub-id><pub-id pub-id-type="pmcid">PMC7496150</pub-id></mixed-citation></ref><ref id="B473"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meo</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Bukhari</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Akram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meo</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Klonoff</surname><given-names>D. C.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of pfizer/BioNTech and Moderna vaccines</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source><volume>25</volume>, <fpage>1663</fpage>&#8211;<lpage>1669</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_202102_24877</pub-id><pub-id pub-id-type="pmid">33629336</pub-id></mixed-citation></ref><ref id="B474"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title>. <source>Nature</source><volume>586</volume>, <fpage>583</fpage>&#8211;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></mixed-citation></ref><ref id="B475"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertens</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Vos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martiny</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jassoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mirazimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuypers</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Development and potential usefulness of the COVID-19 Ag respi-strip diagnostic assay in a pandemic context</article-title>. <source>Front. Med.</source><volume>7</volume>, <fpage>225</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.00225</pub-id><pub-id pub-id-type="pmcid">PMC7227790</pub-id><pub-id pub-id-type="pmid">32574326</pub-id></mixed-citation></ref><ref id="B476"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coppens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Le Mercier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Lammens</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Monitoring the SARS-CoV-2 pandemic: Screening algorithm with single nucleotide polymorphism detection for the rapid identification of established and emerging variants</article-title>. <source>Clin. Microbiol. Infect.</source><volume>28</volume>, <fpage>124</fpage>&#8211;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2021.09.007</pub-id><pub-id pub-id-type="pmid">34537361</pub-id><pub-id pub-id-type="pmcid">PMC8444474</pub-id></mixed-citation></ref><ref id="B477"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miles</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Mcclellan</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Montanide ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations</article-title>. <source>Vaccine</source><volume>23</volume>, <fpage>2530</fpage>&#8211;<lpage>2539</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.08.049</pub-id><pub-id pub-id-type="pmid">15752840</pub-id></mixed-citation></ref><ref id="B478"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Cybulski</surname><given-names>V.</given-names></name><name name-style="western"><surname>Whitacre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bess</surname><given-names>L. S.</given-names></name><name name-style="western"><surname>Livesay</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Novel lipidated imidazoquinoline TLR7/8 adjuvants elicit influenza-specific Th1 immune responses and protect against heterologous H3N2 influenza challenge in mice</article-title>. <source>Front. Immunol.</source><volume>11</volume>, <fpage>406</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00406</pub-id><pub-id pub-id-type="pmid">32210973</pub-id><pub-id pub-id-type="pmcid">PMC7075946</pub-id></mixed-citation></ref><ref id="B479"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Min</surname><given-names>Y. Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Immune evasion of SARS-CoV-2 from interferon antiviral system</article-title>. <source>Comput. Struct. Biotechnol. J.</source><volume>19</volume>, <fpage>4217</fpage>&#8211;<lpage>4225</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2021.07.023</pub-id><pub-id pub-id-type="pmid">34336145</pub-id><pub-id pub-id-type="pmcid">PMC8310780</pub-id></mixed-citation></ref><ref id="B480"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miorin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kehrer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sanchez-Aparicio</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>R. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume>, <fpage>28344</fpage>&#8211;<lpage>28354</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2016650117</pub-id><pub-id pub-id-type="pmid">33097660</pub-id><pub-id pub-id-type="pmcid">PMC7668094</pub-id></mixed-citation></ref><ref id="B481"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirjalali</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nazemalhosseini-Mojarad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yadegar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohebbi</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Baghaei</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shahrokh</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The necessity of stool examination in asymptomatic carriers as a strategic measure to control further spread of SARS-CoV-2</article-title>. <source>Front. Public Health</source><volume>8</volume>, <fpage>553589</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2020.553589</pub-id><pub-id pub-id-type="pmid">33194955</pub-id><pub-id pub-id-type="pmcid">PMC7661577</pub-id></mixed-citation></ref><ref id="B482"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Haley</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Engineering precision nanoparticles for drug delivery</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>20</volume>, <fpage>101</fpage>&#8211;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></mixed-citation></ref><ref id="B483"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyoshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komagome</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoshizumi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagano</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Environmental investigation of SARS-CoV-2 in a karaoke bar: A survey for a cluster of COVID-19 in hokkaido, Japan, 2020</article-title>. <source>Jpn. J. Infect. Dis.</source><volume>74</volume>, <fpage>495</fpage>&#8211;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.7883/yoken.jjid.2021.021</pub-id><pub-id pub-id-type="pmid">33642436</pub-id></mixed-citation></ref><ref id="B484"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moabelo</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Fadaka</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Sibuyi</surname><given-names>N. R. S.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Madiehe</surname><given-names>A. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Nanotechnology-based strategies for effective and rapid detection of SARS-CoV-2</article-title>. <source>Mater. (Basel)</source><volume>14</volume>, <fpage>7851</fpage>. <pub-id pub-id-type="doi">10.3390/ma14247851</pub-id><pub-id pub-id-type="pmcid">PMC8703409</pub-id><pub-id pub-id-type="pmid">34947447</pub-id></mixed-citation></ref><ref id="B485"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghadas</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shoukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>B. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The implications of silent transmission for the control of COVID-19 outbreaks</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume>, <fpage>17513</fpage>&#8211;<lpage>17515</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2008373117</pub-id><pub-id pub-id-type="pmid">32632012</pub-id><pub-id pub-id-type="pmcid">PMC7395516</pub-id></mixed-citation></ref><ref id="B486"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohsen</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Augusto</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The 3Ds in virus-like particle based-vaccines: "Design, delivery and dynamics</article-title>. <source>Immunol. Rev.</source><volume>296</volume>, <fpage>155</fpage>&#8211;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12863</pub-id><pub-id pub-id-type="pmid">32472710</pub-id><pub-id pub-id-type="pmcid">PMC7496916</pub-id></mixed-citation></ref><ref id="B487"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moitra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alafeef</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dighe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>7617</fpage>&#8211;<lpage>7627</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c03822</pub-id><pub-id pub-id-type="pmid">32437124</pub-id><pub-id pub-id-type="pmcid">PMC7263075</pub-id></mixed-citation></ref><ref id="B488"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mokuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ishitoku</surname><given-names>M.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>N(1)-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes</article-title>. <source>Cytotechnology</source><volume>74</volume>, <fpage>503</fpage>&#8211;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1007/s10616-022-00540-4</pub-id><pub-id pub-id-type="pmid">35791402</pub-id><pub-id pub-id-type="pmcid">PMC9245880</pub-id></mixed-citation></ref><ref id="B489"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondelli</surname><given-names>M. U.</given-names></name><name name-style="western"><surname>Colaneri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seminari</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Baldanti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Low risk of SARS-CoV-2 transmission by fomites in real-life conditions</article-title>. <source>Lancet. Infect. Dis.</source><volume>21</volume>, <fpage>e112</fpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30678-2</pub-id><pub-id pub-id-type="pmid">33007224</pub-id><pub-id pub-id-type="pmcid">PMC7524520</pub-id></mixed-citation></ref><ref id="B490"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T. C.</given-names></name></person-group> (<year>2008</year>). <article-title>Cervarix: A vaccine for the prevention of HPV 16, 18-associated cervical cancer</article-title>. <source>Biologics.</source><volume>2</volume>, <fpage>97</fpage>&#8211;<lpage>105</lpage>.<pub-id pub-id-type="pmcid">PMC2727782</pub-id><pub-id pub-id-type="pmid">19707432</pub-id></mixed-citation></ref><ref id="B491"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morais</surname><given-names>P.</given-names></name><name name-style="western"><surname>Adachi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y. T.</given-names></name></person-group> (<year>2021</year>). <article-title>The critical contribution of pseudouridine to mRNA COVID-19 vaccines</article-title>. <source>Front. Cell Dev. Biol.</source><volume>9</volume>, <fpage>789427</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.789427</pub-id><pub-id pub-id-type="pmid">34805188</pub-id><pub-id pub-id-type="pmcid">PMC8600071</pub-id></mixed-citation></ref><ref id="B492"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morawska</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Airborne transmission of SARS-CoV-2: The world should face the reality</article-title>. <source>Environ. Int.</source><volume>139</volume>, <fpage>105730</fpage>. <pub-id pub-id-type="doi">10.1016/j.envint.2020.105730</pub-id><pub-id pub-id-type="pmid">32294574</pub-id><pub-id pub-id-type="pmcid">PMC7151430</pub-id></mixed-citation></ref><ref id="B493"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Fierros</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garc&#237;a-Silva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rosales-Mendoza</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Development of SARS-CoV-2 vaccines: Should we focus on mucosal immunity?</article-title><source>Expert Opin. Biol. Ther.</source><volume>20</volume>, <fpage>831</fpage>&#8211;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1080/14712598.2020.1767062</pub-id><pub-id pub-id-type="pmid">32380868</pub-id></mixed-citation></ref><ref id="B494"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Araba</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Wykoff</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D. R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>119</volume>, <fpage>e2119680119</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2119680119</pub-id><pub-id pub-id-type="pmid">35353667</pub-id><pub-id pub-id-type="pmcid">PMC9169748</pub-id></mixed-citation></ref><ref id="B495"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morsli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Br&#233;chard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delerce</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bedotto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fournier</surname><given-names>P. E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>LamPORE SARS-CoV-2 diagnosis and genotyping: A preliminary report</article-title>. <source>J. Clin. Virol.</source><volume>138</volume>, <fpage>104815</fpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2021.104815</pub-id><pub-id pub-id-type="pmid">33838620</pub-id><pub-id pub-id-type="pmcid">PMC8011304</pub-id></mixed-citation></ref><ref id="B496"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Influenza virosomes as a vaccine adjuvant and carrier system</article-title>. <source>Expert Rev. Vaccines</source><volume>10</volume>, <fpage>437</fpage>&#8211;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1586/erv.11.15</pub-id><pub-id pub-id-type="pmid">21506642</pub-id></mixed-citation></ref><ref id="B497"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudgal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nehul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomar</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Prospects for mucosal vaccine: Shutting the door on SARS-CoV-2</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>16</volume>, <fpage>2921</fpage>&#8211;<lpage>2931</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2020.1805992</pub-id><pub-id pub-id-type="pmid">32931361</pub-id><pub-id pub-id-type="pmcid">PMC7544966</pub-id></mixed-citation></ref><ref id="B498"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mugglestone</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Ratnaraja</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Bak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Bostock</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Presymptomatic, asymptomatic and post-symptomatic transmission of SARS-CoV-2: Joint British infection association (BIA), healthcare infection society (HIS), infection prevention society (IPS) and royal College of pathologists (RCPath) guidance</article-title>. <source>BMC Infect. Dis.</source><volume>22</volume>, <fpage>453</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-022-07440-0</pub-id><pub-id pub-id-type="pmid">35549902</pub-id><pub-id pub-id-type="pmcid">PMC9096060</pub-id></mixed-citation></ref><ref id="B499"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>N. F.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frazar</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moncla</surname><given-names>L. H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State</article-title>. <source>Sci. Transl. Med.</source><volume>13</volume>, <fpage>eabf0202</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abf0202</pub-id><pub-id pub-id-type="pmid">33941621</pub-id><pub-id pub-id-type="pmcid">PMC8158963</pub-id></mixed-citation></ref><ref id="B500"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>C. P.</given-names></name></person-group> (<year>2021</year>). <article-title>Do asymptomatic carriers of SARS-COV-2 transmit the virus?</article-title><source>Lancet Regional Health - Eur.</source><volume>4</volume>, <fpage>100082</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100082</pub-id><pub-id pub-id-type="pmcid">PMC7980082</pub-id><pub-id pub-id-type="pmid">33997832</pub-id></mixed-citation></ref><ref id="B501"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title>. <source>Nature</source><volume>586</volume>, <fpage>589</fpage>&#8211;<lpage>593</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2639-4</pub-id><pub-id pub-id-type="pmid">32785213</pub-id></mixed-citation></ref><ref id="B502"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munnur</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. H. Y.</given-names></name><name name-style="western"><surname>Thery</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection</article-title>. <source>Nat. Immunol.</source><volume>22</volume>, <fpage>1416</fpage>&#8211;<lpage>1427</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-01035-8</pub-id><pub-id pub-id-type="pmid">34663977</pub-id></mixed-citation></ref><ref id="B503"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakurai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Komoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ide</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishihara</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Shedding of viable virus in asymptomatic SARS-CoV-2 carriers</article-title>. <source>mSphere</source><volume>6</volume>, <fpage>e00019</fpage>&#8211;<lpage>e00021</lpage>. <pub-id pub-id-type="doi">10.1128/msphere.00019-21</pub-id><pub-id pub-id-type="pmid">34011679</pub-id><pub-id pub-id-type="pmcid">PMC8265619</pub-id></mixed-citation></ref><ref id="B504"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murewanhema</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mukwenha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dzinamarira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mukandavire</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cuadros</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madziva</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Optimising COVID-19 vaccination policy to mitigate SARS-CoV-2 transmission within schools in Zimbabwe</article-title>. <source>Vaccines (Basel)</source><volume>9</volume>, <fpage>1481</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9121481</pub-id><pub-id pub-id-type="pmid">34960227</pub-id><pub-id pub-id-type="pmcid">PMC8709186</pub-id></mixed-citation></ref><ref id="B505"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Achonu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 workplace outbreaks by industry sector and their associated household transmission, ontario, Canada, january to june, 2020</article-title>. <source>J. Occup. Environ. Med.</source><volume>63</volume>, <fpage>574</fpage>&#8211;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1097/jom.0000000000002201</pub-id><pub-id pub-id-type="pmid">33950040</pub-id><pub-id pub-id-type="pmcid">PMC8247533</pub-id></mixed-citation></ref><ref id="B506"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musa</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>U. M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abdullahi</surname><given-names>Z. U.</given-names></name><name name-style="western"><surname>Lawan</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>He</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Vertical transmission of SARS-CoV-2: A systematic review of systematic reviews</article-title>. <source>Viruses</source><volume>13</volume>, <fpage>1877</fpage>. <pub-id pub-id-type="doi">10.3390/v13091877</pub-id><pub-id pub-id-type="pmid">34578458</pub-id><pub-id pub-id-type="pmcid">PMC8471858</pub-id></mixed-citation></ref><ref id="B507"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Furi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Erdelyi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Madas</surname><given-names>B. G.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Modeling of nursing care-associated airborne transmission of SARS-CoV-2 in a real-world hospital setting</article-title>. <source>Geroscience</source><volume>44</volume>, <fpage>585</fpage>&#8211;<lpage>595</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-021-00512-0</pub-id><pub-id pub-id-type="pmid">34985588</pub-id><pub-id pub-id-type="pmcid">PMC8729098</pub-id></mixed-citation></ref><ref id="B508"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamichi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J. Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Simonson</surname><given-names>P. D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>4802</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-82850-9</pub-id><pub-id pub-id-type="pmid">33637820</pub-id><pub-id pub-id-type="pmcid">PMC7910290</pub-id></mixed-citation></ref><ref id="B509"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I. T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matter</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Overdevest</surname><given-names>J. B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers</article-title>. <source>Cell Rep. Med.</source><volume>2</volume>, <fpage>100421</fpage>. <pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100421</pub-id><pub-id pub-id-type="pmid">34604819</pub-id><pub-id pub-id-type="pmcid">PMC8479532</pub-id></mixed-citation></ref><ref id="B510"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nance</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>J. L.</given-names></name></person-group> (<year>2021</year>). <article-title>Modifications in an emergency: The role of N1-methylpseudouridine in COVID-19 vaccines</article-title>. <source>ACS Cent. Sci.</source><volume>7</volume>, <fpage>748</fpage>&#8211;<lpage>756</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.1c00197</pub-id><pub-id pub-id-type="pmid">34075344</pub-id><pub-id pub-id-type="pmcid">PMC8043204</pub-id></mixed-citation></ref><ref id="B511"><mixed-citation publication-type="webpage"><collab>Nbic+</collab> (<year>2022</year>). <article-title>Here&#8217;s how nanotechnologies tailor face masks for coronavirus era</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://statnano.com/news/67662/Here%E2%80%99s%20HowNanotechnologies-Tailor-Face-Masks-for-Coronavirus-Era,%20StatNano%20Publication" ext-link-type="uri">https://statnano.com/news/67662/Here%E2%80%99s%20HowNanotechnologies-Tailor-Face-Masks-for-Coronavirus-Era,%20StatNano%20Publication</ext-link></comment>.</mixed-citation></ref><ref id="B512"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neerukonda</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Vassell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lusvarghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Echegaray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity</article-title>. <source>Viruses</source><volume>13</volume>, <fpage>2485</fpage>. <pub-id pub-id-type="doi">10.3390/v13122485</pub-id><pub-id pub-id-type="pmid">34960755</pub-id><pub-id pub-id-type="pmcid">PMC8707919</pub-id></mixed-citation></ref><ref id="B513"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Mintri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rabideau</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Besin</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Impact of mRNA chemistry and manufacturing process on innate immune activation</article-title>. <source>Sci. Adv.</source><volume>6</volume>, <fpage>eaaz6893</fpage>. <pub-id pub-id-type="doi">10.1126/sciadv.aaz6893</pub-id><pub-id pub-id-type="pmid">32637598</pub-id><pub-id pub-id-type="pmcid">PMC7314518</pub-id></mixed-citation></ref><ref id="B514"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19</article-title>. <source>Crit. Care (Houten).</source><volume>24</volume>, <fpage>422</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-03120-0</pub-id><pub-id pub-id-type="pmcid">PMC7356137</pub-id><pub-id pub-id-type="pmid">32660650</pub-id></mixed-citation></ref><ref id="B515"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nickels</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Antiviral boost for nanoparticles</article-title>. <source>Metal. Powder Rep.</source><volume>75</volume>, <fpage>330</fpage>&#8211;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1016/j.mprp.2020.10.002</pub-id></mixed-citation></ref><ref id="B516"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alsafi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sohrabi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kerwan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Jabir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iosifidis</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The socio-economic implications of the coronavirus pandemic (COVID-19): A review</article-title>. <source>Int. J. Surg.</source><volume>78</volume>, <fpage>185</fpage>&#8211;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijsu.2020.04.018</pub-id><pub-id pub-id-type="pmid">32305533</pub-id><pub-id pub-id-type="pmcid">PMC7162753</pub-id></mixed-citation></ref><ref id="B517"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemi</surname><given-names>M. E. K.</given-names></name><name name-style="western"><surname>Karjalainen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ganna</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Mapping the human genetic architecture of COVID-19</article-title>. <source>Nature</source><volume>600</volume>, <fpage>472</fpage>&#8211;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03767-x</pub-id><pub-id pub-id-type="pmid">34237774</pub-id><pub-id pub-id-type="pmcid">PMC8674144</pub-id></mixed-citation></ref><ref id="B518"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiyama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kobara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujihara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Novel technique using an echo probe cover prevents oral-fecal transmission of SARS-CoV-2 during urgent colonoscopies</article-title>. <source>Endoscopy</source><volume>52</volume>, <fpage>E349</fpage>&#8211;<lpage>e350</lpage>. <pub-id pub-id-type="doi">10.1055/a-1187-1018</pub-id><pub-id pub-id-type="pmid">32559786</pub-id><pub-id pub-id-type="pmcid">PMC7516355</pub-id></mixed-citation></ref><ref id="B519"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nissen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krambrich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Akaberi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lundkvist</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>19589</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-76442-2</pub-id><pub-id pub-id-type="pmid">33177563</pub-id><pub-id pub-id-type="pmcid">PMC7659316</pub-id></mixed-citation></ref><ref id="B520"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Asymptomatic infection and atypical manifestations of COVID-19: Comparison of viral shedding duration</article-title>. <source>J. Infect.</source><volume>81</volume>, <fpage>816</fpage>&#8211;<lpage>846</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.035</pub-id><pub-id pub-id-type="pmcid">PMC7240269</pub-id><pub-id pub-id-type="pmid">32445728</pub-id></mixed-citation></ref><ref id="B521"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nooraei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bahrulolum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoseini</surname><given-names>Z. S.</given-names></name><name name-style="western"><surname>Katalani</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hajizade</surname><given-names>A.</given-names></name><name name-style="western"><surname>Easton</surname><given-names>A. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers</article-title>. <source>J. Nanobiotechnology</source><volume>19</volume>, <fpage>59</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-021-00806-7</pub-id><pub-id pub-id-type="pmid">33632278</pub-id><pub-id pub-id-type="pmcid">PMC7905985</pub-id></mixed-citation></ref><ref id="B522"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notarbartolo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ranzani</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bandera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gruarin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bevilacqua</surname><given-names>V.</given-names></name><name name-style="western"><surname>Putignano</surname><given-names>A. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients</article-title>. <source>Sci. Immunol.</source><volume>6</volume>, <fpage>eabg5021</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abg5021</pub-id><pub-id pub-id-type="pmid">34376481</pub-id></mixed-citation></ref><ref id="B523"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Notomi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okayama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Masubuchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yonekawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Amino</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Loop-mediated isothermal amplification of DNA</article-title>. <source>Nucleic Acids Res.</source><volume>28</volume>, <fpage>E63</fpage>&#8211;<lpage>E63</lpage>. <pub-id pub-id-type="doi">10.1093/nar/28.12.e63</pub-id><pub-id pub-id-type="pmid">10871386</pub-id><pub-id pub-id-type="pmcid">PMC102748</pub-id></mixed-citation></ref><ref id="B524"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nzediegwu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S. X.</given-names></name></person-group> (<year>2020</year>). <article-title>Improper solid waste management increases potential for COVID-19 spread in developing countries</article-title>. <source>Resour. Conserv. Recycl.</source><volume>161</volume>, <fpage>104947</fpage>. <pub-id pub-id-type="doi">10.1016/j.resconrec.2020.104947</pub-id><pub-id pub-id-type="pmid">32412552</pub-id><pub-id pub-id-type="pmcid">PMC7221374</pub-id></mixed-citation></ref><ref id="B525"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obermeyer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jankowiak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barkas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schaffner</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Pyle</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Yurkovetskiy</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness</article-title>. <source>Science</source><volume>376</volume>, <fpage>1327</fpage>&#8211;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1126/science.abm1208</pub-id><pub-id pub-id-type="pmid">35608456</pub-id><pub-id pub-id-type="pmcid">PMC9161372</pub-id></mixed-citation></ref><ref id="B526"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>O. S.</given-names></name></person-group> (<year>2022</year>). <article-title>SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways</article-title>. <source>J. Microbiol.</source><volume>60</volume>, <fpage>290</fpage>&#8211;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1007/s12275-022-1525-1</pub-id><pub-id pub-id-type="pmid">35122601</pub-id><pub-id pub-id-type="pmcid">PMC8817151</pub-id></mixed-citation></ref><ref id="B527"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'hagan</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Nest</surname><given-names>G. V.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Giudice</surname><given-names>G. D.</given-names></name></person-group> (<year>2013</year>). <article-title>The history of MF59(&#174;) adjuvant: A phoenix that arose from the ashes</article-title>. <source>Expert Rev. Vaccines</source><volume>12</volume>, <fpage>13</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1586/erv.12.140</pub-id><pub-id pub-id-type="pmid">23256736</pub-id></mixed-citation></ref><ref id="B528"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohsfeldt</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Choong</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Mc Collam</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Abedtash</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kelton</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Inpatient hospital costs for COVID-19 patients in the United States</article-title>. <source>Adv. Ther.</source><volume>38</volume>, <fpage>5557</fpage>&#8211;<lpage>5595</lpage>. <pub-id pub-id-type="doi">10.1007/s12325-021-01887-4</pub-id><pub-id pub-id-type="pmid">34609704</pub-id><pub-id pub-id-type="pmcid">PMC8491188</pub-id></mixed-citation></ref><ref id="B529"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olia</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Tsybovsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nazzari</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity</article-title>. <source>J. Biol. Chem.</source><volume>297</volume>, <fpage>101127</fpage>. <pub-id pub-id-type="doi">10.1016/j.jbc.2021.101127</pub-id><pub-id pub-id-type="pmid">34461095</pub-id><pub-id pub-id-type="pmcid">PMC8393506</pub-id></mixed-citation></ref><ref id="B530"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ong</surname><given-names>S. W. X.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y. K.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>B. C. H.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C. G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Environmental contamination in a coronavirus disease 2019 (COVID-19) intensive care unit-What is the risk?</article-title><source>Infect. Control Hosp. Epidemiol.</source><volume>42</volume>, <fpage>669</fpage>&#8211;<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1017/ice.2020.1278</pub-id><pub-id pub-id-type="pmid">33081858</pub-id><pub-id pub-id-type="pmcid">PMC7653228</pub-id></mixed-citation></ref><ref id="B531"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onyeaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anumudu</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Al-Sharify</surname><given-names>Z. T.</given-names></name><name name-style="western"><surname>Egele-Godswill</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mbaegbu</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 pandemic: A review of the global lockdown and its far-reaching effects</article-title>. <source>Sci. Prog.</source><volume>104</volume>, <fpage>003685042110198</fpage>. <pub-id pub-id-type="doi">10.1177/00368504211019854</pub-id><pub-id pub-id-type="pmcid">PMC10454957</pub-id><pub-id pub-id-type="pmid">34061685</pub-id></mixed-citation></ref><ref id="B532"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortega</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nozari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Canelli</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Personal protective equipment and covid-19</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>e105</fpage>. <pub-id pub-id-type="doi">10.1056/nejmvcm2014809</pub-id><pub-id pub-id-type="pmid">32427435</pub-id></mixed-citation></ref><ref id="B533"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osan</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Talukdar</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ann Demontigny</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>K. L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Goblet cell hyperplasia increases SARS-CoV-2 infection in COPD</article-title>. <comment>bioRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2020.11.11.379099</pub-id><pub-id pub-id-type="pmcid">PMC9430117</pub-id><pub-id pub-id-type="pmid">35862971</pub-id></mixed-citation></ref><ref id="B534"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Talukdar</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Demontigny</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>K. L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Goblet cell hyperplasia increases SARS-CoV-2 infection in chronic obstructive pulmonary disease</article-title>. <source>Microbiol. Spectr.</source><volume>10</volume>, <fpage>e0045922</fpage>. <pub-id pub-id-type="doi">10.1128/spectrum.00459-22</pub-id><pub-id pub-id-type="pmid">35862971</pub-id><pub-id pub-id-type="pmcid">PMC9430117</pub-id></mixed-citation></ref><ref id="B535"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osipiuk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wydorski</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Lanham</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Tesar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Endres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Engle</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin</article-title>. <comment>bioRxiv</comment>. <pub-id pub-id-type="doi">10.1101/2021.09.15.460543</pub-id><pub-id pub-id-type="pmcid">PMC10126577</pub-id><pub-id pub-id-type="pmid">37185902</pub-id></mixed-citation></ref><ref id="B536"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'toole</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mccrone</surname><given-names>J. T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool</article-title>. <source>Virus Evol.</source><volume>7</volume>, <fpage>veab064</fpage>. <pub-id pub-id-type="doi">10.1093/ve/veab064</pub-id><pub-id pub-id-type="pmid">34527285</pub-id><pub-id pub-id-type="pmcid">PMC8344591</pub-id></mixed-citation></ref><ref id="B537"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2</article-title>. <source>PLoS Pathog.</source><volume>17</volume>, <fpage>e1009212</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1009212</pub-id><pub-id pub-id-type="pmid">33465165</pub-id><pub-id pub-id-type="pmcid">PMC7845965</pub-id></mixed-citation></ref><ref id="B538"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oude Munnink</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Sikkema</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Nieuwenhuijse</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Molenaar</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Munger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Molenkamp</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans</article-title>. <source>Science</source><volume>371</volume>, <fpage>172</fpage>&#8211;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1126/science.abe5901</pub-id><pub-id pub-id-type="pmid">33172935</pub-id><pub-id pub-id-type="pmcid">PMC7857398</pub-id></mixed-citation></ref><ref id="B539"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouyang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Downregulated gene expression spectrum and immune responses changed during the disease progression in patients with COVID-19</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume>, <fpage>2052</fpage>&#8211;<lpage>2060</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa462</pub-id><pub-id pub-id-type="pmid">32307550</pub-id><pub-id pub-id-type="pmcid">PMC7188184</pub-id></mixed-citation></ref><ref id="B540"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Overton</surname><given-names>E. T.</given-names></name><name name-style="western"><surname>Weir</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Zanni</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Macarthur</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Aberg</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Asymptomatic SARS-CoV-2 infection is common among ART-treated people with HIV</article-title>. <source>J. Acquir. Immune Defic. Syndr.</source><volume>90</volume>, <fpage>377</fpage>&#8211;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000003000</pub-id><pub-id pub-id-type="pmid">35413022</pub-id><pub-id pub-id-type="pmcid">PMC9246928</pub-id></mixed-citation></ref><ref id="B541"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owida</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Al-Nabulsi</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Turab</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Louzi</surname><given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>Nanotechnology role development for COVID-19 pandemic management</article-title>. <source>J. Nanotechnol.</source><volume>2022</volume>, <fpage>1</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2022/1872933</pub-id></mixed-citation></ref><ref id="B542"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pachaiappan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rajendran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Show</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Manavalan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Naushad</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Metal/metal oxide nanocomposites for bactericidal effect: A review</article-title>. <source>Chemosphere</source><volume>272</volume>, <fpage>128607</fpage>. <pub-id pub-id-type="doi">10.1016/j.chemosphere.2020.128607</pub-id><pub-id pub-id-type="pmid">33097236</pub-id></mixed-citation></ref><ref id="B543"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pairo-Castineira</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clohisey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klaric</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bretherick</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Rawlik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pasko</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Genetic mechanisms of critical illness in COVID-19</article-title>. <source>Nature</source><volume>591</volume>, <fpage>92</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-03065-y</pub-id><pub-id pub-id-type="pmid">33307546</pub-id></mixed-citation></ref><ref id="B544"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mallery</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Albecka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Cattin-Ortol&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luptak</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion</article-title>. <source>PLoS Pathog.</source><volume>17</volume>, <fpage>e1009246</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1009246</pub-id><pub-id pub-id-type="pmid">33493182</pub-id><pub-id pub-id-type="pmcid">PMC7861537</pub-id></mixed-citation></ref><ref id="B545"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Delivery routes for COVID-19 vaccines</article-title>. <source>Vaccines (Basel)</source><volume>9</volume>, <fpage>524</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9050524</pub-id><pub-id pub-id-type="pmid">34069359</pub-id><pub-id pub-id-type="pmcid">PMC8158705</pub-id></mixed-citation></ref><ref id="B546"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parr</surname><given-names>C. J. C.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kotake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kameda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakashita</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells</article-title>. <source>Nucleic Acids Res.</source><volume>48</volume>, <fpage>e35</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa070</pub-id><pub-id pub-id-type="pmid">32090264</pub-id><pub-id pub-id-type="pmcid">PMC7102939</pub-id></mixed-citation></ref><ref id="B547"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Parshina-Kottas</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saget</surname><given-names>B.</given-names></name><name name-style="western"><surname>Patanjali</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fleisher</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gianordoli</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>This 3-D simulation shows why social distancing is so important</article-title>. <comment>NY Times Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://issues.org/creative-response/3-d-simulation-shows-why-social-distancing-is-so-important/" ext-link-type="uri">https://issues.org/creative-response/3-d-simulation-shows-why-social-distancing-is-so-important/</ext-link></comment>(<comment>accessed 14 4 2020)</comment>.</mixed-citation></ref><ref id="B548"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Passarelli</surname><given-names>V. C.</given-names></name><name name-style="western"><surname>Faico-Filho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>L. V. L.</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>J. M. A.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>G. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Asymptomatic COVID-19 in hospital visitors: The underestimated potential of viral shedding</article-title>. <source>Int. J. Infect. Dis.</source><volume>102</volume>, <fpage>412</fpage>&#8211;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.10.057</pub-id><pub-id pub-id-type="pmid">33129961</pub-id><pub-id pub-id-type="pmcid">PMC7592020</pub-id></mixed-citation></ref><ref id="B549"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastorino</surname><given-names>B.</given-names></name><name name-style="western"><surname>Touret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gilles</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Charrel</surname><given-names>R. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Prolonged infectivity of SARS-CoV-2 in fomites</article-title>. <source>Emerg. Infect. Dis.</source><volume>26</volume>, <fpage>2256</fpage>&#8211;<lpage>2257</lpage>. <pub-id pub-id-type="doi">10.3201/eid2609.201788</pub-id><pub-id pub-id-type="pmid">32579874</pub-id><pub-id pub-id-type="pmcid">PMC7454106</pub-id></mixed-citation></ref><ref id="B550"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patane</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cadamuro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Massazza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pirola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stagnati</surname><given-names>V.</given-names></name><name name-style="western"><surname>Comerio</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Evidence of vertical transmission of SARS-CoV-2 and interstitial pneumonia in second-trimester twin stillbirth in asymptomatic woman. Case report and review of the literature</article-title>. <source>Am. J. Obstet. Gynecol. MFM</source><volume>4</volume>, <fpage>100589</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajogmf.2022.100589</pub-id><pub-id pub-id-type="pmid">35131495</pub-id><pub-id pub-id-type="pmcid">PMC8815276</pub-id></mixed-citation></ref><ref id="B551"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pater</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Bosmeny</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>White</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Sylvain</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Eddington</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Parasrampuria</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>High throughput nanopore sequencing of SARS-CoV-2 viral genomes from patient samples</article-title>. <source>J. Biol. Methods</source><volume>8</volume>, <fpage>e155</fpage>. <pub-id pub-id-type="doi">10.14440/jbm.2021.360</pub-id><pub-id pub-id-type="pmid">34631911</pub-id><pub-id pub-id-type="pmcid">PMC8493558</pub-id></mixed-citation></ref><ref id="B552"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fraceto</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>E. V. R.</given-names></name><name name-style="western"><surname>Rodriguez-Torres</surname><given-names>M. D. P.</given-names></name><name name-style="western"><surname>Acosta-Torres</surname><given-names>L. S.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Nano based drug delivery systems: Recent developments and future prospects</article-title>. <source>J. Nanobiotechnology</source><volume>16</volume>, <fpage>71</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-018-0392-8</pub-id><pub-id pub-id-type="pmid">30231877</pub-id><pub-id pub-id-type="pmcid">PMC6145203</pub-id></mixed-citation></ref><ref id="B553"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paules</surname><given-names>C. I.</given-names></name><name name-style="western"><surname>Marston</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus infections-more than just the common cold</article-title>. <source>JAMA</source><volume>323</volume>, <fpage>707</fpage>&#8211;<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.0757</pub-id><pub-id pub-id-type="pmid">31971553</pub-id></mixed-citation></ref><ref id="B554"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Goldhill</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baillon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Frise</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swann</surname><given-names>O. C.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets</article-title>. <source>Nat. Microbiol.</source><volume>6</volume>, <fpage>899</fpage>&#8211;<lpage>909</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-021-00908-w</pub-id><pub-id pub-id-type="pmid">33907312</pub-id></mixed-citation></ref><ref id="B555"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peacock</surname><given-names>T. P.</given-names></name><name name-style="western"><surname>Sheppard</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Goonawardane</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin</article-title>. <source>bioRxiv</source>, <fpage>446163</fpage>. <pub-id pub-id-type="doi">10.1101/2021.05.28.446163</pub-id></mixed-citation></ref><ref id="B556"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pecora</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malacari</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Mozgovoj</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>M. L. A.</given-names></name><name name-style="western"><surname>Peralta</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Cacciabue</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Anthropogenic infection of domestic cats with SARS-CoV-2 alpha variant B.1.1.7 lineage in buenos aires</article-title>. <source>Front. Vet. Sci.</source><volume>9</volume>, <fpage>790058</fpage>. <pub-id pub-id-type="doi">10.3389/fvets.2022.790058</pub-id><pub-id pub-id-type="pmid">35310416</pub-id><pub-id pub-id-type="pmcid">PMC8925007</pub-id></mixed-citation></ref><ref id="B557"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peek</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Middaugh</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Berkland</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Nanotechnology in vaccine delivery</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>60</volume>, <fpage>915</fpage>&#8211;<lpage>928</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2007.05.017</pub-id><pub-id pub-id-type="pmid">18325628</pub-id><pub-id pub-id-type="pmcid">PMC7103321</pub-id></mixed-citation></ref><ref id="B558"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name></person-group> (<year>2021a</year>). <article-title>Cell entry by SARS-CoV-2</article-title>. <source>Trends biochem. Sci.</source><volume>46</volume>, <fpage>848</fpage>&#8211;<lpage>860</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2021.06.001</pub-id><pub-id pub-id-type="pmid">34187722</pub-id><pub-id pub-id-type="pmcid">PMC8180548</pub-id></mixed-citation></ref><ref id="B559"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Point-of-care test system for detection of immunoglobulin-G and -M against nucleocapsid protein and spike glycoprotein of SARS-CoV-2</article-title>. <source>Sensors Actuators B Chem.</source><volume>331</volume>, <fpage>129415</fpage>. <pub-id pub-id-type="doi">10.1016/j.snb.2020.129415</pub-id><pub-id pub-id-type="pmcid">PMC7833039</pub-id><pub-id pub-id-type="pmid">33519091</pub-id></mixed-citation></ref><ref id="B560"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Greer</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Thudium</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Legg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector</article-title>. <source>J. Virol.</source><volume>77</volume>, <fpage>10394</fpage>&#8211;<lpage>10403</lpage>. <pub-id pub-id-type="doi">10.1128/jvi.77.19.10394-10403.2003</pub-id><pub-id pub-id-type="pmid">12970424</pub-id><pub-id pub-id-type="pmcid">PMC228391</pub-id></mixed-citation></ref><ref id="B561"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kastner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khadke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roces</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Manufacturing methods for liposome adjuvants</article-title>. <source>Methods Mol. Biol.</source><volume>1494</volume>, <fpage>127</fpage>&#8211;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6445-1_9</pub-id><pub-id pub-id-type="pmid">27718190</pub-id></mixed-citation></ref><ref id="B562"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Touch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mccloskey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mwaba</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Rapid spread of Zika virus in the americas--implications for public health preparedness for mass gatherings at the 2016 Brazil olympic games</article-title>. <source>Int. J. Infect. Dis.</source><volume>44</volume>, <fpage>11</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2016.02.001</pub-id><pub-id pub-id-type="pmid">26854199</pub-id></mixed-citation></ref><ref id="B563"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petkar</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Chavhan</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Kunda</surname><given-names>N. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An overview of nanocarrier-based adjuvants for vaccine delivery</article-title>. <source>Pharmaceutics</source><volume>13</volume>, <fpage>455</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13040455</pub-id><pub-id pub-id-type="pmid">33801614</pub-id><pub-id pub-id-type="pmcid">PMC8066039</pub-id></mixed-citation></ref><ref id="B564"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Yavuz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing</article-title>. <source>J. Clin. Microbiol.</source><volume>59</volume> (<issue>6</issue>), <fpage>e03271-20</fpage>. <pub-id pub-id-type="doi">10.1128/JCM.03271-20</pub-id><pub-id pub-id-type="pmid">33782112</pub-id><pub-id pub-id-type="pmcid">PMC8315953</pub-id></mixed-citation></ref><ref id="B565"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettifor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Diprete</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Shook-Sa</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Premkumar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuczynski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dittmer</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic</article-title>. <source>PLoS One</source><volume>17</volume>, <fpage>e0267353</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0267353</pub-id><pub-id pub-id-type="pmid">35468150</pub-id><pub-id pub-id-type="pmcid">PMC9037948</pub-id></mixed-citation></ref><ref id="B566"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pezzini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padovani</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Lifting the mask on neurological manifestations of COVID-19</article-title>. <source>Nat. Rev. Neurol.</source><volume>16</volume>, <fpage>636</fpage>&#8211;<lpage>644</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-020-0398-3</pub-id><pub-id pub-id-type="pmid">32839585</pub-id><pub-id pub-id-type="pmcid">PMC7444680</pub-id></mixed-citation></ref><ref id="B567"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Coating and functionalization strategies for nanogels and nanoparticles for selective drug delivery</article-title>. <source>Gels</source><volume>6</volume>, <fpage>6</fpage>. <pub-id pub-id-type="doi">10.3390/gels6010006</pub-id><pub-id pub-id-type="pmid">32033057</pub-id><pub-id pub-id-type="pmcid">PMC7151136</pub-id></mixed-citation></ref><ref id="B568"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pipolo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bottai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fuccillo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aronica</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bruschi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bulfamante</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Evidence of SARS-CoV-2 in nasal brushings and olfactory mucosa biopsies of COVID-19 patients</article-title>. <source>PLoS One</source><volume>17</volume>, <fpage>e0266740</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0266740</pub-id><pub-id pub-id-type="pmid">35413071</pub-id><pub-id pub-id-type="pmcid">PMC9004784</pub-id></mixed-citation></ref><ref id="B569"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pisani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pompa</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Bardi</surname><given-names>G.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential applications of nanomaterials to quench the cytokine storm in coronavirus disease 19</article-title>. <source>Front. Bioeng. Biotechnol.</source><volume>8</volume>, <fpage>906</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2020.00906</pub-id><pub-id pub-id-type="pmid">32974295</pub-id><pub-id pub-id-type="pmcid">PMC7466734</pub-id></mixed-citation></ref><ref id="B570"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plante</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Lokugamage</surname><given-names>K. G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Spike mutation D614G alters SARS-CoV-2 fitness</article-title>. <source>Nature</source><volume>592</volume>, <fpage>116</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2895-3</pub-id><pub-id pub-id-type="pmid">33106671</pub-id><pub-id pub-id-type="pmcid">PMC8158177</pub-id></mixed-citation></ref><ref id="B571"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plescia</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>David</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amiar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles</article-title>. <source>J. Biol. Chem.</source><volume>296</volume>, <fpage>100103</fpage>. <pub-id pub-id-type="doi">10.1074/jbc.ra120.016148</pub-id><pub-id pub-id-type="pmid">33214224</pub-id><pub-id pub-id-type="pmcid">PMC7832013</pub-id></mixed-citation></ref><ref id="B572"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plummer</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Manchester</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Viral nanoparticles and virus-like particles: Platforms for contemporary vaccine design</article-title>. <source>WIREs. Nanomed. Nanobiotechnol.</source><volume>3</volume>, <fpage>174</fpage>&#8211;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1002/wnan.119</pub-id><pub-id pub-id-type="pmcid">PMC7169818</pub-id><pub-id pub-id-type="pmid">20872839</pub-id></mixed-citation></ref><ref id="B573"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poggio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arciola</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Greggi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scribante</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dagna</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Copper-alloy surfaces and cleaning regimens against the spread of SARS-CoV-2 in dentistry and orthopedics. From fomites to anti-infective nanocoatings</article-title>. <source>Mater. (Basel)</source><volume>13</volume>, <fpage>3244</fpage>. <pub-id pub-id-type="doi">10.3390/ma13153244</pub-id><pub-id pub-id-type="pmcid">PMC7435369</pub-id><pub-id pub-id-type="pmid">32707757</pub-id></mixed-citation></ref><ref id="B574"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>2603</fpage>&#8211;<lpage>2615</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id><pub-id pub-id-type="pmid">33301246</pub-id></mixed-citation></ref><ref id="B575"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polechova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>P.</given-names></name><name name-style="western"><surname>Crozier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beiglbock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plevka</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 rapid antigen tests provide benefits for epidemic control - observations from Austrian schools</article-title>. <source>J. Clin. Epidemiol.</source><volume>145</volume>, <fpage>14</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2022.01.002</pub-id><pub-id pub-id-type="pmid">35041972</pub-id><pub-id pub-id-type="pmcid">PMC8760838</pub-id></mixed-citation></ref><ref id="B576"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name></person-group> (<year>2021a</year>). <article-title>Recombinant protein vaccines, a proven approach against coronavirus pandemics</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>170</volume>, <fpage>71</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2021.01.001</pub-id><pub-id pub-id-type="pmid">33421475</pub-id><pub-id pub-id-type="pmcid">PMC7788321</pub-id></mixed-citation></ref><ref id="B577"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>17</volume>, <fpage>2356</fpage>&#8211;<lpage>2366</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2021.1901545</pub-id><pub-id pub-id-type="pmid">33847226</pub-id><pub-id pub-id-type="pmcid">PMC8054496</pub-id></mixed-citation></ref><ref id="B578"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollock</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Szubert</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Libri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Owen</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial</article-title>. <source>EClinicalMedicine</source><volume>44</volume>, <fpage>101262</fpage>. <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101262</pub-id><pub-id pub-id-type="pmid">35043093</pub-id><pub-id pub-id-type="pmcid">PMC8759012</pub-id></mixed-citation></ref><ref id="B579"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popescu</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#350;tefan</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>&#350;tefan</surname><given-names>M.</given-names></name><name name-style="western"><surname>V&#259;leanu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tomescu</surname><given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>ICU-associated costs during the fourth wave of the COVID-19 pandemic in a tertiary hospital in a low-vaccinated eastern European country</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>19</volume>, <fpage>1781</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph19031781</pub-id><pub-id pub-id-type="pmid">35162804</pub-id><pub-id pub-id-type="pmcid">PMC8834984</pub-id></mixed-citation></ref><ref id="B580"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poudel</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>N.</given-names></name><name name-style="western"><surname>Roderick</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alwan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tarrant</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Impact of covid-19 on health-related quality of life of patients: A structured review</article-title>. <source>PLoS One</source><volume>16</volume>, <fpage>e0259164</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0259164</pub-id><pub-id pub-id-type="pmid">34710173</pub-id><pub-id pub-id-type="pmcid">PMC8553121</pub-id></mixed-citation></ref><ref id="B581"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cherian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Team</surname><given-names>I.-N. N.</given-names></name></person-group> (<year>2020</year>). <article-title>Transmission electron microscopy imaging of SARS-CoV-2</article-title>. <source>Indian J. Med. Res.</source><volume>151</volume>, <fpage>241</fpage>&#8211;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.ijmr_577_20</pub-id><pub-id pub-id-type="pmid">32362648</pub-id><pub-id pub-id-type="pmcid">PMC7224615</pub-id></mixed-citation></ref><ref id="B582"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prates-Syed</surname><given-names>W. A.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>L. C. S.</given-names></name><name name-style="western"><surname>Crema</surname><given-names>K. P.</given-names></name><name name-style="western"><surname>Vuitika</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lira</surname><given-names>A.</given-names></name><name name-style="western"><surname>C&#244;rtes</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>VLP-based COVID-19 vaccines: An adaptable technology against the threat of new variants</article-title>. <source>Vaccines (Basel)</source><volume>9</volume>, <fpage>1409</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9121409</pub-id><pub-id pub-id-type="pmid">34960155</pub-id><pub-id pub-id-type="pmcid">PMC8708688</pub-id></mixed-citation></ref><ref id="B583"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premkumar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Segovia-Chumbez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jadi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Raut</surname><given-names>R.</given-names></name><name name-style="western"><surname>Markmann</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients</article-title>. <source>Sci. Immunol.</source><volume>5</volume>, <fpage>eabc8413</fpage>. <pub-id pub-id-type="doi">10.1126/sciimmunol.abc8413</pub-id><pub-id pub-id-type="pmid">32527802</pub-id><pub-id pub-id-type="pmcid">PMC7292505</pub-id></mixed-citation></ref><ref id="B584"><mixed-citation publication-type="webpage"><collab>Promethean-Particles-Ltd</collab> (<year>2022</year>). <article-title>Promethean particles puts its nano-copper to the test in the fight against viruses</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://prometheanparticles.co.uk/promethean-particles-puts-its-nano-copper-to-the-test-in-the-fht-against-viruses/" ext-link-type="uri">https://prometheanparticles.co.uk/promethean-particles-puts-its-nano-copper-to-the-test-in-the-fight-against-viruses/</ext-link></comment>.</mixed-citation></ref><ref id="B585"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ptasinska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Whalley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bosworth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poxon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bryer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Machin</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Diagnostic accuracy of loop-mediated isothermal amplification coupled to nanopore sequencing (LamPORE) for the detection of SARS-CoV-2 infection at scale in symptomatic and asymptomatic populations</article-title>. <source>Clin. Microbiol. Infect.</source><volume>27</volume>, <fpage>1348</fpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2021.04.008</pub-id><pub-id pub-id-type="pmcid">PMC8064897</pub-id><pub-id pub-id-type="pmid">33901668</pub-id></mixed-citation></ref><ref id="B586"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puelles</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>L&#252;tgehetmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lindenmeyer</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Sperhake</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Allweiss</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Multiorgan and renal tropism of SARS-CoV-2</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>590</fpage>&#8211;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2011400</pub-id><pub-id pub-id-type="pmcid">PMC7240771</pub-id><pub-id pub-id-type="pmid">32402155</pub-id></mixed-citation></ref><ref id="B587"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2020a</year>). <source>Recent Progress on the Versatility of Virus-Like Particles</source>, <volume>8</volume>. <publisher-loc>Basel</publisher-loc>: <publisher-name>Vaccines</publisher-name>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8010139</pub-id><pub-id pub-id-type="pmcid">PMC7157238</pub-id><pub-id pub-id-type="pmid">32244935</pub-id></mixed-citation></ref><ref id="B588"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>A. H. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>COVID-19 transmission within a family cluster by presymptomatic carriers in China</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume>, <fpage>861</fpage>&#8211;<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa316</pub-id><pub-id pub-id-type="pmid">32201889</pub-id><pub-id pub-id-type="pmcid">PMC7184331</pub-id></mixed-citation></ref><ref id="B589"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kullak-Ublick</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>5268</fpage>&#8211;<lpage>5277</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c02439</pub-id><pub-id pub-id-type="pmid">32281785</pub-id></mixed-citation></ref><ref id="B590"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loman</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Duraffour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Severi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cowley</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Real-time, portable genome sequencing for Ebola surveillance</article-title>. <source>Nature</source><volume>530</volume>, <fpage>228</fpage>&#8211;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1038/nature16996</pub-id><pub-id pub-id-type="pmid">26840485</pub-id><pub-id pub-id-type="pmcid">PMC4817224</pub-id></mixed-citation></ref><ref id="B591"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grubaugh</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Pullan</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I. M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Gangavarapu</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples</article-title>. <source>Nat. Protoc.</source><volume>12</volume>, <fpage>1261</fpage>&#8211;<lpage>1276</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2017.066</pub-id><pub-id pub-id-type="pmid">28538739</pub-id><pub-id pub-id-type="pmcid">PMC5902022</pub-id></mixed-citation></ref><ref id="B592"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ra</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G. U.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. H.</given-names></name></person-group> (<year>2021</year>). <article-title>Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection</article-title>. <source>Thorax</source><volume>76</volume>, <fpage>61</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2020-215042</pub-id><pub-id pub-id-type="pmid">32963115</pub-id></mixed-citation></ref><ref id="B593"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajme-Lopez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gonzalez-Lara</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Ortiz-Brizuela</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roman-Montes</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Santiago-Cruz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mendoza-Rojas</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Large-scale screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among healthcare workers: Prevalence and risk factors for asymptomatic and pauci-symptomatic carriers, with emphasis on the use of personal protective equipment (PPE)</article-title>. <source>Infect. Control Hosp. Epidemiol.</source><volume>43</volume>, <fpage>513</fpage>&#8211;<lpage>517</lpage>. <pub-id pub-id-type="doi">10.1017/ice.2021.68</pub-id><pub-id pub-id-type="pmid">33622448</pub-id><pub-id pub-id-type="pmcid">PMC8111176</pub-id></mixed-citation></ref><ref id="B594"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Ranjan</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19: Unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies</article-title>. <source>Biomolecules</source><volume>11</volume>, <fpage>993</fpage>. <pub-id pub-id-type="doi">10.3390/biom11070993</pub-id><pub-id pub-id-type="pmid">34356617</pub-id><pub-id pub-id-type="pmcid">PMC8301790</pub-id></mixed-citation></ref><ref id="B595"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>D. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial</article-title>. <source>Lancet</source><volume>396</volume>, <fpage>1979</fpage>&#8211;<lpage>1993</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></mixed-citation></ref><ref id="B596"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaseshan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sundarrajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barhate</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Lala</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Ramakrishna</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Functionalized polymer nanofibre membranes for protection from chemical warfare stimulants</article-title>. <source>Nanotechnology</source><volume>17</volume>, <fpage>2947</fpage>&#8211;<lpage>2953</lpage>. <pub-id pub-id-type="doi">10.1088/0957-4484/17/12/021</pub-id></mixed-citation></ref><ref id="B597"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dzakah</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta</article-title>. <source>Virus Res.</source><volume>296</volume>, <fpage>198350</fpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2021.198350</pub-id><pub-id pub-id-type="pmid">33626380</pub-id><pub-id pub-id-type="pmcid">PMC7897408</pub-id></mixed-citation></ref><ref id="B598"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashidzadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Danafar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mozafari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salehiabar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rahmati</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): Diagnosis, treatment, therapy and future perspectives</article-title>. <source>Nanomedicine (Lond)</source><volume>16</volume>, <fpage>497</fpage>&#8211;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2020-0441</pub-id><pub-id pub-id-type="pmid">33683164</pub-id><pub-id pub-id-type="pmcid">PMC7938776</pub-id></mixed-citation></ref><ref id="B599"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saloua</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Nemati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Recent Progress in Nanotechnology for COVID-19 Prevention, Diagnostics and Treatment</article-title>. <source>Nanomater. (Basel)</source>. <volume>11</volume>, <fpage>1788</fpage>. <pub-id pub-id-type="doi">10.3390/nano11071788</pub-id><pub-id pub-id-type="pmcid">PMC8308319</pub-id><pub-id pub-id-type="pmid">34361174</pub-id></mixed-citation></ref><ref id="B600"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Schwendt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S. O.</given-names></name><name name-style="western"><surname>Petsch</surname><given-names>B.</given-names></name></person-group> (<year>2021</year>). <article-title>mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents</article-title>. <source>NPJ Vaccines</source><volume>6</volume>, <fpage>57</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-021-00311-w</pub-id><pub-id pub-id-type="pmid">33863911</pub-id><pub-id pub-id-type="pmcid">PMC8052455</pub-id></mixed-citation></ref><ref id="B601"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Valderrama</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Kuhar</surname><given-names>D. T.</given-names></name></person-group> (<year>2019</year>). <article-title>Improving the use of personal protective equipment: Applying lessons learned</article-title>. <source>Clin. Infect. Dis.</source><volume>69</volume>, <fpage>S165</fpage>&#8211;<lpage>s170</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciz619</pub-id><pub-id pub-id-type="pmid">31517978</pub-id></mixed-citation></ref><ref id="B602"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sommerfield</surname><given-names>A.</given-names></name><name name-style="western"><surname>Von Ungern-Sternberg</surname><given-names>B. S.</given-names></name></person-group> (<year>2021</year>). <article-title>The role of fit testing N95/FFP2/FFP3 masks: A narrative review</article-title>. <source>Anaesthesia</source><volume>76</volume>, <fpage>91</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1111/anae.15261</pub-id><pub-id pub-id-type="pmid">32932556</pub-id></mixed-citation></ref><ref id="B603"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>A. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance</article-title>. <source>World J. Clin. Cases</source><volume>10</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.12998/wjcc.v10.i1.1</pub-id><pub-id pub-id-type="pmid">35071500</pub-id><pub-id pub-id-type="pmcid">PMC8727245</pub-id></mixed-citation></ref><ref id="B604"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Reports</surname><given-names>W. C. D. C.-S.</given-names></name></person-group> (<year>2020</year>). <article-title>Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/</ext-link></comment>.</mixed-citation></ref><ref id="B605"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rha</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>I. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>PD-1-Expressing SARS-CoV-2-specific CD8(+) T cells are not exhausted, but functional in patients with COVID-19</article-title>. <source>Immunity</source><volume>54</volume>, <fpage>44</fpage>&#8211;<lpage>52.e3</lpage>. <comment>e43</comment>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.12.002</pub-id><pub-id pub-id-type="pmid">33338412</pub-id><pub-id pub-id-type="pmcid">PMC7834198</pub-id></mixed-citation></ref><ref id="B606"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rios</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lacoux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>V.</given-names></name><name name-style="western"><surname>Diamant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lebrigand</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lazuka</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Monitoring SARS-CoV-2 variants alterations in Nice neighborhoods by wastewater nanopore sequencing</article-title>. <source>Lancet Regional Health - Eur.</source><volume>10</volume>, <fpage>100202</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100202</pub-id><pub-id pub-id-type="pmcid">PMC8372489</pub-id><pub-id pub-id-type="pmid">34423327</pub-id></mixed-citation></ref><ref id="B607"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivett</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sparkes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Routledge</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission</article-title>. <source>Elife</source><volume>9</volume>, <fpage>e58728</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.58728</pub-id><pub-id pub-id-type="pmid">32392129</pub-id><pub-id pub-id-type="pmcid">PMC7314537</pub-id></mixed-citation></ref><ref id="B608"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Melo</surname><given-names>G. D.</given-names></name><name name-style="western"><surname>Lazarini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bruel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>4354</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-24521-x</pub-id><pub-id pub-id-type="pmid">34272374</pub-id><pub-id pub-id-type="pmcid">PMC8285531</pub-id></mixed-citation></ref><ref id="B609"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez-Ares</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lamas-Francis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Trevi&#241;o</surname><given-names>M.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cea</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#243;pez-Valladares</surname><given-names>M. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 in conjunctiva and tears and ocular symptoms of patients with COVID-19</article-title>. <source>Vis. (Basel)</source><volume>5</volume>, <fpage>51</fpage>. <pub-id pub-id-type="doi">10.3390/vision5040051</pub-id><pub-id pub-id-type="pmcid">PMC8544743</pub-id><pub-id pub-id-type="pmid">34698308</pub-id></mixed-citation></ref><ref id="B610"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohilla</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19</article-title>. <source>Drug Dev. Res.</source><volume>82</volume>, <fpage>12</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/ddr.21720</pub-id><pub-id pub-id-type="pmid">33216381</pub-id></mixed-citation></ref><ref id="B611"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rajasekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shenoy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iddya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dorairajan</surname><given-names>S. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Reprocessing of N95 masks: Experience from a resource-limited setting in India</article-title>. <source>Int. J. Infect. Dis.</source><volume>104</volume>, <fpage>41</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.12.070</pub-id><pub-id pub-id-type="pmid">33383222</pub-id><pub-id pub-id-type="pmcid">PMC7770488</pub-id></mixed-citation></ref><ref id="B612"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gundrum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sianis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Safo</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19</article-title>. <source>JAMA Netw. Open</source><volume>3</volume>, <fpage>e2029058</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.29058</pub-id><pub-id pub-id-type="pmid">33301018</pub-id><pub-id pub-id-type="pmcid">PMC7729428</pub-id></mixed-citation></ref><ref id="B613"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Gerasimova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruiz-Vega</surname><given-names>R.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>2054</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-06091-0</pub-id><pub-id pub-id-type="pmid">35136154</pub-id><pub-id pub-id-type="pmcid">PMC8826425</pub-id></mixed-citation></ref><ref id="B614"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schunk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sothmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bretzel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Froeschl</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wallrauch</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>970</fpage>&#8211;<lpage>971</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2001468</pub-id><pub-id pub-id-type="pmcid">PMC7120970</pub-id><pub-id pub-id-type="pmid">32003551</pub-id></mixed-citation></ref><ref id="B615"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowan</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Moral</surname><given-names>R. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Disposable face masks and reusable face coverings as non-pharmaceutical interventions (NPIs) to prevent transmission of SARS-CoV-2 variants that cause coronavirus disease (COVID-19): Role of new sustainable NPI design innovations and predictive mathematical modelling</article-title>. <source>Sci. Total Environ.</source><volume>772</volume>, <fpage>145530</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2021.145530</pub-id><pub-id pub-id-type="pmid">33581526</pub-id><pub-id pub-id-type="pmcid">PMC7848491</pub-id></mixed-citation></ref><ref id="B616"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title>. <source>Intensive Care Med.</source><volume>46</volume>, <fpage>846</fpage>&#8211;<lpage>848</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-05991-x</pub-id><pub-id pub-id-type="pmid">32125452</pub-id><pub-id pub-id-type="pmcid">PMC7080116</pub-id></mixed-citation></ref><ref id="B617"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rydyznski Moderbacher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity</article-title>. <source>Cell</source><volume>183</volume>, <fpage>996</fpage>&#8211;<lpage>1012.e19</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.09.038</pub-id><pub-id pub-id-type="pmid">33010815</pub-id><pub-id pub-id-type="pmcid">PMC7494270</pub-id></mixed-citation></ref><ref id="B618"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>384</volume>, <fpage>2187</fpage>&#8211;<lpage>2201</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id><pub-id pub-id-type="pmid">33882225</pub-id></mixed-citation></ref><ref id="B619"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><name name-style="western"><surname>De Groot</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>384</volume>, <fpage>1824</fpage>&#8211;<lpage>1835</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2034201</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id><pub-id pub-id-type="pmid">33440088</pub-id></mixed-citation></ref><ref id="B620"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ez-Llorens</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lanata</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aranguren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Celis</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Cornejo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deantonio</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study</article-title>. <source>Vaccine. X</source><volume>11</volume>, <fpage>100189</fpage>. <pub-id pub-id-type="doi">10.1016/j.jvacx.2022.100189</pub-id><pub-id pub-id-type="pmid">35791320</pub-id><pub-id pub-id-type="pmcid">PMC9247226</pub-id></mixed-citation></ref><ref id="B621"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sah</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Juden-Kelly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moghadas</surname><given-names>S. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>17513</fpage>&#8211;<lpage>17515</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2008373117</pub-id><pub-id pub-id-type="pmcid">PMC8403749</pub-id><pub-id pub-id-type="pmid">34376550</pub-id></mixed-citation></ref><ref id="B622"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saify Nabiabad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demirdas</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Specific delivering of RNAi using spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-covid drug in a clinical case study</article-title>. <source>Chem. Biol. Drug Des.</source><volume>99</volume>, <fpage>233</fpage>&#8211;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1111/cbdd.13978</pub-id><pub-id pub-id-type="pmid">34714580</pub-id><pub-id pub-id-type="pmcid">PMC8653378</pub-id></mixed-citation></ref><ref id="B623"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salamanna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maglio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Landini</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Fini</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Body localization of ACE-2: On the trail of the keyhole of SARS-CoV-2</article-title>. <source>Front. Med.</source><volume>7</volume>, <fpage>594495</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.594495</pub-id><pub-id pub-id-type="pmcid">PMC7744810</pub-id><pub-id pub-id-type="pmid">33344479</pub-id></mixed-citation></ref><ref id="B624"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salehi-Vaziri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fazlalipour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seyed Khorrami</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Azadmanesh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pouriayevali</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The ins and outs of SARS-CoV-2 variants of concern (VOCs)</article-title>. <source>Arch. Virol.</source><volume>167</volume>, <fpage>327</fpage>&#8211;<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-022-05365-2</pub-id><pub-id pub-id-type="pmid">35089389</pub-id><pub-id pub-id-type="pmcid">PMC8795292</pub-id></mixed-citation></ref><ref id="B625"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salian</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Vedell</surname><given-names>P. T.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kandimalla</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 transmission, current treatment, and future therapeutic strategies</article-title>. <source>Mol. Pharm.</source><volume>18</volume>, <fpage>754</fpage>&#8211;<lpage>771</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00608</pub-id><pub-id pub-id-type="pmid">33464914</pub-id></mixed-citation></ref><ref id="B626"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salleh</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Derrick</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Deris</surname><given-names>Z. Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>, <fpage>7425</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22147425</pub-id><pub-id pub-id-type="pmid">34299045</pub-id><pub-id pub-id-type="pmcid">PMC8306177</pub-id></mixed-citation></ref><ref id="B627"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salmenjoki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Korhonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puisto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vuorinen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Alava</surname><given-names>M. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Modelling aerosol-based exposure to SARS-CoV-2 by an agent based Monte Carlo method: Risk estimates in a shop and bar</article-title>. <source>PLoS One</source><volume>16</volume>, <fpage>e0260237</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0260237</pub-id><pub-id pub-id-type="pmid">34807943</pub-id><pub-id pub-id-type="pmcid">PMC8608316</pub-id></mixed-citation></ref><ref id="B628"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvador</surname><given-names>F. S.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>D. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Entry routes for Zika virus in Brazil after 2014 world cup: New possibilities</article-title>. <source>Travel Med. Infect. Dis.</source><volume>14</volume>, <fpage>49</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.tmaid.2015.10.004</pub-id><pub-id pub-id-type="pmid">26627575</pub-id></mixed-citation></ref><ref id="B629"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvador</surname><given-names>A.</given-names></name><name name-style="western"><surname>Igartua</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Pedraz</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines</article-title>. <source>J. Drug Deliv.</source><volume>2011</volume>, <fpage>1</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1155/2011/181646</pub-id><pub-id pub-id-type="pmcid">PMC3134826</pub-id><pub-id pub-id-type="pmid">21773041</pub-id></mixed-citation></ref><ref id="B630"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turbyfill</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Daniel-Wayman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shonkwiler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Kuhring</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Community transmission of SARS-CoV-2 associated with a local bar opening event - Illinois, february 2021</article-title>. <source>MMWR. Morb. Mortal. Wkly. Rep.</source><volume>70</volume>, <fpage>528</fpage>&#8211;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7014e3</pub-id><pub-id pub-id-type="pmid">33830981</pub-id><pub-id pub-id-type="pmcid">PMC8030980</pub-id></mixed-citation></ref><ref id="B631"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>San</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Ngcapu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanzi</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Tegally</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Giandhari</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Transmission dynamics of SARS-CoV-2 within-host diversity in two major hospital outbreaks in South Africa</article-title>. <source>Virus Evol.</source><volume>7</volume>, <fpage>veab041</fpage>. <pub-id pub-id-type="doi">10.1093/ve/veab041</pub-id><pub-id pub-id-type="pmid">34035952</pub-id><pub-id pub-id-type="pmcid">PMC8135343</pub-id></mixed-citation></ref><ref id="B632"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Gomez Parra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ozden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rijkers</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Which jobs are most vulnerable to COVID-19? What an analysis of the European union reveals</article-title>. <source>Res. Policy Briefs World Bank Malays. Hub</source><volume>34</volume>, <fpage>1</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1596/33737</pub-id></mixed-citation></ref><ref id="B633"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santarpia</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Morwitzer</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Creager</surname><given-names>H. M.</given-names></name><name name-style="western"><surname>Santarpia</surname><given-names>G. W.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Author Correction: Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>13892</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-70939-6</pub-id><pub-id pub-id-type="pmid">32782290</pub-id><pub-id pub-id-type="pmcid">PMC7421442</pub-id></mixed-citation></ref><ref id="B634"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarfraz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M. W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Development of dual drug loaded nanosized liposomal formulation by A reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies</article-title>. <source>Pharmaceutics</source><volume>10</volume>, <fpage>151</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics10030151</pub-id><pub-id pub-id-type="pmid">30200557</pub-id><pub-id pub-id-type="pmcid">PMC6161256</pub-id></mixed-citation></ref><ref id="B635"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savoji</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Haghighat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mirzaee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Golkaran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mirzaee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Esfandiari</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Formulation of HBs antigen in Montanide ISA266 shows superiority to commercial HBsAg vaccine in the induction of humoral immune responses</article-title>. <source>Gastroenterol. Hepatol. Bed Bench</source><volume>12</volume>, <fpage>292</fpage>&#8211;<lpage>300</lpage>.<pub-id pub-id-type="pmid">31749917</pub-id><pub-id pub-id-type="pmcid">PMC6820835</pub-id></mixed-citation></ref><ref id="B636"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawatzki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Puryear</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Foss</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Stone</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Runstadler</surname><given-names>J. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>118</volume>, <fpage>e2025601118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2025601118</pub-id><pub-id pub-id-type="pmid">33858941</pub-id><pub-id pub-id-type="pmcid">PMC8106344</pub-id></mixed-citation></ref><ref id="B637"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sayers</surname><given-names>E. W.</given-names></name><name name-style="western"><surname>Cavanaugh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pruitt</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Schoch</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Sherry</surname><given-names>S. T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>GenBank</article-title>. <source>Nucleic Acids Res.</source><volume>49</volume>, <fpage>D92</fpage>&#8211;<lpage>d96</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1023</pub-id><pub-id pub-id-type="pmid">33196830</pub-id><pub-id pub-id-type="pmcid">PMC7778897</pub-id></mixed-citation></ref><ref id="B638"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoenmaker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Witzigmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability</article-title>. <source>Int. J. Pharm.</source><volume>601</volume>, <fpage>120586</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120586</pub-id><pub-id pub-id-type="pmid">33839230</pub-id><pub-id pub-id-type="pmcid">PMC8032477</pub-id></mixed-citation></ref><ref id="B639"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwendener</surname><given-names>R. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Liposomes as vaccine delivery systems: A review of the recent advances</article-title>. <source>Ther. Adv. Vaccines</source><volume>2</volume>, <fpage>159</fpage>&#8211;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1177/2051013614541440</pub-id><pub-id pub-id-type="pmid">25364509</pub-id><pub-id pub-id-type="pmcid">PMC4212474</pub-id></mixed-citation></ref><ref id="B640"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seah</surname><given-names>I.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals</article-title>. <source>Ocul. Immunol. Inflamm.</source><volume>28</volume>, <fpage>391</fpage>&#8211;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1080/09273948.2020.1738501</pub-id><pub-id pub-id-type="pmid">32175797</pub-id><pub-id pub-id-type="pmcid">PMC7103678</pub-id></mixed-citation></ref><ref id="B641"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedighi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sieber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Rezayan</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Huwyler</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Rapid optimization of liposome characteristics using a combined microfluidics and design-of-experiment approach</article-title>. <source>Drug Deliv. Transl. Res.</source><volume>9</volume>, <fpage>404</fpage>&#8211;<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1007/s13346-018-0587-4</pub-id><pub-id pub-id-type="pmid">30306459</pub-id></mixed-citation></ref><ref id="B642"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>K. B.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>5135</fpage>&#8211;<lpage>5142</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c02823</pub-id><pub-id pub-id-type="pmid">32293168</pub-id></mixed-citation></ref><ref id="B643"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sercombe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Veerati</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moheimani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Sood</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances and challenges of liposome assisted drug delivery</article-title>. <source>Front. Pharmacol.</source><volume>6</volume>, <fpage>286</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2015.00286</pub-id><pub-id pub-id-type="pmid">26648870</pub-id><pub-id pub-id-type="pmcid">PMC4664963</pub-id></mixed-citation></ref><ref id="B644"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serrano-Aroca</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tu&#241;&#243;n-Molina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seyran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Pal Choudhury</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Carbon-based nanomaterials: Promising antiviral agents to combat COVID-19 in the microbial-resistant era</article-title>. <source>ACS Nano</source><volume>15</volume>, <fpage>8069</fpage>&#8211;<lpage>8086</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c00629</pub-id><pub-id pub-id-type="pmid">33826850</pub-id></mixed-citation></ref><ref id="B645"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Setti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Passarini</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Gennaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barbieri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Borelli</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Airborne transmission route of COVID-19: Why 2 meters/6 feet of inter-personal distance could not Be enough</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>17</volume>, <fpage>2932</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph17082932</pub-id><pub-id pub-id-type="pmid">32340347</pub-id><pub-id pub-id-type="pmcid">PMC7215485</pub-id></mixed-citation></ref><ref id="B646"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaffer</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>15 drugs being tested to treat COVID-19 and how they would work</article-title>. <source>Nat. Med.</source><pub-id pub-id-type="doi">10.1038/d41591-020-00019-9</pub-id><pub-id pub-id-type="pmid">32415251</pub-id></mixed-citation></ref><ref id="B647"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ugozzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otten</surname><given-names>G. R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance</article-title>. <source>J. Pharm. Sci.</source><volume>104</volume>, <fpage>1352</fpage>&#8211;<lpage>1361</lpage>. <pub-id pub-id-type="doi">10.1002/jps.24337</pub-id><pub-id pub-id-type="pmid">25600347</pub-id></mixed-citation></ref><ref id="B648"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Cell entry mechanisms of SARS-CoV-2</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume>, <fpage>11727</fpage>&#8211;<lpage>11734</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2003138117</pub-id><pub-id pub-id-type="pmid">32376634</pub-id><pub-id pub-id-type="pmcid">PMC7260975</pub-id></mixed-citation></ref><ref id="B649"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aihara</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title>. <source>Nature</source><volume>581</volume>, <fpage>221</fpage>&#8211;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id><pub-id pub-id-type="pmid">32225175</pub-id><pub-id pub-id-type="pmcid">PMC7328981</pub-id></mixed-citation></ref><ref id="B650"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of pandemic outbreak on economies: Evidence from business history context</article-title>. <source>Front. Public Health</source><volume>9</volume>, <fpage>632043</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2021.632043</pub-id><pub-id pub-id-type="pmid">33777885</pub-id><pub-id pub-id-type="pmcid">PMC7994505</pub-id></mixed-citation></ref><ref id="B651"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankar</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>The impact of COVID-19 on IT services industry - expected transformations</article-title>. <source>Brit. J. Manage.</source><volume>31</volume>, <fpage>450</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12423</pub-id></mixed-citation></ref><ref id="B652"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dixit</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Covaxin: An overview of its immunogenicity and safety trials in India</article-title>. <source>Bioinformation</source><volume>17</volume>, <fpage>840</fpage>&#8211;<lpage>845</lpage>. <pub-id pub-id-type="doi">10.6026/97320630017840</pub-id><pub-id pub-id-type="pmid">35574502</pub-id><pub-id pub-id-type="pmcid">PMC9070630</pub-id></mixed-citation></ref><ref id="B653"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Amankwah-Amoah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 pandemic in the new era of big data analytics: Methodological innovations and future research directions</article-title>. <source>Brit. J. Manage.</source><volume>32</volume>, <fpage>1164</fpage>&#8211;<lpage>1183</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12441</pub-id></mixed-citation></ref><ref id="B654"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shereen</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses</article-title>. <source>J. Adv. Res.</source><volume>24</volume>, <fpage>91</fpage>&#8211;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmid">32257431</pub-id><pub-id pub-id-type="pmcid">PMC7113610</pub-id></mixed-citation></ref><ref id="B655"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H. H.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain</article-title>. <source>Virol. J.</source><volume>9</volume>, <fpage>215</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422x-9-215</pub-id><pub-id pub-id-type="pmid">22995185</pub-id><pub-id pub-id-type="pmcid">PMC3489719</pub-id></mixed-citation></ref><ref id="B656"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro</surname><given-names>T.</given-names></name></person-group><collab>Food and Drug Administration</collab> (<year>2021</year>). <article-title>Allergic reactions including anaphylaxis After receipt of the first dose of pfizer-BioNTech COVID-19 vaccine - United States, december 14-23, 2020</article-title>. <source>MMWR. Morb. Mortal. Wkly. Rep.</source><volume>70</volume>, <fpage>46</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7002e1</pub-id><pub-id pub-id-type="pmid">33444297</pub-id><pub-id pub-id-type="pmcid">PMC7808711</pub-id></mixed-citation></ref><ref id="B657"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grewe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bojkova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity</article-title>. <source>Nature</source><volume>587</volume>, <fpage>657</fpage>&#8211;<lpage>662</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2601-5</pub-id><pub-id pub-id-type="pmid">32726803</pub-id><pub-id pub-id-type="pmcid">PMC7116779</pub-id></mixed-citation></ref><ref id="B658"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O. A.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title>. <source>Nat. Nanotechnol.</source><volume>15</volume>, <fpage>646</fpage>&#8211;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id></mixed-citation></ref><ref id="B659"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhikha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoosain</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Archary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy of NVX-CoV2373 covid-19 vaccine against the B.1.351 variant</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>384</volume>, <fpage>1899</fpage>&#8211;<lpage>1909</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2103055</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id><pub-id pub-id-type="pmid">33951374</pub-id></mixed-citation></ref><ref id="B660"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shive</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J. M.</given-names></name></person-group> (<year>1997</year>). <article-title>Biodegradation and biocompatibility of PLA and PLGA microspheres</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>28</volume>, <fpage>5</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/s0169-409x(97)00048-3</pub-id><pub-id pub-id-type="pmid">10837562</pub-id></mixed-citation></ref><ref id="B661"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singanayagam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hakki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dunning</surname><given-names>J.</given-names></name><name name-style="western"><surname>Madon</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Crone</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Koycheva</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: A prospective, longitudinal, cohort study</article-title>. <source>Lancet Infect. Dis.</source><volume>22</volume>, <fpage>183</fpage>&#8211;<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00648-4</pub-id><pub-id pub-id-type="pmid">34756186</pub-id><pub-id pub-id-type="pmcid">PMC8554486</pub-id></mixed-citation></ref><ref id="B662"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Burn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sivan</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>A letter in response to the SIMFER document on the impact of COVID-19 on Italian rehabilitation services and activities</article-title>. <source>Eur. J. Phys. Rehabil. Med.</source><volume>56</volume>, <fpage>368</fpage>&#8211;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.23736/s1973-9087.20.06296-6</pub-id><pub-id pub-id-type="pmid">32293816</pub-id></mixed-citation></ref><ref id="B663"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mcarthur</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mossman</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Evolutionary trajectory of SARS-CoV-2 and emerging variants</article-title>. <source>Virol. J.</source><volume>18</volume>, <fpage>166</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-021-01633-w</pub-id><pub-id pub-id-type="pmid">34389034</pub-id><pub-id pub-id-type="pmcid">PMC8361246</pub-id></mixed-citation></ref><ref id="B664"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivakumar</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Safhi</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Kannadasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sukumaran</surname><given-names>N.</given-names></name></person-group> (<year>2011</year>). <article-title>Vaccine adjuvants - current status and prospects on controlled release adjuvancity</article-title>. <source>Saudi Pharm. J.</source><volume>19</volume>, <fpage>197</fpage>&#8211;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsps.2011.06.003</pub-id><pub-id pub-id-type="pmid">23960760</pub-id><pub-id pub-id-type="pmcid">PMC3744968</pub-id></mixed-citation></ref><ref id="B665"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Assessing viral shedding and infectivity of asymptomatic or mildly symptomatic patients with COVID-19 in a later phase</article-title>. <source>J. Clin. Med.</source><volume>9</volume>, <fpage>2924</fpage>. <pub-id pub-id-type="doi">10.3390/jcm9092924</pub-id><pub-id pub-id-type="pmid">32927798</pub-id><pub-id pub-id-type="pmcid">PMC7563591</pub-id></mixed-citation></ref><ref id="B666"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohrabi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G.</given-names></name><name name-style="western"><surname>Franchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kerwan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soleil</surname><given-names>C. D. M. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training - a review</article-title>. <source>Int. J. Surg.</source><volume>86</volume>, <fpage>57</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijsu.2020.12.008</pub-id><pub-id pub-id-type="pmid">33444873</pub-id><pub-id pub-id-type="pmcid">PMC7833269</pub-id></mixed-citation></ref><ref id="B667"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommerstein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fux</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Vuichard-Gysin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marschall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Balmelli</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19</article-title>. <source>Antimicrob. Resist. Infect. Control</source><volume>9</volume>, <fpage>100</fpage>. <pub-id pub-id-type="doi">10.1186/s13756-020-00763-0</pub-id><pub-id pub-id-type="pmid">32631450</pub-id><pub-id pub-id-type="pmcid">PMC7336106</pub-id></mixed-citation></ref><ref id="B668"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Immunological and inflammatory profiles in mild and severe cases of COVID-19</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>3410</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17240-2</pub-id><pub-id pub-id-type="pmid">32641700</pub-id><pub-id pub-id-type="pmcid">PMC7343781</pub-id></mixed-citation></ref><ref id="B669"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19</article-title>. <source>Korean J. Intern. Med.</source><volume>36</volume>, <fpage>11</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.3904/kjim.2020.325</pub-id><pub-id pub-id-type="pmid">32972123</pub-id><pub-id pub-id-type="pmcid">PMC7820639</pub-id></mixed-citation></ref><ref id="B670"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sonnleitner</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Prelog</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sonnleitner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinterbichler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Halbfurter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kopecky</surname><given-names>D. B. C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host</article-title>. <source>Nat. Commun.</source><volume>13</volume>, <fpage>2560</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-30163-4</pub-id><pub-id pub-id-type="pmid">35538074</pub-id><pub-id pub-id-type="pmcid">PMC9090742</pub-id></mixed-citation></ref><ref id="B671"><mixed-citation publication-type="webpage"><collab>Sonovia-Sonomask</collab> (<year>2022</year>). <article-title>Sonovia-Sonomask</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sonoviastore.com/" ext-link-type="uri">https://sonoviastore.com/</ext-link></comment></mixed-citation></ref><ref id="B672"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chiani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farhangi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mehrabi</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Nourouzian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raahemifar</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Anti-COVID-19 nanomaterials: Directions to improve prevention, diagnosis, and treatment</article-title>. <source>Nanomater. (Basel)</source><volume>12</volume>, <fpage>783</fpage>. <pub-id pub-id-type="doi">10.3390/nano12050783</pub-id><pub-id pub-id-type="pmcid">PMC8912597</pub-id><pub-id pub-id-type="pmid">35269270</pub-id></mixed-citation></ref><ref id="B673"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sportelli</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Izzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kukushkina</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>S. I.</given-names></name><name name-style="western"><surname>Picca</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Ditaranto</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Can nanotechnology and materials science help the fight against SARS-CoV-2?</article-title><source>Nanomater. (Basel)</source><volume>10</volume>, <fpage>802</fpage>. <pub-id pub-id-type="doi">10.3390/nano10040802</pub-id><pub-id pub-id-type="pmcid">PMC7221591</pub-id><pub-id pub-id-type="pmid">32326343</pub-id></mixed-citation></ref><ref id="B674"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Groot</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Immunogenicity of the Ad26.COV2.S vaccine for COVID-19</article-title>. <source>Jama</source><volume>325</volume>, <fpage>1535</fpage>&#8211;<lpage>1544</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.3645</pub-id><pub-id pub-id-type="pmid">33704352</pub-id><pub-id pub-id-type="pmcid">PMC7953339</pub-id></mixed-citation></ref><ref id="B675"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#345;&#237;&#382;ov&#225;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bart&#367;&#328;kov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smr&#382;</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Can wearing face masks in public affect transmission route and viral load in COVID-19?</article-title><source>Cent. Eur. J. Public Health</source><volume>28</volume>, <fpage>161</fpage>&#8211;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.21101/cejph.a6290</pub-id><pub-id pub-id-type="pmid">32592550</pub-id></mixed-citation></ref><ref id="B676"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>St&#252;der</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petit</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Engelen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mendoza-Parra</surname><given-names>M. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Real-time SARS-CoV-2 diagnostic and variants tracking over multiple candidates using nanopore DNA sequencing</article-title>. <source>Sci. Rep.</source><volume>11</volume>, <fpage>15869</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-95563-w</pub-id><pub-id pub-id-type="pmid">34354202</pub-id><pub-id pub-id-type="pmcid">PMC8342707</pub-id></mixed-citation></ref><ref id="B677"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lausted</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>C. L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19</article-title>. <source>Cell</source><volume>183</volume>, <fpage>1479e1420</fpage>&#8211;<lpage>1495.e20</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.037</pub-id><pub-id pub-id-type="pmid">33171100</pub-id><pub-id pub-id-type="pmcid">PMC7598382</pub-id></mixed-citation></ref><ref id="B678"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>T. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Self-assembled peptide nanomaterials for biomedical applications: Promises and pitfalls</article-title>. <source>Int. J. Nanomedicine</source><volume>12</volume>, <fpage>73</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s117501</pub-id><pub-id pub-id-type="pmid">28053525</pub-id><pub-id pub-id-type="pmcid">PMC5191618</pub-id></mixed-citation></ref><ref id="B679"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T. Z.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2</article-title>. <source>Cell Res.</source><volume>31</volume>, <fpage>1011</fpage>&#8211;<lpage>1023</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-021-00531-8</pub-id><pub-id pub-id-type="pmid">34267349</pub-id><pub-id pub-id-type="pmcid">PMC8280646</pub-id></mixed-citation></ref><ref id="B680"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Mcdonald</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Isolation of SARS-CoV-2 in viral cell culture in immunocompromised patients with persistently positive RT-PCR results</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>12</volume>, <fpage>804175</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2022.804175</pub-id><pub-id pub-id-type="pmid">35186791</pub-id><pub-id pub-id-type="pmcid">PMC8847756</pub-id></mixed-citation></ref><ref id="B681"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surnar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kamran</surname><given-names>M. Z.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19</article-title>. <source>ACS Pharmacol. Transl. Sci.</source><volume>3</volume>, <fpage>1371</fpage>&#8211;<lpage>1380</lpage>. <pub-id pub-id-type="doi">10.1021/acsptsci.0c00179</pub-id><pub-id pub-id-type="pmid">33330844</pub-id><pub-id pub-id-type="pmcid">PMC7724756</pub-id></mixed-citation></ref><ref id="B682"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svitkin</surname><given-names>Y. V.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>T.</given-names></name><name name-style="western"><surname>Presnyak</surname><given-names>V.</given-names></name><name name-style="western"><surname>John</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sonenberg</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>). <article-title>N1-methyl-pseudouridine in mRNA enhances translation through eIF2&#945;-dependent and independent mechanisms by increasing ribosome density</article-title>. <source>Nucleic Acids Res.</source><volume>45</volume>, <fpage>6023</fpage>&#8211;<lpage>6036</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx135</pub-id><pub-id pub-id-type="pmid">28334758</pub-id><pub-id pub-id-type="pmcid">PMC5449617</pub-id></mixed-citation></ref><ref id="B683"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>I. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Why the mask? The effectiveness of face masks in preventing the spread of respiratory infections such as COVID-19 - a home testing protocol</article-title>. <source>J. Med. Eng. Technol.</source><volume>44</volume>, <fpage>334</fpage>&#8211;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1080/03091902.2020.1797198</pub-id><pub-id pub-id-type="pmid">32716230</pub-id></mixed-citation></ref><ref id="B684"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swanson</surname><given-names>P. A.</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Padilla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoyland</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mcglinchey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fields</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T(H)1 response with a diverse TCR repertoire</article-title>. <source>Sci. Transl. Med.</source><volume>13</volume>, <fpage>eabj7211</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abj7211</pub-id><pub-id pub-id-type="pmid">34591596</pub-id><pub-id pub-id-type="pmcid">PMC9924073</pub-id></mixed-citation></ref><ref id="B685"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabaeizadeh</surname><given-names>S. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Airborne transmission of COVID-19 and the role of face mask to prevent it: A systematic review and meta-analysis</article-title>. <source>Eur. J. Med. Res.</source><volume>26</volume>, <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1186/s40001-020-00475-6</pub-id><pub-id pub-id-type="pmid">33388089</pub-id><pub-id pub-id-type="pmcid">PMC7776300</pub-id></mixed-citation></ref><ref id="B686"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Drelich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Luchsinger</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2</article-title>. <source>Cell Res.</source><volume>30</volume>, <fpage>932</fpage>&#8211;<lpage>935</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-020-0387-5</pub-id><pub-id pub-id-type="pmid">32759966</pub-id><pub-id pub-id-type="pmcid">PMC7403570</pub-id></mixed-citation></ref><ref id="B687"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talebian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conde</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Why go NANO on COVID-19 pandemic?</article-title><source>Matter</source><volume>3</volume>, <fpage>598</fpage>&#8211;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.matt.2020.08.005</pub-id><pub-id pub-id-type="pmid">32905308</pub-id><pub-id pub-id-type="pmcid">PMC7466941</pub-id></mixed-citation></ref><ref id="B688"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Viral transmission and clinical features in asymptomatic carriers of SARS-CoV-2 in wuhan, China</article-title>. <source>Front. Med.</source><volume>7</volume>, <fpage>547</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2020.00547</pub-id><pub-id pub-id-type="pmcid">PMC7461982</pub-id><pub-id pub-id-type="pmid">33015099</pub-id></mixed-citation></ref><ref id="B689"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Rijal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rahikainen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keeble</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Schimanski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>542</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20654-7</pub-id><pub-id pub-id-type="pmid">33483491</pub-id><pub-id pub-id-type="pmcid">PMC7822889</pub-id></mixed-citation></ref><ref id="B690"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jaimes</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Bidon</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Straus</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2021</year>). <article-title>Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: Potential role of proteases beyond furin</article-title>. <source>ACS Infect. Dis.</source><volume>7</volume>, <fpage>264</fpage>&#8211;<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.0c00701</pub-id><pub-id pub-id-type="pmid">33432808</pub-id><pub-id pub-id-type="pmcid">PMC7839419</pub-id></mixed-citation></ref><ref id="B691"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Do&#287;anay</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;ner</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Azap</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey</article-title>. <source>Lancet</source><volume>398</volume>, <fpage>213</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(21)01429-x</pub-id><pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></mixed-citation></ref><ref id="B692"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tzou</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Nouhin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kosakovsky Pond</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The biological and clinical significance of emerging SARS-CoV-2 variants</article-title>. <source>Nat. Rev. Genet.</source><volume>22</volume>, <fpage>757</fpage>&#8211;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-021-00408-x</pub-id><pub-id pub-id-type="pmid">34535792</pub-id><pub-id pub-id-type="pmcid">PMC8447121</pub-id></mixed-citation></ref><ref id="B693"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatsis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>H. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Adenoviruses as vaccine vectors</article-title>. <source>Mol. Ther.</source><volume>10</volume>, <fpage>616</fpage>&#8211;<lpage>629</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2004.07.013</pub-id><pub-id pub-id-type="pmid">15451446</pub-id><pub-id pub-id-type="pmcid">PMC7106330</pub-id></mixed-citation></ref><ref id="B694"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teijaro</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Farber</surname><given-names>D. L.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 vaccines: Modes of immune activation and future challenges</article-title>. <source>Nat. Rev. Immunol.</source><volume>21</volume>, <fpage>195</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-021-00526-x</pub-id><pub-id pub-id-type="pmid">33674759</pub-id><pub-id pub-id-type="pmcid">PMC7934118</pub-id></mixed-citation></ref><ref id="B695"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenchov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bird</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curtze</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2021</year>). <article-title>Lipid nanoparticles-from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement</article-title>. <source>ACS Nano</source><volume>15</volume>, <fpage>16982</fpage>&#8211;<lpage>17015</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c04996</pub-id><pub-id pub-id-type="pmid">34181394</pub-id></mixed-citation></ref><ref id="B696"><mixed-citation publication-type="journal"><collab>The-Covid-Host-Genetics-Initiative</collab> (<year>2020</year>). <article-title>The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic</article-title>. <source>Eur. J. Hum. Genet.</source><volume>28</volume>, <fpage>715</fpage>&#8211;<lpage>718</lpage>. <pub-id pub-id-type="doi">10.1038/s41431-020-0636-6</pub-id><pub-id pub-id-type="pmid">32404885</pub-id><pub-id pub-id-type="pmcid">PMC7220587</pub-id></mixed-citation></ref><ref id="B697"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Naleway</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Tyner</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Meece</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>385</volume>, <fpage>320</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2107058</pub-id><pub-id pub-id-type="pmcid">PMC8262622</pub-id><pub-id pub-id-type="pmid">34192428</pub-id></mixed-citation></ref><ref id="B698"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dufva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>M. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Homogeneous circle-to-circle amplification for real-time optomagnetic detection of SARS-CoV-2 RdRp coding sequence</article-title>. <source>Biosens. Bioelectron. X.</source><volume>165</volume>, <fpage>112356</fpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2020.112356</pub-id><pub-id pub-id-type="pmid">32510339</pub-id></mixed-citation></ref><ref id="B699"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>372</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmid">33446655</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id></mixed-citation></ref><ref id="B700"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiboni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casettari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Illum</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?</article-title><source>Int. J. Pharm. X.</source><volume>603</volume>, <fpage>120686</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120686</pub-id><pub-id pub-id-type="pmcid">PMC8099545</pub-id><pub-id pub-id-type="pmid">33964339</pub-id></mixed-citation></ref><ref id="B701"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tidu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janvier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sosnowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hammann</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation</article-title>. <source>Rna</source><volume>27</volume>, <fpage>253</fpage>&#8211;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1261/rna.078121.120</pub-id><pub-id pub-id-type="pmid">33268501</pub-id><pub-id pub-id-type="pmcid">PMC7901841</pub-id></mixed-citation></ref><ref id="B702"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tikellis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M. C.</given-names></name></person-group> (<year>2012</year>). <article-title>Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and </article-title>d<article-title>isease</article-title>. <source>Int. J. Pept.</source><volume>2012</volume>, <fpage>256294</fpage>. <pub-id pub-id-type="doi">10.1155/2012/256294</pub-id><pub-id pub-id-type="pmcid">PMC3321295</pub-id><pub-id pub-id-type="pmid">22536270</pub-id></mixed-citation></ref><ref id="B703"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinkle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mcneil</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>M&#252;hlebach</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bawa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barenholz</surname><given-names>Y. C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Nanomedicines: Addressing the scientific and regulatory gap</article-title>. <source>Ann. N. Y. Acad. Sci.</source><volume>1313</volume>, <fpage>35</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1111/nyas.12403</pub-id><pub-id pub-id-type="pmid">24673240</pub-id></mixed-citation></ref><ref id="B704"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>To</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>I. F.</given-names></name><name name-style="western"><surname>Ip</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Coronavirus disease 2019 (COVID-19) Re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing</article-title>. <source>Clin. Infect. Dis.</source><volume>73</volume>, <fpage>e2946</fpage>&#8211;<lpage>e2951</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1275</pub-id><pub-id pub-id-type="pmid">32840608</pub-id><pub-id pub-id-type="pmcid">PMC7499500</pub-id></mixed-citation></ref><ref id="B705"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toback</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galloway</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Swift</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial</article-title>. <source>Lancet. Respir. Med.</source><volume>10</volume>, <fpage>167</fpage>&#8211;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(21)00409-4</pub-id><pub-id pub-id-type="pmid">34800364</pub-id><pub-id pub-id-type="pmcid">PMC8598212</pub-id></mixed-citation></ref><ref id="B706"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toscano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palmerini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ravaglia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Invernizzi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cuzzoni</surname><given-names>M. G.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Guillain-barr&#233; syndrome associated with SARS-CoV-2</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>2574</fpage>&#8211;<lpage>2576</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2009191</pub-id><pub-id pub-id-type="pmcid">PMC7182017</pub-id><pub-id pub-id-type="pmid">32302082</pub-id></mixed-citation></ref><ref id="B707"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsivgoulis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palaiodimou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Katsanos</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Caso</surname><given-names>V.</given-names></name><name name-style="western"><surname>K&#246;hrmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Neurological manifestations and implications of COVID-19 pandemic</article-title>. <source>Ther. Adv. Neurol. Disord.</source><volume>13</volume>, <fpage>175628642093203</fpage>. <pub-id pub-id-type="doi">10.1177/1756286420932036</pub-id><pub-id pub-id-type="pmcid">PMC7284455</pub-id><pub-id pub-id-type="pmid">32565914</pub-id></mixed-citation></ref><ref id="B708"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuaillon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bollor&#233;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pisoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Debiesse</surname><given-names>S.</given-names></name><name name-style="western"><surname>Renault</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marie</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients</article-title>. <source>J. Infect.</source><volume>81</volume>, <fpage>e39</fpage>&#8211;<lpage>e45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.05.077</pub-id><pub-id pub-id-type="pmcid">PMC7834649</pub-id><pub-id pub-id-type="pmid">32504735</pub-id></mixed-citation></ref><ref id="B709"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>O'halloran</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Kalaidina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J. Q.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses</article-title>. <source>Nature</source><volume>596</volume>, <fpage>109</fpage>&#8211;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03738-2</pub-id><pub-id pub-id-type="pmid">34182569</pub-id><pub-id pub-id-type="pmcid">PMC8935394</pub-id></mixed-citation></ref><ref id="B710"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uhm</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Hyun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>S. J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Patterns of viral clearance in the natural course of asymptomatic COVID-19: Comparison with symptomatic non-severe COVID-19</article-title>. <source>Int. J. Infect. Dis.</source><volume>99</volume>, <fpage>279</fpage>&#8211;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.070</pub-id><pub-id pub-id-type="pmid">32763446</pub-id><pub-id pub-id-type="pmcid">PMC7403105</pub-id></mixed-citation></ref><ref id="B711"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Underwood</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Yankie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nawrocki</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Palanigobu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gotvyanskyy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Calhoun</surname><given-names>V. C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Rapid automated validation, annotation and publication of SARS-CoV-2 sequences to GenBank</article-title>. <source>Database (Oxford).</source><volume>2022</volume>, <fpage>baac006</fpage>. <pub-id pub-id-type="doi">10.1093/database/baac006</pub-id><pub-id pub-id-type="pmid">35230423</pub-id><pub-id pub-id-type="pmcid">PMC9216562</pub-id></mixed-citation></ref><ref id="B712"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacca</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fiannaca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tramuto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cancila</surname><given-names>V.</given-names></name><name name-style="western"><surname>La Paglia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mazzucco</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Direct RNA nanopore sequencing of SARS-CoV-2 extracted from critical material from swabs</article-title>. <source>Life (Basel)</source><volume>12</volume>, <fpage>69</fpage>. <pub-id pub-id-type="doi">10.3390/life12010069</pub-id><pub-id pub-id-type="pmid">35054462</pub-id><pub-id pub-id-type="pmcid">PMC8778588</pub-id></mixed-citation></ref><ref id="B713"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vahedifard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chakravarthy</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Nanomedicine for COVID-19: The role of nanotechnology in the treatment and diagnosis of COVID-19</article-title>. <source>emergent Mat.</source><volume>4</volume>, <fpage>75</fpage>&#8211;<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1007/s42247-021-00168-8</pub-id><pub-id pub-id-type="pmcid">PMC7881345</pub-id><pub-id pub-id-type="pmid">33615140</pub-id></mixed-citation></ref><ref id="B714"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valcourt</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Scully</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Day</surname><given-names>E. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Nanoparticle-Mediated Co-delivery of notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>3378</fpage>&#8211;<lpage>3388</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b09263</pub-id><pub-id pub-id-type="pmid">32083466</pub-id><pub-id pub-id-type="pmcid">PMC7098846</pub-id></mixed-citation></ref><ref id="B715"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valdez-Salas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beltran-Partida</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Salvador-Carlos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valdez-Salas</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Curiel-Alvarez</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Promotion of surgical masks antimicrobial activity by disinfection and impregnation with disinfectant silver nanoparticles</article-title>. <source>Int. J. Nanomedicine</source><volume>16</volume>, <fpage>2689</fpage>&#8211;<lpage>2702</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s301212</pub-id><pub-id pub-id-type="pmid">33854315</pub-id><pub-id pub-id-type="pmcid">PMC8039202</pub-id></mixed-citation></ref><ref id="B716"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valencak</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Csiszar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Szalai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Podlutsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tarantini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fazekas-Pongor</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Animal reservoirs of SARS-CoV-2: Calculable COVID-19 risk for older adults from animal to human transmission</article-title>. <source>Geroscience</source><volume>43</volume>, <fpage>2305</fpage>&#8211;<lpage>2320</lpage>. <pub-id pub-id-type="doi">10.1007/s11357-021-00444-9</pub-id><pub-id pub-id-type="pmid">34460063</pub-id><pub-id pub-id-type="pmcid">PMC8404404</pub-id></mixed-citation></ref><ref id="B717"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jankelow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kindratenko</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ganguli</surname><given-names>A.</given-names></name><name name-style="western"><surname>White</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 point-of-care diagnostics: Present and future</article-title>. <source>ACS Nano</source><volume>15</volume>, <fpage>7899</fpage>&#8211;<lpage>7906</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.1c02981</pub-id><pub-id pub-id-type="pmid">33984237</pub-id></mixed-citation></ref><ref id="B718"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Jeught</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Koker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bialkowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tjok Joe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perche</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety</article-title>. <source>ACS Nano</source><volume>12</volume>, <fpage>9815</fpage>&#8211;<lpage>9829</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.8b00966</pub-id><pub-id pub-id-type="pmid">30256609</pub-id></mixed-citation></ref><ref id="B719"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dijk</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Jaszczyszyn</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Naquin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thermes</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>The third revolution in sequencing technology</article-title>. <source>Trends Genet.</source><volume>34</volume>, <fpage>666</fpage>&#8211;<lpage>681</lpage>. <pub-id pub-id-type="doi">10.1016/j.tig.2018.05.008</pub-id><pub-id pub-id-type="pmid">29941292</pub-id></mixed-citation></ref><ref id="B720"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dongen</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Berendsen</surname><given-names>J. T. W.</given-names></name><name name-style="western"><surname>Steenbergen</surname><given-names>R. D. M.</given-names></name><name name-style="western"><surname>Wolthuis</surname><given-names>R. M. F.</given-names></name><name name-style="western"><surname>Eijkel</surname><given-names>J. C. T.</given-names></name><name name-style="western"><surname>Segerink</surname><given-names>L. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Point-of-care CRISPR/Cas nucleic acid detection: Recent advances, challenges and opportunities</article-title>. <source>Biosens. Bioelectron. X.</source><volume>166</volume>, <fpage>112445</fpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2020.112445</pub-id><pub-id pub-id-type="pmcid">PMC7382963</pub-id><pub-id pub-id-type="pmid">32758911</pub-id></mixed-citation></ref><ref id="B721"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doorn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hak</surname><given-names>E.</given-names></name></person-group> (<year>2016</year>). <article-title>Safety and tolerability evaluation of the use of montanide ISA&#8482;51 as vaccine adjuvant: A systematic review</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>12</volume>, <fpage>159</fpage>&#8211;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1071455</pub-id><pub-id pub-id-type="pmid">26378866</pub-id><pub-id pub-id-type="pmcid">PMC4962750</pub-id></mixed-citation></ref><ref id="B722"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1564</fpage>&#8211;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2004973</pub-id><pub-id pub-id-type="pmcid">PMC7121658</pub-id><pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation></ref><ref id="B723"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vandenberg</surname><given-names>O.</given-names></name><name name-style="western"><surname>Martiny</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rochas</surname><given-names>O.</given-names></name><name name-style="western"><surname>Van Belkum</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kozlakidis</surname><given-names>Z.</given-names></name></person-group> (<year>2021</year>). <article-title>Considerations for diagnostic COVID-19 tests</article-title>. <source>Nat. Rev. Microbiol.</source><volume>19</volume>, <fpage>171</fpage>&#8211;<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1038/s41579-020-00461-z</pub-id><pub-id pub-id-type="pmid">33057203</pub-id><pub-id pub-id-type="pmcid">PMC7556561</pub-id></mixed-citation></ref><ref id="B724"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varahachalam</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Lahooti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chamaneh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chhibber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanomedicine for the SARS-CoV-2: State-of-the-Art and future prospects</article-title>. <source>Int. J. Nanomedicine</source><volume>16</volume>, <fpage>539</fpage>&#8211;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.s283686</pub-id><pub-id pub-id-type="pmid">33519200</pub-id><pub-id pub-id-type="pmcid">PMC7837559</pub-id></mixed-citation></ref><ref id="B725"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varypataki</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Van Der Maaden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>). <article-title>Cationic liposomes loaded with a synthetic long peptide and poly(I:C): A defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity</article-title>. <source>Aaps J.</source><volume>17</volume>, <fpage>216</fpage>&#8211;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-014-9686-4</pub-id><pub-id pub-id-type="pmid">25387996</pub-id><pub-id pub-id-type="pmcid">PMC4287297</pub-id></mixed-citation></ref><ref id="B726"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazquez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Negatu</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Dittmar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>H. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms</article-title>. <source>PLoS One</source><volume>16</volume>, <fpage>e0253089</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0253089</pub-id><pub-id pub-id-type="pmid">34166398</pub-id><pub-id pub-id-type="pmcid">PMC8224853</pub-id></mixed-citation></ref><ref id="B727"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbeke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lentacker</surname><given-names>I.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Dewitte</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>The dawn of mRNA vaccines: The COVID-19 case</article-title>. <source>J. Control. Release</source><volume>333</volume>, <fpage>511</fpage>&#8211;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2021.03.043</pub-id><pub-id pub-id-type="pmid">33798667</pub-id><pub-id pub-id-type="pmcid">PMC8008785</pub-id></mixed-citation></ref><ref id="B728"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbeke</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Will the COVID-19 pandemic really change the governance of global value chains?</article-title><source>Brit. J. Manage.</source><volume>31</volume>, <fpage>444</fpage>&#8211;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12422</pub-id></mixed-citation></ref><ref id="B729"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdoni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gervasoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruggeri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciuffreda</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>An outbreak of severe kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>1771</fpage>&#8211;<lpage>1778</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31103-x</pub-id><pub-id pub-id-type="pmid">32410760</pub-id><pub-id pub-id-type="pmcid">PMC7220177</pub-id></mixed-citation></ref><ref id="B730"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viehweger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krautwurst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lamkiewicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Madhugiri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ziebuhr</surname><given-names>J.</given-names></name><name name-style="western"><surname>H&#246;lzer</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Direct RNA nanopore sequencing of full-length coronavirus genomes provides novel insights into structural variants and enables modification analysis</article-title>. <source>Genome Res.</source><volume>29</volume>, <fpage>1545</fpage>&#8211;<lpage>1554</lpage>. <pub-id pub-id-type="doi">10.1101/gr.247064.118</pub-id><pub-id pub-id-type="pmid">31439691</pub-id><pub-id pub-id-type="pmcid">PMC6724671</pub-id></mixed-citation></ref><ref id="B731"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villoutreix</surname><given-names>B. O.</given-names></name><name name-style="western"><surname>Badiola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Khatib</surname><given-names>A.-M.</given-names></name></person-group> (<year>2022</year>). <article-title>Furin and COVID-19: Structure, function and chemoinformatic analysis of representative active site inhibitors</article-title>. <source>Front. Drug Discov. (Lausanne).</source><volume>2</volume>. <pub-id pub-id-type="doi">10.3389/fddsv.2022.899239</pub-id></mixed-citation></ref><ref id="B732"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Waddington</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mytton</surname><given-names>O.</given-names></name><name name-style="western"><surname>Booy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Transmission of SARS-CoV-2 by children and young people in households and schools: A meta-analysis of population-based and contact-tracing studies</article-title>. <source>J. Infect.</source><volume>84</volume>, <fpage>361</fpage>&#8211;<lpage>382</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2021.12.026</pub-id><pub-id pub-id-type="pmid">34953911</pub-id><pub-id pub-id-type="pmcid">PMC8694793</pub-id></mixed-citation></ref><ref id="B733"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitiello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferrara</surname><given-names>F.</given-names></name><name name-style="western"><surname>Troiano</surname><given-names>V.</given-names></name><name name-style="western"><surname>La Porta</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 vaccines and decreased transmission of SARS-CoV-2</article-title>. <source>Inflammopharmacology</source><volume>29</volume>, <fpage>1357</fpage>&#8211;<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1007/s10787-021-00847-2</pub-id><pub-id pub-id-type="pmid">34279767</pub-id><pub-id pub-id-type="pmcid">PMC8287551</pub-id></mixed-citation></ref><ref id="B734"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kinnear</surname><given-names>E.</given-names></name><name name-style="western"><surname>Busse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Erbar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>K. C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses</article-title>. <source>Mol. Ther.</source><volume>26</volume>, <fpage>446</fpage>&#8211;<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.017</pub-id><pub-id pub-id-type="pmid">29275847</pub-id><pub-id pub-id-type="pmcid">PMC5835025</pub-id></mixed-citation></ref><ref id="B735"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpatti</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Matranga</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Cortinas</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Delcassian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>K. B.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Glucose-responsive nanoparticles for rapid and extended self-regulated insulin delivery</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>488</fpage>&#8211;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b06395</pub-id><pub-id pub-id-type="pmid">31765558</pub-id></mixed-citation></ref><ref id="B736"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Geidelberg</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England</article-title>. <source>Nature</source><volume>593</volume>, <fpage>266</fpage>&#8211;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03470-x</pub-id><pub-id pub-id-type="pmid">33767447</pub-id></mixed-citation></ref><ref id="B737"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Wintersdorff</surname><given-names>C. J. H.</given-names></name><name name-style="western"><surname>Dingemans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Alphen</surname><given-names>L. B.</given-names></name><name name-style="western"><surname>Wolffs</surname><given-names>P. F. G.</given-names></name><name name-style="western"><surname>Van Der Veer</surname><given-names>B. M. J. W.</given-names></name><name name-style="western"><surname>Hoebe</surname><given-names>C. J. P. A.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Infections with the SARS-CoV-2 Delta variant exhibit fourfold increased viral loads in the upper airways compared to Alpha or non-variants of concern</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>13922</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-18279-5</pub-id><pub-id pub-id-type="pmid">35978025</pub-id><pub-id pub-id-type="pmcid">PMC9382600</pub-id></mixed-citation></ref><ref id="B738"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voskarides</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Animal-to-Human viral transitions: Is SARS-CoV-2 an evolutionarily successful one?</article-title><source>J. Mol. Evol.</source><volume>88</volume>, <fpage>421</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1007/s00239-020-09947-z</pub-id><pub-id pub-id-type="pmid">32377932</pub-id><pub-id pub-id-type="pmcid">PMC7201112</pub-id></mixed-citation></ref><ref id="B739"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S. a. C.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L. Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, south Africa, and the UK</article-title>. <source>Lancet</source><volume>397</volume>, <fpage>99</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></mixed-citation></ref><ref id="B740"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wafa</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A. K.</given-names></name></person-group> (<year>2017</year>). <article-title>The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response</article-title>. <source>Acta Biomater.</source><volume>50</volume>, <fpage>417</fpage>&#8211;<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2017.01.005</pub-id><pub-id pub-id-type="pmid">28063991</pub-id><pub-id pub-id-type="pmcid">PMC5316298</pub-id></mixed-citation></ref><ref id="B741"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wake</surname><given-names>A. D.</given-names></name></person-group> (<year>2022</year>). <article-title>Intrauterine vertical transmission of SARS-CoV-2 infection among confirmed cases of pregnant women: "A double burden for the pregnant women"-A systematic review</article-title>. <source>Glob. Pediatr. Health</source><volume>9</volume>, <fpage>2333794X2210897</fpage>. <pub-id pub-id-type="doi">10.1177/2333794x221089765</pub-id><pub-id pub-id-type="pmcid">PMC8977699</pub-id><pub-id pub-id-type="pmid">35386229</pub-id></mixed-citation></ref><ref id="B742"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Fiala</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wrenn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2</article-title>. <source>Cell.</source><volume>183</volume>, <fpage>1367</fpage>&#8211;<lpage>1382.e17</lpage>. <comment>e1317</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.10.043</pub-id><pub-id pub-id-type="pmid">33160446</pub-id><pub-id pub-id-type="pmcid">PMC7604136</pub-id></mixed-citation></ref><ref id="B743"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mcguire</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group> (<year>2020b</year>). <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell.</source><volume>181</volume>, <fpage>1735</fpage>&#8211;<lpage>2292</lpage>. <comment>e286</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.11.032</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="B744"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study</article-title>. <source>medRxiv.</source>, <volume>2020</volume>.<fpage>20176651</fpage>. <pub-id pub-id-type="doi">10.1101/2020.08.17.20176651</pub-id></mixed-citation></ref><ref id="B745"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E. E.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R. W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Falsey</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Safety and immunogenicity of two RNA-based covid-19 vaccine candidates</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>383</volume>, <fpage>2439</fpage>&#8211;<lpage>2450</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2027906</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id><pub-id pub-id-type="pmid">33053279</pub-id></mixed-citation></ref><ref id="B746"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Receptor recognition by the novel coronavirus from wuhan: An analysis based on decade-long structural studies of SARS coronavirus</article-title>. <source>J. Virol.</source><volume>94</volume>, <fpage>001277</fpage>. <pub-id pub-id-type="doi">10.1128/jvi.00127-20</pub-id><pub-id pub-id-type="pmcid">PMC7081895</pub-id><pub-id pub-id-type="pmid">31996437</pub-id></mixed-citation></ref><ref id="B747"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kream</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Stefano</surname><given-names>G. B.</given-names></name></person-group> (<year>2020a</year>). <article-title>An evidence based perspective on mRNA-SARS-CoV-2 vaccine development</article-title>. <source>Med. Sci. Monit.</source><volume>26</volume>, <fpage>e924700</fpage>. <pub-id pub-id-type="doi">10.12659/msm.924700</pub-id><pub-id pub-id-type="pmid">32366816</pub-id><pub-id pub-id-type="pmcid">PMC7218962</pub-id></mixed-citation></ref><ref id="B748"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2</article-title>. <source>Cell.</source><volume>182</volume>, <fpage>713</fpage>&#8211;<lpage>721.e9</lpage>. <comment>e719</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.008</pub-id><pub-id pub-id-type="pmid">32778225</pub-id><pub-id pub-id-type="pmcid">PMC7275151</pub-id></mixed-citation></ref><ref id="B749"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>J. Q.</given-names></name><name name-style="western"><surname>Du</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells</article-title>. <source>Signal Transduct. Target. Ther.</source><volume>5</volume>, <fpage>283</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00426-x</pub-id><pub-id pub-id-type="pmid">33277466</pub-id><pub-id pub-id-type="pmcid">PMC7714896</pub-id></mixed-citation></ref><ref id="B750"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M. Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D. P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J. M.</given-names></name></person-group> (<year>2020d</year>). <article-title>SARS-CoV-2: Structure, biology, and structure-based therapeutics development</article-title>. <source>Front. Cell. Infect. Microbiol.</source><volume>10</volume>, <fpage>6</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2020.00006</pub-id><pub-id pub-id-type="pmid">33324574</pub-id><pub-id pub-id-type="pmcid">PMC7723891</pub-id></mixed-citation></ref><ref id="B751"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020e</year>). <article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title>. <source>Cell.</source><volume>181</volume>, <fpage>894</fpage>&#8211;<lpage>904.e9</lpage>. <comment>e899</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id><pub-id pub-id-type="pmid">32275855</pub-id><pub-id pub-id-type="pmcid">PMC7144619</pub-id></mixed-citation></ref><ref id="B752"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Han</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020f</year>). <article-title>Detection of SARS-CoV-2 in different types of clinical specimens</article-title>. <source>JAMA</source><volume>323</volume>, <fpage>1843</fpage>&#8211;<lpage>1844</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.3786</pub-id><pub-id pub-id-type="pmid">32159775</pub-id><pub-id pub-id-type="pmcid">PMC7066521</pub-id></mixed-citation></ref><ref id="B753"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020g</year>). <article-title>Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of wuhan, China</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume>, <fpage>2132</fpage>&#8211;<lpage>2138</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa629</pub-id><pub-id pub-id-type="pmid">32442265</pub-id><pub-id pub-id-type="pmcid">PMC7314201</pub-id></mixed-citation></ref><ref id="B754"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X. J.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>TiO2 supported single Ag atoms nanozyme for elimination of SARS-CoV2</article-title>. <source>Nano Today</source><volume>40</volume>, <fpage>101243</fpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2021.101243</pub-id><pub-id pub-id-type="pmid">34249143</pub-id><pub-id pub-id-type="pmcid">PMC8260506</pub-id></mixed-citation></ref><ref id="B755"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>E. Y.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huck</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Jaycox</surname><given-names>J. R.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Diverse functional autoantibodies in patients with COVID-19</article-title>. <source>Nature</source><volume>595</volume>, <fpage>283</fpage>&#8211;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03631-y</pub-id><pub-id pub-id-type="pmid">34010947</pub-id></mixed-citation></ref><ref id="B756"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021c</year>). <article-title>ORF3a protein of severe acute respiratory syndrome coronavirus 2 inhibits interferon-activated janus kinase/signal transducer and activator of transcription signaling via elevating suppressor of cytokine signaling 1</article-title>. <source>Front. Microbiol.</source><volume>12</volume>, <fpage>752597</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.752597</pub-id><pub-id pub-id-type="pmid">34650546</pub-id><pub-id pub-id-type="pmcid">PMC8506155</pub-id></mixed-citation></ref><ref id="B757"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021d</year>). <article-title>SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation</article-title>. <source>Cell. Mol. Immunol.</source><volume>18</volume>, <fpage>945</fpage>&#8211;<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-00619-y</pub-id><pub-id pub-id-type="pmid">33637958</pub-id><pub-id pub-id-type="pmcid">PMC7907794</pub-id></mixed-citation></ref><ref id="B758"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bollas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Au</surname><given-names>K. F.</given-names></name></person-group> (<year>2021e</year>). <article-title>Nanopore sequencing technology, bioinformatics and applications</article-title>. <source>Nat. Biotechnol.</source><volume>39</volume>, <fpage>1348</fpage>&#8211;<lpage>1365</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-021-01108-x</pub-id><pub-id pub-id-type="pmid">34750572</pub-id><pub-id pub-id-type="pmcid">PMC8988251</pub-id></mixed-citation></ref><ref id="B759"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>J. C. C.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Finkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Viant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021f</year>). <article-title>Enhanced SARS-CoV-2 neutralization by dimeric IgA</article-title>. <source>Sci. Transl. Med.</source><volume>13</volume>, <fpage>eabf1555</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.abf1555</pub-id><pub-id pub-id-type="pmid">33288661</pub-id><pub-id pub-id-type="pmcid">PMC7857415</pub-id></mixed-citation></ref><ref id="B760"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hozumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>G. W.</given-names></name></person-group> (<year>2022a</year>). <article-title>Emerging vaccine-breakthrough SARS-CoV-2 variants</article-title>. <source>ACS Infect. Dis.</source><volume>8</volume>, <fpage>546</fpage>&#8211;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00557</pub-id><pub-id pub-id-type="pmid">35133792</pub-id><pub-id pub-id-type="pmcid">PMC8848511</pub-id></mixed-citation></ref><ref id="B761"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2022b</year>). <article-title>Genetic surveillance of five SARS-CoV-2 clinical samples in henan province using nanopore sequencing</article-title>. <source>Front. Immunol.</source><volume>13</volume>, <fpage>814806</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.814806</pub-id><pub-id pub-id-type="pmid">35444655</pub-id><pub-id pub-id-type="pmcid">PMC9013895</pub-id></mixed-citation></ref><ref id="B762"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2022c</year>). <article-title>Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies</article-title>. <source>Nat. Commun.</source><volume>13</volume>, <fpage>871</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-28528-w</pub-id><pub-id pub-id-type="pmid">35169135</pub-id><pub-id pub-id-type="pmcid">PMC8847413</pub-id></mixed-citation></ref><ref id="B763"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wawina-Bokalanga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Logist</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Sinnesael</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Holm</surname><given-names>B.</given-names></name><name name-style="western"><surname>Delforge</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Struyven</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Genomic evidence of co-identification with omicron and delta SARS-CoV-2 variants: A report of two cases</article-title>. <source>Int. J. Infect. Dis.</source><volume>122</volume>, <fpage>212</fpage>&#8211;<lpage>214</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2022.05.043</pub-id><pub-id pub-id-type="pmid">35605952</pub-id><pub-id pub-id-type="pmcid">PMC9121643</pub-id></mixed-citation></ref><ref id="B764"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry</article-title>. <source>Nat. Metab.</source><volume>2</volume>, <fpage>1391</fpage>&#8211;<lpage>1400</lpage>. <pub-id pub-id-type="doi">10.1038/s42255-020-00324-0</pub-id><pub-id pub-id-type="pmid">33244168</pub-id></mixed-citation></ref><ref id="B765"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weisblum</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dasilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poston</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>. <source>Elife</source><volume>9</volume>, <fpage>e61312</fpage>. <pub-id pub-id-type="doi">10.7554/elife.61312</pub-id><pub-id pub-id-type="pmid">33112236</pub-id><pub-id pub-id-type="pmcid">PMC7723407</pub-id></mixed-citation></ref><ref id="B766"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Carriere</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fusco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Capua</surname><given-names>I.</given-names></name><name name-style="western"><surname>Regla-Nava</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Pasquali</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Toward nanotechnology-enabled approaches against the COVID-19 pandemic</article-title>. <source>ACS Nano</source><volume>14</volume>, <fpage>6383</fpage>&#8211;<lpage>6406</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c03697</pub-id><pub-id pub-id-type="pmid">32519842</pub-id></mixed-citation></ref><ref id="B767"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of schools in driving SARS-CoV-2 transmission: Not just an open-and-shut case</article-title>. <source>Cell. Rep. Med.</source><volume>3</volume>, <fpage>100556</fpage>. <pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100556</pub-id><pub-id pub-id-type="pmid">35474742</pub-id><pub-id pub-id-type="pmcid">PMC8858687</pub-id></mixed-citation></ref><ref id="B768"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whittaker</surname><given-names>G. R.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 spike and its adaptable furin cleavage site</article-title>. <source>Lancet Microbe</source><volume>2</volume>, <fpage>e488</fpage>&#8211;<lpage>e489</lpage>. <pub-id pub-id-type="doi">10.1016/s2666-5247(21)00174-9</pub-id><pub-id pub-id-type="pmid">34396356</pub-id><pub-id pub-id-type="pmcid">PMC8346238</pub-id></mixed-citation></ref><ref id="B769"><mixed-citation publication-type="journal"><collab>WHO</collab> (<year>1987</year>). <article-title>Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group on Biologicals</article-title>. <source>World Health Organ. Tech. Rep. Ser.</source><volume>747</volume>, <fpage>1</fpage>&#8211;<lpage>29</lpage>.<pub-id pub-id-type="pmid">3107222</pub-id></mixed-citation></ref><ref id="B770"><mixed-citation publication-type="book"><collab>WHO</collab> (<year>2020</year>). <source>Covid-19 vaccines: Safety surveillance manual</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="B771"><mixed-citation publication-type="webpage"><collab>WHO</collab> (<year>2022</year>). <article-title>Modes of transmission of virus causing COVID-19: Implications for IPC precaution recommendations</article-title>. <comment>Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-%20for-ipc-precaution-recommendations" ext-link-type="uri">https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications- for-ipc-precaution-recommendations</ext-link> (accessed on January 1, 2022)</comment>.</mixed-citation></ref><ref id="B772"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widge</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Durability of responses after SARS-CoV-2 mRNA-1273 vaccination</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>384</volume>, <fpage>80</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2032195</pub-id><pub-id pub-id-type="pmcid">PMC7727324</pub-id><pub-id pub-id-type="pmid">33270381</pub-id></mixed-citation></ref><ref id="B773"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilmes</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glod</surname><given-names>F.</given-names></name><name name-style="western"><surname>Veiber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mombaerts</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in Luxembourg</article-title>. <source>Lancet Regional Health - Eur.</source><volume>4</volume>, <fpage>100056</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100056</pub-id><pub-id pub-id-type="pmcid">PMC7912359</pub-id><pub-id pub-id-type="pmid">33997830</pub-id></mixed-citation></ref><ref id="B774"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkler</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection</article-title>. <source>Cell.</source><volume>184</volume>, <fpage>1804</fpage>&#8211;<lpage>1820.e16</lpage>. <comment>e1816</comment>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.02.026</pub-id><pub-id pub-id-type="pmid">33691139</pub-id><pub-id pub-id-type="pmcid">PMC7879018</pub-id></mixed-citation></ref><ref id="B775"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#246;lfel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Guggemos</surname><given-names>W.</given-names></name><name name-style="western"><surname>Seilmaier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zange</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Virological assessment of hospitalized patients with COVID-2019</article-title>. <source>Nature</source><volume>581</volume>, <fpage>465</fpage>&#8211;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></mixed-citation></ref><ref id="B776"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jassat</surname><given-names>W.</given-names></name><name name-style="western"><surname>Walaza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moultrie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Groome</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in south Africa: A data linkage study</article-title>. <source>Lancet</source><volume>399</volume>, <fpage>437</fpage>&#8211;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(22)00017-4</pub-id><pub-id pub-id-type="pmid">35065011</pub-id><pub-id pub-id-type="pmcid">PMC8769664</pub-id></mixed-citation></ref><ref id="B777"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abdul Aziz</surname><given-names>A. B. Z.</given-names></name><name name-style="western"><surname>Chaw</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mahamud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>Y. R.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>High proportion of asymptomatic and presymptomatic COVID-19 infections in air passengers to Brunei</article-title>. <source>J. Travel Med.</source><volume>27</volume>, <fpage>taaa066</fpage>. <pub-id pub-id-type="doi">10.1093/jtm/taaa066</pub-id><pub-id pub-id-type="pmid">32365178</pub-id><pub-id pub-id-type="pmcid">PMC7239182</pub-id></mixed-citation></ref><ref id="B778"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>J. J.</given-names></name></person-group> (<year>2020b</year>). <article-title>Covid-19 and the digestive system</article-title>. <source>J. Gastroenterology Hepatology</source><volume>35</volume>, <fpage>744</fpage>&#8211;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1111/jgh.15047</pub-id><pub-id pub-id-type="pmid">32215956</pub-id></mixed-citation></ref><ref id="B779"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodruff</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Ramonell</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Cashman</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>N. S.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19</article-title>. <source>Nat. Immunol.</source><volume>21</volume>, <fpage>1506</fpage>&#8211;<lpage>1516</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-020-00814-z</pub-id><pub-id pub-id-type="pmid">33028979</pub-id><pub-id pub-id-type="pmcid">PMC7739702</pub-id></mixed-citation></ref><ref id="B780"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>. <source>Science</source><volume>367</volume>, <fpage>1260</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></mixed-citation></ref><ref id="B781"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Nervous system involvement after infection with COVID-19 and other coronaviruses</article-title>. <source>Brain Behav. Immun.</source><volume>87</volume>, <fpage>18</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2020.03.031</pub-id><pub-id pub-id-type="pmid">32240762</pub-id><pub-id pub-id-type="pmcid">PMC7146689</pub-id></mixed-citation></ref><ref id="B782"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>803</fpage>&#8211;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30987-7</pub-id><pub-id pub-id-type="pmid">33548194</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id></mixed-citation></ref><ref id="B783"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wurm</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Griese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bahr</surname><given-names>U.</given-names></name><name name-style="western"><surname>Held</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heckel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karas</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Identification of the enzyme responsible for N1-methylation of pseudouridine 54 in archaeal tRNAs</article-title>. <source>Rna</source><volume>18</volume>, <fpage>412</fpage>&#8211;<lpage>420</lpage>. <pub-id pub-id-type="doi">10.1261/rna.028498.111</pub-id><pub-id pub-id-type="pmid">22274954</pub-id><pub-id pub-id-type="pmcid">PMC3285930</pub-id></mixed-citation></ref><ref id="B784"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Evasion of type I interferon by SARS-CoV-2</article-title>. <source>Cell. Rep.</source><volume>33</volume>, <fpage>108234</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108234</pub-id><pub-id pub-id-type="pmid">32979938</pub-id><pub-id pub-id-type="pmcid">PMC7501843</pub-id></mixed-citation></ref><ref id="B785"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>39</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></mixed-citation></ref><ref id="B786"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G. F.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: A randomised, double-blind, controlled, phase 1/2 trial</article-title>. <source>Lancet Infect. Dis.</source><volume>22</volume>, <fpage>196</fpage>&#8211;<lpage>208</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00462-x</pub-id><pub-id pub-id-type="pmid">34536349</pub-id><pub-id pub-id-type="pmcid">PMC8443232</pub-id></mixed-citation></ref><ref id="B787"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name></person-group> (<year>2021</year>). <article-title>Domains and functions of spike protein in sars-cov-2 in the context of vaccine design</article-title>. <source>Viruses</source><volume>13</volume>, <fpage>109</fpage>. <pub-id pub-id-type="doi">10.3390/v13010109</pub-id><pub-id pub-id-type="pmid">33466921</pub-id><pub-id pub-id-type="pmcid">PMC7829931</pub-id></mixed-citation></ref><ref id="B788"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>Dendrimer advances for the central nervous system delivery of therapeutics</article-title>. <source>ACS Chem. Neurosci.</source><volume>5</volume>, <fpage>2</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1021/cn400182z</pub-id><pub-id pub-id-type="pmid">24274162</pub-id><pub-id pub-id-type="pmcid">PMC3894720</pub-id></mixed-citation></ref><ref id="B789"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Abdalla</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV</article-title>. <source>Viruses</source><volume>12</volume>, <fpage>244</fpage>. <pub-id pub-id-type="doi">10.3390/v12020244</pub-id><pub-id pub-id-type="pmid">32098422</pub-id><pub-id pub-id-type="pmcid">PMC7077191</pub-id></mixed-citation></ref><ref id="B790"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name></person-group> (<year>2020b</year>). <article-title>Corrigendum: Construction of SARS-CoV-2 virus-like particles by mammalian expression system</article-title>. <source>Front. Bioeng. Biotechnol.</source><volume>8</volume>, <fpage>1026</fpage>. <pub-id pub-id-type="doi">10.3389/fbioe.2020.01026</pub-id><pub-id pub-id-type="pmid">32850726</pub-id><pub-id pub-id-type="pmcid">PMC7409377</pub-id></mixed-citation></ref><ref id="B791"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hosseinpour</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ivanovski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>L. J.</given-names></name><name name-style="western"><surname>Khademhosseini</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Nanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era</article-title>. <source>Natl. Sci. Rev.</source><volume>9</volume>, <fpage>nwac124</fpage>. <pub-id pub-id-type="doi">10.1093/nsr/nwac124</pub-id><pub-id pub-id-type="pmid">36196115</pub-id><pub-id pub-id-type="pmcid">PMC9522393</pub-id></mixed-citation></ref><ref id="B792"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Mohandas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shete</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques</article-title>. <source>Nat. Commun.</source><volume>12</volume>, <fpage>1386</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-21639-w</pub-id><pub-id pub-id-type="pmid">33654090</pub-id><pub-id pub-id-type="pmcid">PMC7925524</pub-id></mixed-citation></ref><ref id="B793"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakovleva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kovalenko</surname><given-names>G.</given-names></name><name name-style="western"><surname>Redlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liulchuk</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Bortz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zadorozhna</surname><given-names>V. I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Tracking SARS-COV-2 variants using nanopore sequencing in Ukraine in summer 2021</article-title>. <source>Res. Sq.</source><volume>12</volume>, <fpage>15749</fpage>. <pub-id pub-id-type="doi">10.21203/rs.3.rs-1044446/v1</pub-id><pub-id pub-id-type="pmcid">PMC9491264</pub-id><pub-id pub-id-type="pmid">36131001</pub-id></mixed-citation></ref><ref id="B794"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yakovleva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kovalenko</surname><given-names>G.</given-names></name><name name-style="western"><surname>Redlinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liulchuk</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Bortz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zadorozhna</surname><given-names>V. I.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Tracking SARS-COV-2 variants using Nanopore sequencing in Ukraine in 2021</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>15749</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-19414-y</pub-id><pub-id pub-id-type="pmid">36131001</pub-id><pub-id pub-id-type="pmcid">PMC9491264</pub-id></mixed-citation></ref><ref id="B795"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamayoshi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakai-Tagawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akasaka</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nakachi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparison of rapid antigen tests for COVID-19</article-title>. <source>Viruses</source><volume>12</volume>, <fpage>1420</fpage>. <pub-id pub-id-type="doi">10.3390/v12121420</pub-id><pub-id pub-id-type="pmid">33322035</pub-id><pub-id pub-id-type="pmcid">PMC7764512</pub-id></mixed-citation></ref><ref id="B796"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2020a</year>). <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source>Science</source><volume>367</volume>, <fpage>1444</fpage>&#8211;<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmid">32132184</pub-id><pub-id pub-id-type="pmcid">PMC7164635</pub-id></mixed-citation></ref><ref id="B797"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Long</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name></person-group> (<year>2020b</year>). <article-title>Duration of SARS-CoV-2 viral RNA in asymptomatic carriers</article-title>. <source>Crit. Care (Houten).</source><volume>24</volume>, <fpage>245</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-020-02952-0</pub-id><pub-id pub-id-type="pmcid">PMC7245635</pub-id><pub-id pub-id-type="pmid">32448332</pub-id></mixed-citation></ref><ref id="B798"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Characteristics of viral shedding time in SARS-CoV-2 infections: A systematic review and meta-analysis</article-title>. <source>Front. Public Health</source><volume>9</volume>, <fpage>652842</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2021.652842</pub-id><pub-id pub-id-type="pmid">33816427</pub-id><pub-id pub-id-type="pmcid">PMC8017277</pub-id></mixed-citation></ref><ref id="B799"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</article-title>. <source>Nature</source><volume>586</volume>, <fpage>572</fpage>&#8211;<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2599-8</pub-id><pub-id pub-id-type="pmid">32726802</pub-id></mixed-citation></ref><ref id="B800"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in wuhan, China: A single-centered, retrospective, observational study</article-title>. <source>Lancet Respir. Med.</source><volume>8</volume>, <fpage>475</fpage>&#8211;<lpage>481</lpage>. <pub-id pub-id-type="doi">10.1016/s2213-2600(20)30079-5</pub-id><pub-id pub-id-type="pmid">32105632</pub-id><pub-id pub-id-type="pmcid">PMC7102538</pub-id></mixed-citation></ref><ref id="B801"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>SARS-CoV-2 detected on environmental fomites for both asymptomatic and symptomatic patients with COVID-19</article-title>. <source>Am. J. Respir. Crit. Care Med.</source><volume>203</volume>, <fpage>374</fpage>&#8211;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.202006-2136le</pub-id><pub-id pub-id-type="pmid">33326364</pub-id><pub-id pub-id-type="pmcid">PMC7874322</pub-id></mixed-citation></ref><ref id="B802"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: Two randomised, double-blind, placebo-controlled, phase 1 and 2 trials</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>1107</fpage>&#8211;<lpage>1119</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00127-4</pub-id><pub-id pub-id-type="pmid">33773111</pub-id><pub-id pub-id-type="pmcid">PMC7990482</pub-id></mixed-citation></ref><ref id="B803"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Z.-W.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals</article-title>. <source>Cell. Mol. Immunol.</source><volume>19</volume>, <fpage>588</fpage>&#8211;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-022-00855-4</pub-id><pub-id pub-id-type="pmid">35352010</pub-id><pub-id pub-id-type="pmcid">PMC8961489</pub-id></mixed-citation></ref><ref id="B804"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>D. a.-W.</given-names></name><name name-style="western"><surname>Cappellini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.-P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Coping with coping: International migrants&#8217; experiences of the covid-19 lockdown in the UK</article-title>. <source>Brit. J. Manage.</source><volume>32</volume>, <fpage>1219</fpage>&#8211;<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1111/1467-8551.12512</pub-id></mixed-citation></ref><ref id="B805"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yilmaz</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Ipekoglu</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Bulbul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yildirim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Evcili</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection</article-title>. <source>Allergy</source><volume>77</volume>, <fpage>258</fpage>&#8211;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1111/all.15091</pub-id><pub-id pub-id-type="pmid">34519053</pub-id><pub-id pub-id-type="pmcid">PMC8653174</pub-id></mixed-citation></ref><ref id="B806"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cizmeci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>C. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2</article-title>. <source>JCI Insight</source><volume>6</volume>, <fpage>146242</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.146242</pub-id><pub-id pub-id-type="pmid">33621211</pub-id><pub-id pub-id-type="pmcid">PMC8026190</pub-id></mixed-citation></ref><ref id="B807"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vidic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Auger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vizzini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lippe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Iacumin</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Activity evaluation of pure and doped zinc oxide nanoparticles against bacterial pathogens and <italic toggle="yes">Saccharomyces cerevisiae</italic>
</article-title>. <source>J. Appl. Microbiol.</source><volume>127</volume>, <fpage>1391</fpage>&#8211;<lpage>1402</lpage>. <pub-id pub-id-type="doi">10.1111/jam.14407</pub-id><pub-id pub-id-type="pmid">31386785</pub-id></mixed-citation></ref><ref id="B808"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaneti</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Girardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Spilki</surname><given-names>F. R.</given-names></name><name name-style="western"><surname>Mena</surname><given-names>K.</given-names></name><name name-style="western"><surname>Westphalen</surname><given-names>A. P. C.</given-names></name><name name-style="western"><surname>Da Costa Colares</surname><given-names>E. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Quantitative microbial risk assessment of SARS-CoV-2 for workers in wastewater treatment plants</article-title>. <source>Sci. Total Environ.</source><volume>754</volume>, <fpage>142163</fpage>. <pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.142163</pub-id><pub-id pub-id-type="pmid">32911141</pub-id><pub-id pub-id-type="pmcid">PMC7468340</pub-id></mixed-citation></ref><ref id="B809"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeltins</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Construction and characterization of virus-like particles: A review</article-title>. <source>Mol. Biotechnol.</source><volume>53</volume>, <fpage>92</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1007/s12033-012-9598-4</pub-id><pub-id pub-id-type="pmid">23001867</pub-id><pub-id pub-id-type="pmcid">PMC7090963</pub-id></mixed-citation></ref><ref id="B810"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zha</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mohsen</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Development of a vaccine against SARS-CoV-2 based on the receptor-binding domain displayed on virus-like particles</article-title>. <source>Vaccines (Basel)</source><volume>9</volume>, <fpage>395</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9040395</pub-id><pub-id pub-id-type="pmid">33923573</pub-id><pub-id pub-id-type="pmcid">PMC8073353</pub-id></mixed-citation></ref><ref id="B811"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X. S.</given-names></name><name name-style="western"><surname>Duchaine</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 and health care worker protection in low-risk settings: A review of modes of transmission and a novel airborne model involving inhalable particles</article-title>. <source>Clin. Microbiol. Rev.</source><volume>34</volume>, <fpage>001844</fpage>. <pub-id pub-id-type="doi">10.1128/cmr.00184-20</pub-id><pub-id pub-id-type="pmcid">PMC7605309</pub-id><pub-id pub-id-type="pmid">33115724</pub-id></mixed-citation></ref><ref id="B812"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F. S.</given-names></name></person-group> (<year>2020a</year>). <article-title>Liver injury in COVID-19: Management and challenges</article-title>. <source>Lancet Gastroenterol. Hepatol.</source><volume>5</volume>, <fpage>428</fpage>&#8211;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1016/s2468-1253(20)30057-1</pub-id><pub-id pub-id-type="pmid">32145190</pub-id><pub-id pub-id-type="pmcid">PMC7129165</pub-id></mixed-citation></ref><ref id="B813"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abdalrahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Makris</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Microfluidic-assisted polymer-protein assembly to fabricate homogeneous functionalnanoparticles</article-title>. <source>Mater. Sci. Eng. C</source><volume>111</volume>, <fpage>110768</fpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2020.110768</pub-id><pub-id pub-id-type="pmid">32279782</pub-id></mixed-citation></ref><ref id="B814"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>C. B.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Quinlan</surname><given-names>B. D.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity</article-title>. <source>Nat. Commun.</source><volume>11</volume>, <fpage>6013</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-19808-4</pub-id><pub-id pub-id-type="pmid">33243994</pub-id><pub-id pub-id-type="pmcid">PMC7693302</pub-id></mixed-citation></ref><ref id="B815"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Le Pen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moncada-Velez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020d</year>). <article-title>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19</article-title>. <source>Science</source><volume>370</volume>, <fpage>eabd4570</fpage>. <pub-id pub-id-type="doi">10.1126/science.abd4570</pub-id><pub-id pub-id-type="pmid">32972995</pub-id><pub-id pub-id-type="pmcid">PMC7857407</pub-id></mixed-citation></ref><ref id="B816"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021a</year>). <article-title>Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy</article-title>. <source>Signal Transduct. Target. Ther.</source><volume>6</volume>, <fpage>233</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00653-w</pub-id><pub-id pub-id-type="pmid">34117216</pub-id><pub-id pub-id-type="pmcid">PMC8193598</pub-id></mixed-citation></ref><ref id="B817"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect. Dis.</source><volume>21</volume>, <fpage>181</fpage>&#8211;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></mixed-citation></ref><ref id="B818"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cobat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>J. L.</given-names></name></person-group> (<year>2022a</year>). <article-title>Human genetic and immunological determinants of critical COVID-19 pneumonia</article-title>. <source>Nature</source><volume>603</volume>, <fpage>587</fpage>&#8211;<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-04447-0</pub-id><pub-id pub-id-type="pmid">35090163</pub-id><pub-id pub-id-type="pmcid">PMC8957595</pub-id></mixed-citation></ref><ref id="B819"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Almazi</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>H. X.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Ledger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Traini</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022b</year>). <article-title>Nanoparticle delivery platforms for RNAi therapeutics targeting COVID-19 disease in the respiratory tract</article-title>. <source>Int. J. Mol. Sci.</source><volume>23</volume>, <fpage>2408</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23052408</pub-id><pub-id pub-id-type="pmid">35269550</pub-id><pub-id pub-id-type="pmcid">PMC8909959</pub-id></mixed-citation></ref><ref id="B820"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Pseudouridine in a new era of RNA modifications</article-title>. <source>Cell. Res.</source><volume>25</volume>, <fpage>153</fpage>&#8211;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2014.143</pub-id><pub-id pub-id-type="pmid">25367125</pub-id><pub-id pub-id-type="pmcid">PMC4650566</pub-id></mixed-citation></ref><ref id="B821"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wibowo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C. X.</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Nanoparticle vaccines</article-title>. <source>Vaccine</source><volume>32</volume>, <fpage>327</fpage>&#8211;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.11.069</pub-id><pub-id pub-id-type="pmid">24295808</pub-id></mixed-citation></ref><ref id="B822"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019</article-title>. <source>Clin. Infect. Dis.</source><volume>71</volume>, <fpage>2027</fpage>&#8211;<lpage>2034</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa344</pub-id><pub-id pub-id-type="pmid">32221519</pub-id><pub-id pub-id-type="pmcid">PMC7184337</pub-id></mixed-citation></ref><ref id="B823"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Y. Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y. T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 and the cardiovascular system</article-title>. <source>Nat. Rev. Cardiol.</source><volume>17</volume>, <fpage>259</fpage>&#8211;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1038/s41569-020-0360-5</pub-id><pub-id pub-id-type="pmid">32139904</pub-id><pub-id pub-id-type="pmcid">PMC7095524</pub-id></mixed-citation></ref><ref id="B824"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X. G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source><volume>579</volume>, <fpage>270</fpage>&#8211;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></mixed-citation></ref><ref id="B825"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Viral dynamics in asymptomatic patients with COVID-19</article-title>. <source>Int. J. Infect. Dis.</source><volume>96</volume>, <fpage>288</fpage>&#8211;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.030</pub-id><pub-id pub-id-type="pmid">32437933</pub-id><pub-id pub-id-type="pmcid">PMC7211726</pub-id></mixed-citation></ref><ref id="B826"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Applications of nanomaterials as vaccine adjuvants</article-title>. <source>Hum. Vaccin. Immunother.</source><volume>10</volume>, <fpage>2761</fpage>&#8211;<lpage>2774</lpage>. <pub-id pub-id-type="doi">10.4161/hv.29589</pub-id><pub-id pub-id-type="pmid">25483497</pub-id><pub-id pub-id-type="pmcid">PMC4977448</pub-id></mixed-citation></ref><ref id="B827"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X. H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L. H.</given-names></name><etal/></person-group> (<year>2020a</year>). <article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial</article-title>. <source>Lancet</source><volume>396</volume>, <fpage>479</fpage>&#8211;<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></mixed-citation></ref><ref id="B828"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X. H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J. X.</given-names></name><etal/></person-group> (<year>2020b</year>). <article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial</article-title>. <source>Lancet</source><volume>395</volume>, <fpage>1845</fpage>&#8211;<lpage>1854</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></mixed-citation></ref><ref id="B829"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020c</year>). <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>727</fpage>&#8211;<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa2001017</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref><ref id="B830"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020d</year>). <article-title>Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19</article-title>. <source>Biosens. Bioelectron. X.</source><volume>166</volume>, <fpage>112437</fpage>. <pub-id pub-id-type="doi">10.1016/j.bios.2020.112437</pub-id><pub-id pub-id-type="pmcid">PMC7361114</pub-id><pub-id pub-id-type="pmid">32692666</pub-id></mixed-citation></ref><ref id="B831"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zieli&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carreir&#243;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pires</surname><given-names>B.</given-names></name><name name-style="western"><surname>Venkatesh</surname><given-names>D. N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology</article-title>. <source>Molecules</source><volume>25</volume>, <fpage>3731</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25163731</pub-id><pub-id pub-id-type="pmid">32824172</pub-id><pub-id pub-id-type="pmcid">PMC7464532</pub-id></mixed-citation></ref><ref id="B832"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Znaidia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Demeret</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Der Werf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Komarova</surname><given-names>A. V.</given-names></name></person-group> (<year>2022</year>). <article-title>Characterization of SARS-CoV-2 evasion: Interferon pathway and therapeutic options</article-title>. <source>Viruses</source><volume>14</volume>, <fpage>1247</fpage>. <pub-id pub-id-type="doi">10.3390/v14061247</pub-id><pub-id pub-id-type="pmid">35746718</pub-id><pub-id pub-id-type="pmcid">PMC9231409</pub-id></mixed-citation></ref><ref id="B833"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title>. <source>N. Engl. J. Med. Overseas. Ed.</source><volume>382</volume>, <fpage>1177</fpage>&#8211;<lpage>1179</lpage>. <pub-id pub-id-type="doi">10.1056/nejmc2001737</pub-id><pub-id pub-id-type="pmcid">PMC7121626</pub-id><pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation></ref><ref id="B834"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gentili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cervellati</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zuliani</surname><given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Viral load difference between symptomatic and asymptomatic COVID-19 patients: Systematic review and meta-analysis</article-title>. <source>Infect. Dis. Rep.</source><volume>13</volume>, <fpage>645</fpage>&#8211;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.3390/idr13030061</pub-id><pub-id pub-id-type="pmid">34287354</pub-id><pub-id pub-id-type="pmcid">PMC8293148</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>